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Abstract 
Zinc is essential to the structure and function of numerous proteins and enzymes so 
requires tight homeostatic control at both the systemic and cellular level. Two families 
of zinc transporters – ZIP (SLC39) and ZnT (SLC30) – contribute to zinc homeostasis. 
There are at least 10 members of the human ZnT family, and the expression profile and 
regulation of each varies depending on tissue type. Little is known about the role and 
expression pattern of ZnT10; however in silico data predict restricted expression to 
foetal tissue. In this thesis I show a differential expression profile for ZnT10 in adult 
human tissue by RT-qPCR and detect highest levels of expression in small intestine, 
liver and brain tissues. I present data revealing the functional activity of ZnT10 to be in 
the efflux direction. Using a plasmid construct to express ZnT10 with an N-terminal 
FLAG-epitope tag, subcellular localisation in a neuroblastoma cell line (SH-SY5Y) is 
shown to be at the Golgi apparatus under standard conditions of culture, with trafficking 
to the plasma membrane observed at higher extracellular zinc concentrations of 100 
µM. I demonstrate using RT-qPCR down-regulation of ZnT10 mRNA levels in cultured 
intestinal and neuroblastoma cell lines in response to extracellular zinc, a response 
which is mirrored at the protein level. Furthermore, I demonstrate reduced transcription 
from the putative ZnT10 promoter at an elevated extracellular zinc concentration.  
Reduction in ZnT10 mRNA expression in response to increased extracellular cobalt and 
conversely, an up-regulation of ZnT10 mRNA levels in response to increased 
extracellular nickel has also been observed by RT-qPCR in both SH-SY5Y and Caco-2 
cells.  Neither of these responses were reflected at the level of transcription using the 
ZnT10 promoter construct. In transiently transfected SH-SY5Y cells Western blotting 
reveals a reduction in p3xFLAG-ZnT10 protein levels in response to extracellular zinc; 
however both extracellular cobalt and nickel caused an increase in the level of 
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p3xFLAG-ZnT10 protein measured. Trafficking was observed with both cobalt and 
nickel treatments. Movement from the Golgi apparatus to a more diffuse localisation 
pattern was observed with cobalt treatment, whereas nickel elicited a response similar to 
zinc, with trafficking toward the plasma membrane. Extracellular copper did not induce 
a change at any level of investigation.  
These features of ZnT10 localisation, regulation and function, together with the 
discovery that ZnT10 is expressed at high levels in brain tissue, indicate that ZnT10 has 
a role in regulating zinc homeostasis in the brain. Further investigation highlighted a 
down-regulation of ZnT10 in human Alzheimer’s disease brain tissue and in the 
APP/PS1 transgenic mouse brain. Zinc was also shown to influence splicing events of 
β-secretase enzyme, known to be involved in Alzheimer’s disease pathology. Zinc 
promoted an increase in the most active isoform at the mRNA level and thus the 
measured dysregulation of ZnT10 and therefore potential changes in levels of zinc may 
have relevance to the development of neurodegenerative disease. 
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Chapter 1: Introduction 
1.1 Biological importance of zinc 
Zinc is the most widely utilised divalent cation in biology despite not being the most 
abundant metal in this group. Biochemically zinc is essential for the function of many 
enzymes from all six enzyme classes (oxidoreductases, ligases, transferases, 
hydrolyases, isomerases, lyases) as established by the International Union of 
Biochemistry (Vallee and Falchuk, 1993). In fact, more recently knowledge of zinc has 
increased exponentially with bioinformatic estimates of approximately 2800 human 
proteins which are potentially zinc-binding in vivo, corresponding to 10 % of the human 
proteome (Andreini et al., 2006). However, this is a substantial increase from lower 
organisms as the zinc proteome represents about 5 % to 6 % in prokaryotes (Andreini et 
al., 2009). It can act in various ways in order to maintain the function of proteins and 
enzymes (Table 1.1). Firstly, zinc can act as a catalyst for many different enzymes. 
These enzymes are classified as zinc metalloenzymes if the removal of zinc decreases 
enzymatic activity without affecting the protein as a whole and adding zinc back into 
the system restores activity, for example, this is the case for carbonic anhydrase 
(reviewed by Liljas et al., 1994). Secondly, zinc can act as an integral structural element 
to various proteins. For example in zinc finger motifs where four cysteines or histidines 
coordinate a zinc ion so that it forms a tetrahedral complex. Proteins with this structure 
are involved in a number of cellular processes such as differentiation, proliferation, 
signal transduction, adhesion and transcription (Vallee and Falchuk, 1981). 
Furthermore, it has been established that in addition to its catalytic effect, zinc is also 
required to maintain structural elements of enzymes. One example of such is 
copper/zinc superoxide dismutase, where the divalent cation copper acts as the catalyst, 
zinc is vital for the configuration (Bannister et al., 1987). Other examples include zinc 
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as a cofactor for DNA polymerase, RNA polymerase and reverse transcriptase (Truong-
Tran et al., 2001a). The third biochemical function of zinc is in the regulation of gene 
expression. The most characterised of these is for metal response element (MRE)-
binding transcription factor-1 (MTF-1), this contains a zinc-finger DNA-binding 
domain which requires coordination of zinc ions so that it maintains its structure in 
order to bind to MREs in promoter regions of genes to regulate downstream expression 
(Heuchel et al., 1994, Langmade et al., 2000, Lichtlen et al., 2001, Wang et al., 2004c) 
(this will be discussed further in Section 1.5). Zinc appears to be particularly important 
in the central nervous system where it is found in presynaptic vesicles of certain 
glutamatergic neurones and, along with glutamate, is released during neurotransmission 
(Frederickson and Bush, 2001). Zinc can also act as an intracellular signalling molecule 
with the ability to influence cellular machinery at several levels (Glover et al., 2003). 
Known effectors of zinc signalling include protein tyrosine kinases (Hogstrand et al., 
2009), protein kinase CK2 (Taylor et al., 2012), plasma membrane calcium ATPase 
(PMCA) (Hogstrand et al., 1999) and tight junction proteins (Finamore et al., 2008). 
The ability of zinc to act in these ways can be attributed to its properties as an early 
transition metal. The transition metals have high melting points, mechanical strength 
and high density properties because of their relatively small atomic radius. The 
versatility afforded by a variable coordination sphere and being redox inert are distinct 
features of zinc within this chemical group that are likely to account for its widespread 
use in biology. In serum the majority of zinc is found bound to albumin (70 %), α-
macroglobulin (18 %) and the remainder is bound to proteins such as transferrin 
therefore relatively little  free zinc is available in solution within biological systems 
(Gibson et al., 2008), with free zinc estimates of 1.70×10
−12
 mol/l (Powell et al., 1999).  
In most cases zinc carries out its biochemical functions as a bound divalent cation. 
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Intracellular zinc is found predominantly bound to metallothioneins (MTs). This is a 
group of cysteine rich proteins, of which there are four major isoforms: MTI and MTII 
found ubiquitously, MTIII found mainly in the brain and MTIV, which is predominant 
in stratified tissues (Bell and Vallee, 2009).  Due to their cysteine rich nature, MTs can 
bind up to 7 zinc atoms and the concentration of the MTs respond readily to changes in 
dietary zinc, implying a role in zinc homeostasis. At high intracellular zinc 
concentrations, MT levels increase therefore sequestering zinc. At low zinc 
concentrations, MT is able to release its bound zinc ions before being degraded. This 
zinc buffering property maintains a constant level of available zinc to carry out its 
numerous biological functions, despite fluctuations in total levels. The buffering 
capacity of MT is demonstrated in inflammation whereby, in the liver, MT can increase 
as much as 100-fold within 2 to 4 hours when in an inflammatory state. This 
subsequently increases hepatic uptake of plasma zinc (Coyle et al., 2002, Mocchegiani 
et al., 2006a). In addition to its role in inflammation, zinc has a role in reducing 
oxidative damage within cells, by both stimulating the activity of several antioxidants 
and stabilising lipids and/or proteins in order to protect cellular membranes (Frazzini et 
al., 2006). Furthermore, a role for zinc in adequate  immune system response is evident 
in the zinc deficiency disease acrodermatitis enteropathica (AE),  where symptoms 
include reduced immune function and increased susceptibility to infections from fungi, 
bacteria and viruses (Neldner and Hambidge, 1975, Haase and Rink, 2009, Prasad, 
2000). 
It has been demonstrated that zinc has a role in apoptosis, although its function remains 
ambiguous. Evidence suggests that high levels of zinc (300 µM) induce apoptosis in 
cultured cortical neurones (Sensi et al., 1999). In vitro studies using the fluorescent zinc 
marker, Zinquin, have shown there is a major redistribution of intracellular zinc during 
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the early stages of apoptosis. These studies are without the addition of extracellular zinc 
so imply a release of zinc from intracellular stores or metalloproteins (Zalewski et al., 
1994). In addition it is proposed that there are two anti-apoptotic mechanisms of zinc. In 
the first instance zinc has a direct influence over regulators of apoptosis. For example, 
in the human acute lymphoblastic leukaemia cell line (Molt4) 10 µM ZnCl2 inhibited 
the apoptopic protease, caspase-3 therefore suppressing apoptosis (Perry et al., 1997). 
Secondly, zinc plays a role in oxidative stress. For example, in 3T3 cells (mouse 
fibroblast) addition of 0.5 µM and 5 µM zinc led to elevated levels of oxidative stress 
markers such as antioxidant enzymes copper/zinc (CuZnSOD) and manganese 
(MnSOD) superoxide dismutases and activated AP-1 as compared to both control cells 
and those with the addition of 50 µM zinc (Oteiza et al., 2000). Indeed a link between 
these two pathways can be hypothesised as a deficiency in intracellular zinc can both 
lead to oxidative stress and therefore caspase activation as well as directly influencing 
caspase activation pathways (reviewed by Truong-Tran et al., 2001b). 
The role for zinc in the regulation of intracellular processes is not limited to apoptosis. 
It has been highlighted as an important signalling molecule involved in transcriptional 
regulation (Section 1.6). Zinc has also been implicated in bone metabolism where it is 
involved in stimulating osteoblast formation (Yamaguchi and Hashizume, 1994) and 
inhibiting osteoclast formation (Kishi and Yamaguchi, 1994). Zinc deficiency is known 
to retard bone growth (Oner et al., 1984) and interestingly, osteoporotic women have 
been shown to excrete higher concentrations of urinary zinc (Herzberg et al., 1990). 
Additionally, neurotransmission in glutamatergic neurones also involves zinc release 
from intracellular synaptic vesicles into the extracellular space which is then thought to 
interact with membrane transporters on the post-synaptic membrane (Frederickson and 
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Bush, 2001) (see Section 1.7). These emphasise only a few of the numerous roles of 
zinc throughout biological systems (Table 1.1).  
1.2 Zinc as a nutrient  
In utero zinc is imperative for normal foetal development. However, its role is not 
limited to the developing embryo and the importance of zinc carries on throughout the 
lifespan of humans. Cells that are most sensitive to zinc deprivation are foetal and 
juvenile cells with high turnover opposed to those cells from tissues that are more 
stationary. Processes such as, but not limited to, growth and mental development in 
childhood require zinc. In adolescence zinc is important for the development of the 
reproductive system and through into adulthood zinc is required to maintain a healthy 
appetite and immune function. The total body content of zinc is only estimated to be 
about 2 g, distributed as approximately 60 %  in skeletal muscle and 30 % in bone with 
lower levels throughout the organs (skin > liver > brain > kidneys > heart > hair > 
plasma) (Table 1.2) (Wastney et al., 1986, King et al., 2000, Jackson, 1989). Due to its 
low levels in plasma (< 0.1% of total body zinc, 12-16 µM) zinc is referred to as a trace 
element (Brown et al., 2001, King et al., 2000). There is no mechanism to enhance 
release of zinc from either bone or muscle and therefore neither can function as a zinc 
store, because of this it is essential to maintain an adequate supply of dietary zinc. These 
requirements are described in the UK as reference nutrient intakes (RNI) and are 
currently set as 9.5 and 7.0 mg/day for men and women respectively (age 18-50) (Table 
1.3) (Henderson et al., 2003a). Due to the nature of zinc it is found bound to proteins, 
for example foods rich in this nutrient are red meats and some shellfish with lesser 
amounts in white meat, fish, cheese, cereals and legumes. In the case of cereals and 
pulses it is found bound to the endosperm. 
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1.2.1 Zinc deficiency 
The essential role of zinc was first established by Raulin in 1869 when it was shown 
that the nutrient is required by Aspergillus niger in order to grow. Since then the 
importance has been established in animals and in humans. The first animal studies 
were in 1934 in rats (O'Dell and Reeves, 1989) and subsequently, in 1961 Prasad et al., 
first described a zinc deficiency syndrome in humans (Prasad et al., 1961). Prasad 
observed that a 21 year old male from Iran had symptoms of anaemia, hypogonadism, 
skin alterations and growth and mental retardation. In altering his diet from that of 
negligible levels of zinc to sources of increased zinc the clinical features of the patient 
were corrected. Severe zinc deficiency is evident in the human autosomal recessive 
disorder Acrodermatitis Enteropathica (AE). The clinical symptoms of this disease 
include circumoral and acral dermatitis, diarrhoea, alopecia as well as neuropsychiatric 
manifestations. AE is caused by an inborn error in zinc metabolism attributed to 
mutations in the intestinal zinc transporter ZIP4 (Section 1.4.1) (reviewed by Andrews, 
2008). Investigation of AE and other milder nutritional zinc deficiencies have advanced 
knowledge into the physiological role of zinc. Extensive research has shown that 
insufficient zinc during pregnancy leads to congenital malformations and compromises 
immune functions, neurobehaviour, and overall neonatal survival. A dramatic example 
of the devastating effects of severe maternal zinc deficiency can be found in mothers 
with AE. In such cases low birth weight, spontaneous abortion, ancephalic foetus or 
dwarfism occurred in five out of seven cases (King et al., 2000).  Milder zinc 
deficiencies during pregnancy have also been identified, with intraurine growth 
retardation, low birth weights and complications during labour being described in the 
literature (Shah and Sachdev, 2006).  Deficiency can also contribute to certain states in 
adult humans, such as infertility and neurosensory disorders. For example, in men with 
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Crohn’s disease (an autoimmune inflammatory disease of the alimentary tract, usually 
affecting the intestines) it has been hypothesised that zinc deficiency causes poor sperm 
function and therefore male infertility (El-Tawil, 2003). In relation to neurosensory 
disorders, it has been shown that zinc deficiency triggers abnormal glucocorticoid 
secretion inducing changes in functions of certain areas of the brain such as the 
hippocampus (Takeda and Tamano, 2009). The hippocampus is involved in learning 
and memory therefore this is one function of the brain that can be affected by zinc status 
throughout life. Studies in rats have shown that treatment with the zinc chelator; 
Clioquinol (CQ) impaired memory function of adult rats (Takeda et al., 2010) and 
indeed zinc ion availability has been implicated in the decline of function in the aged 
human brain (Mocchegiani et al., 2005). 
The difficulty diagnosing zinc deficiency is the pleiotropic nature of such symptoms, 
i.e. it does not just affect one metabolic pathway as is the case for iron; zinc is involved 
in numerous pathways. Also mild zinc deficiency may not have clinical symptoms..  
Homeostasis of zinc is tightly controlled and therefore markers such as blood plasma or 
serum zinc concentration can take long periods of deficiency in order to alter. This was 
evident when over a 6 month period on a zinc deficient diet (2.6 mg zinc/d), no 
significant changes were found in plasma zinc levels or in the activity of zinc-
containing enzymes in a cohort of five postmenopausal women, age 50-63 years (Milne 
et al., 1987). A further complication with the use of plasma zinc concentrations as a 
measure of zinc adequacy, is that the levels naturally fluctuate daily with ever changing 
inflammatory and immune status, as well as with the use of oral contraceptives 
(Fairweather-Tait et al., 2008). Other biomarkers that may prove more useful are 
differential erythrocyte zinc transporter or metallothionein gene or protein expression 
which seem to rapidly respond to zinc treatments where plasma zinc does not however, 
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these may not be sensitive enough in order to measure marginal zinc deficiency (Ryu et 
al., 2008, Wood, 2000). 
The risk of zinc deficiency in world populations is increased in regions where diets are 
predominantly high in plant-based foods and low in animal protein. This is not only due 
to the lower intake of zinc itself but also to the high concentrations of phytates found in 
cereals and pulses. Phytate chelates zinc therefore reducing dietary absorption. There 
are other groups that are at risk of zinc deficiency, despite living in regions with readily 
available sources of zinc. These include lactating women and growing infants which 
require an increase in their dietary intake of zinc due to a higher demand (Table 1.3). In 
addition, there are groups that have abnormalities that lead to malabsorption of 
nutrients, such as individuals with Crohn’s disease, which may require supplementation 
in order to meet their daily requirements. 
1.2.2 Zinc toxicity  
Due to the tight regulation of zinc homeostasis ingestion of zinc is essentially non-toxic 
in humans.  Intriguingly, however, adverse reactions to zinc have been reported in rare 
incidences when there is inhalation of zinc fumes or ingestion of unusually large 
amounts of zinc from food and beverages stored in galvanized containers (Vallee, 
1988). In these cases excess zinc can causes nausea, fever and diarrhoea. There is a 
certain relationship between other divalent cations and zinc, therefore metabolism of 
other trace elements can be affected by long-term high zinc intake. This interaction is 
especially profound in the case of copper. A defect in copper metabolism is found in the 
autosomal recessive condition, termed Wilson’s disease, such that there is an excessive 
hepatic copper accumulation. This can be fatal if the disease is not treated. High levels 
of zinc have been shown to be therapeutic in the condition, in that supplementation with 
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zinc (up to 150 mg/d) stimulates intestinal MT, which in turn chelates copper in the 
intestine, reducing accumulation and increases excretion in patient stools (Marcellini et 
al., 2005). Whilst this study assessed the zinc supplementation after 10 years, the 
efficacy of using longer term zinc supplements has not been investigated. 
1.3 Systemic zinc homeostasis  
Errors in homeostatic mechanisms, whether genetic and/ or environmental cause disease 
states and these highlight the importance of controlling such processes. Zinc is no 
exception, with both the side effects of toxicity and deficiency leading to health risks, so 
it is imperative that internal zinc concentration remains tightly regulated. This is 
achieved through the co-ordination of many proteins involved in absorption, movement, 
storage, trafficking and excretion of zinc. Zinc absorption is related to the amount of 
dietary zinc consumed, this correlation is negative, meaning that reduced intake of zinc 
will consequently increase the rate of absorption of zinc from the diet. This has been 
shown experimentally, where a low dietary intake of zinc (12 µmol/d) in adult males 
over a 15 day period, resulted in an increase in zinc absorption from 38 % to 93 % as 
compared to normal intake (85 µmol/d) (Taylor et al., 1991).  In addition it is important 
to note that zinc absorption also appears to plateau at >308 µmol/d (King, 2011).  
Two families of proteins are known to play a role in zinc homeostasis, these are the zinc 
transporters, ZIPs; that act to increase cytosolic zinc and the ZnTs, that are thought to 
efflux zinc, reducing cytosolic zinc concentrations. These can be differentially regulated 
in response to changing zinc status (see section 1.5), disease state and cases of infection. 
In addition there are binding proteins such as MT that enable storage of small reserves 
of zinc when the levels are adequate and conversely are able to release zinc when it is 
required for its many processes. Furthermore, regulation of MT by zinc enables this 
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protein to be up-regulated to chelate zinc in times of excess and be degraded when zinc 
levels are low. Impressively, studies have shown a constant whole body zinc content 
when dietary zinc differs by a 10-fold range (Kirchgessner, 1993). It is hypothesised 
that it is the response of the zinc transporters and MT to changes in local zinc status that 
allow whole body zinc content to be maintained (King et al., 2000). 
Very early studies established that excess zinc is mainly excreted in faeces. It was 
shown that the level of excretion was equal to dietary intake except where injected 
levels were above 6 mg/day. In these cases excreted zinc levels were higher (McCance 
and Widdowson, 1942).  Zinc for excretion in this manner is released into the 
gastrointestinal tract, the potential sources of such zinc is in pancreatic and biliary 
secretions, gastroduodenal secretions and transepithelial flux from the enterocytes 
(Krebs, 2000). In addition, McCance et al., (1942) noted that the kidneys play little part 
in zinc excretion with a constant level of zinc ions being excreted in the urine despite 
increased dietary intakes and/ or intravenous injections.  However, more recent research 
has shown that zinc excretion in the urine is 6-fold higher in infants than adults, when 
normalised to body weight. This is perhaps a reflection of the maturation state of the 
kidney in infants (Wastney et al., 1999). The state of maturity has also been investigated 
in terms of zinc absorption using adult human intestinal Caco-2 cells against human 
foetal FHs 74 Int cells. The conclusion from this study was that developmental state 
plays an important role in zinc absorption in the intestine through intestinal zinc efflux 
and sequestration and import mechanisms (Jou et al., 2010). Other minor routes of zinc 
excretion include semen, sloughed skin, nails and hair (King et al., 2000). 
Important alterations are made to homeostatic mechanisms during times of increased 
zinc requirements. For example during pregnancy and lactation there is an increased 
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demand for zinc due to the processes of embryogenesis, foetal growth and milk 
secretion (Donangelo et al., 2005).  Zinc absorption during these times increases 
significantly to meet these demands. In times of foetal growth the demands are higher. 
In addition, in early lactation increased absorption allows maintenance of zinc levels 
whilst zinc is excreted from the mammary glands into the colostrum. As secretion 
decreases so too does zinc absorption. Even in cases of low dietary zinc, homeostatic 
mechanisms act to maintain adequate levels in breast milk (Kelleher and Lonnerdal, 
2005). 
1.4 Mammalian zinc transporters 
As described in Section 1.2, there is no specific storage mechanism for zinc within the 
body and therefore zinc must be ingested daily to maintain recommended levels (Table 
1.3). In order to carry out its vital roles within the body, zinc needs to be absorbed from 
the diet, transported around the body and enter and exit a wide range of organs and 
more specifically cells. The absorption and homeostasis of zinc from the diet and within 
the body is undertaken by zinc transporters of which there are two known families; ZIP 
(Zinc-regulated and iron-regulated transporter protein, SLC39 family) and ZnT 
(members of the cation diffusion facilitator, SLC30, family) (Lichten and Cousins, 
2009). Homolgues in species other than humans are referred to as Zip (Slc39) and Znt 
(Slc30). The families have contrasting roles within the cell. ZIPs are concerned with 
increasing cytosolic zinc concentrations, whereas ZnTs are thought to be predominantly 
involved in the efflux of zinc from the cytoplasm either out of the cell or sequestering it 
into intracellular compartments therefore reducing cytosolic zinc concentration. To date, 
there are 10 identified ZnTs in humans and 14 known ZIPs, however the expression of 
each varies depending upon the tissue. In order to play the opposing functions there are 
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distinct structural differences between the two as described in the proceeding sections 
(1.4.1 and 1.4.2). 
1.4.1 ZIP family  
The ZIP family of zinc transporters are named after the yeast Zrt1 protein (Zinc-
regulated transporter 1) and the Arabidopsis Irt1 protein (Iron-regulation transporter 1) 
giving the full title of Zinc-regulated and iron-regulated transporter protein. Most of 
these proteins have a predicted topology of eight transmembrane spanning domains 
(TMD) with extracellular N- and C- termini (Figure 1.1A) (Kambe et al., 2004, Palmiter 
and Huang, 2004). In addition, in most of these transporters there is long loop region 
between TMD III and IV, which predominantly contains histidine-rich domains of 3-5 
histidine residues. Due to the potential of these residues to bind metal it is thought that 
this region may be important in zinc transport or its regulation however this has not 
been shown experimentally in the mammalian transporters (Eide, 2006). Interestingly 
however, the mutation of this region in the yeast Zrt1 seems to affect subcellular 
localisation of the protein rather than the transporter’s function (Gitan et al., 2003). The 
sequences of TMD IV and V are highly conserved and due to their amphipathic nature, 
it is hypothesised that it is this region that forms a pore through which zinc can pass. 
The role described in the literature for ZIP transporters is to increase cytosolic zinc 
concentrations by either importing zinc across a plasma membrane from the 
extracellular space or transporting it from the lumens of organelles into the cytoplasm. 
The ZIP family can be split into a further 4 families depending on their degree of 
sequence conservation. These are subfamilies I, II LIV-1 or gufA (Figure 1.1B) (Gaither 
and Eide, 2001a). 
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The first identified member of the ZIP family, ZIP1 (SLC39A1), is expressed in a wide 
variety of cell types. ZIP1 is an interesting transporter due to its cell-type dependent 
localisation pattern. For example, in the human erthyromyeloblastoid leukaemia cell 
line K562, over-expression of hZIP1 showed a pattern consistent with the plasma 
membrane localisation. This data was obtained by indirect immunofluorescence by 
stably transfecting the hZIP1 construct that contained a haemagglutinin (HA) antigen 
epitope tag (Gaither and Eide, 2001b). However in COS-7 (monkey kidney fibroblast) 
and PC3 (human prostate cancer) cell lines localisation was shown to the endoplasmic 
reticulum (ER). The technique in this case differed slightly from Gaither et al., (2001) in 
that this hZIP1 construct had a FLAG-tag and the cells were transiently transfected 
(Milon et al., 2001). Furthermore, in human embryonic kidney (HEK293) cells stably 
transfected with a construct expressing the mouse homologue of human ZIP1; mZip1, 
with a haemagglutinin (HA) antigen epitope tag, post-translational modification has 
been proposed due to the translocation of mZip1 depending on the zinc status of the 
cell.  In cases of zinc deficiency mZip1 is modified such that endocytosis of the 
transporter is decreased, with an observed higher expression at the plasma membrane, 
which in turn is correlated with an increase in zinc uptake into the cell (Wang et al., 
2004a). In addition, site directed-mutagenesis was used to replace the loop histidines 
between TMD III and IV with alanines to ascertain the function of these highly 
conserved residues. Upon transfection into the PC3 cells, results indicated that these 
histidines are important in zinc transport function but are not involved in the plasma 
membrane localisation (Milon et al., 2006). One example of the importance of human 
ZIP1 in health and disease is in the development of prostate cancer. Down-regulation of 
hZIP1 has been proposed as a critical event in the progression of the disease.  hZIP1 is 
found in the normal peripheral zone glandular epithelium and has been identified as 
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important in the uptake of circulating zinc at the basolateral membrane of prostate cells. 
Under normal conditions the prostate tissue has a high level of zinc accumulated 
however in adenocarinomatous glands, hZIP1 gene and protein expression is decreased, 
thus causing subsequent zinc depletion (Franklin et al., 2005). In support of this 
hypothesis is a study which investigated ZIP1 levels in African Americans, which found 
that incidence rates are highest in this racial group (Rishi et al., 2003). The researchers 
revealed that ZIP1 levels in normal prostate tissues from African American men are 
decreased when compared with age-matched white men. Therefore Franklin et al., 
(2007) have proposed ZIP1 as a tumour suppressor gene (Franklin and Costello, 2007, 
Costello and Franklin, 2006). 
In contrast to ZIP1, the second member of this family of zinc transporters, ZIP2 
(SLC39A2) appears to have a restricted expression pattern in human tissues. It is 
thought to be present at low levels in prostate, uterus, cervical epithelium, optic nerve 
and monocytes (Eide, 2004). Interestingly, this expression pattern is different in mouse 
with higher levels of mZip2 in skin, liver, ovary and visceral yolk sac (Dufner-Beattie et 
al., 2003a). Although both hZIP2 (Gaither and Eide, 2000) and mZip2 (Dufner-Beattie 
et al., 2003a) exhibit the characteristic uptake function in transfected cells when 
expressing ZIP2 from a CMV promoter, their mechanism of regulation appears to be 
different. Human ZIP2 expression was investigated in the monocytic cell line, THP-1, 
and human peripheral blood mononuclear cells and upon depletion of zinc with the 
intracellular zinc chelator TPEN [N,N,N*,N*-tetrakis(2-pyridylmethyl) 
ethylenediamine] hZIP2 mRNA expression increased (Cao et al., 2001). However, 
when pregnant mice underwent dietary restriction of zinc mRNA levels of mZip2 in the 
embryonic visceral endoderm remained unchanged when analysed by semi-quantitative 
reverse-transcriptase (RT)-PCR (Dufner-Beattie et al., 2003a). In line with hZIP1, 
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hZIP2 also shows down-regulation in prostate cancer cells. Intriguingly however, hZIP2 
is expressed at the apical cell membrane and therefore is thought to be involved in 
retaining levels of zinc in the cellular compartments by ‘re-uptaking’ zinc from prostatic 
fluid (Desouki et al., 2007).  
ZIP3 research focuses mainly on the mouse isoform and it is found at low levels in 
numerous tissues however it is most abundant in the testes. Consistent with mZip2, 
when pregnant mice are on a zinc restricted diet mZip3 levels do not change in the 
embryonic visceral endoderm of the intestine (Dufner-Beattie et al., 2003a). The 
localisation pattern of mZip3 appears to be consistent with that of mZip1 whereby in 
stably transfected HEK293 cells under zinc replete conditions the localisation of mZip3 
was to the intracellular organelles with rapid transit between these and the plasma 
membrane. However, in the same cell line model, zinc depletion has been found to 
increase the trans-localisation of mZip3 to the plasma membrane (Wang et al., 2004a). 
Importantly, the function of mZip3 was assessed in transiently transfected HEK293 
cells using 
65
Zn and competitor metal assays. The predicted uptake function was 
observed and was strongly inhibited by excess zinc thereby indicating a carrier mediated 
process. Zinc uptake by mZip3 was also inhibited by other metals (copper, cadmium, 
manganese, cobalt, magnesium and nickel) therefore indicating some promiscuity with 
respect to substrate specificity this transporter (Dufner-Beattie et al., 2003a). The 
research into human ZIP3 is mainly based around the fact that it is also implicated in 
prostate cancer, again exhibiting a down-regulatory effect in diseased cells (Franklin et 
al., 2005). It appears to act in the same way as hZIP2 in that it is localised to the apical 
cell membrane and is involved in ‘re-uptaking’ zinc from the prostatic fluid in order to 
retain zinc levels (Desouki et al., 2007). It is proposed that this down-regulation of 
hZIP1-3 in the development of prostate cancer is due to the epigenetic silencing of gene 
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expression, though this has not been tested experimentally. Due to this role in the 
development of prostate cancer, these genes have been highlighted as potential tumour-
suppressor genes (Franklin and Costello, 2007, Costello and Franklin, 2006). 
ZIP4 (SLC39A4) and ZIP5 (SLC39A5) were both discovered due to their involvement 
in the development of the zinc deficiency disease Acrodermatitis enteropathica (AE). 
This is an autosomal recessive disorder, in which mis-sense mutations, splicing defects 
or transcriptional-inactivation by upstream deletions in the hZIP4 transporter render it 
either inactive or mis-localised, so that it is retained in the ER. hZIP4 is abundant in 
tissues that are important for zinc absorption such as the intestine, colon, stomach and 
the kidneys and in these tissues it is localised to the apical membrane (Wang et al., 
2002). Therefore, inactivation/ mis-localisation limits the body’s ability to absorb 
adequate dietary zinc. Wang et al., (2001) discovered that not all of the mutations that 
cause AE were mapped to the ZIP4 locus (∼3.5-cM region on 8q24), and indeed the 
condition in humans can be overcome by dietary supplementation implying a 
compensatory mechanism for intestinal zinc uptake. Thus they highlighted a putative 
zinc-uptake protein, named ‘hORF1’, as a candidate. Wang and colleagues discovered 
that this gene is expressed primarily in the epithelium of the colon and in 
adenocarcinoma cells by SAGE (Serial Analysis of Gene Expression) data, allowing 
speculation that mutation of this gene could be responsible for cases of AE where the 
locus 8q24.3 is not mutated (Wang et al., 2001, Wang et al., 2002). This ORF1 gene is 
now known as hZIP5. ZIP4 and ZIP5 are 30 % homologous and they display a similar 
pattern of tissue expression, although their roles are somewhat contrasting. 
Investigations in mouse have elucidated the roles of these two transporters. In 
localisation experiments mice were fed a zinc adequate or a zinc deficient diet before 
immunohistochemical analysis of the proximal small intestine (duodenum) and 
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pancreas. The results showed that mZip5 is located on the basolateral membrane when 
cells are zinc replete, but the same state causes internalisation of mZip4 from the apical 
membrane through endocytosis. Furthermore, Western blot analysis of membrane 
proteins from the visceral yolk sacs, showed that in cases of zinc deficiency mZip5 is 
internalised, whereas mZip4 mRNA is stabilised and the protein is translocated to the 
apical membrane. It is mZip5 translation, not transcription, that is zinc responsive with 
mRNA remaining bound to polysomes under zinc deplete states. However, transcription 
run-on assays were performed that indicated there was no difference in transcriptional 
rate of mZip4 between zinc adequate and zinc deficient diets implying post-
transcriptional regulation (Weaver et al., 2007). In contrast to this, Liuzzi et al., (2009) 
have argued that the transcriptional factor Krüppel-like factor 4 (KLF4) is able to bind 
to the mZip4 promoter in zinc deficient conditions in MODE-K cells. This binding is 
hypothesised to be important for the up-regulation of mZip4 (Liuzzi et al., 2009). The 
discrepancies indicated here highlight the importance of validation of the cell line 
models used as it should be noted that low levels of mZip4 can only be detected by RT-
qPCR, and not RT-PCR, in MODE-K cells (Huang et al., 2006). 
ZIP6 (SLC39A6) and ZIP7 (SLC39A7) have been identified as having a role in certain 
breast cancers supporting the hypothesis that transporter dysregulation can lead to 
uncontrolled cell proliferation. Both transporters have widespread expression however 
they have a number of differences. ZIP6 has become a reliable marker of oestrogen-
receptor-positive cancers as it is regulated by oestrogen and has been found to be 
increased in these cases (Tozlu et al., 2006, Schneider et al., 2006). Using FACS 
(Fluorescence activated cell sorting) analysis of transiently transfected Chinese hamster 
ovary (CHO) cells the uptake function of ZIP6 has been confirmed. In addition, CHO 
cells were transiently transfected with ZIP6 with a V5 epitope tag allowing use of an 
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anti-V5 antibody to assess immunostaining and localisation patterns. This gave a pattern 
of localisation consistent with plasma membrane staining (Taylor et al., 2003). 
Conversely, ZIP7 has been shown to be localised to the ER and Golgi apparatus. In 
human lung fibroblasts (WI-38), human prostate epithelial cells (RWPE1), human 
erythroleukemia cells (K-562), and human mammary gland epithelial cells (MCF-7) an 
anti-ZIP7 antibody was used to show a pattern of staining consistent with the Golgi 
apparatus (Huang et al., 2005). In addition, localisation studies in CHO cells transiently 
transfected with ZIP7 with a V5 epitope tag (as with ZIP6) enabled visualisation of an 
ER pattern of localisation using an anti-V5 antibody (Taylor et al., 2004). Both studies 
established the zinc transport ability of ZIP7. Huang et al., (2005) used ZnT7/ZIP7-co-
expressing CHO cells and the fluorescent zinc tracer dye, Zinquin, to show that ZIP7 
negates the zinc accumulation seen in the Golgi apparatus that is found in cells 
expressing ZnT7 alone. Taylor et al., (2004) used FACS analysis of transiently 
transfected CHO cells, as for ZIP6, to confirm transport of zinc concluding that ZIP7 
has the ability to transport intracellular zinc across the membrane on which it is 
positioned. The role for ZIP7 in breast cancer has become apparent in that elevated 
ZIP7 is associated with breast cancer in tamoxifen resistant (TamR) cell lines thus 
leading to elevated zinc levels and increased growth factor activation. The impact of this 
is an increase in cell growth and invasion, this can be reversed by ZIP7 knock-down 
using small interfering RNA (siRNA) thus reducing intracellular zinc levels and growth 
factor activation (Taylor et al., 2008). Further investigation into this mechanism has led 
to ZIP7 being proposed to be important in zinc-mediated tyrosine kinase signalling 
therefore suggesting ZIP7 as a potential therapeutic target in cancer (Hogstrand et al., 
2009). 
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ZIP8 (SLC39A8, originally BIGM103) expression is in the lung, kidney, testis, liver, 
brain, small intestine and the membrane fraction of mature red blood cells (Wang et al., 
2007, Ryu et al., 2008). In four stably transfected human cell lines (HEK-293, RK-13, 
COS-7, and MCF-7) hZIP8 was localised to the lysosomes (Begum et al., 2002), 
however in adult murine erythrocytes anti-mZip8 antibody staining was consistent with 
plasma membrane localisation (Ryu et al., 2008). Zinc transport by ZIP8 has been 
elucidated to as transfected CHO cells accumulated more zinc than their mock-
transfected counterparts (Begum et al., 2002). In addition to its role in zinc transport 
mZip8 has been shown to be responsible for the accumulation and >10-fold increase in 
the rate of intracellular cadmium influx in a mouse fibroblast cell line (Dalton et al., 
2005). In primary human lung epithelia and BEAS-2B cell cultures the inflammatory 
mediator, tumour necrosis factor-α (TNF-α), was shown to induce ZIP8 mRNA 
expression, furthermore the expression of ZIP8 meant an increase in intracellular zinc 
content which coincided with cell survival when stimulated with TNF-α implying a role 
in immune activation of inflammation through cytoprotection (Besecker et al., 2008).  
ZIP8 has also been found to be elevated in breast cancer and more specifically 
Fulvestrant-resistant cell lines. It has been proposed that the elevation of these zinc 
transporters has a role in the development of the Fulvestrant-resistance of the cancers 
(Taylor et al., 2007). 
ZIP9 (SLC39A9) is a less well characterised transporter in the ZIP family. Transient 
transfection of hZIP9 with an HA epitope tag has shown it to localise to the trans-Golgi 
network (TGN) irrespective of zinc status. It is the only known member of the 
subfamily I in mammals and a role in mobilising zinc as part of the secretory pathway 
has been implied because stable expression of hZIP9-HA decreases alkaline 
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phosphatase activity, a marker of zinc homeostasis in this pathway, in DT40 cell lines 
(Matsuura et al., 2009). 
In zebrafish gills, an area studied due to its functional similarities to mammalian 
intestines, excess zinc down-regulates ZIP10 (Slc39a10) mRNA expression as shown 
by real-time RT-PCR (RT-qPCR). Conversely, a decrease in zinc increases ZIP10 
mRNA levels (Zheng et al., 2008). This has led to the discovery of metal regulatory 
elements (MREs) in the zebrafish Zip10 gene. In addition, Zheng et al., (2008) show 
Zip10 functions as an importer using the Xenopus oocyte expression system whereby 
uptake of 
65
Zn into oocytes injected with Zip10 mRNA was compared to water-injected 
controls. Consistent with other members of the ZIP family, ZIP10 is dysregulated in 
breast cancer shown in clinical samples where ZIP10 mRNA expression correlated 
significantly with the metastasis of breast cancer to the lymph node. Furthermore, in 
breast cancer cell line studies the more invasive and metastatic cell lines (MDA-MB-
231 and MDA-MB-435S) have an increased ZIP10 mRNA expression as compared 
with the less metastatic breast cancer cell lines (MCF7, T47D, ZR75-1 and ZR75-30). 
Intriguingly, knockdown experiments using siRNA to assess the involvement of ZIP10 
in cell migration in MDA-MB-231 and MDA-MB-435S cells have revealed that a 
decrease in ZIP10 expression subsequently decreases zinc concentrations and inhibits 
the migratory properties of these cancer cells (Kagara et al., 2007). 
There is little information in the literature relating to ZIP11 (SLC39A11) however, it is 
note-worthy that it is the only ZIP to be a member of the gufA subfamily. Using an anti-
Zip11 antibody it has been shown in mouse mammary epithelial cells (MECs) that 
Zip11 showed a localisation pattern consistent with the Golgi apparatus as it co-
localised with the marker p58. This is thought to be important for zinc export from the 
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Golgi and into milk. Also Zip11 has been postulated to be a key player in the ‘re-
uptake’ of zinc from milk during lactation as protein expression of Zip11 can increase 
more than two-fold during lactation in mice (Kelleher et al., 2012). Despite this more 
research is required to understand the zinc transporting system in mammary glands. 
In neurobiology ZIP12 (SLC39A12) is an interesting candidate for further investigation. 
Although research is severely lacking into this transporter, missense mutations in the 
ORF of ZIP12 occur about twice as regularly in post-mortem brain tissue DNA samples 
from a small number of patients with schizophrenia as compared to controls (62 
unrelated Caucasian schizophrenics versus 35 unrelated and unaffected Caucasians) 
(Bly, 2006). This observation is more compelling when it is coupled with the 
knowledge that zinc concentration in the schizophrenic brain is low compared with 
controls (Kimura and Kumura, 1965). 
Zip13 (Slc39a13) has been found to be located to the Golgi apparatus in mouse 
osteoblasts, chondrocytes, pulpal cells, and fibroblasts with use of an anti-Zip13 
antibody. In addition, in primary dermal fibroblasts from Zip13
-/-
 knockout mice, the 
zinc levels in the Golgi apparatus were increased as compared to wild-type cells as 
measured by electron probe X-ray micro analysis ((EPMA) a technique that is able to 
detect zinc levels in a restricted area of a single cell) implying Zip13 acts to increase the 
zinc concentration of the cytosol by transporting zinc out of the Golgi apparatus 
(Fukada et al., 2008). A 9 bp deletion in exon 4 of ZIP13 leads to the spondylocheiro 
dysplastic form of Ehlers-Danlos syndrome (SDF-EDS) (Giunta et al., 2008). Patient 
phenotype includes the features of EDS: progressive kyphoscoliosis, hypermobility of 
joints, and hyperelasticity of skin combined with severe hypotonia of skeletal muscles, 
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coupled with short stature (Beighton et al., 1998). These phenotypic observations 
implicate a role for ZIP13 in bone and connective tissue development. 
ZIP14 (SLC39A14) is most closely linked to ZIP8 with almost 50 % homology between 
the two transporters. Similar to ZIP8 the transport function of ZIP14 has been identified 
by transfection of CHO cells with a ZIP14 construct, this gave a cellular accumulation 
of zinc (Taylor et al., 2005). Subsequent investigations using the Xenopus oocyte 
expression system have revealed the ability of ZIP14 to transport zinc, cadmium, iron 
and manganese (Pinilla-Tenas et al., 2011). ZIP14 mRNA expression is thought to be 
widespread with highest levels in the liver, pancreas, heart, thyroid gland, and small 
intestine. Localisation studies were completed in CHO cells using a ZIP14 construct 
with a V5 epitope tag. Using an anti-V5 antibody the cells displayed a plasma 
membrane localisation pattern (Taylor et al., 2005). There are 2 splice variants of 
mZip14 that have been identified in mouse: mZip14A and mZip14B. Both variants are 
most highly expressed at the mRNA level in the liver and duodenum however, 
following this, mZip14A abundance is higher in kidney and then testis opposed to 
mZip14B being greater in the brain and then the testis. Researchers showed that both 
mZip14 variant transporters are located on the apical membrane in transiently 
transfected Madin-Darby canine kidney (MDCK) polarised epithelial cells 
(Girijashanker et al., 2008). In experiments that do not distinguish between these 
transcripts, it has been shown that inflammation and lipopolysaccharide (LPS) up-
regulate mZip14 mRNA levels in the mouse liver thereby playing an interesting role in 
inflammation. It is thought that interleukin-6 is the cytokine that mediates this increase 
mZip14 expression because in interleukin-6
-/-
 mice LPS did not induce mZip14 
expression and in primary hepatocyte cell cultures interleukin-6 treatment induced an 
increase in mZip14 mRNA and protein expression with an increase in localisation of the 
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protein to the plasma membrane. This led the investigators to hypothesise that mZip14 
is an acute-phase gene enabling it to contribute to the hypozincaemia of the 
inflammation and infection response (Liuzzi et al., 2005). 
1.4.2 CDF family  
Members of the cation diffusion facilitator (CDF) family are broadly thought to be 
involved in the sequestration of both essential and toxic metals. In bacteria this family 
of transporters  have been shown to be involved in transport of many cations however, 
the homologous proteins in mammals all have known or assumed zinc transport 
function and are therefore known as the ZnT family of zinc transporters. They are 
thought to have an involvement in mammalian zinc
 
homeostasis (reviewed by 
Montanini et al., 2007). Confirmation of this zinc transporter activity has been 
performed for ZnT 1, 2, 4-8, either indirectly by survival of zinc susceptible cells in 
medium with a high zinc content, or by directly measuring uptake or accumulation of 
zinc (using zinc fluorescent probes or radioactive zinc) in transfected or mutated 
mammalian cells, zinc-sensitive yeast strains and Xenopus oocytes (Palmiter and 
Findley, 1995, Palmiter et al., 1996a, Huang and Gitschier, 1997, Kambe et al., 2002, 
Huang et al., 2002, Kirschke and Huang, 2003, Chimienti et al., 2004, Cragg et al., 
2002). An additional method measured zinc transport indirectly in support of the 
Xenopus oocytes experiments for ZnT5vB, this utilised a reporter construct system to 
show movement of zinc (Valentine et al., 2007). This system is based on the β-
galactosidase reporter system used in zinc-sensitive baby hamster kidney (BHK) cell 
lines to measure ZnT1 and ZnT2 function (Palmiter and Findley, 1995, Palmiter et al., 
1996a, Palmiter, 1994). It is likely that these transporters act as secondary active 
transporters or antiporters due to their movement of zinc against a concentration 
gradient (Guffanti et al., 2002). All known members of the human ZnT family of 
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transporters contain a conserved CDF motif in their amino acid sequence. In 
comparison to ZIPs, ZnT family members primarily have six TMD with a basic region 
between TMD IV and V. Conversely to ZIPs however, the topology is such that the N- 
and C- terminals are thought to be intracellular (Figure 1.2), an orientation only proven 
for ZnT1 residing in the plasma membrane (Palmiter and Findley, 1995). Hydropathy 
plots indicate that four of the amphipathic TMDs act to form a channel for the 
translocation of zinc however this has not been validated experimentally. Furthermore, 
motifs have been found that may allow for protein-protein interaction and it is evident 
that some ZnTs act as hetero- or homo-dimers. There are three subfamilies of ZnTs: 
Subfamily I contains only ZnT9, subfamily II contains ZnT 1, 5, 6, 7 and 8 and 
subfamily III contain ZnT 2, 3 and 4 (reviewed by Palmiter and Huang, 2004). Data on 
the subfamily of ZnT10 is not available.  
The sequence that codes for ZnT1 is found on chromosome 1. It is a simple gene 
structure that consists of 2 exons. Much investigation has been carried out into the 
rodent forms of Znt1. It has ubiquitous tissue expression, however is more abundant in 
tissues involved in zinc acquisition such as the small intestine, liver and kidney 
(McMahon and Cousins, 1998, Cousins and McMahon, 2000). In BHK cell lines, Znt1 
is localised to the plasma membrane when visualised using a fluorescently tagged Znt1 
construct (Cousins and McMahon, 2000). In addition, direct investigation of the small 
intestine of mice using a Znt1 specific antibody yielded a localisation pattern to the 
basolateral membrane of enterocytes (McMahon and Cousins, 1998).  It is hypothesised 
that this localisation ideally places this transporter to transfer zinc from the enterocyte 
into the circulation and indeed Palimter et al., (1995) demonstrated this efflux activity 
experimentally using an indirect method. In zinc sensitive BHK cells that stably express 
the MRE-βGeo (a construct involving 5 MRE sequences and a β-galactosidase-
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neomycin phosphotransferase (lacZ-neo) fusion gene) β-galactosidase activity measured 
such that these cells showed increased zinc efflux with transient transfection of Znt1 
(Palmiter and Findley, 1995). Other functions postulated include, recovery of zinc in the 
kidney, from its position on the basolateral membrane of nephron tubules; protection 
against zinc-induced neuronal damage in the brain and maternal to foetus regulation of 
zinc levels in the villous yolk sac membrane (McMahon and Cousins, 1998, Liuzzi et 
al., 2001, Tsuda et al., 1997). Znt1 knock-out mice are embryonic lethal which 
emphasises the importance of Znt1 and, incidentally, zinc in development of the foetus. 
Furthermore, Znt1 has been shown to be expressed in the rat placenta from at least day 
8 of gestation in addition to being found in the villus yolk sac of a day 18 rat placenta 
(Cousins and McMahon, 2000). Interestingly, Znt1 mRNA expression levels are 
increased in both the small intestine and kidney of mice fed a supplemented zinc diet 
(180 mg Zn/kg). This confers resistance to zinc by increasing efflux of zinc out of the 
cell (Liuzzi et al., 2001). There are two MRE (Metal Responsive Element) sequences 
found in the promoter of Znt1 and in vitro DNA-binding assays demonstrated that Metal 
Transcription Factor-1 (MTF1) is able to bind to these to regulate Znt1 expression (see 
section 1.6) (Langmade et al., 2000). Furthermore, Langmade et al., (2000) showed that 
MTF1 is essential for basal levels of Znt1 expression in mouse embryo fibroblasts using 
homozygous deletions of the MTF1 gene.  
ZnT2 has a differential expression pattern with mRNA expression detected in the small 
intestine, kidney, placenta, pancreas, testis, seminal vesicles and the mammary gland 
(Kelleher and Lonnerdal, 2002, Liuzzi et al., 2003, Liuzzi et al., 2001, Clifford and 
MacDonald, 2000, Palmiter et al., 1996b). This transporter is involved in the 
accumulation of zinc into intracellular vesicles, revealed by transient transfection of 
Znt2 into zinc resistant BHK cells. In this system, when extracellular zinc was added 
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(100-200 µM) and the cells were stained with Zinquin, the fluorescence of the dye was 
restricted to the cytoplasm and was punctate therefore implying vesicular localisation 
(Palmiter et al., 1996a). More specifically, it has been hypothesised that these vesicles 
are late endosomes. Due to its vesicular localisation it has been suggested that ZnT2 
acts through an exocytotic pathway, allowing zinc to be incorporated into secreted 
proteins to control endogenous losses. Znt2 is up-regulated at the mRNA level in 
response to increased dietary zinc concentrations in rats. For example, dietary zinc (180 
mg Zn/kg) up-regulates Znt2 in the small intestine and kidney of rats (Liuzzi et al., 
2001) and semi-quantitative RT-PCR techniques were used to show high levels of zinc 
in the lateral lobes of rat prostate tissue correlate with the high levels of Znt2 expression 
(Iguchi et al., 2002).  Late stage gestation and early lactation induces an increase in Znt2 
mRNA and protein expression in both maternal and foetal tissues (Liuzzi et al., 2003). 
The role of ZnT2 in mammary gland zinc homeostasis is a little more ambiguous 
however. A mis-sense mutation in the ZnT2 gene substitutes a conserved histidine at 
amino acid 54 with arginine (H54R) in the ZnT2 transporter in affected mothers. This 
mutation has been linked to a reduction in zinc secretion from mammary epithelial cells 
resulting in transient zinc deficiency in breast-fed infants (Chowanadisai et al., 2006). 
Under normal zinc conditions the observations are that whilst basolateral membrane 
abundance remains constant, apical membrane Znt2 protein expression decreases 
throughout lactation in rat (Kelleher and Lonnerdal, 2003). It is thought that this is due 
to the compartmentalisation of the transporter in order to sequester the physiologically 
high concentrations of zinc. 
The original characterisation of mouse Znt3 demonstrated a restricted mRNA 
expression profile in the brain and testis by Northern blot and RT-PCR (Palmiter et al., 
1996b). In this study Palmiter et al., (1996b) also used an anti-Znt3 antibody to show 
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that staining of Znt3 coronal sections of mouse brain is similar to the Timm’s staining 
(identifying histochemically reactive zinc) of glutamatergic neurones therefore leading 
to the hypothesis that Znt3 functions to package zinc into vesicles in these cells. More 
recent studies have identified a more widespread expression of ZnT3 however. 
Immunohistochemical techniques have detected Znt3 protein in the mouse retina 
(Redenti and Chappell, 2004) and both mRNA and protein, detected by RT-qPCR and 
immunohistochemical techniques respectively, have identified Znt3 present in mouse 
pancreatic islets and beta cells (Smidt et al., 2009). In the rat mRNA has been detected 
by microarray in the duodenal epithelium (Wongdee et al., 2009) and by PCR 
techniques in humans ZnT3 mRNA has been found in the airway epithelium (Ackland 
et al., 2007), adipose epithelium (Smidt et al., 2007) and in the androgen-sensitive 
human prostate adenocarcinoma cell line (LNCaP) (Iguchi et al., 2004). The expression 
in the mouse pancreas has led to speculation of an involvement of ZnT3 in diabetes 
aetiology. Indeed, Smidt et al., (2009) have shown that under conditions of severe beta-
cell stress, Znt3 knock-out mice have impaired glucose metabolism with respect to 
control mice. Furthermore, there was an increased level of apoptosis in rat INS-1E cells, 
a pancreatic β-cell model, coupled with a reduction in insulin secretion with knock-
down of Znt3 using siRNA (Petersen et al., 2011). As mentioned above, in areas of the 
mouse brain Znt3 sequesters zinc into synaptic vesicles of glutamatergic neurones 
(Palmiter et al., 1996b). Levels of Znt3 mRNA are detectable only a matter of days 
before birth but are at adult levels by 3 weeks post-partum. Interestingly, the amount of 
zinc in the synaptic vesicles correlates with the protein levels of Znt3 and studies have 
shown that homozygous disruption of mouse Znt3 gives a marked reduction in the 
amount of detectable zinc in regions of the brain known to express Znt3 and upon 
further investigation there was no trace of zinc in synaptic vesicles (Cole et al., 1999). It 
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is intriguing however, that the Znt3 knockout mouse appeared normal. This normal 
phenotype implies that the lack of zinc in synaptic vesicles can be compensated for by 
another mechanism or indeed is not important in normal physiological conditions. 
Transcriptional regulation of ZnT3 by zinc has not been investigated. 
Znt4 was first discovered in the mouse model of mutant zinc metabolism; lethal milk 
(lm). In this model pups that suckle on lm/lm dams exhibit zinc deficiency symptoms 
and die before weaning. Further investigation showed that the milk was deficient in zinc 
and this inborn mutation was mapped to chromosome 2 and, more specifically, the Znt4 
gene where there is non-sense mutation (C to T substitution) at 934 bp resulting in 
premature termination of translation at codon 297 (Huang and Gitschier, 1997). The 
major side-effect of the mutation is the production of zinc deficient milk. The milk 
being deficient of zinc and not void indicates that other transporters, such as ZnT2, are 
acting to try and maintain zinc levels. Huang et al., (1997) also carried out Northern blot 
analysis to establish that Znt4 is expressed in liver, lung, kidney, spleen, heart and brain 
as well as in both normal mouse mammary gland and mammary gland tumour. Northern 
blot analysis of a broader range of rodent tissues has shown Znt4 to be abundantly 
expressed in rat brain, testes, lung, kidney and intestinal epithelial cells. A ZnT4 
construct with a myc-epitope tag was transiently transfected into Caco-2 cells in order to 
give localisation data. The pattern of staining is consistent with intracellular vesicles, 
such as endosomes, and the Golgi apparatus with translocation from the Golgi apparatus 
to the intracellular vesicles (Murgia et al., 1999). It is thought that the main function of 
ZnT4 is to facilitate zinc entry into secretory vesicles of particular glands therefore 
allowing for zinc secretion of these exocrine glands. In mouse fed zinc deficient (<1 mg 
Zn/kg) or zinc supplemented (180 mg Zn/kg) diets there was no difference in Znt4 
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mRNA expression levels in the small intestine or kidney as compared with those mice 
on a zinc adequate (30 mg Zn/kg) diet (Liuzzi et al., 2001).  
ZnT5 is unusual because it has two isoforms which have different localisation patterns. 
ZnT5 variant A (ZnT5vA) is localised to the Golgi apparatus (Kambe et al., 2002) 
whereas ZnT5 variant B (ZnT5vB) has been shown to localise to the ER and in human 
intestinal Caco-2 cells localise to the apical enterocyte membrane (Cragg et al., 2002, 
Valentine et al., 2007). The sequences of the isoforms vary at the N- and C-terminal 
regions but the differing subcellular localisations have been attributed to their 
alternative C-terminal sequences (Thornton et al., 2011). In addition, it has been 
established that zinc does not induce translocation of either of the variants (Jackson et 
al., 2007). Another difference between the variants is in their functional activity. Over-
expression of a ZnT5vA construct in HeLa cells enabled 
65
Zn uptake into Golgi-
enriched vesicles from HeLa cells thereby decreasing cytosolic zinc implying that 
ZnT5vA acts as an effluxer (Kambe et al., 2002). In addition, ZnT5vA has been 
hypothesised to also act as a heterodimer with ZnT6. Transfection of both constructs 
into model yeast systems that exhibit a zinc-suppressible large cell phenotype (msc2, 
zrg17, msc2 and zrg17 mutants) suppressed the growth defect of the mutants even 
before the addition of zinc implying that these two transporters form a complex that 
functions to deliver zinc into the secretory pathway (Ellis et al., 2005). Uniquely, by 
using direct measurement of 
65
Zn into Xenopus laevis oocytes expressing the ZnT5vB 
construct and indirectly using a promoter reporter gene assay in transiently transfected 
Caco-2 cells ZnT5vB has been found to transport zinc bi-directionally (Cragg et al., 
2002, Valentine et al., 2007). Both ZnT5vA and ZnT5vB are ubiquitously expressed. 
Most studies into this transporter are indiscriminate using cross-reactive experiments 
and therefore report on ZnT5 as a whole. An attempt to distinguish between the two 
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variants and their expression at the mRNA showed a decrease in ZnT5vA mRNA 
expression in response to 150 µM zinc in Caco-2 cells. This study was unsuccessful in 
making a specific ZnT5vB probe but RT-qPCR analysis of total ZnT5 levels also 
displayed this down-regulation in response to 150 µM zinc. Down-regulation in 
response to zinc of a transporter that has been shown to efflux zinc is opposite to what 
would be expected, whether this is due to the bi-directional actions of ZnT5 is 
unknown. Further investigation of this response used actinomycin D, to block gene 
transcription, showed that increasing zinc concentrations had an effect on stabilising 
ZnT5 mRNA (Jackson et al., 2007). 
Northern blot analysis shows presence of two transcripts of mouse Znt6 (1.7 kb and 2.4 
kb in size) that differ in their 3’-untranslated regions corresponding to alternative 
polyadenylation signals. The expression pattern of both transcripts appears to be 
restricted whereby the Northern blot shows the mRNA is present in the liver, brain, 
kidney and small intestine with the 1.7 kb transcript displaying higher levels of 
expression. Western blot analysis shows Znt6 protein to be present in the mouse brain 
with very low levels in the small intestine and kidney. Interestingly, it is thought that 
Znt6 undergoes post-translational modification in the lung as a band of slightly larger 
size (55 kD opposed to 51 kD) was observed in this tissue (Huang et al., 2002). Znt6 
expression in yeast mutants led Huang et al., (2002) to conclude that Znt6 transports 
zinc out of the cytoplasm into either an intracellular pool or out of the cell as over-
expression in yeast displayed the ability of the transporter to diminish the cytoplasmic 
zinc. Moreover, endogenous Znt6 was detected in normal rat kidney (NRK) cells with 
localisation to the trans-Golgi Network (TGN), interestingly though this localisation 
pattern is altered when the cells are treated with medium containing 200 µM zinc. The 
researchers showed that the antibody signal was distributed toward the periphery of the 
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cells with the addition of extracellular zinc therefore indicating zinc-induced 
translocation of the protein. Alkaline phosphatases (ALPs) have been shown to require 
the action of zinc transporters, such as ZnT5, in the DT40 cell line (a chicken B 
lymphocyte-derived cell line) as they are able to transport zinc into the Golgi apparatus 
and ALPs require this zinc for their activation. Therefore, tissue non-specific ALP 
(TNAP) activity has been proposed as a marker to measure zinc supply to the zinc-
requiring enzymes in the secretory pathway (Suzuki et al., 2005a). Given the 
localisation of ZnT6, further investigation into the action of this transporter were 
explored in relation to the TNAP activity. Investigators found that, in DT40 cells where 
ZnT6 was knocked out (ZnT6
-/-
), TNAP activity was reduced by 20 % implying that 
ZnT6 is important in the secretory pathway. Independently, ZnT5
-/-
 cells were also 
found to reduce TNAP activity by a similar amount to the ZnT6
-/-
 mutant and in a 
double mutant (ZnT5
-
ZnT6
-/-
) this reduction in activity was at a similar level still 
implying that ZnT5 and ZnT6 work in the same pathway. In support of this theory, co-
transfection of ZnT5 and ZnT6 constructs restored TNAP activity whereas transfection 
of ZnT5 or ZnT6 independently failed to change TNAP activity. Moreover, co-
immunoprecipitation studies revealed that ZnT6 forms a hetero-dimer with ZnT5 
adding further weight to this hypothesis (Suzuki et al., 2005b).  
Northern blot analysis for Znt7 showed abundant expression of mRNA in the liver, 
spleen, and small intestine with lower levels in the kidney, lung, and brain of mouse 
tissues. The mRNA was barely detectable in the heart. Post-transcriptional and/or post-
translational modification of Znt7 is postulated due to the results of the Western blot 
analysis using an anti-Znt7 antibody. Firstly, protein was not detected in the mouse 
brain, liver, kidney, and heart despite the mRNA being detected in these tissues by the 
Northern blot. Secondly, whilst the protein was detected in the lung and small intestine 
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the apparent molecular mass on the Western blot of Znt7 was higher than the calculated 
42.5 kD thereby implying post-translational modification (Kirschke and Huang, 2003). 
Using the same anti-Znt7 antibody, Kirchke et al., (2003) also stained endogenous Znt7 
in rat small intestinal epithelial cells (hERIE 380) and human lung fibroblasts (WI-38) 
and saw a localisation pattern consistent with the Golgi apparatus. In addition the same 
pattern of staining was found in the NRK cells when cells were transfected with a Znt7-
myc construct and detected using an anti-myc antibody. Furthermore, these researchers 
also looked at the function of Znt7. In transfected CHO cells the zinc probe, Zinquin, 
was found to accumulate in the Golgi apparatus with the addition of 75 µM of 
extracellular zinc, this implies that Znt7 acts to transport zinc into this subcellular 
compartment. Further elucidation of the role of ZnT7 has been achieved by using the 
ALP system mentioned above. ZnT7 has been shown to be required for ALP activity in 
the DT40 cell model thereby suggesting a role in delivering zinc into the secretory 
pathway, similar to ZnT5 and ZnT6 (Suzuki et al., 2005a). However, ZnT7 does not 
require the actions of another transporter as it acts alone, but the co-immunoprecipation 
experiments show it forms homo-oligomer complexes (Suzuki et al., 2005b). Knock-out 
studies in mice, have given zinc-deficient phenotypes; strikingly with a decreased body-
fat composition thus implying that Znt7 plays a role in this process. Such mice are 
irresponsive to dietary zinc supplementation. In addition, the expression of Znt7 in the 
small intestine has been shown to be important in the absorption of zinc as a radioactive 
zinc feeding study displayed lower serum and tissue-associated zinc that were as a result 
of reduced zinc absorption in the gut (Huang et al., 2007). Given the localisation pattern 
of ZnT7 in the Golgi apparatus it is unlikely that ZnT7 is directly involved in zinc 
efflux into the circulation but the evidence suggested that ZnT7 is enterocytes acts to 
traffic zinc across these cells (Wang and Zhou, 2010). 
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ZnT8 research is particularly interesting in the context of diabetes. The ZnT8 gene locus 
has been found to be associated with an increased risk of type II diabetes. A single 
nucleotide polymorphism (SNP) rs13266634 in the SLC30A8 gene was shown to be 
associated with reduced insulin secretion by genotyping of 921 metabolically 
characterised German subjects (Staiger et al., 2007). Using RT-PCR on human tissue 
RNA samples ZnT8 expression was found to be restricted to only the islets of 
Langerhans in the pancreatic β-cells (Chimienti et al., 2004). Further characterisation by 
Chimienti et al., (2004) revealed that in insulin-secreting INS-1 cells (the rat insulinoma 
pancreatic β-cell model) over-expressing a ZnT8-EGFP construct the transporter gave a 
localisation pattern consistent with that of insulin therefore it was concluded that ZnT8 
is associated with the insulin granule secretory pathway. In addition, with the use of 
Zinquin, over-expression of ZnT8-EGFP in HeLa cells showed an accumulation of zinc 
in the cells when 75 µM of extracellular zinc was added to the system. Its role in the 
pancreas is thought to be two-fold. Firstly, it has been shown to transport zinc from the 
cytoplasm so that it accumulates in vesicles. Secondly, the co-localisation with insulin-
secretory granules implies that ZnT8 provides zinc for the insulin maturation process 
and/ or the storage of insulin in these pancreatic β-cells. A theory strengthened by the 
knowledge that zinc is needed for the storage of insulin as it forms a hexamer with two 
zinc ions bound. Therefore, upon release of insulin, zinc is also released into circulation. 
Indeed, ZnT8 knockdown studies using siRNA not only increased the level of apoptosis 
in these cells but also give an increased intracellular content of insulin coupled with a 
lower insulin secretion in INS-1 cells proving that ZnT8 is imperative to this pathway 
(Petersen et al., 2011).  
Little is known about ZnT9. However Northern blot analysis of four human foetal 
tissues (brain, lung, liver, and kidney) showed mRNA expression in all these tissues. 
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RT-PCR showed presence of mRNA in all tested tissues and cells (16 human adult 
tissues and 14 cancer cell lines) therefore displaying widespread expression. Western 
blot analysis using an anti-ZnT9 antibody in the foetal cell line (MRC-5) revealed 
localisation to the cytosolic and nuclear fractions but not membrane fractions (Sim and 
Chow, 1999). Furthermore, Sim et al., (1999) showed that in normal embryonic lung 
cells the anti-ZnT9 antibody displayed a localisation pattern that implied association 
with the cytoskeleton however in liver carcinoma cells the staining was to the nuclei of 
smaller or dividing cells, but giving staining of the peri-nuclear ring in the cytoplasm of 
larger, more mature cells. The importance of this differing localisation remains 
unknown.   
Prior to 2012 knowledge on ZnT10 was limited to a single article. Seve at al., (2004) 
reported bioinformatic data which found the human SLC30A10 gene is localised to 
human chromosome 1 at the position q41. The gene spans 15 kb with an arrangement of 
4 exons, and was predicted to code for a 52.7 kDa protein. When compared to other 
family members ZnT10 is predicted to contain the conserved 6 TMDs and a basic 
region between TMD IV and V. Using ClustalW alignment of amino acid sequences 
ZnT10 was found to be most homologous with ZnT1 with a score of 48.3. An in silico 
method was used to assess the tissue expression pattern. This was performed by using 
an expressed sequence tag (EST) data mining strategy whereby the programme 
BLASTN was used to run the predicted ZnT10 transcript (ORF, 5' and 3' UTRs) against 
the human EST database. This gave a predicted ZnT10 expression profile. Interestingly, 
using this method ZnT10 was predicted to be restricted to foetal tissue and more 
specifically foetal liver and brain (Seve et al., 2004).  
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1.5  Zinc absorption 
Zinc is absorbed across the intestinal enterocyte along the entire gastrointestinal tract. 
Although primarily absorbed in the proximal small intestine (with a proximal to distal 
absorption gradient), the colon has the ability to absorb zinc throughout and evidence of 
up-regulation of absorption from sites within the colon has been observed when small 
intestine absorption is impaired (Seal and Mathers, 1989, Hara et al., 2000). It is known 
that enterocytes contain zinc transporter proteins expressed in their membranes and 
more specifically ZIP4 has been implicated in the uptake of zinc from the 
gastrointestinal lumen across the apical membrane. Furthermore, immunohistochemical 
localisation studies in mice revealed that in cases of zinc restriction Zip4, found on the 
apical membrane of enterocytes is up-regulated along the length of the gastrointestinal 
tract. However, when the body is zinc replete Zip4 is internalised and degraded 
(Dufner-Beattie et al., 2003b). Conversely, Zip5 has been found to be localised to the 
basolateral membrane of enterocytes and therefore is internalised during zinc 
deficiency. Thus it is hypothesised that, in zinc replete conditions, ZIP5 functions to 
influx zinc from the blood stream into enterocytes, ultimately for excretion into the 
intestinal lumen (Dufner-Beattie et al., 2004). Once in the cell one hypothesis for the 
intracellular trafficking of zinc implicates a member of the CDF family, ZnT7, in the 
movement of zinc across the enterocyte. In fact Znt7 null mice exhibited poor appetite 
and reduced body weight gain symptoms that were not alleviated by zinc 
supplementation. In addition these mice were unable to accumulate 
65
Zn in the small 
intestine, in particular the Golgi apparatus of enterocytes, a process required for 
successful dietary zinc absorption (Huang et al., 2007). It is possible that ZnT5vA 
carries out an overlapping role in the enterocytes as it too is localised to the Golgi 
apparatus in the small intestine (Kambe et al., 2002, Yu et al., 2007). It has been shown 
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that ZnT5vB localises to the apical membrane of enterocytes, the alteration in 
localisation is attributed to the C-terminal domain (Thornton et al., 2011). This variant 
exhibiting bi-directional transport across the plasma membrane and is involved in zinc 
uptake in human intestinal Caco-2 cells (Valentine et al., 2007). It is evident that 
metallothionein (MT), an intracellular metal buffer, and ZnT1, a zinc effluxer, regulate 
levels of zinc across the basolateral membrane, out of enterocytes and into the systemic 
circulation (McMahon and Cousins, 1998, Bell and Vallee, 2009). It is not these 
transporters that are exclusively expressed within enterocytes and other members of 
these families play a role in zinc absorption (see section 1.4) (reviewed by Wang and 
Zhou, 2010). Free zinc is toxic therefore zinc is circulated chelated by binding proteins 
such as albumin, α-macroglobulin and transferrin. Zinc is distributed throughout the 
body to all organs. 
Zinc absorption is different to that of other nutrients such as iron because it is the 
dietary zinc intake that reflects the amount of zinc absorbed not the zinc status of the 
individual (King, 2011). The efficiency of the absorption of zinc can also be influenced 
by the presence of phytate as discussed above (section 1.2.1). 
1.6 Molecular mechanisms of gene regulation by zinc 
There are numerous molecular mechanisms of transcriptional control that are sensitive 
to zinc in a wide range of organisms. There are four fundamental mechanisms of zinc-
sensitive transcriptional regulation. Firstly, in conditions of low zinc availability a 
positive regulatory factor binds in order to stimulate transcription. This is evident in the 
yeast Saccharomyces cerevisiase where the DNA motif responsible for this activation of 
the equivalent transporters (ZRT1, 2 and 3) has been identified. It is hypothesised that 
in low zinc conditions a transcriptional regulator; Zap1, is induced and binds to the 11 
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bp Zinc Response Element (ZRE) in the promoter regions of the transporters 
subsequently increasing their transcription so that they can increase cytosolic zinc 
concentrations (Lyons et al., 2000). Secondly, again under conditions of low zinc 
availability, a negative regulatory factor can bind. In bacteria the ArsR-SmtB family 
transcriptional de-repressors act to repress the expression of certain operons at stress-
inducing concentrations of divalent metal ions including zinc. Direct binding of such 
metal ions results in de-repression (reviewed by Busenlehner et al., 2003, Waldron and 
Robinson, 2009). Third is under conditions of high zinc availability a negative 
regulatory factor can bind. For example, the transcriptional repressor Zur binds two zinc 
ions in order to bind to DNA and repress the transcription of a zinc importer in the 
znuABC gene cluster (Patzer and Hantke, 2000) therefore reducing zinc intake. The final 
mode of transcriptional regulation is in conditions of high-zinc availability through 
binding of a positive regulatory factor. This is evident in the case of the transcription 
factor MTF1. MTF1 has 6 zinc fingers and these bind DNA at a specific consensus 
sequence within promoter regions. The DNA motif is a MRE and is characterised by the 
7 bp sequence TGCRCNC (Heuchel et al., 1994). Binding of MTF1 to MREs is known 
to increase expression of genes such as MTI and II and ZnT1 in order to protect cells 
from high zinc concentrations (Langmade et al., 2000, Wimmer et al., 2005). MTF1 can 
also act in a repressive role.  Zip10 expression is increased in the conditional MTF1 
knockout mouse (Wimmer et al., 2005). Further research has shown that Zip10 includes 
MREs downstream of the transcriptional start site and binding of MTF1 to these MREs 
mediates transcriptional repression (Lichten et al., 2011). In addition, the zebrafish 
Zip10 has two distinct transcriptional start sites and experimentation reveals that Zip10 
is regulated by alternative promoters that are oppositely-regulated by zinc. Both 
promoters contain MRE clusters and thus, this shows that MREs can function as both 
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repressor and activation elements (Zheng et al., 2008).  It is possible that MTF1 requires 
accessory proteins in order to form co-activator complexes in order to fulfil these 
contrasting roles. Indeed, activation of the MTI promoter requires transcription factor 
Sp1 and the histone acetyltransferase p300/CPB in complex with MTF1 and this 
activation was reduced by siRNA knockdown of p300/CBP.  However the accessory 
proteins evidently differ between complexes as p300/CBP knockdown did not affect 
MTF1-mediated activation of the mouse Znt1 gene (Li et al., 2008). Interestingly, there 
must be mechanisms in addition to MTF1 that are able to influence zinc induced 
repression as mutation of the consensus MRE sequence in ZnT5 was unable to abolish 
the zinc-induced repression ordinarily observed in transfected Caco-2 cells (Jackson et 
al., 2007).    
Another particularly important mammalian transcription factor that is zinc dependent is 
Nuclear Factor-κB (NF-κB) (Bao et al., 2007). There are many processes where NF-κB 
modulates transcriptional activity of genes such as immunoreceptors and cytokines. In 
fact reactive oxygen species (ROS) can induce a redox-dependent signal transduction 
pathway that leads to NF-κB activation and therefore stimulation of the inflammatory 
immune response. This has been implicated in disease as inflammation causes extensive 
damage in the brain of Alzheimer’s disease (AD) patients (Zimmerman et al., 2004). 
Under normal conditions, NF-κB is maintained in its inactive state in the cytoplasm by 
association with the inhibitory protein, IκB. Zinc has been found to induce 
phosphorylation of IκB thereby stimulating its degradation and activating NF-κB, 
increasing the translocation of NF-κB from the cytosol to the nucleus in HUT-78 cells 
(a T helper 0 cell line) (Bao et al., 2007, Prasad et al., 2001). Conversely, in zinc 
deficiency states NF-κB activation is reduced meaning decreased stimulation of genes 
involved in the inflammatory immune response such as interleukin-2 and its receptor 
Chapter 1: Introduction 
39 
 
(interleukin-2Rα) in the HUT-78 cell line thus providing evidence for a role of zinc in 
the immune system and implications for human health (Prasad, 2008). 
Zinc fingers are common structures in transcription factors that enable binding of the 
proteins to DNA sequences. The transcription factor Sp1 contains three such domains 
and is able to both repress and activate transcription (Li and Davie, 2010). The 
interaction between MTF-1 and Sp1 is intriguing. In cells where MTF1 is present it has 
been found that a complex containing Sp1 and p300 forms when extracellular zinc 
increased (Li et al., 2008). Furthermore, Sp1 may be implicated in dysregulation of 
genes in AD. For example, β-secretase 1 (BACE1) contains a functional Sp1 response 
element and increased expression of Sp1 causes an increase in BACE1 transcription 
ultimately resulting in an increase in the formation of neurotoxic amyloid-β (Aβ) 
peptides (Christensen et al., 2004).  
Zinc transporters are essential for zinc regulation and they are imperative for both efflux 
and influx of zinc across membranes in order to maintain zinc homeostasis. It follows 
therefore that these genes have been shown to be regulated by mechanisms that alter in 
response to the zinc state of the cell. More specifically, studies into the regulation of 
mZip4 identified the transcription factor Krüppel-like factor 4 (KLF4) in the activation 
of mZip4. In the murine intestinal epithelial cell (IEC) line MODE-K both KLF4 and 
mZip4 were up-regulated in zinc deficient conditions but siRNA knockdown studies of 
KLF4 reduced the activation of mZip4 (Liuzzi et al., 2009). Moreover, Liuzzi et al., 
(2009) used electrophoretic mobility shift assays (EMSAs) with the nuclear extracts of 
this MODE-K cells to show that KLF4 binds to the mZip4 promoter, a phenomenon that 
is increased when zinc is limited. Further investigation with reporter constructs 
involving the wild-type and mutated mZip4 promoter led the authors to conclude that 
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regulation of mZip4 is through a KLF4 response element. However, as highlighted in 
section 1.4.1, there are discrepancies in the literature with regards transcriptional 
regulation of mZip4 with Weaver et al., (2007) attributing regulation to post-
transcriptional mechanisms. 
In the ZnT family ZnT1 is known to be regulated by MTF1, mentioned above 
(Langmade et al., 2000). In addition, the regulation of ZnT5 highlights the complexities 
of zinc related transcriptional regulation given that transcription of both variants is 
driven by a single promoter. Five core MREs identified in the putative promoter region 
of the ZnT5 transcript led to speculation that the mode of regulation was via the binding 
of MTF1. However, mutation of the consensus MRE sequence in ZnT5 was unable to 
abolish the zinc-induced repression ordinarily observed in transfected Caco-2 cells 
(Jackson et al., 2007). Furthermore, Jackson et al., (2007) identified a 204 bp region 
comprising -154 bp prior to transcriptional start codon and +50 bp into the ORF of 
ZnT5 that is required for the zinc-induced transcriptional repression of ZnT5. More 
recently, EMSAs have revealed that there is a protein factor that binds to the ZnT5 
promoter in a zinc-dependent manner. Through this Coneyworth et al., (2012) identified 
the binding site in the ZnT5 promoter responsible for zinc-induced transcriptional 
repression, namely the ZTRE (for Zinc Transcriptional Regulatory Element) 
(Coneyworth et al., 2012).  Analysis of this sequence, using a promoter reporter assay in 
Caco-2 cells, confirmed that this region is essential for repression of transcription in 
response to zinc. Further research is required to establish whether such sequences are 
more widespread in biology enabling elucidation of further roles for zinc.  
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1.7 Zinc in the brain 
In the context of my research, the brain is the organ that is particularly relevant. It is 
known that zinc is required in the brain and, as in every organ, it is under strict 
regulation. The brain is no exception in terms of zinc moving through membrane 
channels of cells enabling it to modulate the function of many proteins. Importantly, 
neurological zinc is found in presynaptic vesicles of certain glutamatergic neurones with 
stores of up to 300 µM zinc in nerve terminals and, along with glutamate, zinc is 
released during neurotransmission (Frederickson, 1989, Frederickson et al., 1983). The 
concentration of this release of ‘free’ zinc into the extracellular space is the topic of 
much debate. However, electrical stimulation has led to estimates of between 10 µM 
and 100 µM (Li et al., 2001) with observations of up to 100 nM of ‘free’ zinc under 
conditions when ischaemia and reperfusion were initiated by excitotoxic stimulation 
(Frederickson et al., 2006). However, there are developmental differences, zinc release 
from the immature hippocampus is much more modest than that from the adult due to 
the neurons responsible for such release being developed postnatally (Kay, 2003). The 
cell bodies of these so called ‘gluzinergic’ neurons are predominantly in the cerebral 
cortex or the limbic structures. The limbic system is often referred to as the ‘emotional 
brain’ and includes structures such as the thalamus, hypothalamus, amygdala, and 
hippocampus. The cerebral cortex consists of four lobes; temporal, occipital, parietal 
and frontal which can be attributed to the following functions respectively; language 
and speech, vision, sensory areas (e.g. pressure, touch and pain) and complex brain 
processes such as personality (Kandel et al., 2000).  
The gluzinergic neurones are essential in order to control many physiological and 
pathophysiological brain functions. However the role of zinc in brain function at a 
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cognitive level remains ambiguous despite the importance of the micronutrient for 
learning and memory being repeatedly reported (reviewed by Sindreu and Storm, 2011). 
Postsynaptically, gated channels such as the NMDA (N-methyl-D-aspartate) channels, 
voltage gated calcium channels and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid/kainite) channels seem to be sensitive to extracellular zinc (Paoletti et al., 
2009). Such channels are opened by both glutamate and depolarization of the neuronal 
membrane caused by neuronal activity therefore allowing maximal translocation of zinc 
from the presynaptic neuron into the postsynaptic neuron with intense neuronal activity. 
Translocation means that zinc is able to exhibit downstream effects on synaptic 
transmission thereby triggering synaptic potentiation and initiate signal cascades in the 
postsynaptic neuron, thus modulating processes such as transcription in these cells 
(Sensi et al., 2009).  
Zinc interacts with NMDA and GABAA (γ-aminobutyric acid type A) receptors thereby 
affecting their activity. The actions of these receptors are opposing; NMDA is an 
excitatory receptor and GABAA is an inhibitory receptor. It is through interaction with 
these receptors that zinc is able to influence both excitatory and inhibitory synaptic 
transmission although it is thought, under normal conditions, that the dominant effect of 
zinc is to reduce excitability (Frederickson et al., 2005). The main hypothesis for the 
mode of action of zinc for learning and memory is through the interaction with the 
GABAA receptors on the synapses. It is thought that zinc is required by the inhibitory 
GABAA receptors in order to mediate long-term potentiation (LTP), a process integral 
to memory formation (Kodirov et al., 2006). LTP is inhibited by administration of 
extracellular zinc chelators implying a role for zinc and confirmation of the role of said 
GABAA
 
receptors has been established by the use of a receptor antagonist that 
subsequently restored LTP (Smart et al., 1994).  
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Whilst the processes described above are important physiologically it is also evident 
that zinc can have a detrimental effect on neurons. For example, excitotoxicity is the 
phenomenon whereby excessive glutamate release causes over-activation of glutamate 
receptors. As glutamate is released so too is zinc, the increased translocation of which 
causes zinc-induced cell injury. Moreover, zinc can promote oxidative stress by 
activating reactive oxygen species (ROS)-generating enzymes such as nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase and neuronal nitric oxide (NO) 
synthase (nNOS) (Sensi et al., 2009). Ischaemic neuronal death follows the same 
process; studies investigating such pathways have highlighted the prominence of zinc. 
Ischaemic injury was initially attributed to Ca
2+
 however upon further investigation the 
chelators used in the original studies were found to have a higher affinity for zinc 
(Smith, 2009). During excitotoxic and ischaemic injury there are many mechanisms at 
play. For example, under conditions of oxidative stress and/ or acidosis MTs release 
their intracellular store of zinc thereby activating neuronal apoptosis by the p38 MAPK 
pathway (Pal et al., 2003). Furthermore, under compromised conditions the 
mitochondria play an important role in reducing cytosolic zinc concentrations by 
activation of mitochondrial membrane cation-permeable channels. However, the 
proceeding zinc accumulation within the mitochondria can lead to a loss of 
mitochondrial membrane potential, increased production of ROS and ultimately cell 
death via apoptosis (reviewed by Dineley et al., 2003). Cell death by zinc is not limited 
to apoptosis, zinc can also promote necrosis by inhibiting glycolysis and therefore 
depleting ATP production. In addition, autophagy can be induced by zinc whereby 
increased zinc concentrations in the lysosomes ultimately result in permeabilisation of 
the lysosomal membrane releasing cathepsin D (reviewed by Hoyer-Hansen and 
Jaattela, 2007, Sensi et al., 2009). 
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1.7.1 Role of ZIPs in brain zinc homeostasis 
Nutrients that enter the brain must cross the blood-brain barrier. It is thought that ZIPs 
are expressed in the cells forming the blood-brain barrier and therefore function in the 
uptake of zinc into the brain. However, research is limited into the role of ZIPs in the 
brain. As expected though, in the Zip1 and Zip3 double knockout mouse there was a 50 
% reduction in post-synaptic zinc uptake (Qian et al., 2011), thus indicating that ZIPs in 
the brain, as in other organs, are involved in cellular zinc uptake enabling an increase in 
cytosolic zinc where necessary. Furthermore, in the rat brain Zip1 was found in all brain 
regions tested. Conversely, Zip4 was only found in the choroid plexus and brain 
capillaries (Belloni-Olivi et al., 2009). In addition, Zip1, Zip7, Zip8, Zip9, Zip10 and 
Zip13 were found to be expressed in the mouse brain under conditions of zinc 
deficiency with a 3-fold increase in Zip10 mRNA under dietary restriction (Lichten et 
al., 2011). This is particularly interesting given the blood-brain barrier system means 
that zinc homeostasis in the brain is very tightly regulated. Therefore brain zinc levels 
are not easily disrupted by dietary zinc deficiency. However, zinc deficiency can reduce 
the zinc concentration in the hippocampus (Takeda and Tamano, 2009). Further 
implication of a ZIP family member in brain homeostasis is evident for ZIP12 where 
missense mutations in the ORF of ZIP12 occur about twice as regularly in post-mortem 
brain tissue DNA samples from a small number of patients with schizophrenia as 
compared to controls (62 unrelated Caucasian schizophrenics versus 35 unrelated and 
unaffected Caucasians) (Bly, 2006). The work by Bly et al., (2006) furthers an earlier 
study identifying changes in zinc concentration s in the schizophrenic brain (Kimura 
and Kumura, 1965) and thereby indicates a role for ZIP12 in brain zinc homeostasis.  
To elucidate the mechanisms of the ZIPs in the brain fully, requires further 
investigation. 
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1.7.2 Role of ZnTs in brain zinc homeostasis 
As with other organs the homeostasis of zinc in the neurons has a number of pathways 
of regulation and zinc homeostasis in the neurons cannot be attributed to one 
transporter. In line with other tissues the ZnT family predominantly act to decrease 
cytosolic zinc in their various locations throughout the cell body e.g. ZnT1 on the 
surface membrane. Studies have revealed a neuroprotective role for Znt1 mediating an 
increase in zinc efflux against toxic zinc surges in seizures and/ or ischaemia (Tsuda et 
al., 1997). It is thought that it is nitric oxide that triggers release of zinc in these cases 
and the zinc, in turn, causes an up-regulation of Znt1 expression although the 
mechanism has not been fully elucidated (Aguilar-Alonso et al., 2008). In addition, 
Znt2 and Znt4 were also found to be up-regulated in the rat brain presumably to 
decrease cytosolic zinc concentrations initiated by nitric oxide production. ZnT5, ZnT6 
and ZnT7 have also been found to be expressed in several regions of the brain with 
increased mRNA levels of the transporters tested (ZnT1, ZnT4 and ZnT6) in human AD 
brains (Beyer et al., 2012) and in mouse models of AD (Znt1, Znt4, Znt6 and Znt7) 
(Zhang et al., 2008). 
However, the main body of research in ZnTs in the brain is into ZnT3. In the 
presynaptic neuron the sequestering of zinc into presynaptic vesicles is under the 
control of ZnT3 (section 1.4.2). The process begins in the Golgi apparatus where ZnT3 
is inserted into the membranes of the vesicles and subsequently these vesicles are 
transported down the axon to the presynaptic terminal. It is evident that in this location 
the vesicles contain both zinc and glutamate ready for release via exocytosis when the 
neuron is stimulated (Frederickson et al., 2005). Znt3 knockout mice were used to 
demonstrate that Znt3 is required for zinc transport into these synaptic vesicles. With 
the disruption of the Znt3 gene histochemically reactive zinc was undetectable in these 
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mouse brains (Cole et al., 1999). There is much still to be learnt about the ZnT family 
and their roles in homeostasis of zinc in the brain. 
1.7.3 Role of MTs and the mitochondria in brain zinc homeostasis 
Also in line with whole body zinc homeostasis, another important aspect of brain zinc 
homeostasis is MT. MTI, MTII and MTIII isoforms are all found in the brain.  
Consistent with the other MT’s (Section 0), MTIII can sequester zinc by forming a 
complex coordinated by its cysteine residues. In addition, these cysteine residues can be 
oxidised resulting in the release of zinc ions and so MT act as both a zinc sink and a 
zinc source (reviewed by Palmiter, 1998). This is evident in MTIII knockout mice 
where in certain areas of the hippocampus and the thalamus cell injury is reduced. This 
could imply that MTIII would, under normal physiological conditions, release zinc and 
contribute to this insult (Lee et al., 2003). Conversely, in the CA3 area of the 
hippocampus cell death increases suggesting that MTIII normally chelates zinc in order 
to prevent such toxicity (Ueno et al., 2002).  
A less well characterised component of zinc homeostasis in neurons is in the 
mitochondria. It is known that zinc is sequestered into the mitochondria through both 
the Ca
2+
 uniporter (Saris and Niva, 1994) and a Ca
2+ 
uniporter-independent mechanism 
(Sensi et al., 1999). It has been hypothesised that this elevates the oxidative stress and 
buffering burden of the neurons however the mechanism of this under normal 
conditions has not been elucidated (Sensi et al., 2009). In summary, the homeostasis of 
zinc ions within the neurons is reliant upon the coordination and balance of the three 
systems; coordination of uptake and efflux by ZIPs and ZnTs, MT buffering capacity 
and sequestering of zinc by the mitochondria. The dual personality of this micronutrient 
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and its repeated implication in neurodegenerative diseases only emphasises the 
importance of maintaining the regulation of its actions in the brain. 
1.8 Ageing, zinc and the brain 
The World’s population is ageing at a rapid rate, the UK is no exception (Figure 1.3), 
and so the need to understand the ageing process is becoming increasingly important.  
There are many economic implications for this shifting demographic, with the impact 
on public services and the families involved in the care of individuals being great 
(Dening and Barapatre, 2004). It is well established that an investment in health 
throughout the life course improves prospects for healthy ageing; however there are still 
major limitations to our knowledge of the process of ageing. One major area of concern 
in the elderly is the dramatic decrease in nutritional status due to both physiological and 
pathological changes that induce a loss of taste, smell and appetite and increase satiating 
effects to give end states including age related anorexia (Volkert et al., 2010). Adequate 
nutrition is a factor that affects health at all stages throughout life and in this age group, 
undernutrition reduces the ability of the individual to remain healthy in older years. 
Whilst it is recognised that these changes occur, research at the molecular level to 
determine the underlying causes are incomplete and in particular research into the role 
of zinc is limited.  It is evident that zinc status decreases with age with various theories 
as to why (Mocchegiani et al., 2006b, Mocchegiani et al., 2006a). It could be related to 
inadequate diet (such as consumption of less zinc-rich red meat) (Wong and Ho, 
2012)or a reduced ability of the body to maintain homeostasis of this micronutrient 
(Mocchegiani et al., 2006a). It is also evident that taste acuity declines with age and zinc 
status has been linked with both loss of appetite and ability to taste, both of which rely 
heavily on zinc status (Stewart-Knox et al., 2005, Suzuki et al., 2011). A link with a 
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reduced appetite has been attributed to a relationship between the hormone leptin and 
zinc (Ott and Shay, 2001). In the case of taste acuity it has been shown that the hormone 
gustin is affected by the amount of dietary zinc present (Shatzman and Henkin, 1981). It 
is important to note if appetite is decreased intake of zinc rich foods will be reduced 
therefore exacerbating the other symptoms of zinc deficiency. The cellular mechanisms 
for the influence of zinc on both leptin and gustin are unknown. In addition there are 
tissue specific changes in zinc metabolism. For example, in age-related macular 
degeneration there is an accumulation of zinc in the sub-retinal pigment epithelial 
deposits of eyes implying a dyshomeostasis in these patients (Lengyel et al., 2007). 
However, zinc supplementation can influence immune status of elderly individuals 
(Mocchegiani et al., 2012b) thus displaying the varying roles of the cation. 
Zinc is also important for immune function with zinc deficiency causing defects in both 
innate and adaptive immune responses (reviewed by Prasad, 2008). Furthermore, 
alterations in zinc transporters have been observed with lipopolysaccharide (LPS) 
stimulation ultimately decreasing intracellular zinc concentrations (Kitamura et al., 
2006). Chronic inflammation is a well-documented feature of ageing (Chung et al., 
2006). The pathway towards this disease state is thought to be induced by the cytokine 
interleukin-6. This is known to up-regulate ZIP14 in the liver thereby increasing zinc 
uptake in these cells (Liuzzi et al., 2005). The consequence of this is that zinc is 
redistributed into the liver where it is sequestered and bound to MT (Andrews, 2000). 
As a result plasma zinc concentration decreases significantly, a phenomenon that has 
been repeatedly observed with older age (Fairweather-Tait et al., 2008). 
Physiological ageing of the brain is not fully understood. However it is widely 
recognised that brain ageing can be characterised by a significant reduction in brain 
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weight by approximately 10 % at 80 years of age. These reductions are attributed to 
atrophy of the neurons and their connections (Bertoni-Freddari et al., 2006). Synapses 
are undergoing constant remodelling in order to change in response to events 
throughout an individual’s lifespan. The parameters that alter are the synaptic density, 
the average size of the junctional zones and the overall contact area of the synapses. Old 
age induces a change such that there is an inverse correlation between synaptic density 
and the average size of the junctional zones. In other words, in physiological ageing 
(compared with adulthood) there is a decrease in the synaptic density that is paired to an 
increase in average size of junctional zones. In addition there is a significant reduction 
in the overall contact area of the synapses in old patients (reviewed by Bertoni-Freddari 
et al., 2008).  Whilst the increase in the average size of junctional zones presumably 
indicates a compensatory mechanism for the reduction in synaptic density this, coupled 
with the reduction in overall contact area, explains the progressive impairment in cell-
to-cell communication in the elderly. Cognitively this presents as a decline of brain 
functions such as impairment in learning and memory functions.  
Changes to mitochondria also occur in the aged brain. Synaptic mitochondria have a 
greater burden of oxidative stress and buffering than those at other positions in the 
neurons (see section 1.7.3). With age, mitochondria decrease in number, but so to 
compensate, there is an increase in mitochondrial size meaning that ultimately there is 
no change in mitochondrial volume density (Bertoni-Freddari et al., 1993). Despite this, 
there is a significant decrease in the cytochrome oxidase (COX) activity on the inner 
mitochondrial membrane in the older cohort (Bertoni-Freddari et al., 2003). COX is a 
key component of the mitochondrial electron transport chain and therefore its activity is 
thought to be a reliable marker of neuronal metabolism and, indeed, mitochondrial 
metabolic competence (MMC) (Wong-Riley, 1989). This MMC decline is hypothesised 
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to be a major contributor to the development of the synaptic pathology described above. 
Furthermore, if mitochondria are compromised and are unable to sequester zinc released 
during neurotransmission, then the high intracellular zinc concentrations will persist 
longer than ordinarily needed for its physiological function. The resultant downstream 
effect of this excess zinc is that it is toxic for the neurons (Bertoni-Freddari et al., 2008). 
It is clear that altered zinc homeostasis is implicated in the physiological effects of 
ageing. An important mediator of zinc homeostasis is the ZnT zinc transporters, 
however there is a lack of definitive evidence on whether there are significant 
alterations in transporter expression and function in the aged population (Fairweather-
Tait et al., 2008). 
1.9 Alzheimer’s disease 
Alzheimer’s disease (AD) is the world’s most common form of dementia affecting 
approximately 24 million people worldwide and with the increase in the ageing 
population this incidence is predicted to grow (Mayeux and Stern, 2012). AD is a 
neurodegenerative disease that manifests as progressive global cognitive decline, most 
noticeably there is a deficit in memory functions. Remarkably defects in episodic 
memory (memory of autobiographical events) have been found up to seven years before 
clinical diagnosis (Grober et al., 2008). At a morphological level there is a distinct 
change in neuronal volume, and indeed neuronal survival, in many types of dementia 
(Gemmell et al., 2012). Compared with the elderly population (described above, section 
1.8) AD patients have the same average size of junctional zones but with further 
decreases in synaptic density and overall contact area (Bertoni-Freddari et al., 2008). 
Moreover, the atrophy seen in AD correlates significantly with memory impairment. 
Major contributors to this atrophy are the pathological hallmarks of the disease; senile 
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plaques (SP) composed of aggregated amyloid-β (Aβ) peptide and neurofibrillary 
tangles (NFTs) of the cytoskeletal protein tau (Figure 1.4).  
Although many cognitive tests such as the Mini-Mental State Examination (MMSE) are 
routinely used to predict the incidence of AD in life, the disease can only be diagnosed 
definitively at post-mortem and it is the SP and NFTs that contribute to this diagnosis 
through Thal and Braak staging respectively (Thal et al., 1997, Braak and Braak, 1991). 
Both markers have the same pattern of progression with stages 1 and 2 referring to 
presence in the entorhinal cortex and hippocampus (areas associated with memory 
formation). Stages 3 and 4 indicate progression to the temporal association cortex and 
amygdala (areas associated with emotions and personality). The most advanced stages, 
5 and 6, include progression to most neocortical areas encompassing the four lobes of 
the cerebral cortex and therefore correlate with the devastating decline in a patient’s 
ability to function in routine day-to-day tasks. 
In order to understand the process of SP production it is important to investigate the 
cleavage of amyloid precursor protein (APP) (Figure 1.5). The function of APP is 
unknown. It is a type I membrane protein found on chromosome 21 (Goldgaber et al., 
1987).Interestingly, the implications of up-regulated APP are seen in Down’s syndrome 
patients where, due to the trisomy of chromosome 21 there is an increase of APP 
present. This cohort have a high prevalence of AD at a very early age (Tokuda et al., 
1997). Additionally, studies into familial AD (accounting for approximately 5-10 % of 
AD) have highlighted the importance of correct processing of APP. For example, in a 
Swedish family a double mutation in the APP gene (APPsw) means that there is a shift 
in processing of APP towards the amyloidogenic pathway (see below) and therefore 
neurotoxicity (Citron et al., 1992). There are 3 major isoforms of APP; APP695, 
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APP751, and APP770 (the number corresponding to the number of amino acid 
residues). These arise from alternative splicing events. All three isoforms are expressed 
in both neuronal and non-neuronal cells however there is a high abundance of APP695 
in neurones compared with APP751 and APP770 (Haass et al., 1991). The structure of 
APP is such that it has a large extracellular region, a transmembrane helix and a short 
cytoplasmic tail. At the N-terminal region APP contains an N-terminal growth factor 
domain (N-APP), a copper binding domain (CuBD) and APP protease inhibitor domain 
(APPI). In addition exon 7 includes a Kunitz-type protease inhibitor (KPI) consensus 
sequence. Full-length APP is 770 amino acid residues however the major neuronal form 
is only 695 residues and lacks the Kunitz protease inhibitor (KPI) domain. Intriguingly, 
the level of expression of APP including the KPI domain (KPI-APP) correlates with the 
number of SP found in AD and the expression of APP695 is reduced in these cases 
(Zhan et al., 1995).  
APP is cleaved in the ectodomain, near the transmembrane domain, by either of the 
proteases α-secretase or β-secretase (reviewed by Selkoe, 2001). The zinc 
metalloproteinase, α-secretase, is a member of the disintegrin and metalloprotease 
(ADAM) family and proteolysis via this enzyme follows the non-neurotoxic non-
amyloidogenic pathway. α-secretase cleavage results in release of secretory APP 
(APPsα) and a C-terminal membrane bound fragment, C83 (α-stub). Intramembrane 
proteolysis of C83 is carried out by the integral membrane aspartyl protease γ-secretase. 
γ-secretase is less well characterised but it is known that it consists of the proteins 
presenilin, nicastrin, APH-1 (anterior pharynx-defective 1), and PEN-2 (presenilin 
enhancer 2) and it depends on the presence of all four of these proteins to be active. 
Cleavage of C83 by γ-secretase yields a secretory N-terminal peptide fragment p3 and a 
short lived C-terminal fragment p7 (CTFγ) which is thought to act as a transcriptional 
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regulator. There are two iosforms of p3 (p340 and p342) due to the two cleavage sites 
recognised by γ-secretase. Importantly, the resultant products in the non-amyloidogenic 
pathway do not contribute to SP formation in AD (Figure 1.5).  
Conversely however, β-secretase is the first enzyme in the amyloidogenic pathway 
which results in formation of Aβ peptide which ultimately aggregate in extracellular 
SPs (Blennow et al., 2006). β-secretase (beta-site APP cleaving enzyme; BACE) is a 
novel aspartyl protease. Cleavage of APP by BACE is at a different position to α-
secretase and therefore yields an alternative secretory fragment (APPsβ) and a 
fractionally larger membrane anchored C-terminal segment, C99 (β-stub). Subsequently 
γ-secretase (as described above) cleaves C99 in the transmembrane domain at either of 
the two cleavage sites producing Aβ fragments either Aβ40 or Aβ42 and CTFγ. Both Aβ40 
and Aβ42 are soluble peptides that are secreted from the cells (Figure 1.5). The 
physiological function of Aβ is thought to be the homeostatic control of neuronal 
activity, whereby Aβ is secreted in response to neuronal activity to depress excitatory 
synaptic transmission via AMPA and NMDA receptors (Snyder et al., 2005). Aβ42 is a 
pathogenic peptide that readily forms oligomers. Aβ40 does not aggregate alone however 
it is able to form oligomers with Aβ42. In certain disease states Aβ production increases 
with a shift in Aβ40:Aβ42 ratio towards increased levels Aβ42. The accumulation and 
oligomerisation of Aβ in the neurons has subsequent, yet subtle, effects on synaptic 
efficacy. Snyder et al., (2005) investigated the regulation of NMDA receptors and found 
that Aβ promotes endocytosis, decreasing the phosphorylation of the transcription factor 
cAMP response element binding protein (CREB) and ultimately decreasing the 
transcription of target genes promoting neuronal survival (Snyder et al., 2005). As 
accumulation of Aβ increases, there is gradual extracellular deposition of these 
oligomers such that aggregates form giving a pattern of diffuse SP. Aggregates of Aβ 
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are variable, partly helical structures. Aggregation is dependent upon membrane 
binding, peptide interaction and metal chelation. Furthermore, cations such as copper, 
iron and zinc are coordinated by 3 histidines and a tyrosine in Aβ inducing a β-sheet-
like conformational change and enabling enhanced aggregation (Talmard et al., 2009, 
Faller, 2009). Downstream effects of such peptide oligomers and depositions are via 
initiation of pathways such as microglial and astrocytic activation thus causing neuronal 
injury. It is noteworthy that the toxicity of Aβ is attributed mainly to the Aβ oligomers 
rather than the more advanced SP depositions. Subsequent effects of Aβ complexes are 
altered neuronal ionic homeostasis causing oxidative stress, neurotransmitter deficits 
and triggering the inflammatory response ultimately inducing neuronal dysfunction and 
atrophy (Selkoe, 2001). The involvement of Aβ in the decline of neuronal function in 
AD (the amyloid cascade hypothesis) is the leading argument for pathogenesis of this 
dementia.  
The second pathological hallmark of AD is NFTs. These are aggregations of the 
hyperphosphorylated form of the protein tau. Under normal conditions the physiological 
role of tau is involvement in the stabilisation of microtubules (Kosik, 1990). Therefore 
as a consequence, hyperphosphorylation of tau and subsequent aggregation causes 
disruption of the cytoskeleton of the cell. This contributes to the alteration in cell 
volume and atrophy. NFTs are thought to be secondary to the increased Aβ production 
described above. It is hypothesised that the accumulation of Aβ peptide promotes 
microglial and astrocytic activation which causes neuronal injury and subsequent 
altering of both kinase and phosphatase activity. The increase in the activity of these 
enzymes means that the tau protein is uncharacteristically hyperphosphorylated. In this 
state tau has a gain-of-function that enables it to sequester normal tau in addition to 
other microtubule associated proteins (MAPs). Ordinarily it is the MAPs that would 
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compensate for the loss of functional tau, however once these essential proteins are 
sequestered the microtubule network is destabilised therefore promoting tangle 
formation (Crouch et al., 2008). One kinase that is particularly prominent in this process 
is glycogen-synthase kinase-3 (GSK3). GSK3 is active in its non-phosphorylated form 
and active GSK3 contributes to tau hyperphosphorylation (Ferrer et al., 2002). In 
addition there is an age related factor regulating GSK3, in that its level of 
phosphorylation is decreased with age, resulting in an increase in kinase activity 
(Tomobe et al., 2012). Therefore an increase in age means an increase in the activity of 
GSK3, thus allowing a larger proportion of tau to be hyperphosphorylated. Furthermore, 
a link between oxidative stress and hyperphosphorylation of tau has been postulated 
(Lovell et al., 2004). In AD there are alterations in protein kinase signalling pathways 
that are known to be sensitive to oxidative stress. These kinases lead to further tau 
hyperphosphorylation and therefore increase NFT burden.  NFT formation enables a 
feedback loop in that, with the changes described, results in neuronal injury 
exacerbating the condition.  
A link between zinc and AD was eluded to when it was discovered that zinc is a key 
component of amyloid plaques (Bush et al., 1993). It has also been shown that zinc is 
implicated in the regulation of APP transcription and enzymes involved in both of its 
processing pathways (Grilli et al., 1995, Izumi et al., 1992). Furthermore, ZnT 
dysregulation is evident for more than one transporter in AD pathology (Zhang et al., 
2008). These findings imply an important role for dyshomeostasis of zinc in AD. 
1.9.1 APP, Aβ, NFTs and the role of zinc 
The transcription of APP is regulated by the zinc-dependent transcription factors Sp1 
and NF-κB (Grilli et al., 1995, Izumi et al., 1992). The promoter of APP contains two 
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NF-κB binding sites in its regulatory region (Quitschke, 1994). When activated, NF-κB 
binding significantly up-regulates APP transcription (Grilli et al., 1995). Similarly, Sp1 
is able to bind to the positive regulatory region of the APP promoter and up-regulate 
transcription of the gene (Izumi et al., 1992). It is also noteworthy that Aβ itself can 
trigger downstream activation of NF-κB, in turn increasing APP transcription and 
ultimately increasing Aβ accumulation (Kaltschmidt et al., 1997). 
As discussed in section 1.9, APP is processed via either the non-amyloidogenic or the 
amyloidogenic pathway (producing fragment p3 or Aβ, respectively). Zinc has a 
detrimental effect on both of these pathways. APP has a zinc binding site and when zinc 
is bound it subsequently inhibits proteolytic cleavage by α-secretase (non-
amyloidogenic pathway) as well as inhibiting APP degradation, thus further APP is 
available for conversion to Aβ by BACE (amyloidogenic pathway) (Bush et al., 1993). 
In addition, soluble forms of Aβ peptides are degraded by the matrix metalloproteinase-
2 (MMP-2) under normal conditions. MMPs depend on the presence of zinc at their 
catalytic site in order to be active therefore alteration in zinc status could further 
exacerbate the condition by the reduction of Aβ degradation (Baramova and Foidart, 
1995). 
Zinc is able to promote formation of Aβ oligomers and aggregates at physiological 
concentrations available in the brain by binding Aβ at 3 N-terminal histidine residues. It 
is evident that these intermediate Aβ oligomers are the most toxic form of Aβ and 
indeed that it is these oligomers that are required for the Aβ mediated inhibition of 
synaptic transmission. Interestingly, rodents do not present with AD pathology under 
physiological conditions (Bush et al., 1994). One explanation for this is that in rodent 
Aβ there are three amino acid substitutions that alter one of the crucial bridging 
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histidines. Logically, the disruption of zinc binding to Aβ has been explored as a 
therapeutic target. Initially the chelating agent EDTA showed a disruption of the Aβ-
metal interaction, therefore reducing aggregation. Subsequently, CQ, a moderate metal 
chelating agent capable of crossing the blood-brain barrier, was administered initially to 
an AD transgenic (Tg) mouse model. These mice showed a decrease in SP burden by 49 
% (Cherny et al., 2001). Furthermore, it is hypothesised that the beneficial effects of CQ 
on Aβ are two-fold. In addition to preventing zinc-Aβ aggregates ZnCQ complexes 
were found to activate Aβ-degrading MMPs. The proposed mode of action is that CQ 
delivers bound zinc to the cell which activates the phosphoinositol-3 kinase pathway 
resulting in the up-regulation of MMPs (Cherny et al., 2001, Crouch et al., 2008). 
Aside from its effects on Aβ, CQ was used to demonstrate the effect of zinc on GSK3 
and therefore NFT formation. In agreement with the positive effects seen for the ZnCQ 
complex on Aβ burden, in this instance ZnCQ complexes were found to increase 
phosphorylation of GSK3, therefore decreasing tau phosphorylation and NFT formation 
(White et al., 2006). 
In humans the results for CQ were positive where it reached Phase 2 clinical trials. 
However due to the controversy over the efficacy of the drug, more recently a CQ 
derivative, PBT2 is being tested for its therapeutic uses in AD (Lannfelt et al., 2008). 
1.9.2 ZnT dysregulation in AD 
The research into ZnT expression in AD is of particular importance given the possible 
role of zinc in AD pathology. Zhang et al., (2008) found that at the protein level Znt1, 
Znt3, Znt4, Znt6 and Znt7 showed a significant increase in the hippocampus and 
neocortex of APP/PS1 transgenic mice. The largest increase in expression was for Znt3, 
particularly relevant due to its role in neurotransmission. Znt5 showed an increase that 
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was not significant. Furthermore, the SPs from these mouse models were tested by 
immunoreactions to ascertain whether there is expression of Znts within these 
aggregates. Intriguingly there was a distinct expression pattern evident with Znt1 and 
Znt4 found throughout the SPs whereas Znt3, Znt5 and Znt6 were in peripheral regions 
and Znt7 predominantly in the core (Zhang et al., 2008). 
Human studies of ZnT dysregulation in AD have corroborated the mouse model results, 
however they have also highlighted an important factor in disease progression. The 
decline in multiple cognitive functions in the progression of AD is thought to begin with 
an interim stage labelled mild cognitive impairment (MCI) with only 5 % of these 
patients remaining stable i.e. not developing dementia. In addition, there is a condition 
which is described as preclinical AD (PCAD). In this case the patient does not have any 
overt clinical manifestations of AD but does have significant AD pathology at post-
mortem (Galvin et al., 2005). There are differences in ZnT expression profiles between 
AD and the precursor states in the ZnTs tested. For example in both MCI and PCAD 
ZnT1 expression is significantly lower than controls (Lovell et al., 2005, Lyubartseva et 
al., 2009) however ZnT1 has been found to be up-regulated in the human AD brain 
(Beyer et al., 2012). It is hypothesised that down-regulation in MCI and PCAD leads to 
an increase in intracellular zinc. The effect of this is thought to be two-fold in that an 
increase in intracellular zinc means more available zinc to bind to both APP and Aβ in 
order to exacerbate disease progression as well as the presence of zinc itself being able 
to up-regulate ZnT1 transporter expression as a compensatory mechanism. The increase 
of ZnT1 evident in AD brain tissue is thought to cause an increase in zinc ions available 
in the extracellular space for initiation of Aβ deposition and SP formation. Interestingly, 
in terms of the nutritional status of the elderly which is known to be deficient in zinc 
(Fairweather-Tait et al., 2008), it is perhaps note-worthy that mice fed a zinc deficient 
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diet had a decrease in Znt1 expression (Dong et al., 2008). These are important aspects 
of research that have not been fully explored. 
Research into ZnT4 and ZnT6 has also emphasised the need for more understanding of 
ZnT regulation in the disease state. ZnT4 and ZnT6 have also been implicated in AD 
progression, with elevated protein levels of both transporters in the hippocampus of AD 
patients (Smith et al., 2006). ZnT6 is located in the Golgi apparatus and therefore it has 
been hypothesised that the increase in levels of this transporter in AD results in an 
increase in zinc in this organelle. The importance of this is related to the localisation of 
both APP and the enzymes that metabolise APP, which are found in the Golgi 
apparatus. Therefore, the accumulation of zinc could subsequently promote Aβ 
formation by binding to APP and inhibiting α-secretase (Lyubartseva et al., 2009). ZnT4 
is found in the lysosomal and endosomal compartments in hippocampal tissue and 
similarly an increase in ZnT4 transporter expression would be expected to enable the 
sequestration of zinc into these compartments. This is evident further by reports of Aβ 
accumulation in this system in the post-mortem AD brain (Takahashi et al., 2002). 
Interestingly, researchers have found that there is a positive correlation between Braak 
score (NFT pathology) and ZnT1 levels that is significant such that ZnT1 increases with 
an increase in Braak score. A trend towards significance was also revealed for ZnT6 
(Lovell et al., 2005, Lyubartseva et al., 2009). 
For research into the implications of zinc in AD it is intriguing that ZnT3 has been 
found to be localised predominantly in the membranes of zinc-rich synaptic vesicles in 
the hippocampus (Palmiter and Huang, 2004).  As discussed above, synaptic zinc has 
been shown to facilitate the precipitation of Aβ.  Furthermore, Znt3 knockout mice are 
devoid of zinc in these zinc-enriched terminals. In the transgenic mouse model of AD, 
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tg2576, there is an over-expression of the Swedish mutated human form of APP. It is 
interesting to note that there is an age-dependent hyperactivity of the Znt3 protein in the 
female Tg2576 mouse model when compared to the male Tg2576 mice which is 
abolished in the Znt3 knockout mouse (Lee et al., 2002). This is particularly relevant 
with AD being more prevalent in the female population. Indeed, in the AD Tg2576 
mouse model, ablation of Znt3 inhibits the production of Aβ pathology. The translation 
of research into ZnT3 in humans however, reveals some discrepancies between species. 
The expression of ZnT3 appears to be decreased in the cortical regions of human AD 
patients (Beyer et al., 2009, Adlard et al., 2010) which is in contrast to the increase 
found in mouse models (Zhang et al., 2008). 
It follows that further understanding of the ZnT family and their interactions may 
elucidate a role for ZnTs and zinc in the progression and pathology of AD. 
1.9.3 Genes in AD 
Familial AD accounts for approximately 5-10 % of AD. Studies of these cases have 
highlighted a few genes that are implicated in the disease. For example, chromosome 19 
hosts a coding sequence (Apolipoprotein E, APOE) which can be linked to familial AD 
(Strittmatter et al., 1993). In this instance the frequency of the specific allele ε4 is 
increased in AD sufferers and for those people who are homozygous for the ε4 allele the 
age of onset is earlier than those with either ε2 or ε3 alleles (Corder et al., 1993). There 
are many hypotheses for these observations however there are no conclusive data for the 
association. In addition, Presenilin 1 (PS1) is located on chromosome 14 (Sherrington et 
al., 1995) and this gene has a homologue on chromosome 1 known as Presenilin 2 
(PS2). Presenilin is part of the larger γ-secretase complex that is known to cleave APP 
in the transmembrane domain (Brown et al., 2000). The presence of either PS1 or PS2 is 
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essential for γ-secretase activity (Figure 1.5) and mutations give an increase in Aβ42 
production (Citron et al., 1997). Mutations at the N-terminal of this gene have been 
implicated in familial AD (Berezovska et al., 2005).  
Interestingly, it has been shown that there are different splice variants that are more 
prevalent in sporadic AD. Alternative splicing of the N-terminal region of PS1 results in 
either the presence or absence of four amino-acids. It is thought that the addition of 
these amino acids means the addition of a potential phosphorylation site and thus 
functional differences between the isoforms. It is hypothesised that these may play a 
role in the pathogenesis of AD (Scheper et al., 2004). Moreover, Presenilin 2 has a 
truncated variant (PS2V) and the protein levels of this variant are significantly increased 
in the cortex of AD patients (Smith et al., 2004) which supports previous work that 
found that this splice variant was generated in hypoxic neuroblastoma cells (Sato et al., 
1999). Also it has been shown that aluminium accelerates and enhances production of 
this isoform (Matsuzaki et al., 2004) and it follows that other metals could have an 
effect in disease aetiology.  
Another gene of interest encodes the enzyme β-secretase (BACE). This is known to be 
involved in the amyloidogenic pathway (Figure 1.5). BACE1 is a type I transmembrane 
aspartic proteinase found on chromosome 11 and it has a homolog BACE2 on 
chromosome 21; however, BACE2 is only expressed at low levels in neurones and does 
not have the same cleavage activity as BACE1 with regards to APP (Vassar et al., 
2009). Moreover, Aβ production correlates positively with BACE1 activity and both 
protein expression and activity of BACE1 are increased in the frontal cortex of human 
post mortem AD brain tissue. In contrast BACE2 activity was not altered in AD and 
there was no correlation with its activity to Aβ production (Ahmed et al., 2010). In 
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BACE1 knockout mice there is an absence of Aβ production and, although these mice 
appear healthy, there is evidence that there is a reduced myelination and some cognitive 
deficits. BACE1 does have four known splice variants and, similarly to PS, the 
enzymatic activity of the alternative splice variants differs (Mowrer and Wolfe, 2008). 
There are nine exons in the BACE1 gene and normal processing results in the full-
length active protein of 501 amino acids (BACE 501) from the normal 5’ splice site of 
exon 3 in combination with the normal 3’ splice site of exon 4 (Figure 1.6). There is an 
alternative 5’ splice site within exon 3 as well as an alternative 3’ splice site within exon 
4. Combinations of the use of these yield the various isoforms. The next largest isoform 
contains 476 amino acids (BACE 476), this results from use of the normal 5’ splice site 
in exon 3 with the use of alternative 3’ splice site in exon 4 giving rise to the in-frame 
deletion of 75 base pairs. Similarly, an in-frame deletion of 132 base pairs is evident for 
the isoform BACE 457 (457 amino acids). In this case the alternative splice site is the 5’ 
splice site of exon 3 in combination with the normal 3’ splice site in exon 4. It follows 
that the final splice variant results from the use of both alternative splice sites (5’ 
alternative splice site of exon 3 in combination with the 3’ alternative splice site of exon 
4) yielding the isoform that is an in-frame deletion of 207 base pairs, BACE 432. BACE 
501 is the isoform that is expressed at the highest levels in AD and the other isoforms 
are expressed at relatively low levels with a decrease in expression correlating to size 
(i.e. BACE 476 > BACE 457 > BACE 432). Investigations into the expression profiles 
have found that there is no significant difference in the splicing pattern between the 
cerebellum, frontal lobe and hippocampus. Importantly however, the activity of the 
alternatively spliced isoforms is considerably reduced compared with BACE 501. The 
difference in activity is attributed to the conformational change and its effect on the 
catalytic site. The important active aspartates site lie within exons 2 and 6 and therefore 
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the alternative splicing between these residues will alter the final folding of the protein 
and presumably, the access of substrates to the active site. Furthermore, influencing the 
splicing events in favour of the alternatively spliced isoforms (i.e. decreasing BACE 
501 but increasing BACE 476, 457 and 432 to varying degrees) reduces the production 
of Aβ in cell line models without having an overall effect on total BACE1 expression 
thereby supporting the argument that BACE 501 is the main contributor to Aβ 
production (Mowrer and Wolfe, 2008). In the tg2576 mouse model of AD it has been 
shown that there is no change in the mRNA level of BACE1 within the brain. Despite 
this, there is increase enzymatic activity of BACE1 within these brains. The rise in 
activity is attributed to an increase in expression of the largest isoform BACE 501 
(Zohar et al., 2005). This has led to the proposal that BACE1 protein expression and 
activity increases in AD brains despite the mRNA levels remaining the same in both 
transgenic mice models (Zohar et al., 2005) and AD patients (Holsinger et al., 2002, 
Fukumoto et al., 2002).  
Metals have been implicated in expression and activity of BACE1. The focus of much 
research has been on copper, due to the presence of a 24-residue peptide in BACE1 C-
terminal that contains cysteine residues able to bind single copper atom with high 
affinity. In addition, BACE1 interacts with the copper chaperone for superoxide 
dismutase-1 (SOD-1) such that when BACE1 is over-expressed in CHO cells SOD-1 
activity is reduced (Angeletti et al., 2005, Dingwall, 2007). Furthermore, copper and 
manganese increase the expression of BACE1 in rat adrenal medulla cells (PC12), 
conversely, zinc, iron and aluminium do not (Lin et al., 2008). It is note-worthy that 
there are discrepancies in the literature for BACE1 expression levels but that the 
majority of work focuses predominantly on total BACE1 rather than extrapolating for 
the isoform differences. Investigation into the splicing events of these isoforms is 
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incomplete and further studies of this and the potential role of metals within these may 
elucidate pathways implicated in AD pathogenesis. 
Overall zinc seems to be implicated in the AD disease process - whether it is metal 
dyshomeostasis that causes these irregularities or vice versa remains to be determined. 
This research is important in order to increase our knowledge and work towards finding 
a solution to this devastating disease. 
1.10 Human intestinal epithelial cell line Caco-2 
Caco-2 cells were originally isolated from a primary colonic tumour in a 72-year-old 
Caucasian male. These cells are widely used as an intestinal epithelial cell line model 
following the observations of Hidalgo IJ et al., (1989). It was found that when Caco-2 
cells are grown on plastic dishes or nitrocellulose filters they develop the characteristics 
of normal enterocytes. For example the cell layers are morphologically polar and have 
well-developed brush borders at their apical surface. Furthermore, this differentiation to 
form a monolayer with microvilli and tight junction formation is evident when grown 
on Transwell polycarbonate membranes enabling many subsequent studies to exploit 
the transport functionality to use them as a model system for intestinal epithelial 
transport (Hidalgo et al., 1989). In addition, the formation of these relevant layers 
means that proteins, such as transporters, are distributed in their physiologically 
appropriate positions (reviewed by Ho et al., 2002, Raffaniello et al., 1992). 
Limitations are evident for this cell line and inherent variability between batches of 
Caco-2 cells must be monitored. Therefore culture conditions must be regulated and 
careful observation of characteristics and passage number is required. Caco-2 cells have 
some subtle differences to native enterocytes in that there are alternations in the 
synthesis and expression levels of certain transporters found in vivo. For example, the 
Chapter 1: Introduction 
65 
 
glycoprotein apoB-100 is found in the cell line opposed to the shorter apo-48 version 
evident in the intestine and there are lower levels of intestinal fatty acid binding protein 
than in the human body (Ho et al., 2002). Despite these differences they do however 
provide a simple cell model that enable collection of data on transporter studies without 
the use of animal models and without interspecies correlation because they are of 
human origin. Thus they enable studies of specific genes in terms of absorption, 
metabolism and gene and protein regulation in order to provide detailed information on 
nutrient interactions (Ho et al., 2002). 
1.11 Human neuroblastoma cell line SH-SY5Y 
In 1970 the SN-K-SH cell line was cloned from a metastatic neuroblastoma cell in a 
four-year old female. SH-SY5Y cells are thrice cloned derivative of these SN-K-SH 
cells that are genetically female and since the early 1980’s have been used as a neuronal 
cell line model. SH-SY5Y cells possess a number of both biochemical and functional 
properties of neurons that enable them to carry out this role (Biedler et al., 1973). For 
example, SH-SY5Y cells act like neuronal cells in that they can convert glutamate to the 
neurotransmitter GABA, they express neurofilament proteins and nerve growth factor 
receptors. Importantly, SH-SY5Y cells are capable of proliferating under standard cell 
culture conditions (Ciccarone et al., 1989). Interestingly, they are also able to 
differentiate like stem cells when induced with retinoic acid (RA) and brain derived 
neurotrophic factor (BDNF) (Singh and Kaur, 2007, Cernaianu et al., 2008).  
As with all cell line models, there are limitations to this cell model in that there are 
inherent variability between batches of SH-SY5Y cells that must be monitored. 
Therefore culture conditions must be regulated and careful observation of characteristics 
and passage number is required. Again, there are differences between SH-SY5Y as a 
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neuronal cell line and native neurons.  For example the expression levels and 
distribution of markers used for mature neurons namely, but not exclusively, β-III 
tubulin; a marker for differentiation and decreased proliferation (Katsetos et al., 2003) 
and synaptic vesicle protein (Sv2); a marker for synapses different in SH-SY5Y cells to 
native neurons (Vautrin, 2009). Although SH-SY5Y cells are widely used to investigate 
AD (Agholme et al., 2010), the tau protein differs in expression in the cell line opposed 
to the adult human brain. In the cell line only the foetal isoform of tau is present (Uberti 
et al., 1997). Not only do expression levels and localisation of this isoform differ 
between the adult human brain and the cultured cells but it also doesn’t form NFTs 
despite being heavily phosphorylated (Alonso et al., 2001). With these limitations taken 
into account however, numerous neurological studies have used the SH-SY5Y cell line 
effectively to study neuronal processes such as differentiation and metabolism in 
addition to pathways involved in neurodegenerative diseases. 
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1.12 Aims and Objectives 
Prior to 2012 the only information regarding the zinc transporter ZnT10 was in silico 
data that predicted its expression to be restricted to foetal tissue only (Seve et al., 2004) 
Therefore the primary aim of the work described herein was to characterise ZnT10. The 
objectives for this were to: 
1. Study the expression profile and subcellular localisation of ZnT10 
Both semi-quantitative RT-PCR and quantitative real-time PCR (RT-qPCR) 
were used to establish the expression pattern of ZnT10 in adult human tissues. 
Immunohistochemical detection of a FLAG-tagged construct was carried out to 
establish the subcellular localisation patterns in SH-SY5Y cells. 
2. Characterise the functional and regulatory properties of ZnT10 in response to 
metals 
To indirectly determine the transport activity of the transporter using a reporter 
gene assay experiment. To determine the expression of ZnT10 in response to 
extracellular metal treatments using both semi-quantitative RT-PCR and RT-
qPCR in SH-SY5Y and Caco-2 cell lines. 
3. To investigate the ZnT10 putative promoter response to zinc 
The Caco-2 cell line was used as a model system for reporter gene assays to 
examine the regulation of the ZnT10 gene at the promoter level. 
4. To further research the area of ZnT dysregulation and the role of zinc in AD  
RT-qPCR was used to explore possible involvement of ZnT10 in AD in both 
human and transgenic (Tg) mouse tissue. In addition to investigate the influence 
of extracellular zinc on the BACE1 splice variants in the SH-SY5Y cell model. 
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Table 1.1 Examples of the biological functions of zinc. AE – acrodermatitis 
enteropathica, MRE – Metal Responsive Element, MTF-1 - Metal Responsive 
Element binding transcription factor. (adapted from  Coneyworth; PhD thesis, 
2009) 
Table 1.1 Examples of the biological functions of zinc. AE – acrodermatitis 
enteropathica, MRE – Metal Responsive Element, MTF-1 - Metal Responsive 
Element binding transcription factor. (adapted from  Coneyworth; PhD thesis, 2009) 
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Table 1.2 Distribution of zinc within the body Example is for a normal adult man 
(70 kg) (adapted  from King et al., 2000) 
Table 1.2 Distribution of zinc within the body Example is for a normal adult man 
(70 kg) (adapted fr  i  t l., ) 
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Table 1.3 UK Dietary reference values for zinc (mg/kg). * No increment. (The 
National Diet and Nutrition Survey, 2003) 
Table 1.3 UK Dietary reference values for zinc (mg/kg). * No increment. (The 
National Diet and Nutrition Survey, 2003) 
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Figure 1.1 Predicted topology and arrangement of the ZIP family members. (A) 
The conserved structure of ZIP proteins is eight transmembrane domains (TMD) with 
extracellular N- and C- termini. The histidine rich region is thought to reside in the 
cytoplasm between TMD III and IV. (B) Phylogenetic tree of the human members of 
the ZIP transporter family, with sub-classes of the ZIP transporters highlighted 
(adapted from Taylor et al., 2007 ).   
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Figure 1.1 Predicted topology and arrangement of the ZIP family members. A. 
The conserved structure of ZIP proteins is eight transmembrane domains (TMD) 
with extracellular N- and C- termini. The histidine rich region is thought to reside in 
the cytoplasm between TMD III and IV. B. Phylogenetic tree of the human members 
of the ZIP transporter family, with sub-classes of the ZIP transporters highlighted 
(adapted from Taylor et al., 2007).   
Chapter 1: Introduction 
72 
 
 
  
Figure 1.2 Predicted topology of the ZnT family members. Most family members 
contain6 TMD with an intracellular N- and C-termini. The conserved CDF motif is 
extracellular and between TMD I and II. There is a conserved cytoplasmic basic 
residue region between TMD IV and V. 
i  .  i  l  
t i  6  it   i tr ll l r -  
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Figure 1.3 Projected UK population demographics for people over 75. 
Data sourced from Office of National Statistics, National Population 
projections 2010-based (http://www.ons.gov.uk/ons/publications/re-
reference-tables.html?edition=tcm%3A77-229866) 
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Figure 1.4 Pathological hallmarks of AD. Section of 
brain tissue stained with A. anti-amyloid beta antibody; 
SP, aggregates of Aβ peptides shown in brown B. Anti-
tau antibody; NFTs, tangles of the microtubule protein 
tau, shown in brown. 
A B 
i re .  t l ic l ll r s f . ecti  f 
rai  tissue stained with: A. anti-amyloid beta 
antibody; SP, aggregates of Aβ peptides shown in 
brow  B. Anti-tau a tibody; NFTs, tangles of the 
microtubule pr tein tau, shown in brown. Brain 
sections from the Newcastle Brain Tissue Resource 
(Newcastle, UK). 
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Figure 1.5 Processing of APP; amyloidgenic and non-amyloidgenic pathways. 
APP is cleaved in the ectodomain, near the TMD. Proteolysis via α-secretase follows 
the non-neurotoxic non-amyloidogenic pathway. α-secretase cleavage results in  
release of secretory APP (APPsα) and a C-terminal membrane bound fragment, C83 
(α-stub). Intramembrane proteolysis of C83 is carried out by the integral membrane 
aspartyl protease γ-secretase, yielding a secretory N-terminal peptide fragment p3. 
The resultant products in the non-amyloidogenic pathway do not contribute to SP 
formation in AD. Cleavage of APP by β-secretase (BACE) is the first step in the 
amyloidogenic pathway yielding the secretory fragment APPsβ, and membrane 
anchored C-terminal segment, C99 (β-stub). Subsequently γ-secretase cleaves C99 in 
the TMD at either of the two cleavage sites producing Aβ fragments either Aβ
40
 or 
Aβ
42
 which aggregate in extracellular SPs.  
Figure 1.5 Processing of APP; a yloidgenic and non-a yloidgenic pathways. 
APP is cleaved in the ectodomain, near the T D. Proteolysis via α-secretase follows 
the non-neurotoxic non-amyloidogenic pathway. α-secretase cleavage results in  
release of secretory APP (APPsα) and a C-terminal membrane bound fragment, C83 
(α-stub). Intramembrane proteolysis of C83 is carried out by the integral membrane 
aspartyl protease γ-secretase, yielding a secretory N-terminal peptide fragment p3. 
The resultant products in the non-amyloidogenic pathway do not contribute to SP 
formation in AD. Cleavage of APP by β-secretase (BACE) is the first step in the 
amyloidogenic pathway yielding the secretory fragment APPsβ, and membrane 
anchored C-terminal segment, C99 (β-stub). Subsequently γ-secretase cleaves C99 in 
the T D at either of the two cleavage sites producing Aβ fragments either Aβ
40
 or 
Aβ
42
 which aggregate in extracellular SPs.  
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Chapter 2: Materials and Methods 
2.1 Tissue culture techniques 
2.1.1 Culture of mammalian cells 
Aseptic techniques were used to culture all mammalian cells used. Procedures were 
carried out in a class II laminar flow hood and all reagents were purchased sterile. A 
high temperature and pressure autoclave was used to ensure that reusable consumables 
were sterile. Routinely cells were cultured in basal media (Sigma) in 75 cm
3
 flasks 
(Greiner) in an environment of 5 % CO2/ 95 % air at 37 °C unless otherwise stated. All 
reagents were purchased from Sigma unless otherwise stated. 
2.1.2 Growth and maintenance of cultured cells 
Caco-2 and SH-SY5Y cells were propagated in basal media; Dulbecco-Modified Eagles 
Medium (DMEM) with 4.5 g/L glucose, 0.11 g/L sodium pyruvate and 0.11 g/L L-
glutamine supplemented with 10 % (v/v) foetal calf serum. Cells were assessed using 
light microscopy and once confluent were passaged (usually every 4-5 days) in an 
appropriate ratio (Caco-2 cells; 1:4, SH-SY5Y cells; 1:9). In order to passage growth 
media was discarded and the cells were washed in sterile phosphate buffered saline 
(PBS: 137 mM NaCl2, 2.7 mM KCl, 4.3 mM Na2HPO4.7H2O, 1.4 mM KH2PO4, pH 
7.3). To detach cells from the flask, cells were incubated in 3 mL x 90 trypsin-EDTA at 
37 °C for 5-10 minutes. The trypsin was neutralized by adding 7 mL of the above 
culture medium. Cells were then reseeded into sterile flasks (Caco-2 cells; 1:5, SH-
SY5Y cells; 1:10). 
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2.1.3 Transient transfection of cultured cells 
Cultured cells were seeded into well plates at the relevant density (24 well plate; 
175,000 cells per well in 0.5 mL culture medium, 12 well plate; 350,000 cells per well 
in 1 mL culture medium and 6 well plate; 700,000 cells per well in 2 mL culture 
medium). Transfection mixes were prepared by incubating Opti-MEM® I Reduced-
Serum Medium (Invitrogen) and the transfection reagent GeneJammer (Stratagene 
Europe, Netherlands; Caco-2 cells) or Lipofectamine 2000 (Invitrogen; SH-SY5Y cells) 
at room temperature for 3-5 min. The volumes were well plate dependent: 24 well plate; 
25 µL Optimem and 1 µL transfection reagent, 12 well plate; 50 µL Optimem and 2.5 
µL transfection reagent and 6 well plate; 125 µL Optimem and 2.5 µL transfection 
reagent. Appropriate plasmid DNA was then added to the mix in the appropriate 
proportions: 24 well plate; 0.5 µg DNA, 12 well plate; 1 µg DNA and 6 well plate; 2.5 
µg DNA and mixes were incubated for 30-45 min at room temperature. Culture medium 
was removed from the cells and replaced with half the well volume of DMEM without 
FBS (24 well plate; 0.25 mL medium, 12 well plate; 0.5 mL medium and 6 well plate; 1 
mL medium). Transfection mixes were added drop-wise to each well and cells were 
incubated at 37 °C (5 % CO2 in air) for 3 hours before the addition of the DMEM with 
20 % FBS to reach the final well volume. Cells were incubated for 24 hours at 37 °C (5 
% CO2 in air) before treatments. 
2.1.4 Treatment of cultured cells 
Twenty four hours post-transfection, seeding medium was replaced with culture 
medium containing the appropriate treatment. Cells were incubated with treatment 
medium in the presence of 10 % FBS for a further 24 hours unless otherwise stated. 
RNA, DNA and protein were extracted as described in sections 2.4. Reporter gene 
assays were carried out as per section 2.7.1. 
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2.1.4.1 Metal Treatments 
For zinc treatments of cultured cells, ZnCl2 was added to the medium at concentrations 
of 50 µM, 100 µM and 150 µM. The concentration of basal culture medium containing 
10 % FBS is 3 µM Zn
2+
 (Cragg et al., 2002). For cobalt and nickel 100 µM of the 
relevant chloride was added to the medium. For copper 100 µM CuSO4 was added to 
the medium. 
2.1.4.2 Angiotensin II, Lipopolysaccharide and tert-Butyl hydroperoxide 
Human angiotensin II (Ang II) (Sigma; A9525) and E. coli Lipopolysaccharide (LPS) 
(Sigma; L 2630) were added to the medium in the absence of FBS at final 
concentrations of 0.1 µM and 100 ng/ mL respectively. Tert-Butyl hydroperoxide 
(tBHP) (Aldrich; 19997) was added to the medium in the presence of 10 % FBS for 40 
min at a final concentration of 0.025 mM and then this was replaced with medium 
containing 10 % FBS for the remainder of the incubation period. 
2.1.5 Cell viability assay 
To assess the viability of the cells alamarBlue® (Invitrogen) was used according to the 
manufacturer’s instructions: briefly, alamarBlue® measures the amount of reduction of 
resazurin to resorufin by respiring, viable cells. AlamarBlue® was added to the cell 
medium at a volume of 10 % of the total well volume 3 hours prior to reading. 
Absorbance values were taken at 570 and 600 nm. Calculated as a percentage, viability 
was assessed as a ratio of oxidised:reduced alamarBlue®.  
2.2 Transgenic mouse brain samples 
Frontal cortex brain tissue samples were obtained from 12 month old female wild-type 
(WT) (n = 5) and APP/PS1 mice (n = 11) (supplied by Dr Paul Adlard, The University 
of Melbourne). Brain samples were removed and snap frozen before being stored in 
Chapter 2: Materials and Methods 
80 
 
RNA Later at -80 °C. Samples were shipped in RNA Later on dry ice and on receipt 
brain samples were ground using liquid nitrogen. RNA was extracted using Trizol as 
described in section 2.4.  
2.3 Human brain bank samples 
Frontal cortex RNA samples from human Alzheimer’s disease pathology cases (n = 13; 
female n = 8, male n = 5) and age-matched controls (n = 10; female n = 3, male n = 7) 
(Appendix I) were supplied by the Newcastle Brain Tissue Resource (Newcastle, UK).  
2.4 RNA, DNA and protein extraction 
2.4.1 Simultaneous RNA/DNA and Protein Extraction from cells and tissues 
RNA, genomic DNA and protein were all extracted from cell and/or tissues using 
TRIzol® Reagent (Invitrogen). Tissues were homogenised in 1 mL TRIzol® reagent 
per 50-100 mg tissue and incubated for 5 min at room temperature. Subsequent volumes 
are relative to 1 mL TRIzol® reagent. A volume of 0.2 mL of chloroform was added 
and samples were shaken by hand for 15 seconds. Samples were incubated at room 
temperature for 2-3 min before centrifugation at 12,000 x g for 15 min at 2-8 °C in 
order to complete phase separation.  
2.4.1.1 RNA Extraction 
The top aqueous phase was transferred to a fresh tube and the RNA was precipitated by 
adding 0.5 mL of isopropyl alcohol. Samples were incubated at room temperature for 10 
min and centrifuged at 12,000 x g for 10 min at 2-8 °C. Supernatant was discarded and 
the pellet washed in 1 mL 75 % ethanol and centrifuged at 7500 x g for 5 min at 2-8 °C. 
Supernatant was discarded and the RNA pellet was air dried for approximately 5 min 
and re-dissolved in RNase-free water (approximately 20 µL). Concentration of RNA 
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was determined by measuring the absorbance on a Nano drop, A260/ A280 ratios were 
taken and samples were stored at -80 °C. 
2.4.1.2 DNA Extraction 
The DNA was precipitated from the interphase and organic phase with 0.3 mL 100 % 
ethanol and mixing by inversion. Samples are incubated for 2-3 min at room 
temperature before sedimenting the DNA by centrifugation at 2000 x g for 5 min at 2-8 
°C. The phenol-ethanol supernatant was removed (saved for Protein Isolation, section 
2.4.1.3). The pellet was washed twice in 1 mL 0.1 M sodium citrate in 10 % ethanol by 
incubating at room temperature for 30 min with periodic mixing and centrifuging at 
2000 x g for 5 min at 2-8 °C. The supernatant was discarded and the DNA pellet 
suspended in 1.5 mL of 75 % ethanol. Samples were stored at 2-8 °C. 
2.4.1.3 Protein Isolation from brain tissues 
Protein was precipitated from the phenol-ethanol supernatant by the addition of 1.5 mL 
isopropanol and incubation for 10 min at room temperature. Protein was sedimented at 
12,000 x g for 10 min at 2-8 °C. The supernatant was discarded and protein pellet 
washed 3 times in 2 mL 0.3 M guanidine hydrochloride in 95 % ethanol by incubation 
for 20 min at room temperature and centrifugation at 7500 x g for 5 min at 2-8 °C. The 
supernatant was discarded and the pellet was washed in 2 mL 100 % ethanol for 20 min 
at room temperature. The samples were centrifuged at 7500 x g for 5 min at 2-8 °C 
before discarding the supernatant and air drying the pellet for 5-10 min. The protein was 
re-dissolved 50 µL 2 x sample buffer (2 % sodium dodecyl sulphate (SDS), 10 % 
glycerol, 125 mM Tris (pH 6.8), 5 % β-mercaptoethanol). Concentration of protein was 
determined by measuring the absorbance at 280 nm on a Nano drop before the samples 
were stored at -20 °C. Dilutions for loading onto SDS-PAGE were into 2 x sample 
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buffer containing bromophenol blue (2 % sodium dodecyl sulphate (SDS), 10 % 
glycerol, 125 mM Tris (pH 6.8), 0.002 % bromophenol blue, 5% β-mercaptoethanol). 
Samples were sonicated and/ or heated to 70 °C for 5 min before being subjected to 
SDS-PAGE (section 2.7.2). 
2.4.2 Protein extraction from cells 
Protein was extracted from cultured cells by first trypsinising the cells then the 
neutralized suspension (plus media) was placed in a 15 mL universal tube and 
centrifuged at 1000 g for 5 min at 4 °C. The supernatant was decanted off and the cells 
were washed in 1 mL PBS and transferred to an 1.5 mL eppendorf tube. Samples were 
centrifuged at 10000 g for 5 min at 4-8 °C before discarding the supernatant and 
resuspending the samples in 50 µL 2 x sample buffer (2 % sodium dodecyl sulphate 
(SDS), 10 % glycerol, 125 mM Tris (pH 6.8), 5 % β-mercaptoethanol). Concentration 
of protein was determined by measuring the absorbance at 280 nm on a Nano drop 
before the samples were stored at -20 °C. Dilutions for loading onto SDS-PAGE were 
into 2 x sample buffer containing bromophenol blue (2 % sodium dodecyl sulphate 
(SDS), 10 % glycerol, 125 mM Tris (pH 6.8), 0.002 % bromophenol blue, 5 % β-
mercaptoethanol). Samples were sonicated and/ or heated to 70 °C for 5 min before 
being subjected to SDS-PAGE (section 2.7.2). 
2.5 RNA procedures 
2.5.1 First strand cDNA synthesis using Superscript III reverse transcriptase 
Superscript III reverse transcriptase was the enzyme of choice for semi-quantitative RT-
PCR. Synthesis of RNA into cDNA was carried out typically with reactions containing 
1 µg of RNA, 1 µL oligo (dT) (VH Bio Ltd, 50 µM), 1 µL dNTP (New England 
Biolabs, 10 mM) into a final volume of 13 µL with RNase free water. The samples were 
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then incubated at 65 °C for 5 min, followed by incubation on ice for 1 min. 
Subsequently, 4 µL 5x First Stand Buffer (Invitrogen, 250 mM Tris-HCl [pH 8.3], 375 
mM KCl, 15 mM MgCl2), 1 µL 0.1 M DTT (Invitrogen), 1 µL Superscript III reverse 
transcriptase (Invitrogen) and RNase free water was added to a total volume of 20 µL. 
Samples were incubated at 50 °C for 60 min before inactivating the enzyme at 70 °C for 
15 min. For negative control reactions water was added instead of the enzyme. 
2.5.2 First strand cDNA synthesis using Moloney Murine Leukaemia Virus 
Reverse Transcriptase (M-MLV RT) 
M-MLV RT was the enzyme of choice for quantitative RT-qPCR. Synthesis of RNA 
into cDNA was carried out typically with reactions containing 1 µg of RNA, 1 µL oligo 
(dT) (VH Bio Ltd, 0.625 mM), into a final volume of 12.5 µL with RNase free water. 
The samples were then incubated at 70 °C for 5 min, followed by incubation on ice for 
1 min. Subsequently, 5 µL 5x First Stand Buffer (Promega, 250 mM Tris-HCl (pH 8.3 
at 25 °C), 375 mM KCl, 15 mM MgCl2 and 50 mM DTT), 2 µL dNTP (New England 
Biolabs, 10 mM), 1 µL M-MLV RT (Promega) and RNase free water was added to a 
total volume of 25 µL. Samples were incubated at 37 °C for 60 min before inactivating 
the enzyme at 70 °C for 15 min. For negative control reactions water was added instead 
of the enzyme. 
2.5.3 Design of PCR Primers 
All primers were synthesised by Integrated DNA Technologies (IDT), Inc. 
Oligonucleotide primers were designed, by hand, to be typically 20-24 base pairs long. 
Where possible, primers were designed such that they had a G or C nucleotide at the 3’ 
and 5’ end. The GC content was ideally approximately 50 % and the melting 
temperature was between 50-60 °C. Additional parameters for RT-qPCR were that they 
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yielded a 100-150 bp product and where possible, either forward or reverse primer was 
over an exon-intron boundary.  
2.5.4 Polymerase Chain Reaction (PCR) 
Amplification of cDNA regions was typically completed in 50 µL reactions containing 
25 µL 2x Taq mastermix (New England Biolabs, UK), 1 µL sense primer (0.2 µM), 1 
µL antisense primer (0.2 µM) and 1 µL template cDNA. Generally denaturation was at 
94 °C for 30 sec, extension was at 72 °C for 60 sec over the course of 35 cycles. 
Individual annealing temperatures were optimised for each PCR product and are given 
alongside primers as detailed in Chapters 3, 4, 5, 6 and 7.  
2.5.4.1 Agarose Gel Electrophoresis 
PCR products were analysed on 2.5 % agarose gels. Agarose was dissolved in 1x TBE 
buffer (89 mM Tris base, 89 mM Boric Acid, 2 mM EDTA) by boiling. Ethidium 
bromide (2 µg/mL) was then added. The cooled solution was poured into gel trays and 
allowed to set. In gel tanks, set gels were immersed in 1x TBE buffer. Samples were 
added to a 0.2 x volume of Orange G loading dye. Samples were compared against 10 
µL of either a 1 kb or a 100 bp DNA ladder (New England Biolabs, UK) to assess the 
size of bands. Gels were run for 40 min at 120 V. Where required, band intensities were 
quantified by densitometry using GeneTools (SynGene). 
2.5.4.2 Purification of PCR products from agarose gel or PCR reactions 
If multiple bands were observed on agarose gels the band of interest was excised from 
the gel so that products could then be subsequently ligated into vectors. This process 
was initiated by cutting the band from an agarose gel using a sterile scalpel blade under 
UV light. The QIAquick gel extraction kit (Qiagen,UK) was used according to the  
manufacturer’s protocol. Briefly, gel slices were weighed and the appropriate amount of 
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high-salt solubilisation buffer (provided in the kit) was used to dissolve the remaining 
gel at 50 °C. The solution was applied to a QIAquick spin column and binding of the 
nucleic acids to the membrane was allowed by centrifugation. Subsequent wash steps 
allowed removal of impurities such as enzymes and salts before the pure DNA was 
eluted into a low salt buffer. DNA extracted was stored at -20 °C. 
PCR products that gave a single band on an agarose gel were purified directly from the 
PCR reaction using QIAquick PCR purification kit according to the manufacturer’s 
protocol. Directly to the PCR reaction a high salt buffer was added and then as above 
the PCR product was bound to a QIAgen spin column by centrifugation before 
purification and elution. 
2.5.4.3 Digestion of PCR products with restriction endonuclease 
Restriction endonucleases were used to digest PCR products in order to be able to ligate 
them together (section 2.6.6). Typically, digest reactions contained the appropriate 
reaction buffer (NEB biolabs) and 5 – 10 Units of specific restriction endonuclease in a 
final volume of 10 µL. Digest reactions were incubated in a water bath at 37 °C for 1-2 
hours.  
2.5.5 Real-time PCR (RT-qPCR) 
RT-qPCR was performed using the DNA engine opticon 2 (MJ Research). Typical 
reactions contained 7.5 µL Power SYBR Green PCR Master Mix (Applied Biosystems), 
1.5 µL sense primer (0.25 µM), 1.5 µL antisense primer (0.25 µM) and 1 µL template 
cDNA made to 15 µL with RNase free water. Amplification was carried out in ABgene 
96 well plates under the following conditions; denaturation at 95 °C for 10 min 
followed by 40 cycles of 95 °C for 15 sec and an annealing/extension stage of 60 °C for 
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10 sec before the plate was read. A melt curve was subsequently completed over 55-90 
°C with 1 °C increments over 1 sec. Each sample was measured in duplicate. 
2.5.5.1 Standard curves 
Standard curves were generated for all RNA analysed by RT-qPCR and the relevant 
controls in order to determine the relative concentrations of samples. The primers 
designed for RT-qPCR were used to carry out conventional PCR to amplify templates to 
be used for standard curves. These products where ligated into pCR®-TOPO vector 
(Invitrogen, UK, Appendix A) (section 2.6.1) and transformed into chemically 
competent E. coli cells (Top10; Invitrogen) (section 2.6.2). Once the plasmid DNA was 
extracted, serial dilutions were performed on each construct in RNase free water, each 
of these was assigned an arbitrary concentration. A standard curve was created by 
plotting the log of arbitrary concentration against cycle threshold (Ct) value. Analysis 
was performed in duplicate and each RT-qPCR analysis contained the standard curve. 
2.5.5.2 Data analysis 
Expression of the RNA of interest was calculated by taking the Ct value, averaging the 
duplicates, and then reading from the standard curve the arbitrary concentration of the 
samples. These were run alongside a control RNA in order to normalise the results and 
were finally expressed as a ratio of RNA of interest:control RNA. Efficiency values 
were calculated using the equation E = (10(-1/slope) - 1)*100 and were required to fall 
within the range of 80-115 %. 
2.6 Generation of plasmid constructs 
2.6.1 Cloning into TOPOTM TA vector 
In a final volume of 6 µL the PCR products to be cloned, sterile water, 1 µL salt 
solution and 1 µL pCR®-TOPO vector (Invitrogen; Appendix A) were added. The 
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reactions were mixed gently and incubated at room temperature for 5 min. The tubes 
were placed on ice before carrying out the One Shot
TM
 Transformation reaction (section 
2.6.3) or transformation into electrocompetent E. coli cells (section 2.6.6). 
2.6.2 Cloning into TOPOTM pBlue vector 
The –891 to +51 bp region of the ZnT10 promoter was generated by PCR from genomic 
DNA from SH-SY5Y cells with primers and thermal cycling parameters as stated in 
Table 4.2 and subcloned into the vector pBlue-TOPO® (Invitrogen; Appendix B), 
upstream of the β-galactosidase reporter gene. In a final volume of 6 µL the PCR 
products to be cloned, sterile water, 1 µL salt solution and 1 µL pBlue-TOPO® vector 
(Invitrogen) were added. The reactions were mixed gently and incubated at room 
temperature for 5 min. The tubes were placed on ice before carrying out the One Shot
TM
 
Transformation reaction (section 2.6.5) or transformation into electrocompetent E. coli 
cells (section 2.6.7). 
2.6.3 Digestion of plasmids with restriction endonuclease 
Restriction endonucleases were used to digest plasmids to confirm that the plasmid 
contained the correct insert in the correct orientation. Typically, digest reactions 
contained the appropriate reaction buffer (NEB Biolabs) and 5 – 10 Units restriction 
endonuclease in a final volume of 10 µL. Digest reactions were incubated in a water 
bath at 37 °C for 1-2 hours. Analysis was by agarose gel electrophoresis (section 
2.5.4.1) 
2.6.4 Overnight ligations 
After digestion of both the vector and DNA insert by specific restriction endonucleases 
(section 2.6.3) the concentration of the vector and insert was measured using a Nano 
drop. Appropriate vector:insert molar ratios (typically 1:1 or 1:3) were determined 
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where the reaction contained 50 ng vector, 50-200 ng insert, 1 µL 10 x T4 DNA ligase 
buffer (NEB Biolabs, 500 mM Tris-HCl,100 mM MgCl2,10 mM ATP, 100 mM 
Dithiothreitol, pH 7.5), T4 DNA ligase (NEB Biolabs, 1 U/µL) and nuclease free water 
to a volume of 10 µL. Reactions were incubated overnight at 16 °C. Ligation reactions 
were then precipitated with ethanol. 
2.6.5 One ShotTM Transformation reaction 
2 µL of the cloning reaction was added to chemically competent Top10 E. coli cells 
(Invitrogen). They were mixed gently and incubated on ice for 5-30 min. Cells were 
then heat shocked in a water bath at 42 °C for 30 sec. Tubes were transferred to ice and 
250 µL of room temperature LB medium was added. Tightly capped tubes were shaken 
horizontally in an orbital shaker at 37 °C, 200 rpm for 1 h. Transformed cells were 
propagated on LB plates containing 50 µg/ml ampicillin. 
2.6.6 Production of competent cells 
Electrocompetent DH5α cells were generated by initially growing a colony in LB 
(orbital shaker; 37 °C, 200 rpm) until an optical density of 0.5 was reached. All 
centrifuges were pre-cooled and all water and glycerol was cold. Cells were kept on ice 
when not in the centrifuge. The centrifuge steps were: 6000xg for 15 min at 4 °C and 
resuspend in 800 mls water, 6000 x g for 15 min at 4 °C and resuspend in 400 mls 
water, 6000 x g for 15 min at 4 °C and resuspend in 16 mL 10 % glycerol, 6000 x g for 
15 min at 4 °C and resuspend in 3.2 mls 10 % glycerol. Cells were aliquotted on dry ice 
to snap-freeze and stored at -80 °C. 
2.6.7 Transformation into electrocompetent E. coli cells 
1 µL of the cloning reaction was added to electrically competent E. coli cells (section 
2.6.6). This mixture was transferred into a cool cuvette and placed into an electroporator 
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at 25 µFD, 200 OHMS (Ω), 1.5 kV. Room temperature LB medium, 500 µL, was added 
and the mixture transferred to an eppendorf tube containing a further 500 µL of room 
temperature LB medium. Capped tubes were incubated in a water bath at 37 °C for 1 h. 
Transformed cells were propagated on LB plates containing 50 µg/ml ampicillin. 
2.6.8 Generation of full length FLAG-ZnT10 plasmid DNA construct 
Full length cDNA corresponding to ZnT10 was generated by RT-PCR from SH-SY5Y 
RNA and subsequent nested PCR using Velocity Polymerase (Bioline) with primers and 
thermal cycling parameters as stated in Table 3.5. The product was gel purified using 
the QIAquick Gel Extraction Kit according to manufacturer’s instructions (Qiagen) 
(section 2.5.4.2) and subcloned into the vector pCR2.1-TOPO (Invitrogen Appendix A) 
(section 2.6.1). The identity of the pCR2.1-ZnT10 product was confirmed by 
sequencing (MWG Biotech). A large scale plasmid preparation (Plasmid Maxi kit, 
Qiagen) was digested with EcoRI and BamHI (New England Biolabs) (section 2.6.3), 
and the DNA purified from the band resolved by agarose gel electrophoresis using the 
QIAquick Gel Extraction Kit (Qiagen) (section 2.5.4.2). This DNA was subcloned in-
frame into the vector p3xFLAG-CMV-10 (Sigma, Appendix D) to give plasmid 
p3xFLAG–ZnT10, prior to transformation into electrocompetent E. coli cells (section 
2.6.7). The identity of the product was confirmed by sequencing (MWG Biotech) 
(Appendix F). 
2.7 Protein Procedures 
2.7.1 Reporter gene assays 
2.7.1.1 Transient transfection of Caco-2 cells for measurement of reporter gene 
activity  
Caco-2 cells were seeded into 12-well plates at a density of 3.5 x 10
5
 cells per well for 
co-transfection and for individual transfections. Twenty-four hours post-seeding cells 
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were transfected either with pBlue-ZnT10 (section 2.6.2) construct alone or co-
transfected with p3xFLAG-ZnT10 (section 2.6.8) or p3xFLAG-BAP (Sigma-Aldrich; 
Appendix E) plus the reporter gene construct pBlue-MT2a (Helston et al., 2007) using 
GeneJammer transfection reagent (Stratagene), with a ratio of DNA to GeneJammer of 
1.5 µg:2.5 µl. Transfection medium was removed after twenty-four hours and replaced 
with basal medium with or without either 100 µM ZnCl2, 100 µM CoCl2, 100 µM NiCl2, 
100 µM CuSO4. Twenty-four hours post-treatment cell lysates were prepared.  
2.7.1.2 Whole cell lysate preparation 
Reporter gene assays were completed on cells in 12 well plates. Cells were washed with 
1 mL PBS before addition of 100 µL lysis buffer (0.25 M Tris pH 7.4, 0.25 % (v/v) NP-
40, 2.5 mM EDTA) and freezing at -20°C for 30 min. Cells were defrosted at room 
temperature to complete lysis. Sterile cell scrapers (Greiner) were used to harvest cells 
before transfer to 1.5 mL eppendorf tubes. Cell debris was pelleted by centrifugation of 
the cell lysates at 12,000 g for 5 min at 4-8 °C. The supernatant was transferred to a new 
tube for subsequent analysis. 
2.7.1.3 β-Galactosidase reporter assay 
The High Sensitivity β-Galacosidase Assay Kit (Stratagene) was used for reporter gene 
assays. When the β-galactosidase enzyme is expressed by the plasmid it is able to 
catalyse a reaction using the substrate chlorophenol red-β-D-galactopyranoside (CPRG) 
so to induce a colour change from yellow to orange/ red depending on expression levels. 
In a 96 well plate, 130 µL of 1.2 mg/mL CPRG (in buffer containing 100 mM NaCl, 25 
mM MOPS and 10 mM MgCl2, pH 7.5) was added to 20 µL of cell lysate (from section 
2.7.1.2) to give a final volume of 150 µL. Well plates were shielded from light and 
incubated at 37 °C until the colour change occurred. Reactions were stopped by the 
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addition of 80 µL 0.5 M Na2CO3 when the colour change was observed. Incubation time 
was recorded and absorbance was measured at 560 nm using a BioTek Synergy HT 
plate reader. 
2.7.1.4 Determination of protein concentration 
Bradford assays were used to determine cell lysate protein concentrations. The colour of 
Coomassie Brilliant Blue G-250 dye (Bradford reagent; Bio-Rad) changes in response 
to various concentrations of protein due to binding of the dye to primarily basic 
(especially arginine) and aromatic amino acid residues (Bradford, 1976). Bovine Serum 
Albumin (BSA) was used to generate a standard curve 0-100 µg/mL in a volume of 50 
µL, eight replicates were analysed in a 96 well plate. Dilutions of the cell lysates (1:50) 
in a total volume of 50 µL were added to the plate and 200 µL Bradford reagent (Bio-
Rad, UK) diluted 1 in 5 with H2O was added to all reactions. Absorbance was measured 
at 560 nm using a BioTek Synergy HT plate reader and protein concentrations were 
calculated from the standard curve. 
2.7.1.5 Data analysis 
Specific activity of β-galactosidase (U) was calculated by first calculating the nmoles of 
chlorophenol red (CR) formed per mL (optical density at 560 nm x 55). This is then 
converted to nmoles of CR formed (CR x total assay volume (0.23 mL)). The activity of 
β-galactosidase per minute (U x 103) was calculated using the assay time (CR/ length of 
time at 37 °C (min)). Values were corrected for protein concentration measured in each 
sample (U/ (protein concentration of lysate (mg/mL)/ volume of lysate in assay (20 µL)) 
U x 10
3
/mg ). Results are shown as mean ± standard error of the mean (SEM) for all 
experiments. Statistical comparisons were made by Student’s paired t-test (Excel). 
Differences between means were considered significant at p < 0.05. 
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2.7.2 Western blotting procedure 
Proteins (40 µg) were separated on 10 % SDS polyacrylamide gels (SDS-PAGE). A 10 
% acrylamide resolving gel solution was prepared (in 15 mL; 5.1 mL 30 % acrylamide 
mix (29:1 acrylamide:bisacrylamide), 3.9 mL 1.5 M Tris-HCl pH 8.8, 0.15 mL 10 % 
SDS (w/v), 6 mL water) to which 150 µL of 10 % freshly prepared ammonium 
persulphate and 6 µL TEMED polymerisation agent was added. The mixed solution was 
poured between two glass plates (BioRad) to within approximately 3 cm from the top. 
The gel was overlaid with 150 µL water and allowed to set for 15-20 minutes. After the 
gel had set the water was removed with paper tissues. A 5 % stacking gel was prepared 
(in 15 mL; 1.5 mL 30 % acrylamide mix (29:1 acrylamide:bisacrylamide), 1.14 mL 1.5 
M Tris-HCl pH 6.8, 0.09 mL 10 % SDS (w/v), 6.3 mL water) to which 90 µL of 10 % 
freshly prepared ammonium persulphate and 9 µL TEMED polymerisation agent was 
added. The mixed solution was poured on top of the resolving gel and allowed to set for 
20 minutes. Gels were run at 180 V for 1-1.5 hours before being transferred by semi-
wet blotting onto PVDF membranes at 100 V for 90 min.  Blocking of the membranes 
was carried out in 5 % non-fat milk powder in 1x PBS containing 0.1 % (w/v) Tween-
20 for 1 h before membranes were incubated in 1x PBS, pH 7.4, containing 0.01% 
Tween-20 and 5 % non-fat milk powder with primary antibody at the appropriate 
concentration, overnight at 4 ºC followed by incubation for 1 h at room temperature 
with a horseradish peroxidise – conjugated IgG secondary antibody (1:5000 dilution) 
(Sigma).   Primary antibodies were monoclonal mouse anti-FLAG M2 (1:1000, Sigma-
aldrich) and rabbit polyclonal anti-alpha tubulin (1:5000, Abcam). Bound secondary 
antibodies were visualised using a luminol-based enhanced chemiluminescence kit 
(Thermo Scientific). Band intensities were quantified by densitometry using GeneTools 
(SynGene). 
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2.7.3 Subcellular localisation of FLAG-tagged construct 
SH-SY5Y cells were seeded in 24-well plates on glass cover slips at a density of 1.75 x 
10
5
 cells per well in 0.5 mL culture medium. Twenty-four hours post-seeding cells were 
transfected transiently with p3xFLAG-ZnT10 (section 2.6.8) or BAP-FLAG (Sigma, 
Appendix E) using Lipofectamine 2000 reagent (Invitrogen), with a ratio of DNA to 
Lipofectamine 2000 of 0.5 µg:0.5 µl.  In some experiments cells were treated with 100 
µM extracellular ZnCl2 for 24 h post-transfection and incubated for 24 h prior to 
fixation. Twenty-four hours post-transfection, cells were fixed in 4 % paraformaldehyde 
(in 1x PBS) for 15 min at room temperature, and then washed three times with 1x PBS. 
Cells were permeabilised by treatment with 0.1 % Triton X-100 for 10 min followed by 
washing in 0.1% Tween-20 in 1x PBS. Cells were incubated with monoclonal anti-
FLAG M2-FITC antibody (1:1000, Sigma-Aldrich) for 1 h at 4 ºC then washed three 
times with 0.1 % Tween-20 in 1x PBS. Cells were co-stained with 2 µg/mL rhodamine-
labelled wheat germ agglutinin (WGA) for 5 min at room temperature before washing 
twice with 0.1 % Tween-20 in 1x PBS and visualising using fluorescence microscopy 
(Olympus BX61 Fluorescent microscope). 
2.8 Bioinformatics tools 
2.8.1 Protein topology prediction 
The database TMpred was used to predict the putative membrane topology of ZnT10. 
This uses an algorithm derived from the statistical analysis of the TMbase database of 
naturally occurring transmembrane protein segments (Hofmann and Stoffel, 1993). The 
web site used to access this software was 
http://www.ch.embnet.org/software/TMPRED_form.html. This pattern was confirmed 
by TMHMM, an algorithm model for TransMembrane prediction using Hidden Markov 
Models which was accessed through the use of InterProScan 
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(http://www.ebi.ac.uk/Tools/pfa/iprscan/). This database enabled simultaneous searches 
for conserved signal peptides and the cation diffusion facilitator (CDF) motif using 
SignalP and TIGRFAM respectively. The presence of a CDF motif was confirmed using 
ScanProsite (http://expasy.org/tools/scanprosite/). N-glycosylated sites, O-glycosylated 
sites, phosphorylation sites and sequence alignments were completed using NetNGlyc, 
NetOGlyc, NetPhos and ClustalW respectively. The software was accessed via the 
websites: 
http://www.cbs.dtu.dk/services/NetNGlyc/ 
http://www.cbs.dtu.dk/services/NetOGlyc/ 
http://www.cbs.dtu.dk/services/NetPhos/ 
http://www.genome.jp/tools/clustalw/ 
2.8.2 Nucleotide consensus sequences 
The database fuzznuc was used to search for appropriate nucleotide consensus sequence 
patterns such as Metal Response Elements (MREs) and the putative Zinc 
Transcriptional Regulatory Element (ZTRE). This was accessed via the website 
http://emboss.bioinformatics.nl/cgi-bin/emboss/fuzznuc.  
2.9 Statistical Analysis 
Experiments were performed routinely in triplicate and each experiment was repeated at 
least twice. Results are expressed as means ± SEM throughout. Statistical comparisons 
were made using one-way ANOVA followed be Bonferroni’s multiple comparisons 
post hoc test (Microsoft SPSS) or by Student’s paired t-test (Excel). Differences 
between means were considered significant at p < 0.05. 
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Chapter 3: Characterisation of ZnT10 
3.1 Outline 
The work presented in this chapter is concerned with characterising the putative zinc 
transporter, ZnT10 bioinformatically as well as determining its expression pattern and 
establishing its functional response to zinc. Previous bioinformatics research into ZnT10 
has been published (Seve et al., 2004) and this chapter aims to both confirm and extend 
these findings. Seve et al., (2004) provided only in silico data relating to all ten 
members of the ZnTs, but also developed this analysis further for ZnT10. As discussed 
previously in Chapter 1, members of the ZIP transporter family generally function to 
increase cytosolic zinc concentrations, whereas ZnT family members are usually 
involved in lowering cytosolic zinc concentration by effluxing out of the cell or into 
intracellular compartments.  Distinct structural differences between the two families 
may relate to their opposing roles.  In general, members of the ZIP family have eight 
transmembrane domains (TMDs), compared with six in members of the ZnT family and 
the predicted topology is such that the N- and C- termini in ZnT family members are 
intra-cytosolic, but in ZIP family members are extra-cytosolic (Kambe et al., 2004).  
This tenth family member would be predicted, in line with other family members, to 
contain a cation diffusion facilitator (CDF) motif, six TMDs and intracellular N- and C- 
termini although this orientation is only confirmed for ZnT1 (Palmiter and Findley, 
1995). In addition, most ZnT transporters also contain a histidine-rich region, between 
TMDs IV and V. Such regions are predicted to be cytoplasmic and could function as 
potential metal binding domains. In the previously published article, Seve et al., (2004) 
used the programmes BLASTN and TBLASTN, which use nucleotide or protein 
sequences respectively, to identify ZnT10 by analysing genomic DNA and translated 
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sequences of ZnT1 (human, mouse and rat), Znt2 (rat), ZnT3 (human and mouse), ZnT4 
(human, mouse and rat), ZnT5 (human), ZnT6 (human) and ZnT7 (human) for 
homologous sequences.  Previous bioinformatics data predicts, using the internet 
programme TMPred that ZnT10 also contains six transmembrane domains with 
intracellular N- and C- termini (Seve et al., 2004). Furthermore, this work highlighted 
that there is a basic region between TMD IV and V in ZnT10 that is serine rich. The 
expectation according to central dogma is that this region should be histidine rich but 
this basic serine rich region is in concurrence with other zinc transporters, namely 
ZnT6. It was previously found that ZnT6 did not have the characteristic histidine rich 
region but retained serine residues in the same region that were hypothesised to have 
been retained from the prokaryotic ancestors of this family (Huang et al., 2002). It is 
noteworthy that, Seve et al., (2004) found conservation between aspartate at position 
247 in TMD V and position 276 in TMD VI for ZnT10 with aspartate residues in ZnT5 
at position 599 and 621, respectively. Using HEK-293 cells and a construct expressing 
ZnT5 has revealed the importance of Asp599 in zinc binding. In these experiments 
Zinpyr-1, the zinc sensing cell-permeable fluorescent probe, showed that when this 
aspartate was mutated (D599A) zinc was no longer sequestered into the Golgi apparatus 
(Ohana et al., 2009).  
The in silico expressed sequence tag (EST) technique used to look at the expression 
profile of ZnT10 predicted that ZnT10 expression would be restricted to foetal tissue, 
more specifically foetal liver and foetal brain (Seve et al., 2004). This was intriguing in 
that this was the only known zinc transporter to be restricted in this way.   
In order to increase knowledge of this transporter the preliminary aim of the work 
reported in this chapter was to characterise ZnT10 using both in silico and in vitro 
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techniques. This chapter reports novel bioinformatic findings relating to ZnT10 and 
confirms the presence of ZnT10 in foetal tissue but in addition, presents novel findings 
that indicate ZnT10 is also expressed in adult mouse and human tissue. 
Studies to date have revealed that there are at least 10 members of the human ZnT 
family with the mRNA expression of each varying depending upon the tissue type. 
ZnT1 is expressed ubiquitously and is more abundant in tissues involved in zinc 
acquisition such as the small intestine (McMahon and Cousins, 1998, Cousins and 
McMahon, 2000). ZnT2 has a differential expression pattern with mRNA expression 
detected in the small intestine, kidney, placenta, pancreas, testis, seminal vesicles and 
the mammary gland (Kelleher and Lonnerdal, 2002, Liuzzi et al., 2001, Liuzzi et al., 
2003, Clifford and MacDonald, 2000, Palmiter et al., 1996a). Until recently it was 
thought that ZnT3 expression was restricted to the brain and the testis. However, it has 
been reported that ZnT3 exists in the retina, pancreatic cells and some areas of the 
epithelium (Smidt and Rungby, 2012). ZnT4 has been found to be abundantly expressed 
in mammary gland, brain and intestinal epithelial cells (Huang and Gitschier, 1997). In 
contrast, both variants of ZnT5 (A and B) have ubiquitous expression patterns (Kambe 
et al., 2002, Cragg et al., 2002). ZnT6 appears to have a restricted expression profile 
whereby the mRNA is present in the liver, brain, kidney and small intestine (Huang et 
al., 2002). ZnT7 mRNA is more widespread than that of ZnT6, with the mRNA being 
found in liver, kidney, spleen, heart, brain, small intestine and lung (Kirschke and 
Huang, 2003). ZnT8 is expressed only in the islets of Langerhans in pancreatic β-cells 
(Chimienti et al., 2004). Analysis of four human foetal tissues (brain, lung, liver, and 
kidney) showed ZnT9 mRNA expression in all these tissues and in addition RT-PCR 
showed presence of mRNA in all tested tissues and cells (16 human adult tissues and 14 
cancer cell lines) therefore displaying widespread expression. (Sim and Chow, 1999). 
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The majority of above research used both Northern blot and RT-PCR techniques in 
order to determine the expression profile of the ZnTs. The last known member of this 
family has not yet been characterised in this way. Seve et al., (2004) were able to 
elucidate a restricted expression profile using an in silico technique. The EST data 
mining technique uses a sub-sequence from a cDNA sequence in order to search the 
EST database using a search programme such as BLASTN (a programme that enables 
searching of nucleotides) in order to assess whether the cDNA is expected to be found 
in particular tissues. BLASTN was used in the case of ZnT10 to search the human EST 
database using the query sequences of the ORF 5’ and 3’ UTR. As stated above, this 
gave the prediction that ZnT10 would be expressed in foetal tissue only and more 
specifically, it would be restricted to foetal liver and foetal brain. This is unusual as no 
other ZnTs are restricted to foetal tissue alone. ZnT1 levels at birth are extremely low 
and Seve et al., (2004) used ZnT10’s homology to ZnT1 to hypothesise that ZnT10 may 
play a similar role to ZnT1 in the developing foetus.  
The ZnT family of transporters are predominantly thought to be effluxers, reducing 
cytosolic zinc concentrations. Previous measurements for the ZnTs have been indirect 
for all experiments except those for ZnT5 (Valentine et al., 2007, Cragg et al., 2002). 
Such experiments generally use transfected cell lines to assess ‘rescue’ in response to 
zinc treatment. ZnT5vB is the only transporter that has been reported to be bi-
directional thereby able to act to both increase and decrease cytosolic zinc (Valentine et 
al., 2007). These experiments are two-fold, the researchers use radioactive 
65
Zn to 
directly assess transport
 
in Xenopus laevis oocytes. In addition, Valentine et al., (2007) 
used an indirect promoter reporter assay to further characterise ZnT5vB function. 
Indirect measurements are commonplace in measuring ZnT function and similar 
promoter reporter assays have also been used to characterise Znt1 and Znt2. These 
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systems are based on the β-galactosidase reporter system whereby a zinc sensitive 
promoter drives expression of the β-galactosidase gene at differing levels depending on 
the zinc concentration of the cell. For Znt1 and Znt2 in BHK cells that stably express 
the MRE-βGeo (a construct involving 5 MRE sequences and a β-galactosidase-
neomycin phosphotransferase (lacZ-neo) fusion gene), β-galactosidase activity was 
measured with transient transfection of either Znt1 or Znt2 the results showing an 
increased zinc efflux (Palmiter, 1994, Palmiter et al., 1996a, Palmiter and Findley, 
1995).  By comparison, for ZnT5 the effect of increased ZnT5vB transporter expression 
on the intracellular zinc status was analysed by measuring the response of a β-
galactosidase reporter gene to zinc driven by a zinc responsive MT2a construct 
(Valentine et al., 2007, Helston et al., 2007). No functional characterisation of ZnT10 
has been carried out therefore it is important to establish the functional activity of 
ZnT10 especially given its restricted expression profile in adult human tissue. Here I 
report that indirect measurements, as used for functional characterisation of ZnT5vB, 
indicate that ZnT10 follows suit with other family members and effluxes zinc such that 
cytosolic zinc concentrations are reduced. 
3.2 Bioinformatic screening of ZnT10 
There are a number of features present in the sequence of ZnTs, discussed in section 
1.4.2, which are both conserved and/or allow predictions to be made about 
characteristics of the protein. This section confirms those already found in the literature 
as well as identifying novel features. 
3.2.1 Topology modelling 
The ZnT family members have certain conserved structures in their topology. It is 
assumed, although not proven, that the structure is important for zinc binding and 
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transport. One conservation throughout most family members is six TMD which Seve et 
al., (2004) predicted to be present in ZnT10 using the freely available TMPred package. 
This package is based on the protein sequence database SwissProt and it uses an 
algorithm combining several weight-matrices for scoring in order to predict membrane-
spanning regions and their orientation (Hofmann and Stoffel, 1993). Confirmation of 
this topology was established with both TMPred and TMHMM using InterProScan. 
TMHMM is based on a hidden Markov model and whilst the programme agreed with 
TMPred in the number of TMD there were minor differences in the positions of all 
TMD except TMD I (Table 3.1). In line with the other ZnT members, both programmes 
strongly preferred the model with a predicted intracellular N- and C- termini. In addition 
to the above observations, partial sequence alignment with ClustalW highlighted that 
ZnT10 does not contain the histidine rich region of most the other family members 
however, similarly to ZnT6, a serine rich region between TMD IV and V with a high 
predominance of the basic residues lysine and arginine has been identified (Seve et al., 
2004) (Figure 3.1A). Furthermore, using the partial sequence alignment of TMD V and 
VI there are conservation of two asparagine residues (Asp 247 and Asp 276) in ZnT10 
with Asp 599 and Asp 621 of ZnT5 that are thought to be important for zinc binding 
(Figure 3.1B). A summary diagram of the predicted topology of ZnT10 is shown in 
Figure 3.2A.  
3.2.2 CDF sequence identification 
ZnTs are members of the CDF family and are therefore expected to have a CDF motif 
near their N-terminal region, which generally lie between TMD I and II (as represented 
in Figure 3.2A).  The consensus sequence for the CDF motif is given in Figure 3.2B. A 
CDF consensus sequence has been identified in ZnT10, using the freely available 
programme ScanProsite (ExPASy). ScanProsite allows input of a sequence motif and 
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subsequently scans the given protein (or the Prosite database) for the presence of that 
motif. The results identified a CDF motif at amino acids 34-50 
(SiALLSDSFNmlsDLiS) in ZnT10 (Figure 3.2C). This furthers the existing knowledge 
and both the extent to which it matches and its presence at the N-terminus between 
TMD I and II (despite extending into TMD II) implies that ZnT10 is a true member of 
the ZnT, and indeed, the CDF family. 
3.2.3 Identification of sites for post-translational modification 
Proteins contain many sites and/ or sequences that can be modified to create the mature 
protein in order to alter the structure, function or localisation of the protein. One such 
sequence is a signal peptide sequence which enables proteins to be targeted to the 
correct position within the cell (Stryer et al., 2002). One such example of signal peptide 
usage is for the enzyme elastase. This protein needs to pass through channels in the ER 
membrane and into the ER lumen and in order for this translocation to occur the 29 
amino acid signal peptide is required. Protein synthesis begins at the ribosomes of the 
ER and it is during this translation that the signal peptide directs the growing peptide 
through the ER channels. On completion of the translocation the signal peptide is 
cleaved and subsequently degraded (Stryer et al., 2002). The SignalP programme uses 
several artificial neural networks and hidden Markov models in combination in order to 
predict the probability of a signal peptide within a given sequence (Petersen et al., 
2011). Scores > 0.45 result in a positive prediction of a signal peptide. The ZnT10 
amino acid sequence was submitted into this database and the results gave a maximum 
cleavage site probability 0.465 between amino acid position 29 and 30 (G and Y) 
predicting that there is a potential signal peptide present in the N-terminal of the protein 
(Figure 3.2C).  
Chapter 3: Characterisation of ZnT10 
102 
 
A modification commonly involved in the conformation of proteins is N-glycosylation. 
This process is where N-linked glycans are attached to the nitrogen of side chains of 
asparagine or arginine, an important process occurring in the ER that is essential for 
correct protein folding. NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/) 
examines the sequence context of Asn-Xaa-Ser/Thr sequons using artificial neural 
networks in order to predict N-glycosylation sites within an amino acid sequence. 
Scores that are > 0.5 indicate a predicted glycosylation site. Within ZnT10 three N-
glycosylation sites are predicted at amino acids Asp 377, 471 and 481 with scores of 
0.7864, 0.6268 and 0.5148 respectively (Figure 3.2C, Table 3.2).  
Similarly NetOGlyc (http://www.cbs.dtu.dk/services/NetOGlyc/) uses neural networks 
to predict O-glycosylation sites within an amino acid sequence. O-glycosylation is a 
functional modification occurring in the Golgi apparatus. In this process O-linked 
glycans are attached to an hydroxyl oxygen of serine, threonine, tyrosine, hydrolysine or 
hydroxyproline side chains. Again, scores that are > 0.5 indicate a predicted 
glycosylation site. Within ZnT10 one O-glycosylation site is predicted at amino acid 
Thr 183 with a score of 0.595 (Figure 3.2C, Table 3.2).  
Another functional modification within mature proteins is phosphorylation, this 
activates or deactivates many proteins or enzymes. Most commonly the amino acid site 
for phosphorylation is a serine however phosphate can also be added to the side chains 
of threonine and tyrosine. NetPhos (http://www.cbs.dtu.dk/services/NetPhos/) uses 
neural network predictions for the three possible phosphorylation sites; serine, threonine 
and tyrosine. Scores that are > 0.5 indicate a predicted phosphorylation site. Results 
yielded 15 predicted phosphorylation sites within ZnT10; seven serine sites at amino 
acids 5, 69, 149, 197, 233, 363, 446, (scores of 0.955, 0.852, 0.609, 0.998, 0.754, 0.862 
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and 0.998 respectively) four threonine sites at amino acids 8, 192, 196, 219 (scores of 
0.732, 0.974, 0.928 and 0.839 respectively) and four tyrosine at amino acids 278, 359, 
440, 479 (scores of 0.631, 0.836, 0.885 and 0.957 respectively) (Figure 3.2C, Table 
3.2). 
3.3 Adult mouse tissue expression 
All known members of the ZnT family have homologues in mouse. Prior to 2012, all 
data on ZnT10 was in silico therefore, mouse tissue was assessed for the expression of 
Znt10 at the mRNA level. 
3.3.1 ZnT expression in adult mouse brain 
RNA was extracted from mouse brain tissue (section 2.4.1) and, using appropriate 
primers (Table 3.3), a gradient RT-PCR was performed in order to establish the Znts 
present in the mouse brain. Kidney tissue RNA was used as a positive control in all 
cases, as all Znts previously studied are expressed in kidney, except for Znt8 in which 
pancreatic RNA was used because this is the only area where Znt8 is known to be 
expressed (Chimienti et al., 2004). Mt1 and 18S rRNA were used as PCR controls to 
establish the integrity of the RNA and whether the PCR’s had been successful. In all 
cases Mt1 and 18S rRNA were found in mouse brain, kidney and pancreas. All Znts 
except Znt8 were found in the mouse brain (Figure 3.3).  Znt8 was amplified in the 
mouse pancreas, confirming Znt8 is absent from this tissue and not inadequate primer 
design (Figure 3.3B). As expected Znt3 was found in the mouse brain however it was 
absent from mouse kidney (Figure 3.3A). There was difficultly confirming the presence 
of Znt1 initially, however this was attributed to the fact that in the first brain that was 
analysed the cerebellum RNA was lost in the extraction process. The cerebellum has 
been shown to have a high level of Znt1 expression (Sekler et al., 2002). The most 
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surprising of these results was the novel finding that a faint ZnT10 band was present in 
mouse brain, given that this was RNA extracted from an adult mouse brain tissue, an 
area where Znt10 had not been predicted to be expressed (Seve et al., 2004) (Figure 
3.3C). 
3.3.2 Confirmation that Znt10 is expressed in adult mouse tissues 
Using in silico methodologies Znt10 has only been predicted to be found in foetal tissue 
(Seve et al., 2004) specifically foetal liver and brain, therefore it was important to 
establish the specificity of the band found in adult mouse brain.  In order to do this, 
RNA extracted from mouse foetal liver alongside adult mouse brain and kidney samples 
(Section 2.4.1) were used in a standard RT-PCR (Section 2.5.4), using primers specific 
to mouse Znt10 (Table 3.3).  Gel electrophoresis identified distinct bands at the size 
corresponding to Znt10 in mouse foetal liver as well as mouse adult brain.  Bands were 
not observed in the mouse adult kidney sample (Figure 3.4). Positive PCR products 
were sequenced by MWG and confirmed identity with mouse Znt10 
(NM_001033286.2).  This provides the first evidence that Znt10 expression is not 
restricted to foetal tissue, however appears to have a restricted pattern of expression in 
the adult mouse as it is not present in the adult mouse kidney. 
3.4 Adult human tissue expression 
Due to the presence of Znt10 in adult mouse brain research was expanded into the 
expression profile of ZnT10 at the mRNA level in adult human tissues. 
3.4.1 Semi-quantitative analysis 
To assess further the pattern of ZnT10 expression, human ZnT10 primers (Table 3.4) 
were designed. Initially, the ZnT10 primers were used to assess the expression profile of 
ZnT10 in 19 human tissues (Ambion RNA tissue panel) by RT-PCR (see section 2.5.4), 
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using GAPDH as the normalisation control (Table 3.4).  The tissue panel RNA was 
reverse transcribed into cDNA using the reverse transcriptase Superscript III (section 
2.5.1). RT-PCR was carried out over 30 cycles and did not reached saturation. Of the 19 
tissues sampled, seven were shown to express ZnT10 at the mRNA level. The ratio to 
GAPDH of RT-PCR products were calculated using densitometry techniques 
(GeneTools) giving a profile of levels of expression being liver > brain > testes > small 
intestine > colon > ovary > cervix (Figure 3.5). It is important to bear in mind that this 
RT-PCR can only be used semi-quantitatively and therefore can only give an indication 
of relative expression levels as it is impossible to know the position on the curve as to 
whether the PCR reaction has gone to completion. 
3.4.2 Confirmation of relative expression levels of ZnT10 using RT-qPCR 
In order to further quantify the presence of ZnT10 in adult human tissues quantitative 
RT-qPCR (RT-qPCR) was used to investigate the relative expression levels of ZnT10 in 
the tissues. Standards for GAPDH and ZnT10 products were generated by amplifying 
the region between the primers shown in Table 3.4, and subcloned into the vector 
pCR2.1-TOPO TA (Appendix A, Invitrogen) following methods shown in section 2.6.1, 
to give the standards pCR2.1-ZnT10 and pCR2.1-GAPDH. The identity of the products 
was confirmed by sequencing (MWG Biotech). Ten-fold serial dilutions of each of 
pCR2.1-ZnT10 and pCR2.1-GAPDH were used to generate standard curves (see section 
2.5.5.1). For RT-qPCR, a second reference gene was used; DNA topoisomerase I 
(TOPI) in accordance with the MIQE guidelines (Bustin et al., 2009).  TOPI primers 
were purchased from PrimerDesign. A TOPI PCR product was produced and subcloned 
into the pGEM-T-easy vector to give the standard TOPI-pGEM.  To confirm the 
identity of the product it was amplified in end-point PCR, cloned and sequenced 
(generated by Dr Alison Howard). A standard curve was created by performing ten-fold 
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serial dilutions of this standard. All standard curves passed acceptance criteria (Figure 
3.6). The Ambion tissue panel was reverse transcribed into cDNA using the reverse 
transcriptase MMLV (RNase H positive, Promega), as described in section 2.5.2. 
Subsequently, this was used as the template for RT-qPCR giving an expression profile 
in 20 adult human tissues relative to both GAPDH (Figure 3.7) and TOPI (Figure 3.8). 
For RT-qPCR, using GAPDH as the reference gene, there were relatively high levels of 
ZnT10 found in small intestine > liver > testes > brain and lower transcript levels in the 
ovary > colon > cervix > prostate > placenta. In addition low levels of mRNA are 
shown to be in prostate tissue which was not included in the initial semi-quantitative 
analysis (Figure 3.7). Using the TOPI analysis expression levels appeared to differ 
slightly, however higher mRNA levels are found in the liver > brain > testes > small 
intestine and lower mRNA levels found in the ovary > colon > cervix > prostate > 
placenta (Figure 3.8).  
3.5 Functional analysis of ZnT10 
The majority of ZnTs and indeed members of the CDF family have been shown to act 
as effluxers and therefore decrease cation concentrations in the cytoplasm. With the 
exception of ZnT5, which has been shown to have bi-directional capabilities directly 
(Valentine et al., 2007)  measurements of ZnT functional abilities have been researched 
using a range of indirect techniques. In this chapter, we report an indirect measurement 
technique which involves the measurement of activity of the zinc-responsive 
metallothionein 2a (MT2a) promoter when co-expressed with ZnT10 in human 
intestinal Caco-2 cells (see section 2.7.1).  This method has previously been used to 
demonstrate functional activity of ZnT5 (Valentine et al., 2007). RNA extracted from 
SH-SY5Y cells was used as a template to clone full-length ZnT10 (see section 2.6.8). A 
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nested PCR was used in order to generate the appropriate product. Initially the Full-
length ZnT10 primers from Table 3.5 were used to generate a 1727 bp product. This 
PCR mix was subsequently used as the template in a further PCR with the Full-length 
ZnT10 primers (Table 3.5) to produce a 1455 bp product with EcoRI and BamHI 
restriction sites (Figure 3.9A). The band was excised from a 1 % agarose gel, purified 
using QIAgen gel purification kit. NEBcutter was used to establish that PstI and EcoRV 
both have one digest site within ZnT10.  Restriction digests using these enzymes was 
carried out to confirm the identity of the PCR product. Incubation of the ZnT10 PCR 
product with these enzymes yielded fragments of the appropriate sizes (PstI, yielding 
products of 998 bp and 459 bp, and EcoRV, yielding products of 1076 bp and 381 bp; 
Figure 3.9B). This PCR product was subcloned into a number of vectors including 
pEGFP-C1 vector (BD Biosciences Clontech; Appendix C) and FLAG-10 (Appendix 
D) using standard methodology. None of the restriction digests with EcoRI and BamHI 
gave a 1455 bp drop out indicating that the cloning reactions were unsuccessful. An 
alternative method was employed and the full-length ZnT10 PCR product generated 
using Taq polymerase, was subcloned using TA cloning into TOPO TA pCR2.1 vector 
(Appendix A). Restriction digests with EcoRI and BamHI gave the expected 1455 bp 
drop out (Figure 3.10Ai). To further confirm the correct insert the TOPO TA-ZnT10 
construct was used as a template for PCR using ZnT10 primers from Table 3.4 (Figure 
3.10Aii) Identity was confirmed by sequencing and no mutations were observed (MWG 
Biotech). This enabled us to produce an increased concentration of the construct which 
was subsequently cloned into the p3xFLAG-CMV-10 (Sigma) vector. Restriction 
digests of the p3xFLAG-ZnT10 construct with EcoRI and BamHI confirmed the 
presence of the correct size drop out product (Figure 3.10B). Sequencing (MWG 
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Biotech) was used to confirm the presence of the correct insert, without mutation and 
in-frame with the N-terminal FLAG epitope tag (Appendix F).  
This p3xFLAG-ZnT10 construct was used in a promoter reporter assay to indirectly 
assess functional activity of full-length ZnT10. To determine the effect of increased 
ZnT10 expression on intracellular zinc concentration the effect of heterologous over-
expression of ZnT10 in the p3xFLAG vector on the activity of a zinc-activated reporter 
gene, comprising the E. coli β-galactosidase coding sequence downstream of the zinc-
activated human MT2a promoter (pBlue-MT2a) in Caco-2 cells was measured (Helston 
et al., 2007).  This method has been used previously to examine activity of ZnT5vB in 
this cell line with the same reporter construct (pBlue-MT2a model) (Valentine et al., 
2007).  Co-expression of ZnT10 (from plasmid p3xFLAG) decreased β-galactosidase 
activity driven by the MT2a promoter significantly, (approximately two-fold) in 
standard culture medium compared with cells co-transfected with pBlue-MT2a plus 
p3xFLAG-BAP vector (no ZnT10 insert). This two-fold decrease was also observed 
with the addition of 100 µM extracellular zinc when compared with cells co-transfected 
with pBlue-MT2a plus p3xFLAG-BAP vector (no ZnT10 insert).  These results indicate 
a decrease transcription from the zinc-responsive MT2a promoter and so indicate a 
decrease in intracellular zinc concentration (Figure 3.11). Therefore, we would 
speculate that ZnT10 is acting to efflux zinc either out of the cell or into intracellular 
organelles in line with the majority of other family members.   
3.6 Discussion 
ZnT10 is thought to be a member of the CDF family, a ubiquitous family of heavy 
metal transporters first discovered by Nies and Silver (1995). Members of the CDF 
family are found in all three phylogenetic domains; archaea, bacteria, and eukaryote. 
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Across kingdoms all CDF family members are broadly involved in the sequestration of 
both essential and toxic metals. Indeed members of the prokaryotic CDF family are 
implicated in transport and homeostasis of the cations zinc, cobalt, manganese, iron, 
cadmium and nickel (Gaither and Eide, 2001a). Plant CDF members are usually referred 
to as Metal Tolerance Proteins (MTP) whereas their vertebrate equivalents are known as 
ZnTs or Solute Carrier Family 30 (SLC30). The eukaryotic counterparts have 
predominantly been investigated for their zinc transporter role and therefore are thought 
to be involved in homeostasis of the zinc cation (reviewed by Montanini et al., 2007). 
Furthermore, throughout the phylogeny kingdoms, there is evidence that the majority of 
proteins that possess the highly conserved CDF motif (Figure 3.6B) act to efflux cations 
out of the cytoplasm to either outside the cell or into subcellular organelles. Moreover, 
the structure of this family of transporters has also been conserved in that the majority 
of CDF proteins possess six putative TMDs, with cytoplasmic N- and C- termini. Such 
structures have been experimentally demonstrated for bacterial members (Anton et al., 
1999, Wei and Fu, 2005), with predictions only for the eukaryotic counterparts. The 
exception to this is for ZnT1 (Palmiter and Findley, 1995). Importantly, in the context 
of this research, the two splice variants of ZnT5 (ZnT5vA and ZnT5vB) are exceptions 
to this common structural rule, having a predicted 15 and 12 TMD, respectively (Kambe 
et al., 2002, Cragg et al., 2002). The CDF signature sequence is normally found 
between TMDs I and II (Paulsen and Saier, 1997).  Both my investigations and those of 
Seve et al., (2004) show that ZnT10 appears to follow this common pattern. It is 
evident, from this previous in silico work and confirmed here that ZnT10 has a 
predicted putative six TMD with the expected intracellular N- and C- termini (Figure 
3.2A). I have also confirmed the presence of the CDF motif (SiALLSDSFNmlsDLiS; 
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Figure 3.2C) between amino acids 34 and 50 which, incidentally, is between TMD I and 
running into TMD II in line with the position of the motif in other family members.  
One area in which ZnT10 does differ from the majority of its ZnT family members is 
the presence of a basic region consisting of predominantly serine and other basic 
residues (Arg and Lys) with the absence of histidine entirely from this area (Figure 
3.1A). This is opposed to the conserved histidine-rich domain found in most eukaryotic 
ZnTs between TMD IV and V. However this is not without precedence as ZnT6 has a 
non-histidine basic region that, in agreement with ZnT10, is between TMD IV and V 
and therefore is thought to be cytoplasmic (Huang et al., 2002). It is worthy of note that 
the histidine-rich domains of other ZnT family members are also found between TMD 
IV and V and are cytoplasmic. The importance of this is thought to be in the metal 
binding process where these basic residues would be able to coordinate the metal ions 
for transport across membranes. The serine residues found in ZnT6 and ZnT10 may be 
retained from the prokaryotic ancestors of the transporters instead of a histidine-rich 
domain (Huang et al., 2002). Due to the basic nature of both serine and histidine the 
amino acids share many characteristics implying this area of the protein would have 
similar properties.  
In terms of metal binding, the conservation of Asp 247 and Asp 276 in TMD V and VI 
of ZnT10 with Asp 599 and Asp 621 in the TMD equivalent to TMD V and VI in ZnT5 
is of interest (Figure 3.1B). Both of these residues are thought to be important in 
coordination of the zinc ion and Asp 599 of ZnT5 has been shown experimentally to be 
involved in zinc binding (Ohana et al., 2009). Paulsen et al., (1997) hypothesised the 
importance of these residues in the context of the structure of the ZnTs. This group 
found that helices I, II, V and VI were amphipathic and that in these TMD the 
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hydrophobic residues were localised to one side of the helix whereas the semi-polar 
hydrophilic, and intriguingly more conserved, amino acids are positioned on the 
opposite side. In this case the arrangement of the TMD would form a central-water 
filled channel, allowing postulation that the conserved aspartyl residues in TMDs V and 
VI found on the hydrophilic side would face inwards allowing for cation binding to 
occur (Paulsen and Saier, 1997). It is reasonable therefore, to assume that ZnT10 could 
undergo post-translational modification to control its actions or ensure correct topology. 
There are many databases which allow predictions of such modifications relative to the 
amino acid sequence. A selection of these programmes have been used here, in order to 
predict the possibility of modifications. 
The first prediction programme used was SignalP, this allows one to ascertain the 
probability of ZnT10 having a signal peptide which will ensure correct targeting within 
the cell before cleavage (under normal circumstances). The results of this in silico 
programme predicted that ZnT10 has a signal peptide of 29 amino acids with a cleavage 
site between G29 and Y30 (Figure 3.2C). Given that this predicted cleavage site is in 
the N-terminal region, if functional, would need to be taken into consideration when 
carrying out localisation studies with an N-terminal tagged vector (Chapter 4).   
The Net series of databases uses neural networks to predict both glycosylation and 
phosphorylation sites within proteins. There are two forms of glycosylation; N-
glycosylation and O-glycosylation that correspond to conformational or functional 
modifications respectively. N-glycosylation is the process where N-linked glycans are 
attached to the nitrogen of side chains of asparagine or arginine. It occurs in the ER 
ensuring correct protein folding. NetNGlyc predicted 3 N-glycoslyation sites at Asp 
377, 471 and 481 amino acids in ZnT10. For the functional modification O-
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glycosylation, O-linked glycans are attached to an hydroxyl oxygen of serine, threonine, 
tyrosine, hydrolysine or hydroxyproline side chains. One such site is predicted in ZnT10 
at Thr 183 using NetOGlyc.  
Phosphorylation is as a functional modification where a phosphate is added to the side 
chain of a serine or, less commonly, either threonine or tyrosine residue within mature 
proteins. This phosphorylation, acts to activate or deactivate many proteins or enzymes. 
Within ZnT10 there are 15 predicted sites with 7 serine residues and 4 of each threonine 
and tyrosine residues. These data are summarised in Table 3.2. One relatively 
unexplored avenue of research into ZnTs is experimental evidence of post-translational 
modifications. It is evident that a CDF family member found in yeast, Zrt1, is 
ubiquitinated and therefore internalised at high concentrations of zinc (Gitan et al., 
2003) and similar mechanisms have been found for the ubiquitination of some 
mammalian plasma membrane proteins e.g. the growth hormone receptor undergoes 
endocytosis due to the ubiquitination machinery (Hicke, 1997). Of more relevance to 
this study, Western blot analysis of ZnT7 produced many bands on a gel (Kirschke and 
Huang, 2003). One hypothesis the authors drew from this was that ZnT7 could be 
modified e.g. glycosylated post-translationally. Furthermore the phosphorylation of both 
ZIPs and ZnTs is thought to be widespread throughout the families with ZnT1, ZnT3, 
ZnT6, ZIP3, ZIP6, ZIP7, ZIP8 and ZIP10 shown to be phosphorylated at more than one 
site (summarised in Hogstrand et al., 2009). In fact the authors hypothesise that the 
presence of multiple phosphorylation sites may play an important role in zinc 
transporter function, a theory that needs to be investigated experimentally. The 
prediction of post-translational modifications for ZnT10 has yielded a number of 
interesting findings. In particular the prediction of 15 phosphorylation sites supports the 
hypothesis that these are required for zinc transporter function. 
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Information published previously concerning ZnT10 expression is limited.  An article 
reporting in silico analysis of the tissue expression profile of members of the SLC30 
(ZnT) zinc transporter family based on data mining for ESTs reported in cDNA libraries 
has been published (Seve et al., 2004).  This analysis indicated that ZnT10 expression 
was restricted to foetal liver and foetal brain and that foetal-specific expression was 
unique to ZnT10 within the family.  I report here confirmation that ZnT10 is expressed 
in foetal tissues but also identify a pattern of differential expression in adult tissue, 
using a human RNA tissue panel analysed by both semi-quantitative RT-PCR and RT-
qPCR.  Expression in adult tissue was not restricted to human tissue and Znt10 
expression was observed in adult mouse brain, but not adult mouse kidney, mirroring 
approximately the relative levels of expression of ZnT10 in the tissues in humans 
(Figure 3.4). The presence in adult tissue is in agreement with a very recent paper that 
has been published simultaneously with the completion of this PhD research that also 
establishes the presence of ZnT10 in adult tissue (Patrushev et al., 2012).  
Although exact relative levels of ZnT10 mRNA expression differed slightly between the 
two methods and with the two reference genes, it was observed that ZnT10 expression 
levels were highest in liver, brain, small intestine and testes and lowest in ovary and 
cervix, by all three methods.  The exception to this was expression in the colon, where I 
observed high levels of ZnT10 by semi-quantitative analysis but lower levels by RT-
qPCR relative to both reference genes (GAPDH and TOPI). The real-time analysis also 
indicated very small amounts in the placenta and prostate (prostate tissue RNA was not 
present in the original RT-PCR analysis). These inconsistencies in relative levels 
highlight some of the limitations of the techniques and indeed the importance of 
appropriate use of reference genes. For example, semi-quantitative RT-PCR does not 
have the sensitivity of RT-qPCR therefore the placental expression was not evident 
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from this analysis. In addition semi-quantitative RT-PCR indicated high levels of 
ZnT10 transcript in the colon, a result disputed by the use of RT-qPCR compared with 
both TOPI and GAPDH. RT-PCR is an end-point reaction and whilst the PCR 
experiment did not reach saturation we cannot be sure that we are measuring the level of 
PCR product at the same point on the curve for all reactions thus we can only measure 
ZnT10 mRNA levels semi-quantitatively. 
The RT-qPCR showed small discrepancies between results relative to GAPDH and 
TOPI. For both GAPDH and TOPI there are two groups of tissues – those with high 
expression and those with low expression.  The differences lie in those tissues in the 
high expression group. Relative to GAPDH expression of ZnT10 was highest in the 
small intestine > liver > testes > brain tissue compared with highest levels of expression 
in liver > brain > testes > small intestine relative to TOPI. However there is agreement 
for both reference genes in the tissues with relatively low levels of tissue expression 
ovary > colon > cervix > prostate > placenta. Where possible, more than one reference 
gene should be used in analysis but here the apparent difference in the order of 
expression for RT-qPCR analysis can be attributed to the use of different reference 
genes. TOPI (DNA topoisomerase I) is involved in transcription, it is an enzyme that is 
important in the transient breaking and re-joining of a single strand of DNA to allow it 
to pass through one another thereby altering the topology of the DNA. It follows that 
during proliferation events, such as cell proliferation in cancer progression, TOPI is up-
regulated (Romer et al., 2012, Nishioka et al., 2011). The tissue panel used is compiled 
from pooled RNA from tissues from at least three human post-mortem donors (Life 
Technologies). This is worth taking into consideration as the cause of death could be a 
factor in the alteration of transcript levels of TOPI, thereby altering relative ratios in the 
tissues tested. The other reference gene chosen, GAPDH has been shown to be 
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expressed at different levels dependent on tissue type (Barber et al., 2005). Further 
analysis indicates that these differences are small since when the top and bottom 
members of the ‘high group’ are compared as a ratio to GAPDH no significant 
difference between the highest level of expression (small intestine) compared with the 
lowest level of expression in this group (brain; p = 0.2 by Student’s t-test) is observed. 
When I carried out the same analysis relative to TOPI there was no significant 
difference between the observed highest expression levels (liver) with lowest (small 
intestine; p = 0.551 by Student’s t-test). Moreover, for both reference genes there are 
significant differences between the ‘high group’ and the ‘low group’; brain versus ovary 
relative to GAPDH (p = 0.007 by Student’s t-test) and small intestine versus ovary 
relative to TOPI (p = 0.027 by Student’s t-test). 
Importantly, throughout the three experiments the tissues in which there was expression 
are constant thus proving a differential expression pattern for ZnT10. The expression in 
small intestine, liver and brain perhaps reflects a role for ZnT10 in zinc systemic 
homeostasis through the regulation of intestinal and hepatic uptake/efflux and in brain 
where zinc plays a specific role in the modulation of synaptic transmission. 
In terms of zinc transport function, efflux is a characteristic of the CDF family however, 
in the case of the ZnTs these measurements have predominantly been indirect 
observations of zinc transport i.e. the effect of transporter expression on cellular 
responses to zinc. One method of indirect measurement is in cell ‘rescue’ by 
transfection of a zinc transporter into a system which, under normal conditions, displays 
defective zinc transport. An example of this is the investigation of zinc transport for 
Znt4. Over-expression of a Znt4 construct in Δzrc, a yeast model that has a defective 
zinc vacuolar transporter (ZRC1) was able to rescue the growth of Δzrc in a high-zinc 
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medium (Huang and Gitschier, 1997). The same Δzrc yeast model was used to assess 
the zinc transport ability of Znt6, yet in this instance the growth was not rescued. 
However, the yeast models Δzrt1, Δzrt3 and Δmcs2 all have defects such that they 
exhibit a severe decrease in cytoplasmic zinc concentrations. For Δzrt1 the defect is in 
the high affinity zinc uptake protein but for both Δzrt3 and Δmcs2 there are defects in 
the relocation of zinc from the vacuoles, ER and nucleus to the cytoplasm. With the 
over-expression of Znt6 and treatment with 1.0 mM ZnCl2, the growth inhibition seen in 
these mutants was partially alleviated and thus Huang et al., 2002 conclude that Znt6 
does transport zinc. Furthermore, the role of heterodimerisation between ZnT5 and 
ZnT6 has been studied more recently. TNAP activity has been proposed as a marker to 
measure zinc supply to the zinc-requiring enzymes in the secretory pathway (Suzuki et 
al., 2005a). Co-transfection of ZnT5 and ZnT6 constructs restored TNAP activity in 
DT40 ZnT6
-/- 
cells whereas transfection of ZnT6 independently failed to change TNAP 
activity. Moreover, co-immunoprecipitation studies revealed that ZnT6 forms a hetero-
dimer with ZnT5 indicating that ZnT6 is able to transport zinc when it is able to form a 
hetero-dimer with ZnT5 (Suzuki et al., 2005b). 
Zinc sensitive fluorescent dyes and fluorescent probes have also been a useful tool in 
determining the function of ZnTs. Over-expression of the ZnTs is consistent throughout 
the ZnT functional experiments. The role of Znt7 in zinc transport has been investigated 
by using Znt7-myc-expressing CHO cells and the fluorescent zinc probe Zinquin. 
Results revealed increased extracellular zinc lead to accumulation of vesicular zinc in 
the perinuclear regions, implying an efflux role of Znt7 out of the cytoplasm and into 
these vesicles (Kirschke and Huang, 2003). The studies relating to ZnT8 are similar in 
methodology.   A  ZnT8 construct tagged with a GFP epitope was transfected into HeLa 
cells and assessed under different zinc conditions again, using the Zinquin probe. 
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Fluorescence microscopy results indicated that expression of ZnT8-EGFP leads to zinc 
accumulation in intracellular vesicles in the presence of extracellular zinc (Chimienti et 
al., 2004).  However in β-cells (MIN6 cells), where ZnT8 is endogenously expressed, 
over-expression of ZnT8 and use of the fluorescent probes Zinquin, FluoZin-3 and 
RhodZin3-AM showed an influx of zinc at the plasma membrane in addition to the 
accumulation of zinc in the secretary granules eluded to above (Nicolson et al., 2009).  
Promoter reporter assays have been used for numerous studies into the functional 
activity of ZnTs. Measurements for Znt1, Znt2 and Znt3 were taken in zinc sensitive 
baby hamster kidney (BHK) cells stably expressing the MRE-βGeo construct that were 
transfected with the appropriate construct and treated with high levels of extracellular 
zinc. Transfection of Znt1 or Znt2 into this cell line resulted in the reduction of basal β-
galactosidase activity therefore implying a decrease in intracellular zinc concentration. 
This approach was validated by the fact that efflux of radioactive 
65
Zn was increased in 
cells transfected with Znt1 (Palmiter and Findley, 1995). Znt1 efflux has also been 
implicated in neuronal zinc homeostasis with transfection of rat Znt1, wild-type and a 
mutated version, into the neuronal PC12 cells. The mutant was a negative dominant 
(ND) mutation lacking an 83 bp region. In support of previous research it was found 
that wild-type Znt1 was able to increase zinc efflux and therefore provide a zinc 
resistance system in the cells conversely, the mutant displayed the opposite effect (Kim 
et al., 2000). In comparison, investigation with the zinc fluorescent probe Zinquin 
showed Znt2 acts to accumulate zinc into intracellular vesicles (Palmiter et al., 1996a). 
Interestingly for Znt2 the construct was made with a fluorescent tag so it could be 
visualised and this transporter co-localised in the vesicles with Zinquin.  
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Use of both promoter reporter assays and zinc sensitive fluorescent probes were used to 
assess the function of Znt3. This Znt behaves slightly differently to Znt1 and Znt2 in 
that there is no change in the BHK cells with over-expression of the construct in 
response to zinc, or incidentally other heavy metals (copper, cobalt, or cadmium), with 
no evident Zinquin fluorescence (Palmiter et al., 1996b).  The authors suggest that this 
is due to the absence of an unknown necessary chaperone protein(s) that would be 
expressed in an endogenous situation. No other functional experiments have been 
carried out for Znt3 however disruption of the Znt3 in the Znt3 null mouse model shows 
an absence of vesicular zinc in neurons indicating that Znt3 is important in zinc 
accumulation in the synapses (Cole et al., 1999).  
A combination of the techniques described above has been used to assess ZnT5 
functionality. However, ZnT5 is unique in the investigation of efflux as both direct and 
indirect measurements have been used. Interestingly, this is also the only ZnT thus far 
that has shown zinc transport to be bi-directional (Valentine et al., 2007). In 2002, ZnT5 
was shown to act as an effluxer, by indirect measurements by over-expressing a ZnT5 
construct in HeLa cells and assessing the uptake of 
65
Zn. ZnT5 transfection enabled 
65
Zn uptake into Golgi-enriched vesicles from HeLa cells thereby decreasing cytosolic 
zinc (Kambe et al., 2002). However, work carried out at the same time found differing 
results. Using functional expression of ZnT5 in Xenopus laevis oocytes it was reported 
that there is a progressive increase of 
65
Zn across the plasma membrane and therefore it 
was concluded that ZnT5 has the ability to import zinc and increase cytoplasmic zinc 
concentration (Cragg et al., 2002). The differences between these two pieces of research 
may be explained by distinguishing between the two splice variants. Kambe et al., 
(2002) were looking at the function of ZnT5vA and Cragg et al., (2002) at ZnT5vB. 
Furthermore, subsequent direct investigation into ZnT5vB (i.e. the Xenopus Laevis 
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model (Valentine et al., 2007)) showed that this isoform has bi-directional properties. In 
addition, indirect measurement of ZnT5vB confirmed zinc transport in the influx 
direction in a physiologically relevant cell line, Caco-2 cells.  In this model system the 
effect of increased ZnT5 transporter expression on the intracellular zinc status was 
analysed by measuring the response of a β-galactosidase gene to zinc driven by a zinc 
responsive MT2a construct (Valentine et al., 2007).  Furthermore, this study used the 
zinc sensitive fluorescent probe Rhodzin-3 to demonstrate the accumulation of zinc in 
Caco-2 cells transiently transfected with the N-terminal GFP tagged ZnT5vB construct 
further confirming the uptake of zinc by this variant. 
ZnT9 has been found to be implicated in the redistribution of mammary gland zinc 
pools and the secretion of zinc into milk but despite its implication in the "Zn-
transporting network" functional studies on the proposed transporter have yet to be 
carried out (Kelleher et al., 2011). Similarly, the functional role of ZnT10 has not been 
investigated previously and thus I measured the functional ability of ZnT10 in a 
physiologically relevant cell type where I have shown ZnT10 to be endogenously 
expressed.  The effect of over-expression of ZnT10 on the intracellular zinc status of the 
human intestinal cell line Caco-2 was determined by measuring the activity of a zinc-
stimulated reporter gene. This has been described previously to demonstrate the zinc 
uptake function of ZnT5 (Valentine et al., 2007). Moreover, a comparative study by 
Palimter et al., (1995) goes some way to validate promoter reporter assays. Decreased 
activity of the zinc-responsive MT2a promoter when ZnT10 was co-expressed in Caco-
2 cells indicated a decrease in total intracellular zinc content and so I predict that ZnT10 
is a putative effluxer in accordance with the other ZnT family members (Figure 3.11).  
Whilst direct measurements would strengthen this result this would involve the use of 
radioactive zinc (
65
Zn) and therefore would pose a number of health and safety risks. It 
Chapter 3: Characterisation of ZnT10 
120 
 
is also not known whether the use of the Xenopus laevis model system (as used for 
ZnT5) is optimal, for these zinc transporters as in this system bi-directional capacity can 
be shown, depending on the experimental conditions  (Valentine et al., 2007). However, 
the indirect measurement used in this research has previously been reported to be 
suitable and consistent with direct measurements for ZnT5vB. In addition, the promoter 
reporter assays using a similar system have been used and reported for Znt1, Znt2 and 
Znt3 (Palmiter and Findley, 1995, Palmiter et al., 1996a, Palmiter et al., 1996b, 
Valentine et al., 2007). Therefore, I believe the results reported demonstrate ZnT10 
activity as a putative effluxer of zinc, although limitations for all methods should be 
kept in mind.   
Data presented in this chapter furthers our understanding of the characteristics of the 
CDF family member ZnT10. In summary I have found that ZnT10 contains the 
conserved CDF motif placing it in this family. In addition, predicted topology 
modelling indicate that ZnT10 has the conserved structure of six TMD with a basic 
cytoplasmic region between TMD IV and TMD V. In addition there are conserved 
residues in TMD V and VI that are hypothesised to be involved in the binding of zinc. 
ZnT10 is predicted to have a 29 amino acid signal peptide sequence at its N-terminal. 
Post-translationally ZnT10 is predicted to have 3 N-glycosylation sites, 1 O-
glycosylation site and 15 possible sites for phosphorylation. I have found ZnT10 to be 
differentially expressed in adult human tissues with relatively high levels in small 
intestine, liver, brain and testes and lower levels in ovary, colon, cervix, placenta and 
prostate. Finally I provide evidence that ZnT10 is a functional zinc transporter and show 
indirectly that it reduces cytoplasmic zinc and therefore propose ZnT10 transports in the 
efflux direction. 
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Table 3.1 Predicted topology of ZnT10. The programmes used were 
TMPred and TMHMM 
 .  Predicted topology of ZnT10. The programmes used were 
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Figure 3.1 ZnT10 sequence alignments A. Partial sequence alignment of the 
basic region of ZnT6 and ZnT10 using the ClustalW programme. Histidine 
residues are highlighted in black, serine residues highlighted in grey and additional 
ZnT10 basic residues are underlined B. Partial sequence alignment of TMD V and 
VI of ZnT10 with the equivalent regions in ZnT5 using the ClustalW programme 
(adapted from Seve et al., 2004) 
A 
B 
Figure 3.1 ZnT10 sequence alignments A. Partial sequence alignment of the basic 
region of ZnT6 and ZnT10 using the ClustalW programme. Histidine residues are 
highlighted in black, serine residues highlighted in grey and additional ZnT10 basic 
residues are underlined B. Partial sequence alignment of TMD V and VI of ZnT10 
with the equivalent regions in ZnT5 using the ClustalW programme (adapted from 
Seve et al., 2004) 
Chapter 3: Characterisation of ZnT10 
123 
 
  
  
Figure 3.2 A bioinformatic profile of ZnT10 A. Topology Model of ZnT10 using 
TMPred B. CDF motif consensus sequence where [] = can be a number of amino 
acid, X(n) a run of any amino acid, no brackets it must be that amino acid C. 
Predicted protein sequence.  Highlighted in yellow; Position 34-50 CDF motif 
sequence SIALLSDSFNmlsDLiS; Underlined transmembrane domains according to 
TMPred; Highlighted in purple; Signal peptide cleavage site amino acid 29; 
Highlighted in green; N-glycosylation sites amino acid 377, 471 and 481; 
Highlighted in blue; O-glycosylation sites amino acid 183; Highlighted in red; 
phosphorylation sites,7 serine amino acid 5, 69, 149, 197, 233, 363, 446, 4 threonine 
amino acid 8, 192, 196, 219, 4 tyrosine amino acid 278, 359, 440, 479. 
Chapter 3: Characterisation of ZnT10 
124 
 
 
  
Table 3.2 Predicted modification sites of ZnT10. The programme used were 
NetNGlyc, NetOGlyc and NetPhos respectively. 
 .  re icte  odification sites of ZnT10. The progra me used w re 
t l , t l   t  ti l . 
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Table 3.3 RT-PCR primers used on mouse brain RNA to generate Znts, Mt1 
and 18S rRNA. The numbering on each of the oligonucleotides represents its 
position on the gene. *(Helston et al., 2007). 
l  .  -  i     i   t  t  t , t  and 
18S rRNA. The numbering on each of the ligonucle tides repr ents it  po ition on 
the gene. *(H lsto  et al., 2007). 
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Figure 3.3 Expression of Znts and the positive controls (Mt1 and 18S rRNA). A.  
Znt1-7 expression in mouse brain and kidney. B. Expression of Znt8 and the 
reference gene 18S rRNA in the mouse brain and pancreas. C. Expression of Znt9, 
Znt10 and Mt1 (an additional positive control) and 18S rRNA in the mouse brain and 
kidney. Negative control RT-PCR reactions identical to those yielding the products 
shown except for the omission of Superscript III reverse transcriptase resulted in no 
products. 
Znt1 
Znt2 
Znt3 
Znt4 
Znt5 
Znt6 
Znt7 
Znt8 
18S rRNA 
Znt9 
Znt10 
Mt1 
18S rRNA 
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Figure 3.4 Confirmation that expression in adult tissue. ZnT10 is 
expressed in adult mouse brain, but not adult mouse kidney. Primers 
used given in Table 3.3. Bands were generated by RT-PCR from 
RNA samples extracted from mouse tissues indicated. Negative 
control RT-PCR reactions identical to those yielding the products 
shown except for the omission of Superscript III reverse 
transcriptase resulted in no products. 
Figure 3.4 Confirmation of expression in adult mouse tissue. Znt10 is expressed 
in adult mouse brain, but not adult mouse kidney. Primers used given in Table 3.3. 
Bands were generated by RT-PCR from RNA samples extracted from mouse tissues 
indicated. egative control RT-PCR reactions identical to those yielding the products 
shown except for the omission of Superscript III reverse transcriptase resulted in no 
products. 
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Table 3.4 Primer sequences for human ZnT10 and GAPDH RT-PCR and RT-
qPCR analysis *(Valentine et al., 2007)  
le .  ri er sequences for human ZnT10 and GAPDH RT-PCR and RT-
 l sis ( l ti  t l., )  
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Figure 3.5 ZnT10 mRNA is expressed in adult tissues. Relative levels of 
ZnT10 mRNA in a range of adult human tissues (Ambion human tissue panel) 
measured by semi-quantitative RT-PCR, using Taq polymerase (New England 
Biolabs). Data are expressed relative to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA levels measured in the same samples. Negative 
control RT-PCR reactions identical to those yielding the products shown except 
for the omission of Superscript III reverse transcriptase resulted in no products. 
ZnT10 
GAPDH 
Figure 3.5 ZnT10 mRNA is expressed in adult tissues. Relative levels of ZnT10 
mRNA in a ra ge of adult human tissues (Ambion human ti sue p nel) measured by 
semi-quantitative RT-PCR, using Taq polymerase New E gland Biolabs). Data are 
express relative to glyceraldehyde-3-phosphate dehydrog n s  GAPDH) mRNA 
leve s measured in the same samples. Negative control RT-PCR reactions identical to 
those yielding the products shown xcept for th  omission of Superscript III reverse 
tra scriptase resulted in o produ ts. 
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TOPI 
GAPDH 
Figure 3.6 Standard curves generated to measure relative levels of ZnT10 by RT-
qPCR, using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ Research). 
Standards for GAPDH and ZnT10 products were generated by amplifying the region 
between the primers shown in Table 3.4, and subcloned into the vector pCR2.1-TOPO TA 
(Invitrogen). TOPI primers were purchased from PrimerDesign. A TOPI PCR product 
was produced and subcloned into the pGEM-T-easy vector to give the standard TOPI-
pGEM (generated by Dr Alison Howard). The mean log concentration of each dilution 
was plotted against PCR cycle number at which the fluorescent threshold was crossed 
(C
T
).These standard curves were used to calculate relative levels of ZnT10 transcripts.  
Figure 3.6 Standard curves generated to measure relative levels of ZnT10 by 
RT-qPCR, using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ 
Research). Standards for GAPDH and ZnT10 products were generated by amplifying 
the region between the primers shown in Table 3.4, and subcloned into the vector 
pCR2.1-TOPO TA (Invitrogen). TOPI primers were purchased from PrimerDesign. A 
TOPI PCR product was produced and subcloned into the pGEM-T-easy vector to 
give the standard TOPI-pGEM (generated by Dr Alison Howard). The mean log 
concentration of each dilution was plotted against PCR cycle number at which the 
fluorescent threshold was crossed (C
T
).Exclud d data points are shown in red These 
standard curves were used to calculate relative levels of ZnT10 transcripts.  
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Figure 3.7 ZnT10 mRNA expression in adult tissues relative to GAPDH. Relative 
levels of ZnT10 mRNA in a range of adult human tissues (Ambion human tissue 
panel) measured by RT-qPCR, using SYBR green fluorescence and the DNA Engine 
Opticon 2 (MJ Research). Data are expressed relative to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA levels measured in the same samples. Values are 
means (n = 3), with standard errors represented by vertical bars.  
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Figure 3.8 ZnT10 mRNA expression in adult tissues relative to TOPI. Relative 
levels of ZnT10 mRNA in a range of adult human tissues (Ambion human tissue 
panel) measured by RT-qPCR, using SYBR green fluorescence and the DNA Engine 
Opticon 2 (MJ Research). Data are expressed relative to topoisomerase I (TOPI) 
mRNA levels measured in the same samples. Values are means (n = 3), with standard 
errors represented by vertical bars.  
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Table 3.5 RT-PCR primers used to generate full-length ZnT10 construct by 
nested RT-PCR. The numbering on each of the oligonucleotides represents its 
position on the gene. 
able 3.5 RT-PCR primers used to generate full-length ZnT10 construct by 
nested -P . The numbering on each of the oligonucleotides represents its 
position on the gene. 
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Figure 3.9 Generation of full-length ZnT10 PCR product A. Nested PCR products 
for full-length ZnT10 from SH-SY5Y RNA using primers in Table 3.5 B. 
Confirmation of PCR product after PCR clean-up (QIAgen) using restriction enzymes 
PstI, yielding products of 998 bp and 459 bp, and EcoRV, yielding products of 1076 
bp and 381 bp. 
3.9 Generation of full-length ZnT10 PCR product A. Nested PCR 
products for full-length ZnT10 from SH-SY5Y RNA using primers in Table B. 
of PCR product after PCR clean-up (QIAgen) using restriction 
enzymes PstI, yielding products of 998 bp and 459 bp, and EcoRV, yielding products 
of 1076 bp and 381 bp. 
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Figure 3.10 Analysis of full-length construct A. Confirmation of insert 
presence in TOPO-TA vector i) using a restriction digest with enzymes EcoRI 
and BamHI ii) using ZnT10 RT-PCR primers (Table 3.4) and TOPO-TA-ZnT10 
as a template B. Confirmation of insert presence in p3xFLAG vector using a 
restriction digest with enzymes EcoRI and BamHI.  Identity was confirmed by 
sequencing (MWG Biotech) 
i  3.10 Analysi  of full-length construct A. Confirmation of insert pre nce in 
TOPO-TA vector (i) using a restriction digest with enzymes EcoRI and BamHI (ii) 
using ZnT10 RT-PCR primers (Table 3.4) and TOPO-TA-Zn 10 as a template B. 
Confirmation of insert presence in p3xFLAG vector using a restricti n digest with 
enzymes EcoRI and BamHI.  Identity was confirmed by sequencing (MWG 
Biotech). 
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Figure 3.11 The effect of ZnT10 expression on the activity of the zinc-activated 
MT2a promoter. Data are β-galactosidase activity in lysates from Caco-2 cells co-
transfected transiently with an MT2a-promoter-β-galactosidase-reporter construct 
(pBlue-MT2a) plus ZnT10 (p3xFLAG–ZnT10) or corresponding vector only 
(p3XFLAG-BAP vector), as indicated and maintained for 24 h in control medium with 
or without the addition of 100 µM ZnCl
2
.   Values are means (n=3-6), with standard 
errors represented by vertical bars. *** p < 0.001 by Student’s t -test. 
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Chapter 4: Regulation of ZnT10 in response to zinc 
4.1 Outline 
In this chapter it is hypothesised that ZnT10 may be involved in zinc homeostasis due to 
its response to zinc treatments. Results presented here show ZnT10 mRNA expression 
is down-regulated in response to zinc using both semi-quantitative RT-PCR and RT-
qPCR. In addition, Western blotting techniques indicate that this down-regulation is 
evident at the protein level; in p3xFLAG-ZnT10 transiently transfected SH-SY5Y cells. 
Using bioinformatics techniques I identify the presence of a putative Zinc 
Transcriptional Regulatory Element (ZTRE) which appears to be involved in this down-
regulatory response at the transcriptional level. This response is lost when this ZTRE 
sequence is mutated. Furthermore, in SH-SY5Y cells transiently expressing p3xFLAG-
ZnT10 there appears to be a translocation of ZnT10 within the cell in response to zinc 
treatment.  
As discussed in Chapter 1, the body’s ability to regulate homeostasis of nutrients is 
imperative to survival. Zinc is no exception to this. For example zinc deficiency through 
foetal development leads to growth retardation and in the adult human leads to 
immunodeficiency, hair loss and loss of appetite (Prasad et al., 1961). In excess zinc can 
cause nausea, diarrhoea and local neuronal deficits (Vallee, 1988). Zinc has also been 
implicated in disease states such as neurodegenerative diseases and diabetes 
(Frederickson, 1989, Chimienti et al., 2004). Homeostasis of zinc - biosystemically and 
at the cellular level - requires regulated expression and/or activity of zinc transporters 
such as the ZnTs. An example of this is ZnT1, found at the plasma membrane, where a 
major role is to efflux zinc out of the cell (Cousins and McMahon, 2000, Palmiter and 
Findley, 1995).  ZnT1 mRNA expression is up-regulated in response to increased zinc 
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concentrations (Liuzzi et al., 2001), mediated through transcriptional regulation by 
metal response element transcription factor-1 (MTF-1) (Langmade et al., 2000). 
Zinc is obtained through the diet as it is bound to proteins in foods such as shellfish, red 
meat and, to a lesser extent cereals and legumes. The absorption of zinc takes place in 
the gastrointestinal tract by the enterocytes and whilst this is important for zinc 
homeostasis the balance between absorption of exogenous zinc, gastrointestinal 
secretion and excretion of endogenous zinc are critical in order for the body to be able 
to balance this nutrient. Absorption by the enterocytes is mediated by the interplay of 
ZIPs and ZnTs (see section 1.5). For example, transporters found to be expressed in 
these cell types include ZnT1, ZnT2, ZnT4, ZnT5, ZnT6, ZnT7, ZIP4, and ZIP5 
(reviewed by Wang and Zhou, 2010).  
ZnTs have varying localisation patterns depending on their function. For example ZnT1 
is implicated in regulating efflux of zinc across the basolateral membrane, out of 
enterocytes and into systemic circulation (McMahon and Cousins, 1998) whereas ZnT7 
is involved in intracellular trafficking of zinc and is able to facilitate the accumulation 
of zinc in the Golgi apparatus (Huang et al., 2007). Indeed the two transcripts of ZnT5 
give an insight into the importance of cellular localisation with ZnT5vA localising to 
the Golgi apparatus, presumably to fulfil a role in zinc accumulation (Kambe et al., 
2002, Yu et al., 2007). Conversely, ZnT5vB is localised to the apical membrane of 
enterocytes with bi-directional properties important in the uptake of zinc in human 
intestinal Caco-2 cells and to the ER in unpolarised cells (Valentine et al., 2007, 
Thornton et al., 2011).  
Levels of dietary zinc are able to influence expression levels of the ZIPs and ZnTs 
found along the length of the gastrointestinal tract. For instance, studies in mice have 
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revealed alternative processes for Zip4 and Zip5 depending on zinc status. In cases of 
zinc restriction Zip4, found on the apical membrane of enterocytes is up-regulated along 
the length of the gastrointestinal tract in order to maximise zinc absorption however 
Zip5 is internalised during zinc deficiency so that minimal zinc influx takes place from 
the blood stream therefore, ultimately, restricting gastrointestinal secretion (Dufner-
Beattie et al., 2003b, Dufner-Beattie et al., 2004). The converse is also true, when mice 
are zinc replete Zip4 is internalised through endocytosis whereas Zip5 is up-regulated 
on the basolateral membrane (Weaver et al., 2007). In addition, it is evident that buffers 
such as MT, regulate levels of zinc within enterocytes. Regulation of MT by zinc 
enables this protein to be up-regulated to chelate zinc in times of excess and be 
degraded when zinc levels are low (Bell and Vallee, 2009). It is the response of the zinc 
transporters and MT to changes in local zinc status that allow whole body zinc content 
to be maintained (King et al., 2000).  
Results presented in Chapter 3 reveal a differential pattern of expression of ZnT10 
including the small intestine and, to a lesser extent, colon, therefore it too may play a 
role in zinc absorption at this site. 
Zinc homeostasis is not only maintained through the absorption process. Free zinc is 
toxic therefore little or no free zinc is available in solution within biological systems 
and zinc is circulated within serum chelated by binding proteins such as albumin (70 
%), α-macroglobulin (18 %) and bound to other proteins such as transferrin (Gibson et 
al., 2008). Zinc is distributed throughout the body to all organs. As in enterocytes, 
intracellular zinc may be bound to MT. MT plays a very important role in maintaining 
cellular zinc homeostasis. At high intracellular zinc concentrations, MT levels increase 
therefore sequestering zinc. At low zinc concentrations, MT is able to release its bound 
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zinc ions before being degraded. This allows a constant level of zinc in the serum to 
carry out its numerous biological functions (Coyle et al., 2002).  
Significant in the context of this research, in addition to the expression of ZnT10 in the 
gastrointestinal tract, ZnT10 displayed a restricted expression profile that included 
relatively high levels of expression in the brain. In the brain zinc is packaged into pre-
synaptic vesicles by ZnT3 and subsequently released during neurotransmission in 
neurones of the hippocampus (Palmiter et al., 1996b). Znt3 knockout mice have shown 
deficits in spatial memory and behaviour dependent on the hippocampus (Martel et al., 
2011). The dyshomeostasis of zinc within the brain has been implicated in 
neurodegenerative diseases. For example, zinc has been shown to be present in 
aggregates in diseases such as Alzheimer’s providing evidence to strengthen the 
hypothesis that zinc is implicated in neurodegeneration (Frederickson, 1989). 
Furthermore, it has been hypothesised, though not proven, that an observed up-
regulation of ZnT1 expression in the brain contributes to the zinc dyshomeostasis 
identified in Alzheimer’s disease (Zhang et al., 2008), the hypothesis is that the increase 
in ZnT1 expression causes an increase in zinc ions available in the extracellular space 
for the initiation of amyloid-β deposition. Given the relatively high expression levels of 
ZnT10 measured in brain tissue, it suggests a role for this transporter in the homeostasis 
of zinc in this organ. 
Key transcription factors found in bacteria, yeast and higher metazoans have been 
identified through their ability to regulate sets of genes that contribute to the 
maintenance of zinc homeostasis and/or the ability to adapt to differences in the 
availability of zinc.  In bacteria the ArsR-SmtB family of transcriptional de-repressors 
act to repress the expression of certain operons at stress-inducing concentrations of 
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divalent metal ions including zinc. Direct binding of such metal ions results in de-
repression (reviewed by Busenlehner et al., 2003, Waldron and Robinson, 2009). 
Transcriptional activators include the MerR family of DNA-under-winding 
transcriptional activators that are able to bind metal and subsequently under-wind 
promoter regions such that RNA-polymerase recognition sequences are optimally 
aligned (reviewed by Waldron and Robinson, 2009). The less well defined Fur family is 
known to contain structural zinc sites. This family of transcriptional regulators bind 
DNA after binding metals and mainly function to repress transcription however, direct 
activation of transcription is evident for some promoters  (reviewed by Waldron and 
Robinson, 2009).  In E. coli the MerR family factor ZntR has been found to stimulate 
zinc-responsive expression of a zinc exporter ZntA (a cation-translocating ATPase) by 
binding to the DNA and distorting its alignment (Outten et al., 1999). In contrast the 
transcriptional repressor Zur, a member of the Fur family of transcription factors, binds 
two zinc ions in order to bind to DNA and repress the transcription of a zinc importer in 
the znuABC gene cluster (Patzer and Hantke, 2000).  
In S. cerevisiae investigations have identified an 11 bp zinc-responsive element (ZRE) 
in the promoter regions of certain genes, for example; the high affinity zinc uptake 
transporter ZRT1 (Zhao and Eide, 1997) and the vacuolar zinc exporter ZRT3 
(MacDiarmid et al., 2000), as well as many others (Wu et al., 2008). The transcription 
factor Zap1 is itself induced and binds to the ZRE in cases of zinc deficiency thereby 
inducing activation of these genes (Lyons et al., 2000). Conversely, transcriptional 
repression of zinc-dependent alcohol dehydrogenases is achieved by Zap1 under 
conditions of zinc limitation. Zap1 acts to induce an intergenic transcript that in turn is 
able to displace the transcriptional activator (Bird et al., 2006). For the uptake 
transporter ZRT2, transcriptional repression is achieved by the binding of Zap1 to a 
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non-consensus ZRE at a transcriptional start site (Bird et al., 2004).  Transcriptional 
control of the expression of proteins including zinc transporters appears to play a major 
role in zinc homeostasis in plants (reviewed by Sinclair and Kramer, 2012, Palmer and 
Guerinot, 2009), and Arabidopsis transcription factors crucial to the response to zinc 
deficiency, with orthologs in other plant species, have been identified recently 
(Assuncao et al., 2010).     
In higher animals, the increased transcription of genes at higher levels of zinc 
availability is mediated in some instances through binding of the transcription factor 
MRE-binding transcription factor 1 (MFT1). MTF1 has 6 zinc fingers and these bind 
DNA at a specific consensus sequence within promoter regions. The DNA motif is 
called a Metal Responsive Element (MRE) and is characterised by the 7 bp sequence 
TGCRCNC (Heuchel et al., 1994). In order to protect cells from levels of high zinc 
MTF1 mediates transcriptional up-regulation of genes such as mouse metallothoinein-1 
and -2 genes (Mt1 and Mt2) and the gene for the zinc transporter Znt1 (Slc30a1), 
responsible for the efflux of zinc across the plasma membrane (Heuchel et al., 1994, 
Langmade et al., 2000).  Like yeast Zap1, MTF1 can also act in a repressive role.  Zip10 
expression is increased in the conditional MTF1 knockout mouse (Wimmer et al., 
2005). Further research has shown that Zip10 includes MREs downstream of the 
transcriptional start site and binding of MTF1 to these MREs mediates transcriptional 
repression (Lichten et al., 2011). In addition, the zebrafish Zip10 has two distinct 
transcriptional start sites and experimentation reveals that Zip10 is regulated by 
alternative promoters that are oppositely-regulated by zinc. Both promoters contain 
MRE clusters which shows that MREs can function as both repressor and activation 
elements (Zheng et al., 2008).  It is possible that MTF1 requires accessory proteins in 
order to form co-activator complexes in order to fulfil these contrasting roles. Indeed, 
Chapter 4: Regulation of ZnT10 in response to zinc 
143 
 
activation of the Mt1 promoter requires transcription factor Sp1 and the histone 
acetyltransferase p300/CPB in complex with MTF1 and this activation was reduced by 
siRNA knockdown of p300/CBP.  However the accessory proteins evidently differ 
between complexes as p300/CBP knockdown did not affect MTF1-mediated activation 
of the mouse Znt1 gene (Li et al., 2008). Interestingly, there must be mechanisms in 
addition to MTF1 that are able to influence zinc induced repression as mutation of the 
consensus MRE sequence in ZnT5 was unable to abolish the zinc-induced repression 
ordinarily observed in transfected Caco-2 cells (Jackson et al., 2007).   To understand 
zinc homeostasis it is thus essential to uncover additional mechanisms of zinc-regulated 
gene expression. One mode of regulation has been elucidated in the ZIP family of 
transporters, namely ZIP4. It is known that ZIP4 is essential for zinc absorption, as 
highlighted by the disease Acrodermatitis enteropathica (AE) (Wang et al., 2002). It is 
evident that Zip4 protein is stabilised and translocated to the apical membrane in zinc 
deficient conditions (Dufner-Beattie et al., 2004). Researchers have also hypothesised 
that at the level of transcription Zip4 mRNA is up-regulated when cells are zinc deplete. 
In fact, recent studies have identified the transcription factor Krüppel-like factor 4 
(KLF4) in the activation of Zip4. In the murine intestinal epithelial cell (IEC) line 
MODE-K both KLF4 and Zip4 were up-regulated in zinc deficient conditions but 
siRNA knockdown studies of KLF4 reduced the activation of Zip4 (Liuzzi et al., 2009). 
Moreover, Liuzzi et al., (2009) used EMSAs with the nuclear extracts of MODE-K 
cells, to show that KLF4 binds to the Zip4 promoter, a phenomenon that is increased 
when zinc is limited. Further investigation with reporter constructs involving the wild-
type and mutated Zip4 promoter demonstrated that this regulation of Zip4 is through a 
KLF4 response element. These results should be interpreted with caution though given 
the low levels of Zip4 evident in the MODE-K cells (Huang et al., 2006). Data 
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produced by Weaver et al., (2007) indicates that regulation is at a post-transcriptional 
level. 
Similarly, EMSAs have revealed that there is a protein factor that binds to the ZnT5 
promoter in a zinc-dependent manner. Through this there has been identification of the 
binding site in the ZnT5 promoter responsible for zinc-induced transcriptional 
repression, namely the ZTRE (for Zinc Transcriptional Regulatory Element) 
(Coneyworth et al., 2012). Results presented here show the discovery of the presence of 
a ZTRE sequence in the human ZnT10 promoter. Thus, I present evidence for a down-
regulatory response to zinc at both the mRNA and protein level and present a 
transcriptional regulatory process that operates in mammalian cells to repress 
transcription of ZnT10 in response to increased zinc availability.  Abolition of the 
response was evident with mutation of this putative ZTRE region. 
4.2 Regulation of ZnT10 by extracellular zinc at the mRNA level 
4.2.1 Semi-quantitative analysis 
In order to establish whether ZnT10 mRNA transcript levels were altered in response to 
extracellular zinc treatments, semi-quantitative RT-PCR was carried out on human 
neuroblastoma cells, SH-SY5Y. Cells were treated with either basal medium, or 
medium supplemented with 150 µM ZnCl2 for 24 h. SH-SY5Y cell viability was 
established over the concentration range by counting using the Trypan blue exclusion 
method (83.1 % + 2.5 viable untreated cells compared with 80.4 % + 4.4 viable cells at 
150 µM ZnCl2) (Figure 4.1A). Cell viability was further confirmed by measuring the 
reduction of resazurin to resorufin (Alamar Blue, Invitrogen). No significant difference 
between treated (100 µM zinc) and untreated SH-SY5Y cells was observed (p = 0.159) 
(Figure 4.1B). RNA from SH-SY5Y cells was harvested (Section 2.4.1) and RT-PCR 
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performed using primers designed to anneal to human β-actin and MT1(A) and human 
ZnT10 (Table 4.1). When normalized to β-actin, ZnT10 mRNA expression was reduced 
in cells treated with 150 µM extracellular zinc compared with untreated cells (basal 
medium) (Figure 4.2). Levels of metallothionein mRNA, known to be up-regulated by 
zinc (Heuchel et al., 1994), were increased at 150 µM compared with basal media (3 
µM zinc) indicating that the treatments were successful with a significant increase in 
expression (Figure 4.2). 
4.2.2 Real-time quantitative analysis (RT-qPCR) 
To confirm the semi-quantitative findings RT-qPCR was employed as described 
previously (section 2.5.5). Standard curves were generated as described (section 2.5.5.1) 
and for all RT-qPCR standard curves passed acceptance criteria (Figure 4.3). The effect 
of zinc availability on levels of expression of ZnT10 mRNA in both SH-SY5Y cells and 
Caco-2 cells was determined by culturing cells at increasing concentrations of zinc (up 
to 150 µM ZnCl2) for 24 h.  Three concentrations of extracellular zinc (50 µM, 100 µM 
and 150 µM ZnCl2) were analysed in both SH-SY5Y cells and Caco-2 cells. In addition 
to the cell viability data shown in Figure 4.1, it has previously been reported that there 
is no effect on Caco-2 cell viability at this concentration of zinc (Jackson et al., 2007). 
Total RNA was extracted from cells and RT-qPCR was carried out using GAPDH as 
the reference gene.  Cells treated with increasing levels of extracellular zinc showed a 
significant decrease in ZnT10 mRNA expression (Figure 4.4A and 4.4C).  GAPDH 
showed a consistent level of expression independent of the zinc treatment and was 
therefore chosen as the reference gene and normalisation control.  GAPDH has 
previously been used to normalise zinc response by RT-qPCR (Jackson et al., 2007, 
Hojyo et al., 2011).  All levels were assessed as a ratio to GAPDH. Furthermore, using 
Caco-2 mRNA at an extracellular zinc concentration of 100 µM ZnT10 mRNA levels 
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were additionally assessed as a ratio to a further reference gene; TOPI. There was also a 
significant decrease in ZnT10 transcript abundance relative to TOPI in Caco-2 cells 
treated with 100 µM extracellular zinc (Figure 4.4E). A further control experiment, 
using MT1, revealed the expected increase in response to zinc in RNA from the same 
SH-SY5Y and Caco-2 cells (Figure 4.4B and 4.4D).  
In addition, the removal of FBS from the media was investigated to see whether this in 
itself effects ZnT10 expression. The results above show that the addition of 100 µM 
extracellular zinc gives a decrease in ZnT10 expression. Here we also show that 
medium both with and without FBS elicits the same down-regulation in response to the 
extracellular zinc (p = 0.02 without FBS, p = 0.04 with 10 % FBS by Student’s t-test) 
(Figure 4.5). Therefore all experiments herein were completed in the presence of 10 % 
FBS. 
4.3 Identification of a putative ZTRE in the proximal promoter region of ZnT10 
4.3.1 Bioinformatic analysis to identify potential transcriptional element 
sequences 
To date research has focused on transcriptional up-regulation of zinc effluxers such as 
ZnT1 (Langmade et al., 2000). The increased transcription of genes at increased levels 
of zinc availability is mediated, in some instances through binding of the transcription 
factor MTF1 to copies of the MRE in the promoter region.  In addition, it is known that 
MREs can mediate both positive and negative regulation in zebrafish Zip10 however 
this is under the control of alternative promoters (Zheng et al., 2008). Analysis using the 
bioinformatics programme, Fuzznuc (http://www.hpa-
bioinfotools.org.uk/pise/fuzznuc.html), identified two putative MREs in the promoter 
region of ZnT10; TGCGCGC (-60 bp to -54 bp relative to the ATG start site) and 
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TGCGCTC (-44 bp to 38 bp relative to the ATG start site). The data above reveals a 
novel observation concerning the expression of ZnT10, such that there is a reduction in 
ZnT10 mRNA in SH-SY5Y and Caco-2 cells in response to increasing the extracellular 
zinc concentration from 3 µM to 150 µM. The indirect measurement of promoter-
reporter activity shown in Chapter 3 leads to the prediction that this transporter acts as 
an effluxer and therefore I would expect an increase in response to extracellular zinc 
however the down-regulation described above is not without precedence. ZnT5, a 
ubiquitous transporter, also shows this down-regulatory response to extracellular zinc 
(Cragg et al., 2002, Jackson et al., 2007). Further investigation by our group showed 
that there is a region upstream of ZnT5’s ATG start site (-154 to +50, relative to the end 
of the 5’ UTR) responsible for this transcriptional repression (Jackson et al., 2007). 
Recent analysis of this region by EMSAs has enabled the identification of a specific 
sequence known as the Zinc Transcriptional Regulatory Element (ZTRE) found in this 
204 bp promoter region (Coneyworth et al., 2012) (Figure 4.6A). As there is also a 
down-regulatory response of ZnT10 in response to extracellular zinc, the 5’-UTR of 
ZnT10 was investigated to see whether it contained a putative ZTRE sequence. Entrez 
Gene was used to establish that ZnT10 is present on Chromosome 1. A 3 kb upstream 
region from the ATG was screened for the presence of a ZTRE sequence, using the 
software package Fuzznuc. This search identified a putative ZTRE within the mRNA 72 
bp upstream of the translational ATG start site (Figure 4.6B). The identified sequence 
CCCACCT(GTGGCTGCGCGCG)GGGTGGG spans nucleotides 140-166 of the 
ZnT10 transcript sequence NM_0187132.  This sequence differs from the ZTRE in 
ZnT5 at two positions in the upstream half of the (imperfect) palindromic region and at 
one position in the downstream half; these differences are permissive according to the 
analysis of substitutions that retain binding of the protein factor identified by EMSA 
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(Coneyworth et al., 2012).  I thus predicted that ZnT10 promoter activity would respond 
to zinc in a similar manner as ZnT5. 
4.3.2 Response of the putative promoter region of ZnT10 to zinc 
To study transcriptional regulation by zinc of the ZnT10 gene, I measured the response 
of the active promoter region to changes in the extracellular zinc concentration in Caco-
2 and SH-SY5Y cells. I generated a ZnT10 promoter-reporter construct (Figure 4.6B, 
Table 4.2; -762 to +180, relative to the transcription start site, in pBlue-TOPO 
(Appendix B)) in which the candidate ZTRE (position +58 to +84) was retained 
(pBlueSLC30A10prom (Appendix G)) (Section 2.6.2). Cells were transfected 
transiently with the pBlueSLC30A10prom for 24 h in both basal medium or medium 
supplemented with 100 µM ZnCl2.  Reporter gene expression (β-galactosidase activity) 
driven by the ZnT10 promoter was reduced significantly at the higher zinc 
concentration in Caco-2 cells (Figure 4.7A).  A similar, but non-significant down-
regulatory trend was observed in SH-SY5Y cells transfected with the –762 to +180 bp 
ZnT10 promoter- reporter construct (Figure 4.7A).   As a positive control, I carried out 
parallel experiments using the well characterized, zinc-responsive human MT2a 
promoter (Helston et al., 2007) as the insert in the promoter-reporter construct; as 
expected, reporter gene expression was increased at the elevated zinc concentrations 
(Figure 4.7B).   
4.3.3 Response of the putative promoter region of ZnT10 after mutation of the 
ZTRE  
In order to ascertain whether it is indeed the putative ZTRE within the 942 bp promoter 
reporter construct pBlueSLC30A10prom that is responsible for the transcriptional 
repression at elevated zinc concentrations an additional promoter-reporter construct was 
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made; pBlueSLC30A10promMUT (Appendix H). Within the mutated construct, 
pBlueSLC30A10promMUT, the primers shown in Table 4.2 were used to substitute the 
ZTRE of ZnT10, retaining the inter-palindrome linker region but mutating the 
palindromic sequences at either end as shown in Figure 4.8A. This gave an end-product 
of a 942 bp promoter reporter construct to compare with pBlueSLC30A10prom. The 
mutated construct was generated by Georgia Hann. In line with previous experiments, 
Caco-2 cells were transfected transiently with either the pBlueSLC30A10prom or 
pBlueSLC30A10promMUT for 24 hour in both basal medium or medium supplemented 
with 100 µM ZnCl2.  Reporter gene expression (β-galactosidase activity) was reduced at 
the higher zinc concentration for pBlueSLC30A10prom however this response was 
abrogated by substitution of the candidate ZTRE (Figure 4.8B). Again, as a positive 
control, I carried out parallel experiments using the well characterized, zinc-responsive 
human MT2a promoter (Helston et al., 2007) as the insert in the promoter-reporter 
construct; as expected, reporter gene expression was increased at the elevated zinc 
concentrations (Figure 4.8C). 
4.4 ZnT10 expression in response to zinc at the protein level 
To examine the effect of zinc on ZnT10 protein expression, SH-SY5Y cells were 
transiently transfected with the plasmid p3xFLAG–ZnT10, a plasmid construct from 
which ZnT10 was expressed with an N-terminal FLAG epitope tag. Twenty-four hours 
post transfection cells were treated with basal medium or medium supplemented with 
100 µM ZnCl2 for a further 24 hours.  Subsequently the cells were lysed using a buffer 
containing 4 % SDS, 125 mM Tris and 5 % β-mercaptoethanol in order to extract the 
protein (section 2.4.2). This protein was electrophoresed on a denaturing 10 % 
acrylamide gel and blotted onto a PVDF membrane (section 2.7.2). Quantities of protein 
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prepared from cells treated under both conditions, was determined 
spectrophotometrically (Nanodrop). 10 µg of sample was loaded onto gels. Equal 
loading of samples was confirmed by re-immunoprobing blots with an anti-α-tubulin 
antibody.  Western blot analysis used an anti-FLAG antibody (Sigma; 1 in 1000 
dilution) and subsequently an anti-mouse IgG-HRP secondary antibody (GE Healthcare; 
1 in 20000 dilution). These were visualised by enhanced chemiluminescence (ECL) 
HRP substrate (Thermo Scientific). This revealed a protein band of approximately 56 
kDa (the expected size for ZnT10 (53 kDa) plus 3 x FLAG (3 kDa)) in both samples, 
indicating that N-terminal cleavage had not taken place.  Western blots were stripped 
and re-probed, using an anti-α-tubulin primary antibody (Abcam; 1 in 5000 dilution) 
and an anti-rabbit IgG -HRP secondary antibody (Abcam; 1 in 20000 dilution). Analysis 
of ZnT10 expression levels by densitometric quantification of band intensities, 
expressed as a ratio to α-tubulin, revealed a significant decrease in ZnT10 protein 
expression at 100 µM ZnCl2 compared with the untreated cells (Figure 4.9).  
The down-regulatory response at the protein level was not being driven by the strong 
CMV promoter upstream of the ZnT10 ORF in the FLAG vector (p3xFLAG-CMV-10 
(Sigma)). A further promoter-reporter construct, created by cloning the CMV promoter 
region (Genbank accession number X03922.1) into a pBlueTOPO vector (Invitrogen), 
upstream of the β-galactosidase reporter gene was produced and transfected transiently 
into Caco-2 cells. Cells were exposed to basal medium or medium supplemented with 
100 µM and 150 µM ZnCl2 for 24 hours.  Treatment with the higher zinc concentrations 
resulted in an unexpected significant increase in promoter activity compared with basal 
medium (Figure 4.10). This result indicates that the decrease in ZnT10 at the protein 
level is a true response of ZnT10 and does not reflect any effect of zinc on the CMV 
promoter (this experiment was carried out by Lisa Coneyworth). 
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Attempts to investigate endogenous ZnT10 levels were unsuccessful due to the lack of 
antibody specificity to ZnT10. The two commercially available ZnT10 antibodies (sc-
160941, sc-160942; Santa Cruz) did not reveal specific bands for ZnT10 on an 
immunoblot using samples from the SH-SY5Y cells in which we have confirmed 
ZnT10 expression at the mRNA level by RT-PCR. Furthermore, SH-SY5Y cells 
transiently transfected with the plasmid p3xFLAG–ZnT10 which using an anti-FLAG 
antibody revealed a specific band (indicating that transfection was successful) also did 
not produce a signal using either commercial ZnT10 antibody. The specificity of the 
two antibodies was questioned. Contradictory data referring to ZnT10 expression 
enhancing insulin secretion, referred to in the available Santa Cruz data sheet informed 
the investigation into antibody specificity. An investigation was carried out by RT-PCR 
and Western blot analysis. Both ZnT10 commercial antibodies are described as being 
cross-reactive with mouse (Santa Cruz) therefore RT-PCR was carried out using 
primers specific to mouse Znt8 and mouse Znt10 (Table 4.3) on RNA prepared from 
mouse brain and pancreatic tissue.  The results of this experiment as expected revealed 
expression of Znt8 in the pancreas and not in the brain (Chimienti et al., 2004), and 
conversely for Znt10 the opposite was found; Znt10 is present in the brain and not in the 
pancreas (Figure 4.11A), confirming our previous investigations (Chapter 3). 
The Western blot was completed using protein extracted from the same mouse brain and 
pancreas tissue. This was probed with the Znt10 antibodies purchased from Santa Cruz.  
Figure 4.11B, shows cross reactive bands (of approximately 20 kDa and 50 kDa) are 
only visible in the lane loaded with protein from pancreatic tissues and not in the lane 
derived from brain.  These results clearly show that this antibody is not specific for 
Znt10 (which is present in the brain and is not present in the pancreas) and indicate that 
the antibody is potentially picking up Znt8, although our experiments do not prove this. 
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4.5 Intracellular localisation of ZnT10 and its response to extracellular zinc 
treatment 
To examine the intracellular localisation of ZnT10, SH-SY5Y cells were transiently 
transfected with the plasmid p3xFLAG–ZnT10, a plasmid construct from which ZnT10 
was expressed with an N-terminal FLAG epitope tag.  Forty eight hours post 
transfection cells were fixed using 4 % PFA and stained with the anti-FLAG-FITC 
antibody (1:1000, Sigma). Rhodamine conjugated wheat germ agglutinin (WGA), a 
lectin that selectively binds N-acetylglucosamine and N-acetylneuraminic acid, was 
used to stain the Golgi apparatus in cells permeabilised with 0.1 % Triton X-100 
following PFA fixation (WGA; 1:500). ZnT10 showed co-localisation with WGA in 
permeabilised cells, consistent with localisation to the Golgi apparatus (Figure 4.12). 
Alteration in the pattern of localisation by changing the extracellular zinc concentration 
in basal medium with the addition of 100 µM extracellular zinc for a 24 hour period 
immediately prior to viewing the cells revealed a different pattern of localisation, which 
showed a reduced co-localisation with the wheat germ agglutinin in permeabilised cells 
and a more diffuse pattern of localisation including some expression towards the plasma 
membrane (Figure 4.12).  Transfection experiments were carried out in triplicate on two 
separate occasions.  All p3xFLAG-ZnT10 transfected cells revealed an identical pattern 
of localisation under the different zinc treatments.  p3xFLAG-BAP (used as a negative 
control, Appendix E) showed a diffuse pattern of expression throughout the cell in all 
experiments, which was not altered by extracellular zinc treatment (Figure 4.13), 
confirming that localisation of the signal to specific subcellular regions was a function 
of the attached ZnT10 protein. The two commercially available ZnT10 antibodies (sc-
160941, sc-160942; Santa Cruz) did not show any specific staining using this approach. 
The immunocytochemistry with these antibodies showed no difference from the 
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secondary or to the primary. The blocking peptide did not reduce the signal.  I was 
unable to establish specific staining under other conditions tested with these antibodies 
but I believe they are not specific to ZnT10 (section 4.4).   
4.6 Discussion 
In this chapter I show, by both semi-quantitative and RT-qPCR, a decrease in 
endogenous ZnT10 mRNA expression in response to increased extracellular zinc 
concentration in both the Caco-2 and SH-SY5Y cell line models. This is a surprising but 
not unprecedented response for a zinc transporter which has been shown to act as an 
effluxer (section 3.5) but this response is not unique for mammalian zinc transporters. 
The most notable down-regulation of a mammalian zinc transporter is the decrease in 
mRNA expression levels of Zip4 in response to increased levels of zinc with 
internalisation of Zip4 from the apical membrane through endocytosis (Dufner-Beattie 
et al., 2004). Presumably, this is in fact an important way of regulating zinc intake in the 
enterocytes. In the context of this research however, perhaps of more relevance is the 
regulation of ZnT5. In the original paper describing ZnT5vB (referred to as hZLT1) the 
response to zinc at the mRNA level was very intriguing. In Caco-2 cells there was a 
significant increase in ZnT5vB mRNA but no change in ZnT5vB mRNA levels in the 
placental cell line JAR with increased extracellular zinc (Cragg et al., 2002). The tight 
regulation of maternal zinc concentrations through intestinal absorption and 
mobilisation of zinc stores were hypothesised to render placental regulation of zinc 
superfluous. I do not see a cell line dependent response for ZnT10 however both cell 
lines used (intestinal and brain) are from tissues that require very stringent levels of 
control of such nutrients. 
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Subsequently, a body of research has developed looking at the regulation of both splice 
variants of ZnT5. Interestingly, ZnT5vA has been shown to be an effluxer (Kambe et 
al., 2002) and ZnT5vB is capable of bi-directional transport of zinc (Valentine et al., 
2007). It is particularly relevant that with increased levels of extracellular zinc ZnT5vA 
mRNA expression levels decrease significantly, moreover, in the same paper 
researchers show an overall decrease in mRNA levels in response to an increase in 
extracellular zinc (Jackson et al., 2007). All these results highlight a complex system of 
regulation for this transporter especially given that transcription of both variants is 
driven by a single promoter.  
Five core MREs identified in the putative promoter region of the ZnT5 transcript leads 
to speculation that the mode of regulation is via the binding of MTF1. However, 
mutation of the consensus MRE sequence in ZnT5 was unable to abolish the zinc-
induced repression ordinarily observed in transfected Caco-2 cells (Jackson et al., 
2007). Furthermore, ZnT5 mRNA was found to be stabilised by increased extracellular 
zinc thus, the authors concluded that it is a complex interplay between the effect of zinc 
on both transcription of ZnT5 and mRNA stability of the transcript that act in 
opposition that balances mRNA abundance. It remains unclear as to why the efflux 
variant (ZnT5vA) decreases in response to zinc however similarities can be drawn to 
ZnT10 with localisation of both transporters to the Golgi apparatus (see section 4.5). 
Indeed these observations may be commensurate with a mode of transcriptional 
regulation through which expression is repressed at higher zinc levels if the primary 
function of ZnT10 is delivery of zinc to proteins in the Golgi apparatus, rather than 
homeostasis of cytosolic concentrations. The effect of mRNA stability, seen for ZnT5, 
would be an interesting avenue of research as RT-qPCR allows measurement of the 
level of mRNA expression in the cells at that time point however it is unable to 
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establish that the effect seen is at the level of transcription because mRNA level is a 
balance between synthesis and degradation. Therefore the mRNA level seen can be 
affected by mRNA stability and indeed has been shown to be an important factor in the 
regulation of ZnT5 where the first example of zinc mediating stability of mRNA was 
demonstrated (Jackson et al., 2007).  
It is known that MREs can mediate both positive and negative regulation in zebrafish 
Zip10 however this is under the control of alternative promoters (Zheng et al., 2008). In 
contrast, there must be mechanisms in addition to those mediated through the MREs 
that are able to influence zinc induced repression as mutation of the consensus MRE 
sequence in ZnT5 was unable to abolish the zinc-induced repression ordinarily observed 
in transfected Caco-2 cells (Jackson et al., 2007). Furthermore, the authors identified a 
204 bp region comprising -154 bp prior to transcriptional start codon and +50 bp into 
the ORF of ZnT5 that was required for the transcriptional repression seen at increased 
extracellular zinc concentrations (Jackson et al., 2007). Given the response of this 
region was indistinguishable from the promoter as a whole it suggests that this region 
contains the necessary regulatory elements.  More recent EMSA analyses have revealed 
the binding site in the ZnT5 promoter responsible for the zinc-induced transcriptional 
repression, namely the ZTRE. Sequences that concur with the identified ZTRE 
sequence, established to be permissive for binding of a putative transcriptional 
regulatory protein(s) that acts at this site, occur in the 5’UTR of ZnT10. I have 
confirmed that this sequence functions in the same way as the ZTRE in ZnT5 to confer 
transcriptional repression in response to zinc, using a promoter-reporter construct assay. 
In addition, mutation of this ZTRE region truncates this response highlighting the 
importance of the sequence in transcriptional down-regulation. A zinc-dependent 
transcriptional regulatory mechanism based on this principle – zinc induced binding of a 
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transcriptional repressor – has not previously been described in a eukaryotic system but 
this mode of operation is, in principle, analogous to the regulation of the E. coli 
znuABC operon. This transcriptional repression is mediated by a member of the Fur 
family of transcription factors, namely Zur. In this case Zur binds two zinc ions in order 
to bind to DNA at the almost-perfect palindromic binding site sequence for Zur 
(TGTGATATTATAACA) and repress the transcription of a zinc importer in the 
znuABC gene cluster (Patzer and Hantke, 2000).  This sequence does however show no 
similarity with the ZTREs identified in the ZnT family.  The current findings do not 
exclude the possibility that a separate transcriptional regulatory mechanism operates in 
mammalian cells under conditions of zinc deficiency to increase the expression of genes 
involved in zinc scavenging, such as those involved in high affinity uptake across the 
plasma membrane. This is evident in the enterocytes and the up-regulation of Zip4 in 
response to zinc deficiency (Dufner-Beattie et al., 2004). This is mediated by KLF4 
which is able to bind to a KLF4 responsive element in the promoter region of Zip4 so to 
activate transcription (Liuzzi et al., 2009). Although these results for Zip4 should be 
interpreted with caution though given the low levels of Zip4 evident in the MODE-K 
cells (Huang et al., 2006). Data produced by Weaver et al., (2007) indicates that 
regulation is at a post-transcriptional level. 
Results presented here show a decrease in reporter gene activity driven by a region of 
the ZnT10 promoter (-762 to +180 bp, relative to the start of transcription) in response 
to increased extracellular zinc.  Comparison of a 204 bp region of ZnT5 (Jackson et al., 
2007) with the ZnT10 promoter sequence in this reporter construct reveals elements 
with a high level of similarity. A putative ZTRE has been identified in the 5’ UTR of 
the ZnT10 gene and it has been shown that it is functional in a promoter-reporter 
construct.  Inspection of other ZnT family members revealed sequences that concur with 
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what we identify thus far to be permissible as a ZTRE with respect to protein binding in 
the 5’UTR and 500 bp region immediately upstream of the start of transcription. These 
sequences are present in six out of ten ZnTs with ZnT2, ZnT6, ZnT8 and ZnT9 being 
the exception (Coneyworth et al., 2012).  Coordinated regulation of multiple members 
of the gene family through this transcriptional regulatory mechanism is thus implicated.  
For the ZnT5 promoter region substitutions to the ZTRE sequence in the competitor 
oligonucleotide that abrogated protein binding to this region as detected by EMSA have 
been made in only one half of the palindromic sequence, thus it appears that both 
sections of sequence are necessary. It is feasible that two linearly-separated sequences 
in DNA come into proximity to allow binding to both of a single protein or protein 
complex by virtue of the folding of DNA into chromatin.  This phenomenon has yet to 
be investigated for ZnT10 and indeed the analysis of other promoters that contain 
ZTREs would elucidate further genes in which zinc was involved in the regulation. 
Cells transfected transiently to over-express ZnT10 fused to a FLAG epitope tag at the 
N-terminal region revealed a decrease in ZnT10 expression at the protein level with 
increasing levels of extracellular zinc.  The presence of a band of approximately 56 kDa 
(the expected size for ZnT10 (53 kDa) plus 3 x FLAG (3 kDa)) in this N-terminal 
vector indicates that signal peptide cleavage does not occur contrary to the predictions 
of Chapter 3. This strategy to investigate the effects of extracellular zinc on levels of 
ZnT10 protein expression was employed as the commercially available antibodies to 
ZnT10 (Santa Cruz) were not effective in my hands and in fact experiments carried out 
proved non-specificity of these antibodies.  I believe the decrease in protein expression 
in response to extracellular zinc to be a true representation of endogenous protein as 
results reflected effects seen at the mRNA level. Although the ZnT10 ORF was driven 
by the strong CMV promoter in the p3xFLAG-ZnT10 vectors I was able to exclude the 
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possibility that the down-regulatory observation was not a result of zinc activity through 
this CMV promoter used to drive expression. When the CMV promoter was used to 
drive β-galactosidase activity driven by zinc, there was an increased activity in response 
to zinc (experiments carried out by Lisa Coneyworth) and therefore it can be concluded 
that the down-regulatory response measured at the protein level is a true indication of 
ZnT10 response to zinc.   
The subcellular localisation of ZnT10 in SH-SY5Y cells is at the Golgi apparatus in 
cells transfected transiently with an N-terminal FLAG-tagged construct of ZnT10 under 
conditions of 3 µM extracellular zinc (basal medium).  At concentration of 100 µM 
extracellular zinc, ZnT10 was observed to re-localise towards the plasma membrane.  
Several zinc transporters have been shown to alter their localisation in response to 
metals, in particular for members of the ZIP family of zinc transporters, specifically 
ZIP1, 3, 4, 5 and 8 (Wang et al., 2004b, Desouki et al., 2007).  Interestingly 
experimentation into Zip4 and Zip5 indicate that the transporters have antagonistic 
functions in the control of zinc homeostasis. In zinc replete states Zip5 is located on the 
basolateral membrane, but the same state causes internalisation of Zip4 from the apical 
membrane through endocytosis. Conversely, Western blot analysis of membrane 
proteins from the visceral yolk sacs, showed that in cases of zinc deficiency Zip5 is 
internalised, whereas Zip4 mRNA is stabilised and the protein is translocated to the 
apical membrane (Wang et al., 2004b).  Furthermore, some of the AE mis-sense 
mutations cause retention of the protein at high levels in the plasma membrane, 
consistent with impaired zinc sensing to control Zip4 trafficking (Wang et al., 2002). 
The mechanisms underlying the responses of the mammalian ZIP family of zinc 
transporters to dietary zinc are still poorly understood however the mutations found in 
ZIP4 are clearly involved.   
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A better understanding of transporter trafficking comes from investigation of other 
metal transporters, more specifically the Menkes copper transporting protein (MNK). 
MNK was first identified due to the X-linked copper deficiency disorder, Menkes 
disease. MNK is normally localised on the trans-Golgi network (TGN) however, 
trafficking has been reported when cells are exposed to excessive copper such that 
MNK translocates to the plasma membrane presumably to increase efficiency of 
removal of excess copper from cells. Di-leucine motifs in the C-terminal portion of 
MNK have undergone mutation analysis with the conclusion that these motifs mediate 
the copper-induced exocytosis of MNK from the TGN to the plasma membrane, (Petris 
and Mercer, 1999).  Similarly, these motifs also occur in ZnT6 and are predicted to be 
involved in re-localisation of ZnT6 from the TGN to the cytoplasm and plasma 
membrane (Huang et al., 2002).   
Based on the assumption that di-leucine signals consist of an invariant leucine in the 
first position and a hydrophobic residue L, I, V or M in a more tolerant second position, 
di-leucine motifs occur in ZnT10 between amino acid positions 242 and 243 as well as 
286 and 287 and 298 and 299, which are found within the predicted C-terminal 
cytosolic region.  It is possible that the re-distribution of ZnT10 from the Golgi 
apparatus to the plasma membrane is dependent on one or more of these di-leucine 
motifs.  The importance of these motifs in the intracellular distribution and zinc-induced 
redistribution of ZnT10 should be addressed in future experiments in which they are 
deleted by site-directed mutagenesis. It has recently been reported, using a similar 
ZnT10 over-expression approach, that ZnT10 localises to recycling endosomes, in 
vascular smooth muscle cells derived from rat thoracic aortas and HEK293 cells 
(Patrushev et al., 2012). Although I do not observe a similar pattern of localisation, it 
may be explained by the different cell types used in the two experiments. Here 
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physiological cell types are chosen, where endogenous ZnT10 mRNA expression was 
detected (intestine and brain).  Chapter 3 shows I did not detect endogenous expression 
at the mRNA level of ZnT10 in heart, muscle or kidney tissue.  
The translocation seen here coupled with the functional role of ZnT10 referred to in 
chapter 3, leads to speculation that ZnT10 may have two important cellular functions.  
Firstly, ZnT10 may be involved in transporting cytoplasmic zinc into the Golgi 
apparatus, where it may deliver zinc to nascent zinc-containing proteins. Secondly, 
ZnT10 may play a role in cellular zinc homeostasis through zinc export, based on its 
zinc-induced intracellular redistribution to the plasma membrane.  
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Figure 4.1 Response of SH-SY5Y cells to extracellular zinc treatment A. 
Estimated percentage cell death of SH-SY5Y cells after treatment with varying 
concentrations of ZnCl
2
 for 24 hours using trypan blue. All values are shown as 
mean ± SEM, n = 3. (Hollie Ord, BSc Student) B. Cell viability measured by 
the conversion of resazurin to resorufin (Alamar Blue, Invitrogen) in the 
presence of 100 µM extracellular zinc concentration (indicated). All values are 
shown as mean ± SEM, n = 3. 
A 
B 
Figure 4.1 Response of SH-SY5Y cells to extracellular zinc treatment A. 
Estimated percentage cell death of SH-SY5Y cells after treatment with varying 
concentrations of ZnCl
2
 for 24 hours using trypan blue. All values are shown as 
mean ± SEM, n = 3. (Hollie Ord, BSc Student) B. Cell viability measured by the 
conversion of resazurin to resorufin (Alamar Blue, Invitrogen) in the presence of 100 
µM extracellular zinc concentration (indicated). All values are shown as mean ± 
SEM, n = 3. 
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Table 4.1 Primer sequences for human ZnT10 analysis of extracellular zinc 
treatments by RT-PCR and RT-qPCR analysis. The numbering on each of the 
oligonucleotides represents its position on the gene.  *(Cragg et al., 
2005),**(Valentine et al., 2007) 
a le 4.1 ri er se e ces for hu an ZnT10 analysis of extracellular zinc 
treat e ts y -  a  -  analysis. The numbering on each of the 
oligonucleotides represents its position on the gene.  *(Cragg et al., 
2005),**( alentine et al., 2007) 
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Basal Media Basal Media + 
150 µM Zinc 
ZnT10 
β-actin 
Figure 4.2 Analysis of relative ZnT10 mRNA levels in response to 150 µM 
extracellular zinc treatment in SH-SY5Y cells Histograms were obtained by 
densitometric measurement of band intensities from the ethidium bromide-stained 
agarose gels shown. Bands were generated by semi-quantitative RT-PCR from the 
RNA samples generated from SH-SY5Y cells using primers in Table 4.1. Analysis of 
relative ZnT10 mRNA levels and MT1 (as a positive control) are expressed as a ratio 
to β-actin. All values are shown as mean ± SEM, n = 3. *** p < 0.001, ** p < 0.01, 
by Students t-test.  
i  .  l i  f l ti    l l  i   t    
t ll l  i  t t t i  -  ll  i t r  r  t i   
it tri  r t f  i t iti  fr  t  t i i  r i - t i  
r  l  .  r  r t   i- tit ti  -  fr  t  
 l  r t  fr  -  ll  i  ri r  i  l  . . l i  f 
r l ti    l l    (   iti  tr l) r  r    r ti  
t  - ti . ll l  r      ,   .    . ,    . , 
 t e ts t-test.  
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ZnT10 
TOPI 
GAPDH 
Figure 4.3 Standard curves generated to measure relative levels of ZnT10 by 
RT-qPCR, using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ 
Research). Standards for GAPDH and ZnT10 products were generated by 
amplifying the region between the primers shown in Table 4.1, and subcloned into 
the vector pCR2.1-TOPO TA (Invitrogen). TOPI primers were purchased from 
PrimerDesign. A TOPI PCR product was produced and subcloned into the pGEM-T-
easy vector to give the standard TOPI-pGEM (generated by Dr Alison Howard). The 
mean log concentration of each dilution was plotted against PCR cycle number at 
which the fluorescent threshold was crossed (C
T
).These standard curves were used 
to calculate relative levels of ZnT10 transcripts.  
ig re 4.3 ta ar  c rves ge erate  to eas re relative levels of 10 y 
- , si   ree  fl resce ce a  t e  i e tic  2 ( J 
esearc ). Standards for GAPDH and Z T10 products were generated by amplifying 
the region between the primers shown in Table 4.1, and subclone  into the vect r 
pCR2.1-TOPO TA (Invitrogen). TOPI primers were purchased from PrimerDesign. A 
TOPI PCR product was produced and subclone  i to the pGEM-T-easy vector to 
give the standard TOPI-pGEM (generated by Dr Alison Howard). The mean log 
concentration of each dilution was pl tted against PCR cycle number at which the 
fluorescent threshold was crossed (C
T
). Excluded data points are shown in red. These 
standard curves were used to calculate relative levels of ZnT10 transcripts.  
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Figure 4.4 The effect of increased extracellular zinc on ZnT10 mRNA 
expression in SH-SY5Y and Caco-2 cells. Cells were cultured for 24 h in basal 
media (3 µM Zn) or at the zinc concentrations indicated (added as ZnCl
2
) then total 
RNA was extracted. Levels of ZnT10 and MT-1 mRNA were measured by RT-qPCR, 
using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ Research). (A) 
ZnT10 levels in SH-SY5Y cells (B) MT-1 levels in SH-SY5Y cells (C) ZnT10 levels 
in Caco-2 cells (D) MT-1 levels in Caco-2 cells Data are expressed relative to 
GAPDH mRNA levels measured in the same samples. All values are shown as mean 
± SEM, n = 6. *** p < 0.001, ** p < 0.01, significantly different from 3 µM zinc 
(untreated) by one-way ANOVA followed by Bonferroni’s multiple comparisons test.  
(E) ZnT10 levels for Caco-2 cell RNA expressed relative to TOPI mRNA levels, 
values are shown as mean ± SEM, n = 3. *p < 0.05 by Students t-test. 
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Figure 4.5 ZnT10 mRNA expression is affected by extracellular zinc (100 µM) 
but not by FBS concentration in SH-SY5Y cells. SH-SY5Y cells were cultured for 
24 h at 100 µM extracellular zinc (added as ZnCl
2
) in the presence or absence of 10 
% FBS. Total RNA was extracted and levels of ZnT10 mRNA were measured by RT-
qPCR. Data is expressed relative to GAPDH mRNA levels in the same samples. 
Values are shown as mean ± SEM, n = 3. *p < 0.05 by Students t-test. 
Figure 4.5 ZnT10 mRNA expression is affected by extracellular zinc (100 µM) 
but not by FBS concentration in SH-SY5Y cells. SH-SY5Y cells were cultured for 
24 h with basal media (3 µM zinc) or with 100 µM extracellular zinc (added as 
ZnCl
2
) in the presence or absence of 10 % FBS. Total RNA was extracted and levels 
of ZnT10 mRNA were measured by RT-qPCR. Data is expressed relative to GAPDH 
mRNA levels in the same samples. Values are shown as mean ± SEM, n = 3. *p < 
0.05 by Students t-test. 
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  Figure 4.6 Analysis of the ZnT10 promoter region A. The ZTRE sequence B. The 
ZnT10 promoter region annotated to show the putative ZTRE region (+58 to +84) 
(yellow); the primers used for generation of the promoter-reporter construct 
(forward; brown, reverse; green). The ATG start site is shown in red and the 
transcribed but untranslated region is highlighted in blue. The predicted metal 
responsive element (MRE) consensus sequences (Karin at al., 1984, Koizumi et al., 
1999) are highlighted in brown. The predicted copper responsive element (CuRE) 
(Quinn and Merchant 1995) is highlighted in green. 
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Table 4.2 Primer sequences to generate pBlueSLC30A10prom and 
pBlueSLC30A10prom
MUT
 from genomic DNA. 
1
Underlined sequence is 
additional unique random sequence to avoid re-amplification of wild-type 
sequence in the PCR reaction that joins the 5’ and 3’ segments. 
2
Bold, italic 
sequence shows the sequence used to substitute the ZTRE. 
3
Annealing 
temperature reduced from 65 °C by 1 °C every alternate cycle until 50 °C. 
able 4.2 Primer sequences to generate pBlueSLC30A10prom and 
p lueS 30 10pro
UT
 from genomic DNA. 
1
Underlined sequence is additional 
unique random sequence to avoid re-amplification of wild-type sequence in the PCR 
reaction that joins the 5’ and 3’ segments. 
2
Bold, italic sequence shows the sequence 
used to substitute the ZTRE. 
3
Annealing temperature reduced from 65 °C by 1 °C 
every alternate cycle until 50 °C. 
Chapter 4: Regulation of ZnT10 in response to zinc 
169 
 
   
  
A 
B 
*** 
*** 
** 
Figure 4.7 The response of the ZnT10 promoter to elevated extracellular zinc 
concentrations in Caco-2 and SH-SY5Y cells. Promoter activity was detected as 
activity in cell lysates of a β-galactosidase reporter gene immediately downstream of 
the genomic region in the vector pBlue-TOPO (Invitrogen) assayed using the 
substrate chlorophenol red-β-D-galactopyranoside. Negative controls included vector 
only. A. Relative levels of activity of the ZnT10 promoter region (-762 to +180) 
relative to start of transcription) at extracellular zinc concentrations (3 and 100 µM).  
B. Response of the human MT2a promoter (-358 to +40), assayed using the same 
reporter system, to manipulation of the extracellular zinc concentration (100 µM) in 
Caco-2 and SH-SY5Y cells. Values are means ± SEM (n = 3-6). *** p < 0.001, ** p 
< 0.01 compared with 3 µM zinc by Student’s t-test. 
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Figure 4.8 Analysis of ZTRE mutation in Caco-2 cells A. Schematic of ZTRE 
mutation in ZnT10 promoter region B. Relative levels of activity of the 
pBlueSLC30A10prom and pBlueSLC30A10prom
MUT
 at extracellular zinc 
concentrations (3 and 100 µM). The response of the ZnT10 promoter and the mutant 
to elevated extracellular zinc concentrations in Caco-2 Promoter activity was 
detected as activity in cell lysates of a β-galactosidase reporter gene immediately 
downstream of the genomic region in the vector pBlue-TOPO (Invitrogen) assayed 
using the substrate chlorophenol red-β-D-galactopyranoside. Negative controls 
included vector only. C. Response of the human MT2a promoter (-358 to +40), 
assayed using the same reporter system, to manipulation of the extracellular zinc 
concentration in Caco-2 cells. Values are means ± SEM (n = 3). ** p < 0.01 
compared with 3 µM zinc by Student’s t test. 
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Figure 4.9 The effect of increased extracellular zinc on ZnT10 protein expression 
in SH-SY5Y cells.  A.  Expression in SH-SY5Y cells of ZnT10 protein fused with a 
FLAG epitope tag at the N- terminus visualized by immunoblotting at 100 µM of 
extracellular zinc. B Histograms were obtained by densitometric measurement of 
band intensities from the immunoblot shown above and are expressed relative to α-
tubulin protein levels measured in the same samples.  Values are means ± SEM, n = 
3.  ** p < 0.01 by Student’s t test. 
i  4.9 The effect of increased xtr cellular zi c on ZnT10 protein 
expression in SH-SY5Y cells.  A.  Expression in SH-SY5Y cells f ZnT10 protein 
fused with a FLAG epitope tag at the N- terminus visualized by immunoblotting at 
100 µM of extracellular zinc. B Histograms were obtain d by densitometric 
measurement of band intensities from the immunoblot shown above and are 
expressed relative to α-tubulin protein levels measured in the same s mples.  Values 
are means ± SEM, n = 3.  ** p < 0.01 by Student’s t test. 
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Figure 4.10 Response of the CMV promoter to an elevated concentration of 
extracellular zinc in Caco-2 cells. Caco-2 cells were transiently transfected with 
a pBlue-TOPO reporter construct containing the CMV promoter.  Transfected cells 
were exposed to control serum-free medium or serum-free medium supplemented 
with either 100 µM or 150 µM ZnCl
2
 for 24 hours and promoter activity was 
measured as β-galactosidase reporter gene activity.  Values are means ± SEM (n = 
3-9), and are expressed as a ratio of β-galactosidase reporter activity in control 
medium.  *** p < 0.001 by Student’s t test.   
.  es o se of the CMV promoter to an levated concentration of 
ll  r  tr si tl  tra sfecte  ith a 
pBlue-TOPO reporter construct c t i i   promoter.  Transfected cells 
 to control serum-fr e medium or serum-free medium supplemented 
 µ  or 150 µM ZnCl
2
 for 24 hours and promoter activity was 
l      (   3-
9), and are expres ed as  of β-galactosidase reporter activity in control 
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Table 4.3 Primer sequences used to generate mouse Znt8 and mouse Znt10 
products. The numbering on each of the oligonucleotides represents its position on 
the gene. 
ri er sequences used to generate mouse Znt8 and mouse Znt10 
eri  on each of the oligonucleotides represents its position on 
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Figure 4.11.Analysis of the specificity of commercial ZnT10 antibodies A. RT-PCR 
using primers in Table 4.2; specific to mouse Znt10 (lane 1-3) and mouse Znt8 (lane 
4-6) on RNA extracted from mouse brain (Lane 2 and 5) and pancreatic beta MIN6 
cells (Lane 1 and 4).  Lane 3 and Lane 6 are water controls. B. Immunoblotting using 
the ZnT10 (ZnT-10 (Q-14); Santa Cruz) primary antibody (1:1000) followed by a 
secondary donkey anti-goat IgG-HRP antibody (sc-2020; 1:10000; Santa Cruz) on 
SH-SY5Y neuroblastoma cells (brain derived lane 1) and Min6 (pancreas derived lane 
2).  Lane M - Approximate band sizes given using comparison to a pre-stained broad 
range protein marker (NEB).     
  M       1    2 
M    1    2    3           4     5    6 
A 
B 
Figure 4.11.Analysis of the specificity of co mercial ZnT10 antibodies A. RT-
PCR using primers in Table 4.3; specific to mouse Znt10 (lane 1-3) and mouse Znt8 
(lane 4-6) on RNA extracted from mouse brain (Lane 2 and 5) and pancreatic beta 
MIN6 cells (Lane 1 and 4).  Lane 3 and Lane 6 are water controls. B. 
Immunoblotting using the ZnT10 (ZnT-10 (Q-14); Santa Cruz) primary antibody 
(1:1000) followed by a secondary donkey anti-goat IgG-HRP antibody (sc-2020; 
1:10000; Santa Cruz) on SH-SY5Y neuroblastoma cells (brain derived lane 1) and 
Min6 (pancreas derived lane 2).  Lane M - Approximate band sizes given using 
comparison to a pre-stained broad range protein marker (NEB).     
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Figure 4.14 Subcellular localisation of ZnT10 vector only control.  
Representative images of an N-terminal FLAG epitope tag expressed 
with a BAP protein fusion (no ZnT10 insert, negative control in SH-
SY5Y cells. Cells were treated with anti-FLAG antibody (1:1000) 
(green) for 1 h, prior to permeabilisation with 0.1 % Triton X-100 and 
co-staining with Rh-labelled WGA (red). Nuclei are stained with DAPI 
(blue). A. No distinct localisation under low extracellular zinc culture 
conditions (basal media) B. No distinct localisation with the addition of 
100 µM extracellular ZnCl
2
 for 24 h period immediately prior to viewing 
the cells. Experiments were carried out in triplicate and representative 
images shown.   
A 
B 
Figure 4.13 Subcellular localisation of ZnT10 vector only control.  Representative 
images of an N-terminal FLAG epitope tag expressed with a BAP protein fusion (no 
ZnT10 insert, negative control) in SH-SY5Y cells. Cells were treated with anti-
FLAG antibody (1:1000) (green) for 1 h, prior to permeabilisation with 0.1 % Triton 
X-100 and co-staining with Rh-labelled WGA (red). Nuclei are stained with DAPI 
(blue). A. No distinct localisation under low extracellular zinc culture conditio s 
(basal media) B. No distinct ocalisation with the addition of 100 µM extracellular 
ZnCl
2
 for 24 h period immediately prior to viewing the cells. Experiments were 
arried out in triplicate and representative images shown.   
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Chapter 5: The role of other divalent cations in ZnT10 regulation 
5.1 Outline 
The work outlined in this chapter is related to further characterisation of ZnT10, in 
response to the divalent cations copper, cobalt and nickel. The CDF family of ion 
transporters evolutionarily appear to be capable of transporting various divalent cations 
including cobalt, manganese, iron, cadmium and nickel (Anton et al., 1999, Delhaize et 
al., 2003, Grass et al., 2005, Munkelt et al., 2004). The mammalian ZnTs have not been 
fully characterised in relation to their response to these cations however there is a small 
body of research investigating interactions of the ZIP transporters and divalent cations. 
For example, ZIP8 and ZIP14 have been shown to be capable of cadmium transport, in 
addition to zinc with ZIP14 also able to transport manganese. However zinc is the 
preferred substrate for both ZIP8 and ZIP14 (Liu et al., 2008, Pinilla-Tenas et al., 2011). 
Interestingly, whilst ZIP4 has been shown to bind to copper, nickel and zinc it has only 
been shown to be able to transport copper and zinc (Antala and Dempski, 2012). This 
demonstrates that this family of proteins could have transport and indeed binding 
capabilities beyond zinc and these may in fact vary for each family member. Given that 
ZIPs are thought to interact with the divalent cations through their basic region, much 
like ZnTs, it is possible that ZnTs may also bind and be regulated by other metals. Of 
more relevance to this study is a very recent publication that reports ZnT10 can 
transport manganese. ZnT10 was able to restore growth in the manganese sensitive 
Δpmr1 yeast strain (Tuschl et al., 2012). This indicates that ZnT10 will respond to 
cations in addition to zinc. Here I present results that show a regulatory response of 
ZnT10 at both the mRNA and protein level by cobalt and nickel. Subcellular 
localisation is also altered by metal treatments. 
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In the UK, in healthy individuals the RNI for copper is 1.2 mg/d for both men and 
women (age 19-50) (Henderson et al., 2003b). Copper is found in foods such as nuts, 
shellfish and offal. It is an essential nutrient that acts as a cofactor for many enzymes. 
Approximately 1 % of the eukaryotic genome is thought to contain copper binding 
proteins which, biochemically, are involved in processes such as respiration, free radical 
detoxification, iron transport and cross-linking of collagen and elastin (Andreini et al., 
2008a). It is important for growth and development and is required to maintain a healthy 
immune system. Excess copper however can be toxic to cells. There is evidence for a 
synergistic relationship between zinc and copper within the human body, alluded to by 
the defects in copper homeostasis found in patients with Wilson’s disease. This is an 
autosomal recessive condition characterised by a mutation in the copper ATPase 
(ATP7B) that results in an excessive hepatic copper accumulation manifesting as liver 
disease with neurological symptoms (Roberts and Schilsky, 2008). This can be fatal if 
the disease is not treated. High levels of zinc have been shown to be therapeutic in the 
condition, in that supplementation with zinc (up to 150 mg/d) stimulates intestinal MT, 
which in turn chelates copper in the intestine, reducing accumulation and increasing 
excretion in patient stools (Marcellini et al., 2005). Intriguingly, by both microarray and 
RT-qPCR ATP7B mRNA has been shown to decrease in response to zinc treatment in 
JAR cells (Jackson et al., 2009). A search in the putative promoter region has revealed a 
ZTRE sequence -610 bp to -383 bp, relative to the transcriptional start site, an 
interesting observation for future research. Furthermore, the ratio of copper to zinc 
(CZr) has been postulated to be a biomarker of ageing. Subsequent investigation into 
this hypothesis has yielded important initial results that suggest that the CZr showed 
both significant and stronger relationships to physical and functional measures of ageing 
than either copper or zinc alone (Mocchegiani et al., 2012a). In addition study 
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participants in the high CZr tertile had a significantly higher risk of death. Copper 
homeostasis is tightly maintained by a network of proteins. Primarily uptake of copper 
is attributed to the CTR proteins (SLC31A) with CTR1 mediating copper influx across 
the plasma membrane and into cells and CTR2 mediating copper transport within the 
cell (Zhou and Gitschier, 1997). Therefore the CTR proteins act much like the ZIP 
family of transporters for zinc. Conversely, ATP7A and ATP7B control export of 
copper, as the ZnTs do for zinc (Wang et al., 2011b). In addition, copper chaperones 
deliver copper to specific target enzymes. The interplay of zinc and copper and their 
similarities in mechanisms of homeostasis is intriguing. The data presented in this 
chapter shows that ZnT10 is not regulated by copper at the mRNA or the protein level 
and copper does not induce a change in subcellular localisation pattern in SH-SY5Y 
cells transiently expressing p3xFLAG-ZnT10. Moreover, despite the presence of a 
copper responsive element (CuRE), the ZnT10 promoter activity is not altered in 
response to copper. 
Cobalt is an essential trace element that is present in lower levels than zinc and copper 
in metalloproteins, occurring in only 1 % of structurally characterised proteins 
compared with 9 % for zinc (Andreini et al., 2008b). The abundance of cobalt is 
relatively low in nature, but it is known to compete with iron in biological functions 
such as respiration. Cobalt in excess causes toxicity disease states, such as dermatitis, 
pneumonia, allergic asthma and lung cancer (Barceloux, 1999). As with zinc and 
copper, cobalt homeostasis is tightly regulated by uptake systems, efflux systems and 
metallochaperones (reviewed by Okamoto and Eltis, 2011). Cobalamin is a cobalt 
containing cofactor, acting as an electron sink by enabling the coordination of a cobalt 
ion, thereby stabilising the ion and facilitating its use in biochemical reactions. Our 
knowledge of cobalt homeostasis comes from bacterial systems. Interestingly, in these 
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systems regulation of efflux appears to be directly regulated by the cobalt ion, whereas 
uptake seems to be indirectly regulated by cofactors such as cobalamin. The regulation 
of cobalt effluxers identified in bacteria is thought to act at a transcriptional level (Koch 
et al., 2007, Liesegang et al., 1993). In contrast, uptake is thought to be regulated both at 
transcriptional and translation levels (Okamoto and Eltis, 2011). The data presented in 
this chapter reveals that mammalian ZnT10 is regulated by cobalt - decreasing 
expression at the mRNA level, without inducing a change in promoter activity in the 
wild-type ZnT10 promoter construct. Conversely, cobalt appears to up-regulate protein 
expression in cells expressing p3xFLAG-ZnT10 and induces a change the in subcellular 
localisation pattern in SH-SY5Y cells.  
Nickel is an essential nutrient found in eubacteria, archaebacteria, fungi and plants. 
Similarly to zinc, copper and cobalt, nickel is a cofactor for many enzymes (reviewed 
by Li and Zamble, 2009). The only characterised nickel requiring enzyme found in 
eukaryotic systems is urease. This enzyme is absent in vertebrates and in fact nickel 
utilisation is restricted to plants and lower eukaryotes, such as fungi (Zhang et al., 
2009). Most nickel requiring enzymes are limited to expression in microorganisms. 
Humans were thought to produce gastric urease however, discovery of Helicobacter 
pylori has led to the knowledge that the urease comes from this source. Moreover it has 
been hypothesised that gastritis is caused by this bacteria, in part, due to the ammonia 
produced by the urease enzyme thereby inducing toxicity in epithelial cells (Smoot, 
1997). Thus nickel differs from the above metals, in that it is thought to be non-essential 
in the human body. Nickel exposure can however be toxic to humans via ingestion or 
absorption through the skin and comes from the use in manufacture of everyday items 
such as cooking utensils, coins and jewellery (Garrow et al., 2000) and in fact, in terms 
of humans, this toxicity has been the focus of research into nickel. The principle organs 
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effected by environmental exposure to nickel are the skin and the lungs causing 
conditions such as allergic contact dermatitis, lung fibrosis and lung cancer (reviewed 
by Cameron et al., 2011). Although the exact mechanisms of nickel induced 
carcinogenesis are not known, it is thought that it initiates pathogenesis by interfering 
with the metabolism of other essential metals e.g. iron, manganese, calcium, zinc and 
magnesium altering both genetic and epigenetic mechanisms (Kasprzak et al., 2003). 
Furthermore, the presence of nickel in tobacco smoke increases exposure to the metal 
and is thought to induce carcinogenesis in the head and neck in addition to in the lungs 
(Khlifi and Hamza-Chaffai, 2010). In those organisms that require nickel, systems exist 
to maintain homeostasis with importers, effluxers and metallochaperones protecting 
against toxicity. Whilst effluxers act to transport nickel few are specific to this ion. This 
implies that nickel accumulation is controlled primarily by tight regulation of uptake 
(Nies, 2003). Despite this an example of a nickel specific exporter is found in the 
Thlaspi goesingense plant; Metal Tolerance Protein 1 (TgMTP1) (Persans et al., 2001). 
This transporter has been studied due to the hyperaccumulation of nickel/zinc in T. 
Goesingense. The plant has the ability to accumulate up to 1.2 % of its shoot biomass as 
nickel (Kramer et al., 1997). Ordinarily this level of nickel would be toxic however T. 
Goesingense is protected from this effect by vacuole sequestration of nickel thought to 
be mediated partly by TgMTP1 (Kim et al., 2004). This transporter belongs to the CDF 
family and therefore it follows that other CDF family members may possess this same 
ability, even if such a characteristic is redundant. Based on this, the focus of my 
research, in part, was to assess the regulation of ZnT10 in response to nickel. 
Intriguingly the novel results presented in this chapter indicate that ZnT10 can be up-
regulated in response to nickel at both the mRNA and protein level. In addition nickel 
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induces a change in p3xFLAG-ZnT10 protein subcellular localisation in transiently 
transfected SH-SY5Y cells in a manner similar to zinc. 
5.2 Regulation of ZnT10 by extracellular cations at the mRNA level 
The effect of extracellular metal cation availability on levels of expression of ZnT10 
mRNA in SH-SY5Y cells and Caco-2 cells was determined by culturing cells at 100 
µM of copper, 100 µM cobalt and 100 µM nickel for 24h.  Confirmation of metal stock 
concentrations were obtained by inductively coupled plasma mass spectrometry (ICP-
MS) (Table 5.1). Concentrations of metals in basal media are estimated as 0.124 µM 
cobalt, 0.002 µM of copper and 0.054 µM nickel (Versieck et al., 1980). Cell viability 
data as measured by the reduction of resazurin to resorufin (Alamar Blue, Invitrogen) 
for SH-SY5Y cells are shown in Figure 5.1. In addition these concentrations have been 
used previously in the literature with no reported effect on Caco-2 cell viability at this 
concentration. For concentrations of copper it has been determined that there is no 
significant difference in membrane permeability in this cell line at 100 µM copper 
(Tennant et al., 2002) and lactate dehydrogenase (a marker of oxidative stress) only 
gave a significant increase in Caco-2 cells at a copper concentration of 150 µM and 
above (Zodl et al., 2003). Cell viability assays, including Alamar blue assays, for Caco-
2 cells treated with cobalt have demonstrated no significant difference compared with 
controls up to 48 hours, at a concentration as high as 200 µM (Horev-Azaria et al., 
2011). For treatment with nickel, 200 µM of this ion did not affect the permeability of 
the cells (Tallkvist and Tjalve, 1998). Total RNA was extracted from cells and RT-
qPCR carried out using GAPDH as the reference gene.  Primers used for RT-qPCR 
analysis are shown in Table 3.4. Standard curves for all RT-qPCR passed acceptance 
criteria (Figure 5.2). All levels were assessed as a ratio to GAPDH and normalised to 
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untreated samples. Results are shown in Figure 5.3 and Figure 5.4A. Summarising the 
data compared with untreated samples, cobalt gives a significance decrease in ZnT10 
transcript abundance relative to GAPDH in both cell types. For SH-SY5Y cells; p = 
0.05 (Figure 5.3) and for Caco-2 cells; 100 µM cobalt p = 0.04 (Figure 5.4A). 
Conversely, nickel gives a significant increase in ZnT10 transcript abundance relative to 
GAPDH for both cell lines. For SH-SY5Y cells: 100 µM nickel; p = 0.002 (Figure 5.3) 
and for Caco-2 cells 100 µM nickel; p = 0.007 (Figure 5.4A). However there was no 
difference in ZnT10 transcript abundance in either cell line for treatment with copper. 
For SH-SY5Y cells: 100 µM copper; p = 0.63 (Figure 5.3) and for Caco-2 cells 100 µM 
copper; p = 0.12 (Figure 5.4A). In support of GAPDH as a reference gene for these 
experiments ZnT10 transcript abundance relative to TOPI as the reference gene in 
Caco-2 cells treated confirmed the above results with a significant decrease with 100 
µM cobalt (p = 0.003), a significant increase with 100 µM nickel (p = 0.005) and no 
significant difference for 100 µM copper (p = 0.57) (Figure 5.4B). Zinc treatments were 
analysed as an additional control in all cases. Thus I can conclude that along with zinc, 
ZnT10 appears to be down-regulated at the mRNA in response to cobalt treatment, up-
regulated in response to nickel with no change in response to copper. 
5.3 Regulation of the ZnT10 promoter by metal treatments 
Chapter 4 established the transcriptional regulation of ZnT10 in response to zinc is, at 
least in part, attributed to the ZTRE identified in the 5’ UTR of ZnT10. Here the ZTRE 
was investigated to establish whether this response is specific to zinc or whether, as 
seen with mRNA, the promoter activity of this ZTRE region can be influenced by the 
other divalent cations studied. Again copper, cobalt and nickel were tested at a 
concentration of 100 µM. Interestingly, through analysis using the bioinformatic 
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programme, Fuzznuc (http://www.hpa-bioinfotools.org.uk/pise/fuzznuc.html), I 
identified a putative copper responsive element (CuRE) (Quinn and Merchant, 1995) in 
the promoter region of ZnT10; CTGCCA (-282 to 276 bp relative to the ATG start site) 
(Figure 4.6). To my knowledge, cobalt responsive sequences have not been elucidated 
however, I have identified two predicted MREs (Karin et al., 1984, Koizumi et al., 
1999) in this promoter region; TGCGCGC (-60 to -54 bp relative to the ATG start site) 
and TGCGCTC (-44 to 38 bp relative to the ATG start site) (Figure 4.6).  
5.3.1 ZTRE response to extracellular metal treatments 
To study transcriptional regulation by copper, cobalt and nickel of the ZnT10 gene, the 
response of the active promoter region to changes in the extracellular cation 
concentration in Caco-2 cells was measured. As previously described (section 4.3.2) a 
ZnT10 promoter-reporter construct (-762 bp to +180 bp, relative to the transcription 
start site, in pBlue-TOPO) was generated in which the candidate ZTRE (position +58 bp 
to +84 bp) was retained (pBlueSLC30A10prom). Cells were transfected transiently with 
the pBlueSLC30A10prom and maintained for 24 hour in both basal medium or medium 
supplemented with 100 µM zinc, 100 µM copper, 100 µM cobalt or 100 µM nickel.  
Excluding the response to zinc, reporter gene expression (β-galactosidase activity) was 
not changed significantly for any of the metals in Caco-2 cells (copper; p = 0.37, cobalt 
p = 0.66 and nickel; p = 0.83) (Figure 5.5).   
5.3.2 Response of the promoter region of ZnT10 to extracellular metal 
treatments after mutation of the ZTRE  
In order to ascertain whether mutation of this ZTRE region within the 942 bp promoter 
reporter construct pBlueSLC30A10prom had an effect at elevated extracellular copper, 
cobalt or nickel concentrations an additional promoter-reporter construct was made; 
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pBlueSLC30A10promMUT (section 4.3.3). Within this construct, 
pBlueSLC30A10promMUT, the primers shown in Table 4.2 were used to substitute the 
ZTRE present in ZnT10, retaining the inter-palindrome linker region but mutating the 
near palindromic sequences at either end as shown in Figure 4.8A. This gave an end-
product of a 942 bp promoter reporter construct to compare with pBlueSLC30A10prom. 
In line with previous experiments, Caco-2 cells were transfected transiently with either 
the pBlueSLC30A10prom or pBlueSLC30A10promMUT and maintained for 24 hour in 
both basal medium or medium supplemented with 100 µM zinc, 100 µM copper, 100 
µM cobalt or 100 µM nickel.  Reporter gene expression (β-galactosidase activity) was 
unchanged at the higher extracellular concentration for both copper and nickel for both 
promoter reporter constructs; pBlueSLC30A10prom and pBlueSLC30A10promMUT. 
Interestingly, pBlueSLC30A10prom showed no change at the higher concentration of 
cobalt however, the mutated promoter reporter construct, pBlueSLC30A10promMUT, 
showed a significant increase in activity with the addition of 100 µM cobalt (p = 0.002) 
(Figure 5.5).  
5.4 ZnT10 expression in response to extracellular cations at the protein level 
To examine the effect of metal treatment on ZnT10 protein expression, SH-SY5Y cells 
were transiently transfected with the plasmid p3xFLAG–ZnT10, a plasmid construct 
from which ZnT10 was expressed with an N-terminal FLAG epitope tag. Twenty-four 
hours post transfection cells were treated with basal medium or medium supplemented 
with either 100 µM zinc, 100 µM copper, 100 µM cobalt or 100 µM nickel for a further 
24 hours.  Subsequently the cells were lysed using a buffer containing 4 % SDS, 125 
mM Tris and 5 % β-mercaptoethanol in order to extract the protein (section 2.4.2). The 
protein was electrophoresed on a denaturing 10 % acrylamide gel and blotted onto a 
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PVDF membrane (section 2.7.2). Equal quantities of protein prepared from cells treated 
under all conditions, as determined spectrophotometrically (Nanodrop) was loaded onto 
the gel. Equal loading of both samples was further confirmed by re-immunoprobing 
blots with an anti-α-tubulin antibody.  Western blot analysis used an anti-FLAG 
antibody (Sigma; 1 in 1000 dilution) and subsequently an anti-mouse IgG-HRP 
secondary antibody (GE Healthcare; 1 in 20000 dilution). These were visualised by 
enhanced chemiluminescence (ECL) HRP substrate (Thermo Scientific). This revealed 
a protein band of approximately 56 kDa (the expected size for ZnT10 (53 kDa) plus 3 x 
FLAG (3 kDa)) in all samples, indicating that N-terminal cleavage had not taken place.  
Western blots were stripped and re-probed, using an anti-α-tubulin primary antibody 
(Abcam; 1 in 5000 dilution) and an anti-rabbit IgG -HRP secondary antibody (Abcam; 1 
in 20000 dilution). Analysis of ZnT10 expression levels by densitometric quantification 
of band intensities, expressed as a ratio to α-tubulin and normalised to untreated 
samples, revealed a significant increase in p3xFLAG-ZnT10 protein expression at 100 
µM cobalt (p = 0.006) and 100 µM nickel (p = 0.01) compared with the untreated cells. 
However there was no change in protein expression with 100 µM copper treatment (p = 
0.5). Again we see the expected down-regulation at 100 µM zinc (p = 0.03) (Figure 
5.6).  
Attempts to investigate endogenous ZnT10 levels were unsuccessful due to the lack of 
antibody specificity. This work is summarised in Chapter 4. 
5.5 Subcellular localisation of ZnT10 in response to extracellular cations 
To examine the intracellular distribution of ZnT10, SH-SY5Y cells were transiently 
transfected with the plasmid p3xFLAG–ZnT10.  Forty eight hours post transfection 
cells were fixed using 4 % PFA and stained with the anti-FLAG antibody (1:1000, 
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Sigma). Rhodamine conjugated WGA, a lectin that selectively binds N-
acetylglucosamine and N-acetylneuraminic acid, was used to stain the Golgi apparatus 
in cells permeabilised with 0.1 % Triton X-100 following PFA fixation. Chapter 4 
reports that ZnT10 co-localised with WGA in permeabilised cells, consistent with 
localisation to the Golgi apparatus (Figure 4.12). Alteration in the pattern of localisation 
was induced by changing the extracellular metal concentration in basal medium with the 
addition of 100 µM extracellular copper, 100 µM extracellular cobalt or 100 µM 
extracellular nickel for 24 hour period immediately prior to viewing the cells. Treatment 
with 100 µM extracellular cobalt showed a distinctly different localisation pattern to 
untreated cells (Figure 5.7) with no co-localisation with WGA and a more diffuse 
expression pattern. Extracellular nickel at a concentration of 100 µM showed a 
localisation pattern more consistent with zinc treatment (Figure 5.7) whereby there was 
a reduced co-localisation with the WGA in permeabilised cells and a more diffuse 
pattern of localisation including some expression towards the plasma membrane. With 
100 µM extracellular copper, strong Golgi apparatus expression remained, similar to 
untreated cells (Figure 5.7).  Transfection experiments were carried out in triplicate. All 
p3xFLAG-ZnT10 transfected cells revealed an identical pattern of localisation under the 
different treatments.  p3xFLAG-BAP (used as a negative control) showed a diffuse 
pattern of expression throughout the cell in all experiments, which was not altered by 
extracellular cation treatment, confirming that localisation of the signal to specific 
subcellular regions was a function of the attached ZnT10 protein.  
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5.6 Discussion 
In this chapter, using RT-qPCR, I have demonstrated a decrease in endogenous mRNA 
expression of ZnT10 in response to increased extracellular cobalt in both the Caco-2 
and SH-SY5Y cell line models.  This result is novel as regulation of the ZnT family of 
transporters by the divalent cation has not previously been shown. Up-regulation of 
ZnT10 at the mRNA level in response to extracellular nickel in both cell lines was also 
observed. This result was unexpected as nickel is not thought to be important in the 
human body and therefore the regulation of ZnT10 by nickel would not seem necessary. 
Conversely, due to the reported synergy between zinc and copper, and given the 
regulation at the mRNA level by both cobalt and nickel it is curious that copper has no 
effect on the mRNA expression levels of ZnT10. These observations are intriguing 
especially given the recent publication identifying frame-shift mutations in the 
SLC30A10 gene in patients with the neurological conditions dystonia and Parkinsonism 
that lead to hypermanganesemia in brain regions (Quadri et al., 2012). Rescue 
experiments were performed in a yeast mutant demonstrating the ability of wild-type 
ZnT10 to restore growth in a manganese sensitive yeast mutant Δpmr1 (Tuschl et al., 
2012). Analysis of the zinc binding ability of ZnT5 has identified a region within this 
CDF that is known to be involved in selectivity of the transporter (Ohana et al., 2009). 
This region is conserved in ZnT10 (Figure 3.1). Mutational analysis of this region in 
ZnT10 would allow us to ascertain if these residues are involved in selectivity in this 
CDF member. Additionally, ZnT10 has a serine rich region opposed to the conventional 
histidine rich region found in most family members (Seve et al., 2004). It is possible 
that transporter ability may be attributed to this area. Interestingly ZnT6 also contains 
this serine rich region and it is known to act as a heterodimer with ZnT5 in order to 
transport zinc (Huang et al., 2002, Suzuki et al., 2005b). This knowledge could be used 
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in order to support ZnT10 studies if ZnT6 also has manganese transporting capabilities. 
It is difficult to make comparisons with other ZnTs, as this work has not been carried 
out however what should be noted is the universal order of preference of metal binding 
known as the Irving-Williams series. As the ionic radii decreases the normal periodic 
trend would dictate that the stability of which the ion can bind would increase and 
therefore the series gives weakest binding affinities for manganese < iron < cobalt < 
nickel < copper > zinc (Irving and Williams, 1948). It is of note that as the affinities 
increase there is a concurrent increase in how tightly the metal is buffered within the 
cytoplasm with copper being extremely tightly buffered and bound. Following this 
series, if all the metals tested here were present in the cytosol, all proteins would bind 
copper given that it is the divalent cation with the tightest affinity (reviewed by 
Waldron and Robinson, 2009). Interestingly, results indicate that of the metals tested, 
copper is the only one not to exhibit an effect on ZnT10 therefore suggesting that there 
is a mechanism developed to prevent the interaction. Investigation into the effects on 
regulation of both manganese and iron would add further insight into whether this order 
of preference is relevant in the cell line models. Moreover, it would be worthwhile 
assessing the roles of regulation the other ZnT family members in order to establish 
whether the seemingly specific nature, with respect to copper, is maintained throughout 
the mammalian family of transporters. 
Chapter 4 describes mammalian zinc-responsive genomic elements responsible for 
transcriptional repression in response to elevated zinc concentration. Given the response 
of ZnT10 to the cations, nickel and cobalt, at the mRNA and protein level, the ZTRE 
identified was also investigated to establish whether these cations also have a response 
on the same promoter region.  
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The CuRE identified in the region cloned into the promoter-reporter construct; 
CTGCCA (-282 to 276 bp relative to the ATG start site), would lead to a prediction of a 
response to copper, however no copper response was detected in our system. The 
sequences for CuREs were first discovered in Chlamydomonas reinhardtii, where 
copper deficiency induces the expression of cytochrome c6. These elements were 
identified in the promoter region of the gene thereby activating transcription of 
cytochrome c6 in copper deficient cells (Quinn and Merchant, 1995). Here I assessed 
promoter activity of ZnT10 in response to increased extracellular copper. Quinn et al., 
(1995) assessed the CuRE in conditions of both copper deficiency and copper 
supplementation however they did so relative to a minimal promoter element derived 
from the β2-tubulin gene and did not assess the CuRE construct at basal levels of 
copper. Activation appears to be evident but whether repression occurs, relative to wild-
type has not been addressed. It is possible that the arrangement of the CuRE could be a 
factor in this as there is only a single copy of the CuRE. The data presented by Quinn et 
al., (1995) reveals two CuREs although, it is noted that one element seems to function 
independently of its counterpart. Perhaps more relevant are the studies into the yeast 
copper transport proteins FRE1, CTR1 and CTR3 all of which contain an alternative 
CuRE in their promoter; TTTGCTC. This sequence is not present in the upstream 
region of ZnT10 present in the pBlueSLC30A10prom. The CuRE identified here 
repressed transcription of FRE1, CTR1 and CTR3 in the presence of copper, a result 
attributed to this common element (Labbe et al., 1997) and therefore its absence from 
the promoter region of ZnT10 would indicate that it is not influenced by copper. 
MREs have a core consensus sequence of TGCRGNC (Stuart et al., 1985, Culotta and 
Hamer, 1989). Using bioinformatics I have identified two MRE consensus sequences in 
the promoter region of ZnT10; TGCGCGC (-60 to -54 bp relative to the ATG start site) 
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and TGCGCTC (-44 to 38 bp relative to the ATG start site). MREs are cis-acting DNA 
sequences that are known to be required for heavy metal-induced transcriptional 
activation (Karin et al., 1984). Much research has been carried out into the involvement 
of zinc and MREs in mammalian MT genes and importantly the MT2a promoter, 
described in Chapter 4, contains seven MREs (Koizumi et al., 1999). Koizumi et al., 
(1999) reported that it is necessary to have multiple copies of these MREs in the 
promoter sequence and that MRE copies act synergistically. Thus, although research 
focuses on responses to cadmium and zinc (Karin et al., 1984), (Koizumi et al., 1999), 
the presence of two MREs in the promoter of ZnT10 would suggest the ability of a 
response to the divalent cations tested. However promoter activity was not altered by 
treatment with cobalt, copper or nickel. Therefore, for this arrangement neither the 
CuRE nor the MREs allow metal binding in this system. It is interesting that the MREs 
fall over the ZTRE identified in Chapter 4 and it is possible that the conformation 
necessary for an effective ZTRE does not allow for binding of the necessary elements to 
the MREs. In addition, since there are no effects on transcription for these other metals, 
then perhaps the changes in mRNA are in fact due to the stability of the transcripts 
rather than transcriptional control.  
Subsequent experiments investigated the mutation of the ZTRE region in response to 
the other cations. The truncation in response to zinc highlighted the importance of the 
ZTRE sequence, however the lack of response of the wild-type ZTRE to the cations 
would imply that this is not the mode of regulation for these metals. Surprisingly, cobalt 
induced a significant increase in promoter reporter activity in the mutant ZTRE 
construct. It is a possibility that mutation causes a conformational change that works 
two-fold. In the first instance the structural change means that the zinc induced 
transcriptional repressor is unable to bind. Secondly, the restructured conformation 
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allows a cobalt induced transcriptional activator to bind to the now accessible MRE 
thereby increasing promoter activity. This response is restricted to cobalt as neither 
copper nor nickel showed an increase in promoter activity with the mutant construct. 
Future work would include mutation of the MRE within the mutant ZTRE construct to 
see whether this element is responsible for the increase in promoter activity seen.  
Cells transfected transiently to over-express ZnT10 fused to the FLAG epitope tag at the 
N-terminus revealed an increase in ZnT10 expression at the protein level with both 
increased extracellular cobalt and nickel. This result for extracellular cobalt is in 
contrast to that seen at the mRNA level. In line with the mRNA levels however, 
extracellular copper gave no change in the protein level of p3xFLAG-ZnT10. This 
strategy to investigate the effects of metals on levels of ZnT10 protein expression was 
employed as the commercially available antibodies to ZnT10 (Santa Cruz) were not 
effective (see Chapter 4).  Data investigating the effect of cobalt and nickel on the CMV 
promoter would strengthen this result. Intriguingly, cobalt has the opposing effect in the 
protein extracted from transfected cells to the effect at the endogenous mRNA level. 
This could be an effect on the CMV promoter of the vector. If it is a true response at the 
protein level perhaps this effect in part could be explained in term of mRNA stability. 
RT-qPCR allows measurement of the level of mRNA expression in the cells at that time 
point, however it is unable to establish whether this effect is seen at the level of 
transcription because the mRNA level is a balance between synthesis and degradation. 
Therefore the mRNA level quantified can be affected by mRNA stability. The time 
point will have an effect on the results. For example, if the response of ZnT10 to cobalt 
occurs earlier than 24 hours this would enable an increase in ZnT10 at the protein level 
to be observed, however if this mRNA is degraded at a high rate then at this time point 
the observed mRNA level would be less. Future experimentation would enable further 
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insight into the mechanisms at play. The stability of mRNA could also have an effect on 
the response to nickel. I would not expect a human ZnT to be regulated by nickel, 
however the role of certain CDFs to nickel is interesting. One example is TgMTP1 in 
the plant T. goesingense, which helps protect the plant from the ordinarily toxic levels 
of nickel by facilitating the sequestration of nickel in the vacuoles (Kim et al., 2004). 
Indeed, this is a requirement of CDFs further down the evolutionary tree than ZnTs and 
one explanation for the response to nickel in ZnT10 would be that this ability to respond 
has been evolutionarily conserved, despite being thought to be redundant in humans. 
Investigation with other ZnTs would help in elucidating these roles further. In addition, 
assessing endogenous ZnT10 would also accelerate this knowledge and ascertain the 
true protein response to nickel. 
In Chapter 4 the subcellular localisation of ZnT10 in SH-SY5Y cells is reported to be at 
the Golgi apparatus in cells transfected transiently with an N-terminal FLAG-tagged 
construct of ZnT10 with an observed movement towards the plasma membrane with 
addition of 100 µM extracellular zinc.  At extracellular concentrations of 100 µM nickel 
ZnT10 was observed to re-localise towards the plasma membrane a result that 
corresponds to the response seen with zinc. Intracellular trafficking of several zinc 
transporters in response to zinc has been observed, in particular for members of the ZIP 
family of zinc transporters, specifically ZIP1, 3, 4, 5 and 8 (Wang et al., 2004b, Desouki 
et al., 2007) as described in Chapter 4.  Di-leucine motifs occur in ZnT10 between 
amino acid positions 242 and 243 as well as 286 and 287 and 298 and 299, which are 
found within the predicted C-terminal cytosolic region.  It is a possibility that the re-
distribution of ZnT10 from the Golgi apparatus to the plasma membrane is dependent 
on one or more of these di-leucine motifs. These are comparable with motifs that are 
thought to mediate trafficking of other metal transporters, such as the MNK copper 
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transporting protein and ZnT6 which are both translocated from the TGN (Petris and 
Mercer, 1999, Huang et al., 2002).  Moreover, given the similar response of p3xFLAG-
ZnT10 with extracellular nickel as compared to extracellular zinc observed in SH-SY5Y 
cells perhaps this motif is also involved in the trafficking seen with this metal. The 
importance of these motifs in the intracellular distribution and nickel-induced 
redistribution of ZnT10 should be addressed in future experiments in which they are 
deleted by site-directed mutagenesis. The translocation seen here in response to nickel 
acts to support further the hypothesis that this is due to sequences that are conserved 
from evolutionary counterparts that are ordinarily redundant in humans. There has been 
a relatively recent rise in use of the metal in the manufacture of everyday items (Garrow 
et al., 2000). Perhaps the conservation of the sequences that are nickel responsive can be 
interpreted in two ways. Firstly, it is a possibility that the sequences have not been 
selected against despite being redundant. Therefore, the recent rise in environmental 
nickel plays detrimental role in the human body by using these elements, causing 
subsequent toxicity. Alternatively, the nickel responsive sequences may have been 
retained due to the protective properties they offer the cell upon nickel exposure. In this 
instance, the rise in nickel exposure would lead to a saturation of these mechanisms. 
The pattern of expression in response to cobalt is particularly intriguing. Fluorescent 
microscopy revealed a more diffuse pattern of expression throughout the cell as 
compared with all other treatments and with basal medium. Interestingly, for 
metalloproteins it has been shown that the localisation of folding within the protein 
influences the metal to be bound. In fact metal co-factors are important in the folding of 
many proteins and if the correct metal is present at the folding stage only the correct 
metal is able to bind subsequently, therefore, if there is an excess of competing metals 
there is the potential that this will interfere with protein structure. The importance of 
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these factors is evident for cyanobacterium proteins MncA and CucA. MncA is a 
substrate of twin-arginine translocase that is able to acquire manganese by folding in the 
cytoplasm where copper is tightly buffered or bound. The folding of MncA means that 
the site that binds manganese is buried. Conversely, CucA is a substrate of the general 
secretory pathway that acquires the more competitive metal copper by binding in the 
periplasm (Waldron and Robinson, 2009). This also highlights the importance of 
compartmentalising metals. Indeed with respect to the Irving-Williams series, cobalt is 
buffered to a lesser degree as compared with both zinc and nickel. Furthermore, I 
observed an increase in p3xFLAG-ZnT10 expression by Western blotting with 
extracellular cobalt treatment. It is therefore a possibility that the increase in the protein 
coupled and with influx of cobalt from the extracellular treatment enabled the 
interaction with p3xFLAG-ZnT10 and cobalt, when ordinarily the protein would bind to 
zinc, thus resulting in altered folding and therefore localisation. It would be interesting 
to establish whether ZnT10 retains its efflux ability, described in Chapter 3, when cobalt 
is present or whether the localisation pattern observed is indicative of a broader 
spectrum of changes in the protein resulting in lack of function. The reaction of ZnT10 
to cobalt and nickel are novel and exciting results but they require further investigation 
to draw more accurate conclusions as to the relevance of the regulation and localisation 
changes.  
Corresponding to both mRNA and protein expression again copper does not seem to 
have an effect on p3xFLAG-ZnT10. This would indicate that ZnT10 is not regulated by 
this metal and therefore is not involved in its transport. The lack of response of ZnT10 
to copper is not unique in the ZnT family of transporters. ZnT1 has also been found not 
to alter protein expression in response to copper treatment (30 microg/ml) for 48 and 72 
hours in the hepatoblastoma cell line; HepG2 (Urani et al., 2003).  
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Table 5.1 ICP-MS analysis of metal stocks to be diluted for cell treatments l  .   l i   l    il   ll  
Chapter 5: The role of other divalent cations in ZnT10 regulation 
197 
 
 
  
Figure 5.1 Response of SH-SY5Y cells to extracellular cation treatment cell 
viability measured by the conversion of resazurin to resorufin (Alamar Blue, 
Invitrogen) in the presence of 100 µM extracellular cation concentration (indicated). 
All values are shown as mean ± SEM, n = 3. 
Figure 5.1 The effect of extracellular cation treatment on cell viability in SH-
SY5Y cells measured by the conversion of resazurin to resorufin (Alamar Blue, 
Invitrogen) in the presence of 100 µM extracellular cation concentration (indicated). 
All values are shown as mean ± SEM, n = 3. 
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GAPDH 
Figure 5.2 Standard curves generated to measure relative levels of ZnT10 by 
RT-qPCR, using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ 
Research). Standards for GAPDH and ZnT10 products were generated by amplifying 
the region between the primers shown in Table 3.4, and subcloned into the vector 
pCR2.1-TOPO TA (Invitrogen). TOPI primers were purchased from PrimerDesign. A 
TOPI PCR product was produced and subcloned into the pGEM-T-easy vector to 
give the standard TOPI-pGEM (generated by Dr Alison Howard). The mean log 
concentration of each dilution was plotted against PCR cycle number at which the 
fluorescent threshold was crossed (C
T
).These standard curves were used to calculate 
relative levels of ZnT10 transcripts.  
Figure 5.2 Standard curves generated to measure relative levels of ZnT10 by 
RT-qPCR, using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ 
Research). Standards for GAPDH and ZnT10 products were generated by amplifying 
the region between the primers shown in Table 3.4, and subcloned into the vector 
pCR2.1-TOPO TA (Invitrogen). TOPI primers were purchased from PrimerDesign. A 
TOPI PCR product was produced and subcloned into the pGEM-T-easy vector to 
give the standard TOPI-pGEM (generated by Dr Alison Howard). The mean log 
concentration of each dilution was plotted against PCR cycle number at which the 
fluorescent threshold was crossed (C
T
). Excluded data points are shown in red. These 
standard curves were used to calculate relative levels of ZnT10 transcripts.  
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Figure 5.3 Response of SH-SY5Y cells to extracellular cation treatments. ZnT10 
mRNA levels in the presence of 100 µM extracellular cation concentration 
(indicated), relative to GAPDH, normalised to levels with basal medium for each 
condition as determined by RT-qPCR using primers shown in table 3.4. All values 
are shown as mean ± SEM, n = 3. *** p < 0.001, ** p < 0.01, * p < 0.05 by Students 
t-test. 
* 
*** 
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Figure 5.4 Response of Caco-2 cells to extracellular cation treatments. ZnT10 
mRNA levels in the presence of 100 µM extracellular cation concentration 
(indicated), normalised to levels with basal medium for each condition as 
determined by RT-qPCR using primers shown in table 3.4. All values are shown as 
mean ± SEM, n = 3. *** p < 0.001, ** p < 0.01, * p < 0.05 by Students t-test. A. 
Relative to GAPDH B. Relative to TOPI. 
A 
B 
igure 5.4 esponse of Caco-2 cells to extracellular cation treatments. ZnT10 
 levels in the presence of 100 µM extracellular cation concentration 
(indicated), normalised to levels with basal mediu  for each condition as determined 
by RT-qPCR using primers shown in table 3.4. All values are shown as mean ± SEM, 
n = 3. *** p < 0.001, ** p < 0.01, * p < 0.05 by Students t-test. A. Relative to 
GAPDH B. Relative to TOPI. 
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Figure 5.5 The response of the SLC30A10 promoter wild-type 
(pBlueSLC30A10prom) and mutant (pBlueSLC30A10prom
MUT
) to elevated 
extracellular cation concentrations in Caco-2 cells. Promoter activity was detected 
as activity in cell lysates of a β-galactosidase reporter gene immediately downstream 
of the genomic region in the vector pBlue-TOPO (Invitrogen) assayed using the 
substrate chlorophenol red-β-D-galactopyranoside. Negative controls included vector 
only. Relative levels of activity of the SLC30A10 promoter region amplified (-762 to 
+180, relative to the transcription start site) at extracellular cation concentrations 
(100 µM). Values are means (n = 6), with standard errors represented by vertical 
bars. ** p < 0.01, p < 0.05 compared with basal medium by Student’s t-test. 
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Figure 5.6 The effect of increased extracellular cation treatment on ZnT10 
protein expression in SH-SY5Y cells. A. Expression in SH-SY5Y cells of ZnT10 
protein fused with a FLAG epitope tag at the N- terminus visualized by 
immunoblotting at different concentrations of extracellular cations (as indicated). B. 
Histograms were obtained by densitometric measurement of band intensities from the 
immunoblot shown above and are expressed relative to alpha tubulin protein levels 
measured in the same samples. Values are means (untreated; n = 2, treated; n = 3). All 
values are shown as mean ± SEM. **p < 0.01, *p < 0.05 by Student’s t-test. 
A 
B 
Figure 5.6 The effect of increased extracellular cation treatment on ZnT10 
protein expression in SH-SY5Y cells. A. Expression in SH-SY5Y cells of ZnT10 
protein fused with a FLAG epitope tag at the N- terminus visualised by 
immunoblotting at different concentrations of extracellular cations (as indicated; 
replicates shown, UT = untreated). B. Histograms were obtained by densitometric 
measurement of band intensities from the immunoblot shown above and are 
expressed relative to alpha tubulin protein levels measured in the same samples. 
Values are means (untreated; n = 2, treated; n = 3). All values are shown as mean ± 
SEM. **p < 0.01, *p < 0.05 by Student’s t-test. 
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Chapter 6: ZnT10 in neurodegeneration 
6.1 Outline 
The results presented in this chapter are an outcome of an investigation into the 
expression of ZnT10 in Alzheimer’s disease (AD) and explores the effect of oxidative 
stress and the inflammatory immune response, important factors that contribute to 
neurodegeneration. I show that ZnT10 mRNA levels are significantly reduced in AD 
post mortem tissue, a result which I confirmed in a transgenic (Tg) mouse model of AD. 
In addition, this apparent decrease in ZnT10 transporter expression is greater in human 
post-mortem tissue taken from females, an interesting finding given the greater 
prevalence of AD in women. 
Zinc is thought to be involved in AD progression, however there are many questions 
that remain unanswered. It is evident that the transcription of amyloid precursor protein 
(APP) is regulated by the zinc-dependent transcription factors Sp1 and NF-κB 
(Cuajungco and Lees, 1997). In addition, zinc is able to promote formation of Aβ 
oligomers and aggregates at physiological concentrations available in the brain by 
binding Aβ at 3 N-terminal histidine residues (Bush et al., 1993). It follows that these 
mechanisms, that ordinarily act to maintain homeostasis within this tissue, may be 
dysregulated in disease states and indeed the involvement of ZnTs in AD has previously 
been investigated based on this knowledge. There are significant increases at the protein 
level of the transporters Znt1, Znt3, Znt4, Znt6 and Znt7 in the hippocampus and 
neocortex of APP/PS1 Tg mice (Zhang et al., 2008). These are areas of the brain 
important in AD progression. The largest increase in expression was observed for Znt3, 
which is particularly relevant due to its role in neurotransmission (Section 1.7.2). Znt5 
also showed an increase, but this did not reach statistical significance. Furthermore, 
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Zhang et al., (2008) showed in addition to zinc being found and promoting senile plaque 
(SP) formation, immunoreactions of brain sections from these mouse models showed a 
distinct expression pattern of Znts, with Znt1 and Znt4 found throughout the SPs, 
whereas Znt3, Znt5 and Znt6 were localised in peripheral regions and Znt7 
predominantly in the core.  
Human studies of ZnT dysregulation in AD have on the whole corroborated the mouse 
model results. For example up-regulation of the ZnT1 protein is evident in the 
hippocampus in AD brain tissue (Lovell et al., 2005). It is thought that this increase in 
ZnT1 expression in the disease state causes an increase in zinc ions available in the 
extracellular space for initiation of Aβ deposition and SP formation (Lyubartseva et al., 
2009). Interestingly, in terms of the nutritional status of the elderly, which is known to 
be deficient in zinc (Fairweather-Tait et al., 2008), it is perhaps note-worthy that mice 
fed a zinc deficient diet had a decrease in brain Znt1 expression (Dong et al., 2008). 
Lyubartseva et al., (2009) also showed that in the preclinical disease states; Mild 
Cognitive Impairment (MCI) and Pre-clinical AD (PCAD) an initial decrease in ZnT1 is 
observed before progression to AD. This highlights an important aspect of research that 
has not yet been fully explored. 
It is of interest that, researchers have found that there is a positive correlation between 
Braak score (NFT pathology) and ZnT1 levels, such that ZnT1 increases with an 
increase in Braak score. A trend towards significance was also revealed for ZnT6 
(Lovell et al., 2005, Lyubartseva et al., 2009). As described in Chapter 1, ZnT4 and 
ZnT6 have also been implicated in AD progression, with elevated protein levels of both 
transporters in the hippocampus of AD patients (Smith et al., 2006). ZnT6 is located in 
the Golgi apparatus and therefore it has been hypothesised that the increase in levels of 
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this transporter in AD results in an increase in zinc in this organelle. The importance of 
this is related to the localisation of both APP and the enzymes that metabolise APP, 
which are also found in the Golgi apparatus. Therefore, the accumulation of zinc could 
subsequently promote Aβ formation by binding to APP and inhibiting α-secretase 
(section 1.9) (Lyubartseva et al., 2009). ZnT4 is found in the lysosomal and endosomal 
compartments in hippocampal tissue and similarly an increase in ZnT4 transporter 
expression would be expected to enable the sequestration of zinc into these 
compartments. This is evident further by reports of Aβ accumulation in this system in 
the post-mortem AD brain (Takahashi et al., 2002). 
ZnT3 is an important transporter to consider in the context of ZnT regulation in AD. It 
is known that ZnT3 is localised predominantly in the membranes of zinc-rich synaptic 
vesicles in the hippocampus (Palmiter et al., 1996b) and Znt3 knockout mice are devoid 
of zinc in these zinc-enriched terminals. Furthermore, increased amyloid deposition is 
related to the age-related increased activity of Znt3 found in female mice, a 
phenomenon that was abolished in Znt3 knockout mouse models (Lee et al., 2002). This 
result is particularly relevant with AD being more prevalent in the female population. In 
addition, in the AD Tg2576 mouse model, ablation of Znt3 inhibits the production of 
Aβ pathology. The translation of Znt3 mouse research into humans has come with a few 
discrepancies however. The level of mRNA and protein expression of ZnT3 appears to 
be lowered in the cortical regions of human AD patients (Beyer et al., 2009, Adlard et 
al., 2010) whereas the protein level in these mouse models was increased (Zhang et al., 
2008). 
Further understanding of the ZnT family and their interactions in the brain may 
elucidate a role for ZnTs and zinc in the progression and pathology of AD. Now that I 
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have identified ZnT10 expression in brain (Chapter 3) investigation is required to 
determine the role of ZnT10 in the development of AD.  
A pathway implicated in the progression of AD is the Renin-Angiotensin System 
(RAS). This is a hormonal system that regulates blood pressure and fluid balance and it 
therefore has an important role in the development of hypertension (Taquini and 
Taquini, 1961). However, more recent research has revealed that the mammalian brain 
contains all components of the RAS (De Bundel et al., 2008, Speth and Karamyan, 
2008) and in fact the brain has high concentrations of the angiotensin receptors (Gard 
and Rusted, 2004). In summary, angiotensins are synthesised from the conversion of 
angiotensinogen to angiotensin I (Ang I) which is catalysed by the enzyme renin (Figure 
6.1). Ang I is further metabolised to Ang II, by angiotensin converting enzyme (ACE). 
Ang II has multiple fates, all of which are active, however with differing potencies; Ang 
III (Ang2-8), Ang IV (Ang3-8), Ang1-7 or Ang3-7. These peptides act through G-protein 
coupled receptors; angiotensin type (AT) receptors, that are able to signal through 
phospholipase C and Ca
2+
. Ang I is thought to be inactive but Ang II and Ang III are 
able to activate the AT1 and AT2 receptors (de Gasparo et al., 2000). Conversely, Ang 
IV and Ang3–7 bind with low affinity at the AT1 and AT2 receptor subtypes but with 
high affinity to the AT4 receptor (Swanson et al., 1992). Interestingly, Ang II is able to 
act as a neurotransmitter in the brain, mainly acting on osmoreceptors in the 
hypothalamus to influence thirst however it is also known to interact with other 
neurotransmitters such as acetylcholine, blocking its downstream effects (Gard, 2002). 
The cholinergic system is integral to the regulation of cognitive functions, in particular 
synaptic plasticity, specifically in learning and short-term memory therefore its 
inhibition is detrimental to these pathways.  
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Recent research has shown ZnT10 to be down-regulated after 3 days of treatment with 
Ang II thereby inducing senescence in vascular smooth muscle cells (VSMCs). This 
result is intriguing as conversely, the over-expression of ZnT10 in this system has been 
shown to decrease the production of reactive oxygen species (ROS) preventing 
senescence (Patrushev et al., 2012). Elucidation of the role ZnT10 within the brain RAS 
may improve our understanding of this transporter’s role in oxidative stress and 
inflammation, given that these are downstream effects of this system. In the brain RAS, 
downstream of the AT1 receptor is activation of NADPH oxidase; this pathway is 
poorly understood but it is known to require Rac1 and protein kinase C (PKC) 
(Zimmerman et al., 2004, Wang et al., 2006). The consequence of NADPH oxidase 
activation is the conversion of NADPH to NAD
+
 and the by-products of such a reaction 
are ROS. An excess of ROS are known to cause oxidative stress and thus are an 
important consideration in the aetiology of AD. Furthermore, continuous activation of 
the brain RAS in hRN/hANG-Tg mice (human renin (hRN) and human angiotensinogen 
(hANG) transgenic mice), a hypertensive mouse model, enhances oxidative stress and 
causes a decline in cognitive function by excessive stimulation of the AT1 receptor (Zhu 
et al., 2004). In addition ROS can induce a redox-dependent signal transduction 
pathway that leads to NF-κB activation and therefore stimulation of the inflammatory 
immune response. Inflammation also causes extensive damage in the brain of AD 
patients (Zimmerman et al., 2004). AT1 receptor blockers (ARBs) have been suggested 
as a treatment for AD (Danielyan et al., 2010) by reducing cerebral blood flow, 
oxidative stress and inflammation (Horiuchi and Mogi, 2011). Moreover, blockage of 
AT1 by ARBs allows unbound Ang II to stimulate the AT2 receptor, which antagonises 
the effect of AT1 thereby promoting cell differentiation and regeneration in neuronal 
tissue. This negates the oxidative stress and inflammation that results from Ang II 
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activation of AT1 (Horiuchi and Mogi, 2011). Here I demonstrate that, over a short time 
period, ZnT10 mRNA expression increases with Ang II treatment but it is not altered 
under conditions of oxidative stress. As in the AD cases, ZnT10 decreases when the 
inflammatory immune response is induced by LPS. 
6.2 ZnT10 expression in AD 
As stated above, many ZnTs are dysregulated in AD. To date ZnT10 has not been 
studied in this context. Here I show a significant down-regulation in a small number of 
AD patients, which is supported by data in brain tissue from the APP/PS1 Tg mouse 
model in which there is also a significant decrease in Znt10 mRNA expression. 
6.2.1 ZnT10 expression in human AD tissues 
To investigate the effects of AD process, human brain tissue RNA was analysed from 
AD pathology cases (n = 13; female n = 8, male n = 5) and compared with age-matched 
controls (n = 10; female n = 3, male n = 7) (Appendix I). Frontal cortex RNA was 
obtained from the Newcastle Brain Tissue Resource (Newcastle, UK). Due to the pre-
mortem decline in AD the RNA quality was not ideal as measured by RNA integrity 
number (RIN range 2.5-7.3), however RT-qPCR analysis was carried out in order to 
give an indication of expression levels of ZnT10 in AD patients.  Primers used for RT-
qPCR analysis are shown in Table 3.4. Standard curves for all RT-qPCR passed 
acceptance criteria (Figure 6.2). All data are expressed as a ratio to GAPDH. When AD 
patients are normalised to age-matched controls there is a significant decrease in ZnT10 
levels in this small number of brain tissues (p = 0.006) (Figure 6.3A). Moreover, when 
the results are analysed based upon gender there is a gender specific decrease seen only 
in ZnT10 in female AD patients (p = 0.004) but not in males (p = 0.211) (Figure 6.3B). 
This is a particularly important result given the raised prevalence of AD in females. 
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6.2.2 ZnT10 expression in Tg mouse tissues 
In line with the human samples, frontal cortex brain tissue samples were obtained from 
12 month old female WT (n = 5) and APP/PS1 mice (n = 11) (supplied by Dr Paul 
Adlard, The University of Melbourne). APP/PS1 mice contain two transgenes inserted 
at a single locus. The first is the APP sequence that is modified to encode the human 
Swedish mutations K595N/M596L. Secondly, PS1 corresponds to the human presenilin 
1 gene, in this case there is a deletion of exon 9 and is therefore known as the DeltaE9 
mutation (http://jaxmice.jax.org/strain/005864.html). These mice have amyloid beta 
deposits and exhibit deficits in spatial learning (Gimbel et al., 2010). Brain samples 
were removed and snap frozen before being stored in RNA Later at -80°C. Samples 
were shipped in RNA later on dry ice and RNA was extracted using Trizol (section 
2.4.1). Primers used for RT-qPCR analysis are shown in Table 6.1. Standard curves for 
all RT-qPCR passed acceptance criteria (Figure 6.4). RT-qPCR analysis was carried out 
as a ratio to 18S rRNA. These results support the human AD results, with a significant 
decrease in Znt10 mRNA levels in the Tg-hemizygotes compared with the non-carriers 
(p = 0.01) (Figure 6.5). It is note-worthy that all mouse samples were from female mice 
and therefore gender differences could not be explored in this instance. 
6.3 The effect of RAS on expression of ZnT10 mRNA 
Due to published data on the involvement of the RAS in the brain during 
neurodegenerative conditions and the recently published data that indicates a role for 
Ang II in ZnT10 regulation in VSMCs (Patrushev et al., 2012). I designed a system to 
investigate Ang II influence over ZnT10 in the neuroblastoma cell line, SH-SY5Y. In 
addition, the role of oxidative stress and the inflammatory immune response on ZnT10 
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expression was also investigated. A summary of the study design is shown in Figure 
6.6. 
6.3.1 Effect of Ang II on ZnT10 mRNA expression 
Human neuroblastoma SH-SY5Y cells were treated with 0.1 µM Ang II for 24 hours in 
the absence of FBS. This level of Ang II has previously been used in assays 
investigating ZnT10 expression in VSMCs (Patrushev et al., 2012) in addition to 
Na
(+)
/H
(+)
 exchanger assays in SH-SY5Y cells (Reid et al., 2004). I have previously 
shown that removal of FBS does not influence ZnT10 expression levels (Chapter 4; 
Figure 4.5). Primers used for RT-qPCR analysis are shown in Table 3.4. Standard 
curves for all RT-qPCR passed acceptance criteria (Figure 6.2). Analysis of mRNA 
expression was carried out using RT-qPCR as a ratio to both GAPDH and TOPI. 
Results relative to both reference genes show a significant increase in ZnT10 expression 
at the mRNA level in response to extracellular Ang II treatment (p = 0.03 and p = 0.04, 
respectively) (Figure 6.7A and 6.7i inset).  
6.3.2 Effect of oxidative stress on ZnT10 mRNA expression 
Human neuroblastoma SH-SY5Y cells were treated with 0.025 mM tert-Butyl 
hydroperoxide (tBHP) for 40 min in the presence of 10 % FBS. This level of tBHP and 
length of treatment has previously been used to induce oxidative stress in assays in SH-
SY5Y cells (Krishnamurthy et al., 2000). Medium was removed and replaced with basal 
medium plus 10 % FBS for a further 24 hour time period, before RNA was harvested. 
Primers used for RT-qPCR analysis are shown in Table 3.4. Standard curves for all RT-
qPCR passed acceptance criteria (Figure 6.2). Analysis of mRNA expression was 
carried out using RT-qPCR as a ratio to GAPDH and TOPI. As a control experiment, to 
ensure oxidative stress had actually been induced by the treatment, levels of PKR 
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(double-stranded RNA dependant protein kinase) were assessed by semi-quantitative 
RT-PCR as a ratio to GAPDH. Primers used for RT-PCR analysis are shown in Table 
6.2. PKR is a serine-threonine kinase and in response to oxidative stress, it is able to 
catalyse the phosphorylation of the α subunit of eukaryotic translation initiation factor-2 
(eIF2) in order to inhibit protein synthesis (Der et al., 1997). Up-regulation of PKR has 
previously been reported to occur in SH-SY5Y cells in response to induced oxidative 
stress by H2O2 treatment (Mouton-Liger et al., 2012). Here I confirm a significant 
increase in PKR levels in the SH-SY5Y cells treated with tBHP for 40 minutes 
compared with controls (p = 0.001) (Figure 6.7B). Results did not show any significant 
difference in ZnT10 mRNA expression from control samples relative to either GAPDH 
or TOPI (p = 0.66 and  p = 0.45 respectively) (Figure 6.7A and 6.7i inset). This 
indicates that although oxidative stress was induced in the cells tested, levels of ZnT10 
were not altered indicating that ZnT10 is not regulated by this oxidative stress pathway. 
6.3.3 Role of the inflammatory immune response in ZnT10 mRNA expression 
Human neuroblastoma SH-SY5Y cells were treated with 100 ng/ mL 
Lipopolysaccharide (LPS) from E. coli for 24 hours in the absence of FBS. This level of 
LPS has previously been used to induce the inflammatory immune response in assays in 
SH-SY5Y cells (Pandey et al., 2009). Primers used for RT-qPCR analysis are shown in 
Table 3.4. Standard curves for all RT-qPCR passed acceptance criteria (Figure 6.2). 
Analysis of mRNA expression was carried out using RT-qPCR as a ratio to GAPDH 
and TOPI. To ensure that the inflammatory immune response had been induced, levels 
of Toll-like receptor 3 (TLR3) were assessed by semi-quantitative RT-PCR as a ratio to 
GAPDH. Primers used for RT-PCR analysis are shown in Table 6.2. Toll-like receptors 
are present on the cell surface and are able to respond to stimulants produced by 
microorganisms in order to initiate the host defence and to stimulate the release of 
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molecules involved in the inflammatory immune response, such as antimicrobial 
peptides and inflammatory cytokines. LPS from E. coli is known to stimulate TLR3 and 
causes up-regulation of the receptor in SH-SY5Y cells (Nessa B. N. et al., 2006). There 
was a significant increase in the TLR3 mRNA levels in cells treated with LPS compared 
with controls (p = 0.03) (Figure 6.7C). Results relative to both reference genes show a 
significant decrease in ZnT10 expression at the mRNA level in response to extracellular 
LPS treatment (p = 0.01 and p = 0.03 respectively) (Figure 6.7A and 6.7i inset). This 
indicates that the inflammatory immune response may regulate ZnT10 expression at the 
mRNA level and gives evidence for a role of ZnT10 in this pathway. 
6.4 Discussion 
The results presented here show a significant decrease in ZnT10 expression at the 
mRNA level in frontal cortex of brain tissue samples from AD patients compared with 
age-matched controls (p = 0.006) giving the first indication that ZnT10 expression at the 
mRNA level is affected in AD. Furthermore, when separated on the basis of gender 
there is a significant decrease in levels of ZnT10 in female AD cases compared with 
controls (p = 0.004) whereas no significant difference between control and AD cases 
was observed in the samples derived from males (p = 0.211). There is however, no 
significant difference in ZnT10 mRNA levels between the males and females (control 
males versus control females p = 0.66, AD males versus AD females p = 0.67). The 
dysregulation of ZnTs in AD is not without precedence. In fact, at the mRNA level 
ZnT3 has been found to be significantly reduced in AD (Beyer et al., 2009). In this 
study using RT-qPCR the authors found a 45-60 % reduction of ZnT3 mRNA levels in 
the AD patients compared with controls, in all four cortical regions tested (medial 
temporal gyrus, superior occipital gyrus, superior parietal gyrus, and superior frontal 
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gyrus) but there was no significant differences in the expression in the cerebellum. 
Furthermore, there is an age-dependent increased activity of the Znt3 protein in the 
Tg2576 mouse model which is abolished in the Znt3 knockout mouse (Lee et al., 2002). 
This is an intriguing observation, given the seemingly age and gender specific 
relationship associated with expression levels of ZnT10 in AD brain tissue. 
Due to the valuable nature of the post-mortem brain tissue samples only one area of the 
brain, frontal cortex, was tested for ZnT10 and whilst this displays a decrease in 
transporter expression in AD patients, there is no data as yet as to whether this is region 
specific. This is an important factor as transporter dysregulation appears to be localised 
to the cortex and not found in the cerebellum. In addition to the data for ZnT3 mRNA 
levels (described above (Beyer et al., 2009)), mRNA expression for other zinc 
transporters; ZIP1, ZIP6, ZnT1 and ZnT6 in brain tissue has also been shown to 
increase in the four cortical regions (middle temporal gyrus, superior occipital gyrus, 
superior parietal gyrus, and superior frontal gyrus) but not in the cerebellum (Beyer et 
al., 2012). Further research is required to establish whether ZnT10 also follows this 
pattern. 
Another factor that needs to be taken into consideration is the quality of these samples. 
A recognised problem for AD cases is that they usually have a long pre-mortem decline 
and therefore have acidosis and consequently poor RNA quality. Here the RIN (RIN 
range 2.5-7.3) were below what would be desirable in a RT-qPCR experiment (Bustin et 
al., 2009). In addition, the number of samples (AD = 13 cases; 8 female and 5 male, 
Control = 10 cases, 3 female and 7 male) was low due to the difficulty in obtaining 
samples. The inter-individual variation between human samples is high therefore the 
numbers involved in this study are not to the desirable statistical power. Furthermore, I 
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do not have any information on the medication taken prior to death of these patients. 
This is an important factor as this too could influence many pathways and the mRNA 
expression of ZnT10. 
In order to help overcome these issues and to further strengthen the results, RNA was 
extracted from frontal cortex brain tissue samples obtained from 12 month old female 
WT (n = 5) and APP/PS1 mice (n = 11). APP/PS1 mice are a mouse model of 
Alzheimer’s disease containing two transgenes inserted at a single locus. The first is the 
APP sequence that is modified to encode the human Swedish mutations K595N/M596L. 
Secondly, PS1 corresponds to the human presenilin 1 gene. In this case there is a 
deletion of exon 9 therefore known as DeltaE9 mutation 
(http://jaxmice.jax.org/strain/005864.html). As in AD, these mice have Aβ deposits and 
exhibit deficits in spatial learning (Gimbel et al., 2010). The use of this mouse model to 
study AD is widespread and in particular this model has been used to identify 
dysregulation of several Znts using Western Blot analysis. Researchers found there was 
an increase in the protein expression of transporters tested (Znt1, Znt3, Znt4, Znt5, Znt6 
and Znt7) in the hippocampus and neocortex, with only levels for Znt5 failing to reach 
significance (Zhang et al., 2008). Further investigation into Znt expression in AD 
included analysing SPs obtained from these mouse models. These were tested by 
immunoreactions to ascertain whether there is expression of Znts within these 
aggregates. Intriguingly there was a distinct expression pattern evident with Znt1 and 
Znt4 found throughout the SPs whereas Znt3, Znt5 and Znt6 were in peripheral regions 
and Znt7 predominantly in the core (Zhang et al., 2008). The research into ZnT 
distribution in SP has not been translated to humans. This would be an interesting 
consideration but because I was unable to confirm the specificity of the commercial 
ZnT10 antibodies (see Chapter 4) ZnT10 staining of brain tissue sections were 
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unsuccessful as was assessing endogenous levels of protein expression by Western 
blotting for both the mouse and the human AD brain. The translation of results across 
species however must be viewed with caution as data using this mouse model revealed 
an increase in Znt3 protein levels, whereas human results gave a decrease in both 
mRNA and protein levels (Beyer et al., 2009, Adlard et al., 2010). Analysis of our RT-
qPCR results from the female APP/PS1 Tg mouse frontal cortex samples were however 
in agreement with the human AD results, showing a significant decrease in Znt10 
mRNA in the Tg mouse brain (p = 0.01).  
Human studies of ZnT dysregulation in AD have highlighted the importance of 
specifying the stage of disease progression. For example, the decline in multiple 
cognitive functions in the progression of AD is thought to begin with an interim stage 
labelled MCI with only 5 % of these patients remaining stable i.e. not developing 
dementia. In addition, there is a condition which is described as PCAD, in this case the 
patient does not have any overt clinical manifestations of AD however does have 
significant AD pathology at post-mortem. There are differences in ZnT expression 
profiles between AD and the precursor states described in the literature. For example 
ZnT1 shows a significant decrease in the hippocampus of subjects with MCI and PCAD 
(Lovell et al., 2005, Lyubartseva et al., 2009). It is hypothesised that this would lead to 
an increase in intracellular zinc. It is evident that levels of zinc are elevated in the AD 
brain (Cornett et al., 1998) and therefore there is more available zinc to bind to APP and 
Aβ. Furthermore, the presence of zinc itself is able to up-regulate ZnT1 transporter 
expression, as a compensatory mechanism increasing zinc ion availability in the 
extracellular space thereby enabling initiation of Aβ deposition and SP formation and 
exacerbating disease progression. This up-regulation of ZnT1 is evident at the protein 
level in AD brain tissue (Lovell et al., 2005). Research focusing on ZnT4 and ZnT6 has 
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also emphasised the need for more understanding of ZnT regulation in disease states. 
Elevations of both these transporters are found in PCAD (Lyubartseva et al., 2009) 
however there is no significant difference in levels of either transporter between MCI 
and age-matched controls. In AD cases however, both ZnT4 and ZnT6 mRNA levels 
are found to significantly increase in the hippocampus (Smith et al., 2006). It follows 
that the increased levels of ZnT6 and ZnT4 are thought to act as a compensatory 
mechanism for the decrease in levels of ZnT1. Due to the subcellular localisation of 
ZnT6 at the Golgi apparatus (where the γ-secretase complex interacts with APP), it is 
thought that this induces an increase in zinc in this organelle subsequently promoting 
Aβ formation by binding to APP and inhibiting α-secretase. ZnT4 is found in the 
lysosomal and endosomal compartments and will sequester zinc into these 
compartments. Indeed Aβ accumulation has been reported in this system in the post-
mortem AD brain (Takahashi et al., 2002). An area that is important to address, but is 
outside the scope of this research, is regulation of ZnT10 in both PCAD and MCI since 
this could elucidate a role for ZnT10 in the progression of AD. However results from 
my research allude to a mechanism for ZnT10 dysregulation in the final disease state of 
AD. Results presented in Chapter 4 reveal that under basal conditions ZnT10 is 
localised to the Golgi apparatus but undergoes translocation towards the plasma 
membrane with the addition of extracellular zinc. In addition I provided evidence of a 
down-regulation of both ZnT10 mRNA and protein, in response to increasing levels of 
extracellular zinc. Therefore I postulate that the increase in zinc ion levels in the AD 
brain (Cornett et al., 1998) induce a down-regulation of ZnT10 measured at the mRNA 
level in the AD brain tissue. Moreover, the localisation of ZnT10 would exacerbate AD 
disease progression two-fold. Initially, the localisation to the Golgi apparatus would 
allow promotion of Aβ formation by increasing zinc sequestration in this organelle 
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thereby enabling the binding of zinc to APP and the inhibition of α-secretase, in a 
similar manner to that hypothesised for ZnT6 (Lyubartseva et al., 2009). Secondly, 
elevated levels of zinc induce the translocation of ZnT10 towards the plasma 
membrane, allowing ZnT10 to act in the same way as ZnT1, effluxing zinc into the 
extracellular space, so possibly providing zinc ions for initiation of Aβ deposition and 
SP formation. The down-regulation at the mRNA level is intriguing, and further 
investigation is required to establish whether there is a parallel at the protein level and 
indeed in the activity of ZnT10. 
A previous study, using RT-qPCR, has shown that Znt10 mRNA, and incidentally Znt3 
mRNA, are down-regulated in response to 3 days treatment with Ang II. In addition, 
mRNA levels of both transcripts were analysed at both 24 and 48 hours but there was 
no significant difference found. Moreover, over-expression of Znt10 decreased 
production of ROS and prevented senescence. These experiments were carried out in rat 
VSMCs and implicate Znt10 and Znt3 in the RAS (Patrushev et al., 2012). Here I 
present data to suggest that ZnT10 is also involved in the brain RAS. Firstly, I show that 
after 24 hours of treatment with Ang II in SH-SY5Y cells, levels of ZnT10 are 
significantly increased by RT-qPCR (as a ratio to GAPDH p = 0.03, as a ratio to TOPI p 
= 0.04). It is note-worthy that, whilst the result after 24 hour is the opposite of that in 
published data, a down-regulatory response was only detected by the authors using RT-
PCR after 3 days of treatment. RT-PCR is a semi-quantitative technique that is 
potentially not as sensitive as RT-qPCR and therefore these subtle differences may have 
been overlooked and could allow for the variation in results. Furthermore, analysis by 
Patrushev et al., (2012) was in rat VSMCs and, whilst VSMCs themselves were not 
analysed, results in Chapter 3 revealed no endogenous expression of ZnT10 in heart or 
skeletal muscle therefore direct comparisons cannot necessarily be drawn. Differences 
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reported could also be due to tissue and/ or species specific responses and indeed 
variations in the influence of RAS between tissue types.  
Ang II binds to AT1 receptors, the downstream effect of this is activation of NADPH 
oxidase allowing the conversion of NADPH to NAD
+
 and producing ROS as the by-
product. In addition to the above impact of over-expression on ROS, Patrushev et al., 
(2012) also show that knockdown of Znt10 using siRNA increase ROS. Here oxidative 
stress initiated by tBHP had no effect on expression of ZnT10 mRNA as shown by RT-
qPCR (p = 0.66) suggesting that ZnT10 has an effect upstream of ROS production 
affecting the outcome, rather than being regulated by ROS per se. In my system, PKR 
levels confirmed the induction of oxidative stress in the SH-SY5Y cell line with a 
significant increase in treated cells (p = 0.001). Imitation of oxidative stress evidently 
has an effect on expression of certain ZnTs. When oxidative stress was induced in the 
rat cerebral cortex by nitric oxide there was an up-regulation of Znt1, Znt2, and Znt4 
mRNAs, however levels of Znt3 RNA levels were unaffected (Aguilar-Alonso et al., 
2008).  This is puzzling as in the VSMC system Znt3 was shown to be effected in the 
same way as Znt10, in that over-expression of Znt3 decreased ROS and, conversely, 
siRNA knockdown of Znt3 increased ROS (Patrushev et al., 2012) supporting the 
hypothesis that both Znt10 and Znt3 are not regulated by oxidative stress itself but act to 
impact on ROS production upstream. These contradictory results to ours and others 
(Aguilar-Alonso et al., 2008) may be a quirk of the rat VSMCs used. Interspecies 
variation cannot account for differences in the results for Znt3 given Aguilar-Alonso et 
al., (2008) also carried out their experiments in rat.  
Another pathway downstream of RAS is the inflammatory immune response initiated 
by NF-κB. Here LPS induction of this pathway successfully induces the immune 
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response in SH-SY5Y cells, as shown by a significant increase in mRNA expression of 
TLR3 (p = 0.03). Levels of ZnT10 however were significantly decreased in response to 
LPS treatment (as a ratio to GAPDH p = 0.01 and as a ratio to TOPI p = 0.03). Zinc has 
been implicated in the immune system, for instance there are many processes where NF-
κB modulates transcriptional activity of genes such as immunoreceptors and cytokines 
highlighting one role for zinc in the immune system (Zabel et al., 1991). Despite this, 
little is known about the function of ZnTs in the inflammatory immune response. 
Research has revealed that induction of the inflammatory immune response using LPS 
initiates a decrease in intracellular zinc as a result of increased expression of effluxers 
Znt1, Znt4 and Znt6 coupled with decreased expression of importers Zip6 and Zip10 in 
dendritic cells derived from mice (Kitamura et al., 2006). This pathway is stimulated by 
the activation of TLR4 by LPS. Furthermore, the authors showed that both Zip6 over-
expression and zinc supplementation was sufficient to inhibit the up-regulation of major 
histocompatibility complex (MHC) class II molecules ordinarily exhibited with LPS 
treatment. Moreover, investigation in immunologically relevant cell types has 
highlighted the importance of ZnTs in the immune system. In the different leukocyte 
subsets tested ZnT1 appeared to be the most regulated transporter with expression in all 
subsets. Interestingly, ZnT4 was localised to the plasma membrane in these cell types, a 
phenomenon restricted to cells of the immune system. In addition, ZnT8 revealed an 
inter-individual variability not seen for the other transporters. In response to zinc 
deficiency ZnT5, ZnT6 and ZnT7 were up-regulated in contrast to the down-regulation 
of ZnT1 (Overbeck et al., 2008). Combined these results imply a role for ZnTs in the 
homeostasis of zinc in the immune system, an area that requires further experimentation 
with the inclusion of ZnT10.  
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The results presented here further implicate ZnT10 in the aetiology of AD as there is a 
significant decrease in ZnT10 expression at the mRNA level in AD patients. Moreover, 
the inflammatory immune response plays a large role in the aetiology of AD (Akiyama, 
1994). Furthermore, non-steroid anti-inflammatory drugs (NSAIDs) have been shown to 
reduce the cognitive impairment associated with AD (Cote et al., 2012). The down-
regulation of ZnT10 also seen with induction of the inflammatory immune response in 
SH-SY5Y cells indicates that this pathway could be responsible for the overall 
reduction in ZnT10 levels in the AD brain. 
Whilst this chapter establishes novel preliminary data for the role of ZnT10 in the 
progression and aetiology of AD, it also highlights the need for future research into this 
area. 
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Figure 6.1 The Renin-Angiotensin System (RAS) in the brain. Angiotensin’s are 
synthesised from the conversion of angiotensinogen to angiotensin I (Ang I) catalysed by the 
enzyme renin. Ang I is further metabolised to Ang II, by angiotensin converting enzyme 
(ACE) (a zinc metalloprotease.). Ang II acts through the G-protein coupled receptor; 
angiotensin type (AT) receptor 1, that are able to signal through phospholipase C and Ca
2+. 
(de Gasparo et al., 2000). Downstream of the AT
1
 receptor is activation of NADPH oxidase; 
converting NADPH to NAD
+
. The by-products of such a reaction is reactive oxygen species 
(ROS) and ultimately oxidative stress. ROS can also induce a redox-dependent signal 
transduction pathway that leads to NF-κB activation and stimulation of the inflammatory 
immune response.  
 NADPH 
oxidase 
Figure 6.1 The Renin-Angiotensin System (RAS) in the brain. Angiotensins are 
synthesised from the conversion of angiotensinogen to angiotensin I (A  I) catalysed by 
the enzyme renin. Ang I is further met bolised to Ang II, by angiotensin converting 
enzyme (ACE) (a zinc metalloprotease.). Ang II acts thr ugh the G-protein coupled 
receptor; angi tensin type (AT) receptor 1, that are able to signal through phospholipase C 
and Ca
2+. 
(de Gasparo et al., 2000). Downstream of the AT
1
 receptor is activation of 
NADPH oxidase; converting NADPH to NAD
+
. The by-products of such a reaction are 
reactive oxygen species (ROS) and ultimately oxidative stress. ROS can also induce a 
redox-dependent signal transduction pathway that leads to NF-κB activation and 
stimulation of the inflammatory immune response.  
Chapter 6: ZnT10 in neurodegeneration 
223 
 
 
 
  
ZnT10 
TOPI 
GAPDH 
Figure 6.2 Standard curves generated to measure relative levels of ZnT10 by RT-qPCR, 
using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ Research). Standards for 
GAPDH and ZnT10 products were generated by amplifying the region between the primers shown 
in Table 3.4, and subcloned into the vector pCR2.1-TOPO TA (Invitrogen). TOPI primers were 
purchased from PrimerDesign. A TOPI PCR product was produced and subcloned into the pGEM-
T-easy vector to give the standard TOPI-pGEM (generated by Dr Alison Howard). The mean log 
concentration of each dilution was plotted against PCR cycle number at which the fluorescent 
threshold was crossed (C
T
).These standard curves were used to calculate relative levels of ZnT10 
transcripts.  
Figure 6.2 Standard curves generated to measure relative levels of ZnT10 by 
RT-qPCR, using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ 
Research). Standar s for GAPDH and ZnT10 products were generated by 
amplifying the regi  between the primers shown in Table 3.4, and subcloned into 
the vector pCR2.1-TOPO TA (Invitrogen). TOPI primers were purchased from 
PrimerDesign. A TOPI PCR product was produced and subcloned into the pGEM-T-
easy vector to give the standard TOPI-pGEM (generated by Dr Alison Howard). The 
mean log concentration of each dilution was plotted against PCR cycle number at 
which the fluorescent threshold was crossed (C
T
). Excluded data points are shown in 
red. These standard curves were used to calculate relative levels of ZnT10 
transcripts.  
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Figure 6.3 ZnT10 mRNA expression in human frontal cortex brain tissue. 
Relative levels of ZnT10 in brain tissue from AD brains (n = 13; female n = 8 male n 
= 5) and control brains (n = 10; female n = 3, male n = 7). Data are expressed relative 
to GAPDH mRNA levels measured in the same samples. Primers are given in Table 
3.4. All values are shown as mean ± SEM A.  Shows all data combined B. Results are 
stratified based on gender. ** p < 0.01 by Student’s t test. 
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Table 6.2 Primer sequences for mouse Znt10 analysis of brain tissue by RT-qPCR analysis. 
The numbering on each of the oligonucleotides represents its position on the gene.  
Table 6.1 Primer sequences for mouse Znt10 analysis of brain tissue by RT-
qPCR analysis. The numbering on each of the oligonucleotides represents its 
position on the gene.  
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Figure 6.4 Standard curves generated to measure relative levels of Znt10 by RT-
qPCR, using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ 
Research). Standards for 18S rRNA and mouse Znt10 products were generated by 
amplifying the region between the primers shown in Table 6.1, and subcloned into 
the vector pCR2.1-TOPO TA (Invitrogen). The mean log concentration of each 
dilution was plotted against PCR cycle number at which the fluorescent threshold 
was crossed (C
T
). Excluded data points are shown in red. These standard curves were 
used to calculate relative levels of mouse Znt10 transcripts.  
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Figure 6.5 Znt10 mRNA expression in frontal cortex mouse brain tissue. 
Relative levels of Znt10 in brain tissue from APP/PS1 Tg mouse brains (n = 11) and 
control mouse brains (n = 5). Data are expressed relative to 18S rRNA mRNA levels 
measured in the same samples. Primers are given in table 6.1. All values are shown 
as mean ± SEM ** p < 0.01 by Student’s t test. 
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Figure 6.6 Schematic of the study design for studying the Renin-Angiotensin System (RAS) in 
SH-SY5Y cells. Treatments are shown in blue. Cells were treated with Angiotensin II at a 
concentration of 0.1 µM for 24 hours prior to RNA extraction.  tBHP (0.025 mM; 40 minutes) was 
used to generate ROS and initiate oxidative stress. LPS from E. coli (100 ng/mL; 24 hours) was 
used to activate NF-κB activation and stimulate the inflammatory immune response.  
Figure 6.6 hematic of the study design for studying the Renin-Angiotensin 
System (RAS) in SH-SY5Y cells. Treatments are shown in blue. Cells were treated 
with Angiotensin II at a concentration of 0.1 µM for 24 hours prior to RNA 
extraction.  tBHP (0.025 mM; 40 minutes) was used to generate ROS and initiate 
oxidative stress. LPS from E. coli (100 ng/mL; 24 hours) was used to activate NF-κB 
activation and stimulate the inflammatory immune response.  
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  Figure 6.7 Does the RAS have an effect on ZnT10 mRNA expression in SH-
SY5Y cells? SH-SY5Y cells were cultured for 24 h with Ang II or LPS orSH-SY5Y 
cells were cultured for 40 min with tBHP before culturing for a further 24 h in basal 
media (n = 3). RNA was extracted and levels of A. ZnT10 were measured by RT-
qPCR. Data are expressed relative to GAPDH (or TOPI inset (i)) mRNA levels 
measured in the same samples. Primers are given in table 3.4. Levels of B. PKR and 
C. TLR3 were measured by RT-PCR. Primers are given in table 6.2. All values are 
shown as mean ± SEM ** p < 0.01, * p < 0.05 by Student’s t test. 
. 
Chapter 6: ZnT10 in neurodegeneration 
230 
 
 
  
Table 6.2 Primer sequences for PKR and TLR3 by RT-PCR analysis. 
*(Mouton-Liger et al., 2012) **(Nessa B. N. et al., 2006) 
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Figure 6.8 Schematic of the overall results for the study design of the Renin-Angiotensin 
System (RAS) in SH-SY5Y cells. Treatments are shown in blue. Ang II caused a significant 
increase in ZnT10 mRNA expression (p < 0.05). tBHP was used to generate ROS and initiate 
oxidative stress this caused no significant change in ZnT10 mRNA expression levels. LPS 
was used to activate NF-κB activation and stimulate the inflammatory immune response, this 
caused a significant decrease in ZnT10 mRNA expression levels (p < 0.05).  
Figure 6.8 Schematic summarising the observations made based on experiments 
probing the effect of the Renin-Angiotensin System (RAS) in SH-SY5Y cells. 
Treatments are s own in blue. Cells were treated with Angiotensin II at a 
concentration of 0.1 µM for 24 h urs prior to RNA extracti n.  tBHP (0.025 mM; 40 
minutes) was used to generate ROS and initiate oxidative stress. LPS from E. coli 
(100 ng/mL; 24 hours) was used to activate NF-κB activation and stimulate the 
inflammatory immune response. Ang II caused a significant increase in ZnT10 
mRNA expression (p < 0.05). tBHP was used to generate ROS and initiate oxidative 
stress this caused no significant change in ZnT10 mRNA expression levels. LPS was 
used to activate NF-κB activation and stimulate the inflammatory immune response, 
this caused a significant decrease in ZnT10 mRNA expression levels (p < 0.05).  
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Chapter 7: The effect of metals on BACE1 splicing events 
7.1 Outline 
In this chapter I continue to investigate the involvement of zinc in AD. Zinc transporter 
dysregulation plays a role in AD aetiology, as discussed in Chapter 6, and so it follows 
that alterations in levels of zinc transporters will ultimately result in differing levels of 
intracellular zinc. A broad overview of the involvement of zinc in AD was given in 
Chapter 1. Here I will focus on the role of zinc and other metal cations in the alternative 
splicing of the enzyme β-secretase ‘BACE’. BACE1 is a type I transmembrane aspartic 
proteinase known to be involved in the amyloidogenic pathway described in Chapter 1 
(Figure 1.5) where it is involved in the processing of APP thereby promoting the 
production of the neurotoxic peptide Aβ. The homolog BACE2 is only expressed at low 
levels in neurones and does not have the same cleavage activity as BACE1 with regards 
to APP (Vassar et al., 2009) and therefore is not discussed. This chapter reveals that the 
cations zinc, copper, cobalt and nickel are involved, to differing levels, in the BACE1 
alternative splicing events at the mRNA level. 
BACE1 has four known splice variants, each with a different enzymatic activity 
(Mowrer and Wolfe, 2008). Interestingly, levels of total BACE1 activity and protein 
expression correlate positively with Aβ production. This also has implications in the AD 
brain as BACE1 levels are increased in the frontal cortex of human post mortem AD 
brain tissue (Ahmed et al., 2010). In BACE1 knockout mice there is an absence of Aβ 
production and, although these mice appear healthy, there is evidence that there is a 
reduced myelination and some cognitive deficits (Willem et al., 2006).  
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There are nine exons in the BACE1 gene and normal processing results in the full-
length active protein of 501 amino acids (BACE501). Transcription is initiated from the 
normal 5’ splice site in exon 3 in combination with the normal 3’ splice site in exon 4 
(indicated on Figure 7.1A). There is an alternative 5’ splice site within exon 3 as well as 
an alternative 3’ splice site within exon 4 and, as stated in Chapter 1, combinations of 
the use of these yield the various isoforms (indicated on Figure 7.1). The next largest 
isoform is 476 amino acids (BACE476), which results from use of the normal 5’ splice 
site in exon 3 but an alternative 3’ splice site in exon 4 gives rise to the in-frame 
deletion of 75 base pairs giving a protein product 25 amino acids shorter (Figure 7.1B). 
A similar, an in-frame deletion of 132 base pairs is evident for the isoform BACE457 
(457 amino acids). In this case the alternative splice site used is an alternative 5’ splice 
site in exon 3 in combination with the normal 3’ splice site in exon 4 (Figure 7.1C). It 
follows that the final splice variant results from the use of both alternative splice sites; 
5’ alternative splice site in exon 3 in combination with the 3’ alternative splice site in 
exon 4 (Figure 7.1D) yielding the isoform that is an in-frame deletion of 207 base pairs, 
resulting in the smallest BACE1 isoform of 432 amino acids (BACE432) (Mowrer and 
Wolfe, 2008). The multiple sequence alignment of all four splice variants is shown in 
Appendix J. 
Intriguingly, the level of expression of each isoform correlates with size such that 
BACE501 is expressed at the highest levels > BACE476 > BACE457 > BACE432 in 
pathologically normal brains. BACE501 has also been found to be the most active 
isoform with the difference in activity attributed to the conformational change caused by 
the alternative splicing between important active site, aspartates in exons 2 and 6. 
Researchers have predicted that these splicing events alter the final folding of the 
protein and presumably, the access of substrates to the catalytic site (Mowrer and 
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Wolfe, 2008). Investigations into these splicing events are of importance in the 
pathology of AD, due to the role of BACE1 in Aβ production. Influencing splicing 
events so as to decrease BACE501 levels and increase levels of the less active 
BACE476 and BACE457 forms could ultimately reduce Aβ production without having 
an overall effect on total BACE1 expression, thus supporting the argument that 
BACE501 is the main contributor to Aβ production (Mowrer and Wolfe, 2008). In the 
transgenic mouse model of AD, tg2576, there is an over-expression of the Swedish 
mutated human form of APP (APPsw). This is a double mis-sense mutation in exon 16 
of the APP gene located on chromosome 21 that was originally identified due to its 
prevalence in a large Swedish pedigree. In fibroblast cell cultures, transfection of 
APPsw increases production of Aβ up to 7-fold compared with wild-type cells 
(Johnston et al., 1994). Intriguingly though, in the mouse model it has been shown that 
there is no change in the mRNA level of BACE1 within the brain. Despite this, there is 
increased enzymatic activity of BACE1 within these brains. The rise in activity is 
attributed to an increase in expression of the largest isoform BACE 501 (Zohar et al., 
2005). This has led to the proposal that BACE1 protein expression and activity is 
increased in AD brains, despite mRNA levels remaining constant in both transgenic 
mice models (Zohar et al., 2005) and AD patients (Holsinger et al., 2002, Fukumoto et 
al., 2002).  
Metals have been implicated in expression and activity of BACE1. In particular most 
research has focused on copper, due to a 24-residue peptide in the C-terminus of the 
BACE1 enzyme that contains cysteine residues that are able to bind a single copper 
atom with high affinity. Furthermore, in mammalian cells BACE1 has been shown to 
interact with the copper chaperone CCS. CCS is a copper delivery protein for the 
copper/zinc superoxide dismutase, SOD1. SOD1 binds both copper and zinc, the 
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cellular role of which is to destroy superoxide radicals that ultimately would result in 
oxidative stress. Over-expression of BACE1 in mammalian cells causes a reduction in 
the activity of SOD-1 due to an interaction of BACE1 with the CCS thus demonstrating 
a further role for BACE1 in metal homeostasis (Angeletti et al., 2005, Dingwall, 2007). 
Interestingly in previous research total BACE1 mRNA expression in rat adrenal 
medulla cells (PC12) increased with the addition of both copper and manganese but 
remained unchanged when extracellular zinc, iron and aluminium were added (Lin et 
al., 2008).  
It is note worthy that there are discrepancies in the literature for BACE1 mRNA 
expression levels, with the majority of work focusing predominantly on total BACE1, 
rather than investigating the isoform differences. Knowledge into the splicing events of 
these isoforms is lacking and further studies of these and the potential role of metals in 
regulating these events could help to elucidate pathways implicated in AD pathogenesis. 
Results presented in this chapter are interpreted on the basis of the different BACE1 
splice variants and here I report changes in the mRNA expression levels of the 
alternative splice variants in response to treatment of SH-SY5Y cells with extracellular 
zinc, copper, cobalt and nickel. These results could indicate a role for these cations in 
regulating these splicing events. 
In line with my studies investigating the role of the brain RAS and mRNA expression I 
also investigated the role of RAS in splicing of BACE1. As summarised in Chapter 6 
the RAS is a hormonal system well documented to control and regulate blood pressure 
and fluid balance and it has been extensively researched because of its importance in 
hypertension (Taquini and Taquini, 1961). The RAS is shown in Figure 6.1. Recent 
research has shown that the mammalian brain contains all components of the RAS (De 
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Bundel et al., 2008, Speth and Karamyan, 2008) and the brain has high concentrations 
of angiotensin receptors (Gard and Rusted, 2004). A metabolite of the system is Ang II 
which activates the AT1 and AT2 receptors (de Gasparo et al., 2000). Importantly, Ang 
II is able to act as a neurotransmitter in the brain, mainly acting to influence 
osmoreceptors in the hypothalamus to regulate the thirst response however it is also 
known to interact with other neurotransmitters such as acetylcholine, blocking its 
downstream effects (Gard, 2002). The cholinergic system is integral to the regulation of 
cognitive functions, in particular synaptic plasticity, specifically in learning and short-
term memory therefore its inhibition is detrimental to these pathways. Here I show 
BACE1 splicing events are affected by levels of Ang II in the SH-SY5Y cell line 
model, with an increase in BACE501 and BACE457 mRNA being detected alongside a 
decrease in BACE476 mRNA manifesting as a non-significant overall change in total 
BACE1. 
Downstream of the AT1 receptor is activation of NADPH oxidase. As stated previously 
(see Chapter 6), a consequence of NADPH oxidase activation is the conversion of 
NADPH to NAD
+
 and the by-products of such a reaction is ROS. An excess of ROS is 
known to cause oxidative stress and this is an important consideration in the aetiology 
of AD. Furthermore, continuous activation of the brain RAS in hRN/hANG-Tg mice 
(human renin (hRN) and human angiotensinogen (hANG) transgenic mice), a 
hypertensive mouse model, enhances oxidative stress and causes a decline in cognitive 
function by excessive stimulation of the AT1 receptor (Zhu et al., 2004). Moreover, the 
Aβ complexes caused as a by-product of the amyloidogenic pathway, initiate altered 
neuronal ionic homeostasis resulting in the production of ROS and therefore oxidative 
stress. In addition to the usual side effects of oxidative stress, a further concern in AD is 
the alterations to protein kinase signalling pathways induced by this cellular state 
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causing kinases, such as GSK3, to be activated, thereby leading to tau 
hyperphosphorylation and subsequently exacerbating NFT burden, as classified by 
Braak staging at post-mortem. Oxidative stress has been previously shown to affect 
splicing events (Soliman et al., 2009). It is evident that oxidative stress increases total 
BACE1 protein levels in SH-SY5Y cells induced with H2O2 (Mouton-Liger et al., 
2012). In this chapter I confirm an increase in BACE476, BACE457 and BACE432 
isoforms with a decrease in the BACE501 isoform through induced oxidative stress in 
SH-SY5Y cells. Interestingly this is manifested as an overall significant increase in total 
BACE1 at the mRNA level.  
ROS can also induce a redox-dependent signal transduction pathway that leads to NF-
κB activation and therefore stimulation of the inflammatory immune response - 
inflammation can also cause extensive damage in the brain of AD patients (Zimmerman 
et al., 2004). Western blot analysis shows that LPS induced inflammatory response is 
able to increase levels of total BACE at the protein level, inducing neuroinflammation 
and an increase in Aβ and memory impairments in mouse models (Lee et al., 2008). The 
RT-qPCR data presented herein shows the converse to this with a significant decrease in 
total BACE1 mRNA expression, contributed to by significant reductions in both 
BACE501 and BACE476 splice variant expression. 
Elucidation of the role of the brain RAS in activation of differential splicing events of 
BACE1, will further knowledge of this enzyme’s role in oxidative stress and 
inflammation. Here I show novel results concerning the splice variants of BACE1. 
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7.2 The effect of zinc treatment on expression of different BACE1 splice variants 
The effect of zinc availability on splicing events of BACE1 and therefore levels of 
expression of mRNA in SH-SY5Y cells was determined by culturing cells at 100 µM 
ZnCl2 for 24 hour.  Cell viability data for SH-SY5Y cells are presented in Chapter 4. 
Total RNA was extracted from cells (section 2.4.1) and standard curves were generated 
for each splice variant as described in section 2.5.5.1 before RT-qPCR was performed. 
Primer alignment used for RT-qPCR analysis of the splice variants is shown in Figure 
7.1 and primer sequences are given in Table 7.1. Standard curves for all RT-qPCR 
passed acceptance criteria (Figure 7.2). GAPDH showed a consistent expression 
independent of the extracellular zinc treatment and in Chapter 5 I validated the use of 
GAPDH in these experiments by showing there is no difference in the results of 
extracellular zinc treatment relative to either reference gene GAPDH or TOPI and 
therefore GAPDH was chosen as the reference gene and normalisation control. GAPDH 
has also previously been used to normalise zinc response by RT-qPCR (Jackson et al., 
2007, Hojyo et al., 2011).  All levels of BACE1 were assessed as a ratio to the reference 
gene GAPDH.  
Cells treated with an increased level of extracellular zinc manifested as a significant 
increase in total BACE1 mRNA expression when compared with untreated cells (p = 
0.01) (Figure 7.3). Interestingly, when extrapolated for the individual variants, this was 
revealed as an increase in the splice variants BACE501 (p = 0.004) and BACE432 (p = 
0.001), however a significant decrease in BACE476 was observed (p = 0.05). No 
change was observed in BACE457. In addition a standard curve was generated, as 
described in Section 2.5.5.1, for the MT1 control (Figure 7.2), in order to assess the 
increase in response to 100 µM extracellular zinc (Figure 7.3i inset). Thus I can 
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conclude that total BACE1 appears to be up-regulated at the mRNA level in response to 
extracellular zinc treatments, by altering levels in splicing such that BACE501 and 
BACE432 are significantly increased in treated cells. However, extracellular zinc 
treatment induces a significant decrease in BACE476. These results implicate zinc as a 
regulator of splicing events in BACE1. Alternatively to effects on splicing, it is note 
worthy that overall effects on total BACE1 may also reflect differences in mRNA 
stability of the alternative splice variants. Thus, if zinc has an effect on an individual 
variant mRNA stability that will be reflected as an increase in that variant manifested by 
an increase in total BACE1 mRNA levels. 
7.3 The effect of other extracellular cations on expression of BACE1 splice variants 
The effect of the extracellular cations (copper, cobalt and nickel) availability on splicing 
events of BACE1 and therefore levels of expression of mRNA in SH-SY5Y cells was 
determined by culturing cells at 100 µM copper (as CuSO4), 100 µM cobalt (as CoCl2) 
and 100 µM nickel (as NiCl2) for 24 hour.  Cell viability data for SH-SY5Y cells are 
presented in Chapter 5. Total RNA was extracted from cells (section 2.4.1), and 
standard curves were generated for each splice variant as described in section 2.5.5.1. 
Primers used for RT-qPCR analysis are shown in Table 7.1. Standard curves for all RT-
qPCR passed acceptance criteria (Figure 7.2). GAPDH showed a consistent expression 
independent of the extracellular cation treatment and in Chapter 5 I validated the use of 
GAPDH in these experiments by showing there is no difference in the results of 
extracellular cation treatments relative to either reference gene GAPDH or TOPI and 
therefore GAPDH was chosen as the reference gene and normalisation control. All 
levels of BACE1 were assessed as a ratio to the reference gene GAPDH.  
Chapter 7: The effect of metals on BACE1 splicing events 
240 
 
Cells treated with 100 µM extracellular copper manifested as a significant increase in 
total BACE1 mRNA expression when compared with untreated cells (p = 0.01) (Figure 
7.4). Individually, this revealed a decrease in the most active splice variant form 
BACE501 (p = 0.001) with significant increases in all other variants; BACE476 (p = 
0.007), BACE457 (p = 0.03) and BACE432 (p = 0.005) observed. 
Cells treated with 100 µM extracellular cobalt showed a significant decrease in total 
BACE1 mRNA expression (p = 0.02) (Figure 7.4). This alteration was due to a decrease 
in splice variant BACE501 (p = 0.03) and BACE476 (p = 0.07) with a non-significant 
decrease in BACE457 (p = 0.25) and BACE432 (p = 0.43).  
Cells treated with 100 µM extracellular nickel showed a significant decrease in total 
BACE1 mRNA expression when compared with untreated cells (p = 0.02) (Figure 7.4). 
This seems to be due to non-significant decreases in all of the splice variants; BACE501 
(p = 0.26), BACE476 (p = 0.24), BACE457 (p = 0.19) and BACE432 (p = 0.25).  
Thus I can conclude that total BACE1 appears to be regulated at the mRNA level in 
response to different extracellular cation treatment, by altering levels of the different 
splice variants expressed. Total BACE1 was up-regulated significantly with copper 
treatment, but down-regulated with both cobalt and nickel treatment. The individual 
splice variants, which contribute to these overall changes, also differ depending on 
treatments. BACE501 decreases significantly with both copper and cobalt treatment. 
BACE476 is up-regulated with copper treatment but conversely is down-regulated with 
cobalt treatment. BACE457 and BACE432 are both up-regulated with copper 
treatments and showed a non-significant decrease with cobalt treatments. All of the 
splice variants displayed a non-significant down-regulation with nickel treatments. The 
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combination of these data shows varying roles of cations in the transcriptional 
regulation and/ or mRNA stability of BACE1.  
7.4 Levels of BACE1 splice variants in AD brain tissue 
The amyloid cascade hypothesis has been prominent in AD research and despite 
findings to the contrary, it still remains dominant (reviewed by Pimplikar, 2009). 
Central to this hypothesis is the formation of Aβ by BACE1 which is able to cleave 
APP in the Golgi apparatus. Previously, only total BACE1 has been investigation in AD 
patients therefore, here I assess the levels of the BACE1 splice variants in AD patients 
relative to age-matched controls and compare human results to the APP/PS1 Tg mouse 
model. 
7.4.1 Levels of BACE1 splice variants in human brain tissue 
To investigate the effects of the disease process human brain tissue RNA was analysed 
from AD pathology cases (n = 13; female n = 8, male n = 5) and compared with age-
matched controls (n = 10; female n = 3, male n = 7) (Appendix I). Frontal cortex RNA 
was obtained from the Newcastle Brain Tissue Resource (Newcastle, UK). Due to the 
pre-mortem decline in AD the RNA quality was not ideal as measured by RNA integrity 
number (RIN range 2.5-7.3), however RT-qPCR analysis was carried out in order to 
give an indication of expression levels of BACE1 splice variant expression levels in AD 
patients. Primers used for RT-qPCR analysis are shown in Table 7.1. Standard curves 
for all RT-qPCR passed acceptance criteria (Figure 7.2). All data are expressed as a 
ratio to GAPDH. When AD patients are compared with age-matched controls there was 
a non-significant decrease in total BACE1 levels when compared with controls (p = 
0.08) (Figure 7.5). This reaches significance for BACE457 (p = 0.03) and BACE432 (p 
= 0.05) in this small number of brain tissues (Figure 7.5). Moreover, when the results 
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are analysed based upon gender, there is significant decrease total BACE1 expression in 
female AD patients compared with female controls (p = 0.02). This reaches significance 
for BACE457 (p = 0.008) and BACE432 compared with female controls (p = 0.00002) 
(Figure 7.6A). This is not observed in brain samples from males (Figure 7.6B). This is a 
particularly important result given the raised prevalence of AD in females.  
7.4.2 Expression levels of BACE1 splice variants in Tg mouse brain tissues 
In line with the human samples, frontal cortex brain tissue samples were obtained from 
12 month old female WT (n = 5) and APP/PS1 mice (n = 11) (Dr Paul Adlard, 
University of Melbourne). APP/PS1 mice contain two transgenes inserted at a single 
locus. The first is the APP sequence that is modified to encode the human Swedish 
mutations K595N/M596L. Secondly, PS1 corresponds to the human presenilin 1 gene, 
in this case there is a deletion of exon 9 therefore known as DeltaE9 mutation 
(http://jaxmice.jax.org/strain/005864.html). These mice have Aβ deposits and exhibit 
deficits in spatial learning (Gimbel et al., 2010). Brain samples were removed and snap 
frozen before being stored in RNA Later at -80°C. Samples were shipped in RNA later 
on dry ice and RNA was extracted using Trizol (section 2.4.1).  Primers used for RT-
qPCR analysis are shown in Table 7.1. Standard curves for all RT-qPCR passed 
acceptance criteria (Figure 7.2). RT-qPCR analysis was carried out as a ratio to 18S 
rRNA. These results were not comparable to the human AD results and showed no 
change in total BACE1 (p = 0.88) and splice variant BACE501 (p = 0.93) and 
BACE432 mRNA expression (p = 0.23), compared with controls. In contrast BACE476 
and BACE457 show significant increases in expression levels in the hemizygotes 
compared with the control non-carriers (p = 0.03 and p = 0.01 respectively) (Figure 
7.7). This differs from results seen in human brain samples. It is note-worthy that all 
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mouse samples were from female mice and therefore gender differences could not be 
explored in this instance. 
7.5 BACE1 splice variant mRNA expression in the RAS 
As published data indicates an involvement of the brain RAS in neurodegenerative 
conditions experiments were derived to investigate the effect of Ang II on BACE1 
splice variant mRNA expression in SH-SY5Y cells including experimentation into the 
role of oxidative stress and the inflammatory immune response on BACE1 splice 
variant expression. A summary of the study design is shown in Figure 7.8. 
7.5.1 Effect of Ang II on BACE1 splice variant mRNA expression 
Human neuroblastoma SH-SY5Y cells were treated with 0.1 µM Ang II for 24 hours in 
the absence of FBS. This level of Ang II has previously been used in Na
(+)
/H
(+)
 
exchanger assays in SH-SY5Y cells (Reid et al., 2004). Primers used for RT-qPCR 
analysis are shown in Table 7.1. Standard curves for all RT-qPCR passed acceptance 
criteria (Figure 7.2). Analysis of mRNA expression was carried out using RT-qPCR as a 
ratio to GAPDH. In Chapter 6 I validated the use of GAPDH in these experiments by 
showing there is no difference in the results of Ang II treatments relative to either 
reference gene GAPDH or TOPI and therefore GAPDH was chosen as the reference 
gene and normalisation control. Results relative to GAPDH show no change in total 
BACE1 expression at the mRNA level in response to extracellular Ang II treatment 
(Figure 7.9A). However, when the splice variants were analysed, a significant increase 
in BACE501 (p = 0.001) compared with untreated cells was observed. This is not 
reflected in BACE457 (p = 0.22). Conversely, there were significant decreases in both 
BACE476 (p = 0.03) and BACE432 mRNA expression (p = 0.002) compared with 
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untreated cells. These results indicate that BACE1 splice variants are regulated within 
the brain by the RAS. 
7.5.2 Effect of oxidative stress on BACE1 splice variant mRNA expression 
Human neuroblastoma SH-SY5Y cells were treated with 0.025 mM tBHP for 40 min in 
the presence of 10 % FBS. This level of tBHP has previously been used to induce 
oxidative stress in assays in SH-SY5Y cells (Krishnamurthy et al., 2000). Medium was 
removed and replaced with basal medium plus 10 % FBS for a further 24 hour time 
period, before RNA was harvested. Primers used for RT-qPCR analysis are shown in 
Table 7.1. Standard curves for all RT-qPCR passed acceptance criteria (Figure 7.2). 
Analysis of mRNA expression was carried out using RT-qPCR as a ratio to GAPDH. In 
Chapter 6 I validate the use of GAPDH in these experiments by showing there is no 
difference in the results of tBHP treatments relative to either reference gene GAPDH or 
TOPI and therefore GAPDH was chosen as the reference gene and normalisation 
control. As a control experiment, to ensure that oxidative stress had actually been 
induced by the treatment, levels of PKR (double-stranded RNA dependant protein 
kinase) were assessed by semi-quantitative RT-PCR as a ratio to GAPDH. Primers used 
for RT-PCR analysis are shown in Table 6.2. PKR is a serine-threonine kinase and in 
response to oxidative stress signals it is able to catalyse the phosphorylation of the α 
subunit of eukaryotic translation initiation factor-2 (eIF2) in order to inhibit protein 
synthesis (Der et al., 1997). Up-regulation of PKR has been found to occur in SH-SY5Y 
cells in response to induced oxidative stress by H2O2 treatment (Mouton-Liger et al., 
2012). Here I confirm a significant increase in PKR levels in the SH-SY5Y cells treated 
with tBHP as compared with controls (p = 0.001) (Figure 7.9Bi inset). Results 
manifested as a non-significant increase in total BACE1 in tBHP treated samples 
compared with untreated samples (p = 0.07) (Figure 7.9B). This was a result of 
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significant increases in the mRNA expression of the individual splice variants 
BACE476 (p = 0.004), BACE457 (p = 0.03) and BACE432 (p = 0.005) when compared 
with untreated samples (Figure 7.9B). Interestingly however, BACE501 showed a 
significant decrease in the tBHP treated samples (p = 0.008) compared with untreated 
cells. This indicates that oxidative stress is implicated in the regulation of the splicing 
events seen in BACE1.  
7.5.3 Role of the inflammatory immune response in BACE1 splice variant 
mRNA expression 
Human neuroblastoma SH-SY5Y cells were treated with 100 ng/ mL LPS for 24 hours 
in the absence of FBS. This level of LPS has previously been used to induce the 
inflammatory immune response in assays in SH-SY5Y cells (Pandey et al., 2009). 
Primers used for RT-qPCR analysis are shown in Table 7.1. Standard curves for all RT-
qPCR passed acceptance criteria (Figure 7.2). Analysis of mRNA expression was 
carried out using RT-qPCR as a ratio to GAPDH. In Chapter 6 I validated the use of 
GAPDH in these experiments by showing there is no difference in the results of LPS 
treatments relative to either reference gene GAPDH or TOPI and therefore GAPDH was 
chosen as the reference gene and normalisation control. To ensure that the inflammatory 
immune response had been induced, levels of Toll-like receptor 3 (TLR3) were assessed 
by semi-quantitative RT-PCR as a ratio to GAPDH. Primers used for RT-PCR analysis 
are shown in Table 6.2. Toll-like receptors are present on the cell surface and are able to 
respond to stimulants produced by microorganisms in order to initiate the host defence 
and to stimulate the release of molecules involved in the inflammatory immune 
response, such as antimicrobial peptides and inflammatory cytokines. LPS is known to 
stimulate TLR3 and causes up-regulation of the receptor in SH-SY5Y cells (Nessa B. N. 
et al., 2006). There was a significant increase in the TLR3 mRNA levels in cells treated 
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with LPS compared with untreated cells (p = 0.03) (Figure 7.9Ai inset).  Results show a 
non-significant decrease in total BACE1 expression at the mRNA level in response to 
extracellular LPS treatment compared with untreated cells (p = 0.07) (Figure 7.9). This 
was as a result of significant decreases in both BACE501 (p = 0.04) and BACE476 (p = 
0.04) isoforms with a non-significant increase in BACE457 (p = 0.09) and no change in 
BACE432 (p = 0.78). This indicates that the inflammatory immune response may in 
part regulate splicing events in BACE1. 
7.6 Discussion 
There is much controversy in the literature about expression levels of BACE1 mRNA in 
AD and what this means for protein levels and enzyme activity. It is note worthy that 
the majority of work published focuses predominantly on total BACE1 rather than 
looking at the different isoforms. This is particularly important given the activity of 
splice variants BACE476, BACE457 and BACE432 are significantly reduced compared 
with BACE501 (Tanahashi and Tabira, 2001, Mowrer and Wolfe, 2008). This 
difference in activity of the variants should be taken into account when investigating 
BACE1 regulation. Moreover, in addition to transcriptional regulation, BACE1 appears 
to undergo translational modification at multiple levels (De Pietri Tonelli et al., 2004). 
Therefore these factors should be taken into consideration both in experimental design 
and interpretation of data. However translational regulation is outside the scope of this 
chapter. An additional consideration, not assessed in this work is mRNA stability of the 
individual variants. It is important to bear in mind that overall effects on total BACE1 
may also reflect differences in mRNA stability of the alternative splice variants. Thus, if 
a treatment has an effect on an individual variant mRNA stability that will be shown as 
an increase in that variant manifested by an increase in total BACE1 mRNA levels. 
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Metals have been implicated in expression at the protein level and the activity of 
BACE1 previously. The focus of much research has been on copper due to the presence 
of a 24-residue peptide in the BACE1 C-terminal, which contains cysteine residues able 
to bind a single copper atom with high affinity. In mammalian cells BACE1 has been 
shown to interact with the copper chaperone CCS. CCS is a copper delivery protein for 
the copper/zinc superoxide dismutase, SOD1. SOD1 binds both copper and zinc, the 
cellular role of which is to destroy superoxide radicals that ultimately would result in 
oxidative stress. Over-expression of BACE1 in mammalian cells causes a reduction in 
the activity SOD-1 due to an interaction of BACE1 with the CCS thus elucidating a 
further role for BACE1 in metal homeostasis (Angeletti et al., 2005, Dingwall, 2007). 
Furthermore, copper and manganese increase the expression of BACE1 mRNA in rat 
adrenal medulla cells (PC12), with zinc, iron and aluminium not affecting expression in 
this model (Lin et al., 2008). Interestingly is has been established that BACE1 gene 
expression is regulated by the zinc dependent transcription factor Sp1 (Christensen et 
al., 2004). It should be noted that in these experiments total BACE1 levels were 
measured only and incorrect alignment of primers from published results means that the 
area of the BACE1 transcript tested cannot be ascertained.  
Copper and zinc have been implicated in AD as both can bind APP competitively at 
physiological concentrations in the extracellular domain, inducing large conformational 
changes and, presumably, altering physiological function and processing of APP 
(Dahms et al., 2012). Additionally, both metals are found at high levels in SP of AD 
patients (Lovell et al., 1998). The first experiments presented here show that splicing 
events can be influenced by the metal cations zinc, copper, cobalt and nickel. The 
results presented here are in support of previous studies for copper, with a significant 
increase in total BACE1 at the mRNA level (p = 0.01) with the addition of 100 µM 
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extracellular copper but what is intriguing is that copper appears to down-regulate the 
most active splice variant form BACE501 (p = 0.001). In contrast, copper treatment 
increased expression of BACE476, BACE457 and BACE432 (p = 0.007, p = 0.03 and p 
= 0.005 respectively). In these experiments I also show that the addition of 100 µM of 
extracellular zinc causes a significant increase in total BACE1 levels (p = 0.01), with 
the most active variant (BACE501) showing an increase in expression along with 
BACE432 (p = 0.004 and p = 0.001 respectively), with a significant decrease in 
BACE476 (p = 0.05). This shows that although the overall effect of copper and zinc 
treatment is the same, (i.e. total BACE1 increases) it is imperative to measure individual 
splice variant expression, because their profile differs with treatment. This differs from 
reports in the literature, where zinc induced a decrease in BACE1 expression, however 
incorrect publication of the primer sequences meant that I was unable to establish where 
in the sequence the primers annealed and therefore whether it is actually total BACE1 
that was measured, or one of the variants (Lin et al., 2008). To my knowledge there is 
no data on the direct influence of zinc or copper on BACE1 variant activity. This would 
be a very interesting avenue for further research. 
There is a down-regulation of all BACE1 splice variants in response to 100 µM cobalt 
treatment resulting in a significant decrease in total BACE1 (p = 0.02). For the 
individual variants however the down-regulation only reaches significance for 
BACE501 (p = 0.03). The only research relating to cobalt and BACE1, measures levels 
of total BACE1 in retinol ganglion cells (RGCs) where 200 µM of cobalt acted to 
increase BACE1 levels (Zhu et al., 2009). BLAST searches were unable to establish the 
whereabouts of the primers in the sequence. The differences may be due to alterations in 
cell types or the possible measurement of alternative splice variants rather than total 
BACE1. In addition, the study described used 200 µM of cobalt as opposed to 100 µM 
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used here. There are no cell viability data in the paper therefore I am unable to 
determine whether the increased concentration is appropriate for the RGCs. There has 
been no experiments to establish whether the effect of cobalt is dose dependent and 
therefore this would also need to be ascertained. 
The final cation to be tested for its effect on BACE1 mRNA expression was nickel. 
Nickel is not thought to be essential in the human body although, it is known to be toxic 
in high doses and cause conditions such as or allergic contact dermatitis. Nickel 
exposure comes from the use in manufacture of everyday items such as cooking 
utensils, coins and jewellery (Garrow et al., 2000). The expression of BACE1 mRNA 
levels to 100 µM nickel was comparable to the response to cobalt with a non-significant 
down-regulation observed for all splice variants in response to nickel treatment 
cumulating in a significant decrease in total BACE1 (p = 0.02). The similarity in 
response to cobalt is in itself intriguing, and further research into both cations would 
elucidate further roles in BACE1 regulation and/or activity. 
In summary, these results indicate that both zinc and copper act to increase total BACE1 
mRNA expression and in contrast cobalt and nickel appear to down-regulate total 
BACE1 mRNA expression levels. Intriguingly though, zinc seems to influence splicing 
events such that the most active isoform, BACE501 mRNA expression increases and 
BACE476 mRNA expression decreases whereas copper influences events so as to 
decrease BACE501 expression but increase expression of BACE476 mRNA. How these 
events translate into overall activity of BACE1, and ultimately Aβ production, would be 
an interesting avenue of research. 
The analysis of human brain RNA from patients diagnosed with AD further emphasised 
the importance of measuring BACE1 splice variants individually, rather than total 
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levels. It is known that BACE1 protein expression and activity is increased in the 
human AD brain (Holsinger et al., 2002, Fukumoto et al., 2002) but this is the first time 
that BACE1 splice variants have been measured in tissues from AD patients. Frontal 
cortex RNA was analysed by RT-qPCR in order to establish a BACE1 splice variant 
expression profile. To summarise, the main findings of this experiment revealed an 
overall significant decrease in BACE457 and BACE432 (p = 0.03 and p = 0.05 
respectively) in AD patients. Separation on the basis of gender strengthened this 
response in the female AD brain; BACE457 p = 0.008 and BACE432 p = 0.00002, with 
a gender specific significant decrease in total BACE1 expression (p = 0.02) observed in 
females. This response was not evident in males. Whether this response is truly gender 
specific or whether it can attributed to the small number of samples or the quality of the 
RNA samples is not known. Sample quality is an important consideration in any 
experiment and here the range of RIN values (2.5-7.3) is below what would be desirable 
for RT-qPCR.  
In order to try and support the human AD samples, brain tissue from the APP/PS1 Tg 
mouse model was sought to investigate BACE1 splice variant expression levels in a 
model of AD. In the literature studies investigating BACE1 levels in the Tg2576 
transgenic mouse model of AD have yielded some interesting results. In this Tg mouse 
there is an over-expression of the Swedish mutated human form of APP. Research in 
this model has shown that there is no change in the mRNA level of BACE1 within the 
Tg brain. Despite this, there is increase enzymatic activity of BACE1 within these 
brains. The rise in activity is attributed to an increase in expression of the largest 
isoform BACE501 (Zohar et al., 2005). This result was confirmed by RT-qPCR in the 
mouse brain for this splice variant. Zohar et al., (2005) concluded that the over-
expression of APP in these mice induces a change in splicing events such that 
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BACE501 is increased. This being the most active isoform of BACE1 means that 
BACE1 activity subsequently increases despite the mRNA levels of total BACE1 
remaining the same. In the APP/PS1 splice variant there is no overall change in total 
BACE1 mRNA levels in line with the Tg2576 findings. However, in contrast my results 
reveal there is also no alteration in BACE501 expression in the hemizygotes compared 
with non-carriers, however a significant increase in both BACE476 and BACE457 (p = 
0.03 and p = 0.01 respectively) was measured. This may be due to the different Tg mice 
used. APPsw is a double missense mutation in exon 16 of the APP gene located on 
chromosome 21 that was originally identified due to its prevalence in a large Swedish 
pedigree. In fibroblast cell cultures, transfection of APPsw increases production of Aβ 
up to 7-fold compared with wild-type cells (Johnston et al., 1994). The APP/PS1 mouse 
contains two transgenes, the first is the APPsw, however additionally the PS1 
corresponds to the human presenilin 1 gene, in this case there is a deletion of exon 9 
therefore known as DeltaE9 mutation (http://jaxmice.jax.org/strain/005864.html). The 
effect of this second mutation and indeed the presence of two mutations instead of one 
could in itself have an effect on BACE1 splice variant expression. It is worth bearing in 
mind that all of the mouse tissues were from female mice and that comparison to the 
human female AD cases shows a contrasting pattern of expression, with only BACE501 
giving an agreement of no change. This species difference is not without precedence, as 
researchers have shown differences in BACE1 splice variant levels between human and 
rat in non-diseased tissue. They established that BACE501 and BACE457 are found at 
high levels in the frontal cortex of both human and rat brain but that BACE432 was 
only expressed highly in rat (Zohar et al., 2003). The hypothesis that was proposed was 
that BACE1 transcripts may have different evolutionary conservation and therefore it 
follows that BACE1 transcripts could also differ between mouse and human. This 
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would be supported by the knowledge that rodents do not ordinarily form SP and 
therefore caution must be applied when translating the data both between mouse models 
and to humans. In addition, data was not available for the treatments of the patients with 
AD, not only could pharmaceuticals have an effect on the BACE1 splicing events and/ 
or expression this also presents an issue in terms of translation of studies from mice to 
humans.  
There is a growing body of evidence that the brain RAS is involved in the development 
and progression of AD (Kehoe et al., 2009). Therefore, echoing studies used to 
investigate ZnT10, I investigated the role of the RAS on BACE1 splice variant mRNA 
expression in SH-SY5Y cells (summarised in Figure 7.10). The first step examined was 
treatment with 0.1 µM Ang II over a 24 hour time period. The result of this experiment 
was no change in total BACE1 mRNA in treated SH-SY5Y cells compared with 
controls. Interestingly however the ratio of splice variants did change, with a significant 
increase of BACE501 (p = 0.001) and significant decreases in BACE476 and BACE432 
(p = 0.03 and 0.002 respectively). In a previous study the activity of BACE1 in 
HEK293 cells transfected with AT1 and APP or PS1 and treated with Ang II at varying 
concentrations (10 nM to 1000 nM) was investigated. The conclusion of this study was 
that there is no change in BACE1 activity with Ang II treatment after 24 hours (Wang et 
al., 2011a). In combination with the results presented here, the implication would be 
that the increase in BACE501 is negated by the decrease observed in BACE476 and 
BACE432 to give no overall change in total BACE1 expression and ultimately activity 
of BACE1. These results do not prove this and the differences in experimental 
parameters must be taken into consideration. 
Chapter 7: The effect of metals on BACE1 splicing events 
253 
 
Oxidative stress has been shown to be an important factor in the progression of AD 
(Zhu et al., 2004). Here, in line with previous experiments in SH-SY5Y cells 
(Krishnamurthy et al., 2000), 0.025 mM of tBHP was used to induce oxidative stress in 
these cells. This was confirmed by a significant increase in PKR in the treated cells. For 
the BACE1 splice variants total BACE1 displayed a near significant increase in the 
treated cells (p = 0.07) with significant increases observed for the variants BACE476, 
BACE457 and BACE432 (p = 0.004, p = 0.03 and p = 0.005 respectively) but a 
significant decrease in BACE501 (p = 0.008). It has been reported that oxidative stress 
acts to increase protein expression of BACE1 in SH-SY5Y cells, where oxidative stress 
was induced by treatment with 0.2 mM and 0.5 mM H2O2 for up to 16 hours. 
Additionally, RT-qPCR analysis showed an increase of BACE1 mRNA expression after 
1 hour treatment with 0.5 mM H2O2 (Mouton-Liger et al., 2012). This is in accordance 
with the results presented here but again caution should be employed as there are 
differences in experimental parameters. Our experiments also show the importance of 
measuring the BACE1 splice variants. 
The final implication of the RAS is inducing the inflammatory immune response with 
ROS stimulating NF-κB production. The inflammatory immune response plays a large 
role in the aetiology of AD (Akiyama, 1994) and in fact non-steroid anti-inflammatory 
drugs (NSAIDs) have been shown to reduce the cognitive impairment associated with 
AD (Cote et al., 2012). Explored here is the effect of the inflammatory immune 
response on BACE1 splice variant expression at the mRNA level. The inflammatory 
immune response was induced in SH-SY5Y cells using 100 ng/ mL LPS for 24 hours. 
Induction of the response was confirmed using RT-PCR to show a significant increase 
in TLR3 levels in the treated cells. Total BACE1 expression levels did not reach 
significance for LPS treated cells but did display a down-regulatory trend in response to 
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LPS treatment (p = 0.07). In the individual variants both BACE501 and BACE476 
decreased significantly in the treated cells (p = 0.04 and p = 0.04 respectively) but no 
significant changes in BACE457 and BACE432 were observed (p = 0.09 and p = 0.78 
respectively). The role of LPS on BACE1 splice variants at the mRNA level has not 
been investigated previously in SH-SY5Y cells. Memory impairment induced by LPS in 
mouse models has been attributed to the accumulation of Aβ as a result of 
neuroinflammation (Lee et al., 2008). A subsequent study demonstrated that this 
accumulation was due to an increase in BACE1 protein levels induced by the NF-κB 
pathway (Choi et al., 2012). Regulation at the transcriptional level and subsequent 
activity of BACE1 protein requires further investigation in order to unravel the 
complicated process to control BACE1 and its isoforms, however I present a number of 
novel findings to add to this growing body of data. 
This chapter highlights the importance of measuring the individual splice variants 
opposed to only total BACE1.  Differences in splice variant mRNA expression may not 
manifest as overall changes in total BACE1 mRNA expression, but may correspond to 
important alterations in activity of the enzyme ultimately having a down-stream effect 
on the production of the neurotoxic Aβ. 
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Figure 7.1 Schematic of the BACE1 splice variants. A. BACE 501. Transcription 
is initiated from the normal 5’ splice site in exon 3 in combination with the normal 3’ 
splice site in exon 4. B. BACE 476. Transcription is initiated from the normal 5’ 
splice site in exon 3 in combination with the alternative 3’ splice site in exon 4. C. 
BACE 457. Transcription is initiated from the alternative 5’ splice site in exon 3 in 
combination with the normal 3’ splice site in exon 4. D. BACE 432.  Transcription is 
initiated from the alternative 5’ splice site in exon 3 in combination with the 
alternative 3’ splice site in exon 4. Schematic of primer design for each BACE1 
splice variants are indicated (adapted from Mowrer and Wolfe, 2008).  
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Table 7.1 Primer sequences for analysis of BACE1 splice variants using RT-
qPCR analysis. The numbering on each of the oligonucleotides represents its 
position on the gene. *(Mowrer and Wolfe, 2008), **(Valentine et al., 2007), 
***(Cragg et al., 2005). 
Table 7.1 Primer sequences for analysis of BACE1 splice variants using RT-
qPCR analysis. The numbering on each of the oligonucleotides represents its 
position on the gene. *(Mowrer and Wolfe, 2008), **(Valentine et al., 2007), 
***(Cragg et al., 2005). 
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Figure 7.2 Standard curves generated to measure relative levels of BACE1 
splice variants by RT-qPCR, using SYBR green fluorescence and the DNA Engine 
Opticon 2 (MJ Research). Standards for GAPDH, BACE1 splice variants and MT1 
products were generated by amplifying the region between the primers shown in 
Table 7.1, and subcloned into the vector pCR2.1-TOPO TA (Invitrogen). The mean 
log concentration of each dilution was plotted against PCR cycle number at which 
the fluorescent threshold was crossed (C
T
). Excluded data points are shown in red. 
These standard curves were used to calculate relative levels of BACE1 splice variant 
transcripts.  
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Figure 7.3 The effect of increased extracellular zinc on BACE1 splice 
variant mRNA expression in SH-SY5Y cells. Cells were cultured for 24 h at 
100 µM zinc (added as ZnCl
2
) then total RNA was extracted and levels of 
BACE1 splice variant and MT-1 (i) mRNA were measured by RT-qPCR, using 
SYBR green fluorescence and the DNA Engine Opticon 2 (MJ Research). 
Primers are given in Table 7.1. Data are expressed relative to GAPDH mRNA 
levels measured in the same samples. All values are shown as mean ± SEM, n 
= 6. *** p < 0.001, ** p < 0.01, significantly different from 3 µM zinc 
(untreated) by Students t-test. 
Figure 7.3 The effect of increased extracellular zinc on BACE1 splice variant 
mRNA expression in SH-SY5Y cells. Cells were cultured for 24 h in basal media (3 
µM Zn) or at 100 µM extracellular zinc (added as ZnCl
2
) then total RNA was 
extracted and levels of BACE1 splice variant and (i) MT1 mRNA were measured by 
RT-qPCR, using SYBR green fluorescence and the DNA Engine Opticon 2 (MJ 
Research). Primers are given in Table 7.1. Data are expressed relative to GAPDH 
mRNA levels measured in the same samples. All values are shown as mean ± SEM, 
n = 6. *** p < 0.001, ** p < 0.01, significantly different from 3 µM zinc (untreated) 
by Students t-test. 
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Figure 7.4 The effect of extracellular cation treatment on BACE1 splice variant 
mRNA expression in SH-SY5Y cells. Cells were cultured for 24 h at 100 µM 
copper (as CuSO
4
), 100 µM cobalt (as CoCl
2
) or 100 µM nickel (as NiCl
2
) as 
indicated. Total RNA was extracted and levels of BACE1 splice variant mRNA were 
measured by RT-qPCR, using SYBR green fluorescence and the DNA Engine 
Opticon 2 (MJ Research). Primers are given in table 7.1. Data are expressed relative 
to GAPDH mRNA levels measured in the same samples. All values are shown as 
mean ± SEM, n = 6. *** p < 0.001, ** p < 0.01, significantly different from 3 µM 
zinc (untreated) by Students t-test. 
** 
**
* 
** 
* 
** * 
**
* 
** 
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Figure 7.5 BACE1 splice variant mRNA expression in human brain tissue. 
Relative levels of BACE1 splice variants in brain tissue from control brains (n = 10) 
and AD brains (n = 13) . Data are expressed relative to GAPDH mRNA levels 
measured in the same samples. Primers are given in Table 7.1. All values are shown 
as mean ± SEM * p < 0.05 significantly different from controls by Students t-test. 
Figure 7.5 BACE1 splice variant mRNA expression in human brain frontal 
cortex tissue. Relative levels of BACE1 splice variants in brain tissue from control 
brains (n = 10) and AD brains (n = 13). Data ar  expressed rel tive to GAPDH 
mRNA levels measured in the same samples. Primers are given in Table 7.1. All 
values are shown as mean ± SEM * p < 0.05 significantly different fro  controls by 
Students t-test. 
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Figure 7.6 BACE1 splice variant mRNA expression in human brain frontal 
cortex tissue stratified for gender. Relative levels of BACE1 splice variants in 
brain tissue from A. Female control brains (n = 3) and female AD brains (n = 8) and 
B. Male control brains (n = 5) and male AD brains (n = 7). Data are expressed 
relative to GAPDH mRNA levels measured in the same samples. Primers are given 
in table 7.1. All values are shown as mean ± SEM * p < 0.05, ** p < 0.01, *** p < 
0.001 significantly different from controls by Students t-test. 
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Figure 7.7 BACE1 splice variant mRNA expression in mouse brain tissue. 
Relative levels of BACE1 splice variants in brain tissue from APP/PS1 control 
mouse brains (n = 5) and Tg mouse brains (n = 11) . Data are expressed relative to 
S18 rRNA mRNA levels measured in the same samples. Primers are given in Table 
7.1. All values are shown as mean ± SEM * p < 0.05, ** p < 0.01 significantly 
different from controls by Students t-test. 
Figure 7.7 BACE1 splice variant RNA expression in ouse brain frontal 
cortex tissue. Relative levels of BACE1 splice variants in brain tissue from APP/PS1 
control mouse brains (n = 5) and Tg mouse brains (n = 11). Data are expressed 
relative to 18S rRNA mRNA levels measured in the same samples. Primers are given 
in Table 7.1. All values are shown as mean ± SEM * p < 0.05, ** p < 0.01 
significantly different from controls by Students t-test. 
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Figure 7.8 Schematic of the study design for studying the Renin-
Angiotensin System (RAS) in SH-SY5Y cells. The RAS in the brain. 
Angiotensins are synthesised from the conversion of angiotensinogen to 
angiotensin I (Ang I) catalysed by the enzyme renin. Ang I is further 
metabolised to Ang II, by angiotensin converting enzyme (ACE) (a zinc 
metalloprotease.) Ang II acts through the G-protein coupled receptor; 
angiotensin type (AT) receptor 1, that are able to signal through phospholipase 
C and Ca
2+. 
(de Gasparo et al., 2000). Downstream of the AT
1
 receptor is 
activation of NADPH oxidase; converting NADPH to NAD
+
. The by-products 
of such a reaction is reactive oxygen species (ROS) and ultimately oxidative 
stress. ROS can also induce a redox-dependent signal transduction pathway that 
leads to NF-κB activation and stimulation of the inflammatory immune 
response. Treatments are shown in blue. Cells were treated with Angiotensin II 
at a concentration of 0.1 µM for 24 hours prior to RNA extraction.  tBHP (0.025 
mM; 40 minutes) was used to generate ROS and initiate oxidative stress. LPS 
from E. coli (100 ng/mL; 24 hours) was used to activate NF-κB activation and 
stimulate the inflammatory immune response.  
Figure 7.8 Schematic of the study design for studying the Renin-Angiotensin 
System (RAS) in SH-SY5Y cells. The RAS in the brain. Treatments are shown in 
blue. Cells were treated with Angiotensin II at a concentration of 0.1 µM for 24 
hours prior to RNA extraction.  Ang II acts through the G-protein coupled receptor; 
angiotensin type (AT) receptor 1, that is able to signal through phospholipase C and 
Ca
2+. 
(de Gasparo et al., 2000). Downstream of the AT
1
 receptor is activation of 
NADPH oxidase; converting NADPH to NAD
+
. The by-products of such a reaction 
is reactive oxygen species (ROS) and ultimately oxidative stress. tBHP (0.025 mM; 
40 minutes) was used to generate ROS and initiate oxidative stress. ROS can also 
induce a redox-dependent signal transduction pathway that leads to NF-κB activation 
and stimulation of the inflammatory immune response. LPS from E. coli (100 
ng/mL; 24 hours) was used to activate NF-κB activation and stimulate the 
inflammatory immune resp se  
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Figure 7.9 Does the RAS have an effect on BACE1 splice variant mRNA 
expression in SH-SY5Y cells? SH-SY5Y cells were cultured for 24 h with Ang II or 
LPS (shown in A.) or SH-SY5Y cells were cultured for 40 min with tBHP before 
culturing for a further 24 h in basal media (shown in B.). n = 3 for all treatments. 
RNA was extracted and levels of BACE1 splice variants were measured by RT-
qPCR. Primers are given in table 7.1. Levels of B.(i) PKR and A.(i) TLR3 were 
measured by RT-PCR. Data are expressed relative to GAPDH mRNA levels 
measured in the same samples. Primers are given in table 6.3. All values are shown 
as mean ± SEM ** p < 0.01, * p < 0.05 significantly different from controls by 
Students t-test. 
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Figure 7.10 Schematic of the overall results for the study of the Renin-
Angiotensin System (RAS) in SH-SY5Y cells. Treatments are shown in blue. 
Cells were treated with Angiotensin II at a concentration of 0.1 µM for 24 
hours prior to RNA extraction.  tBHP (0.025 mM; 40 minutes) was used to 
generate ROS and initiate oxidative stress. LPS from E. coli (100 ng/mL; 24 
hours) was used to activate NF-κB activation and stimulate the inflammatory 
immune response. Ang II caused a significant increase in BACE501 mRNA 
expression  and significant decreases in BACE476 and BACE432 isoforms. 
tBHP was used to generate ROS and initiate oxidative stress this caused 
significant increases in BACE476, BACE457 and BACE432 mRNA 
expression levels and a significant decrease in BACE501 mRNA expression. 
LPS was used to activate NF-κB activation and stimulate the inflammatory 
immune response, this caused significant decreases in BACE501 and 
BACE476 mRNA expression levels.  
Figure 7.10 Schematic summarising the observations made based on 
experiments probing the effect of the Renin-Angiotensin System (RAS) in SH-
SY5Y cells. Treatments are shown in blue. Cells were treated with Angiotensin II at 
a concentration of 0.1 µM for 24 hours prior to RNA extraction.  tBHP (0.025 mM; 
40 minutes) was used to generate ROS and initiate oxidative stress. LPS from E. coli 
(100 ng/mL; 24 hours) was used to activate NF-κB activation and stimulate the 
infla atory immune response. Ang II caused a significant increase in BACE501 
mRNA expression and significant decreases in BACE476 and BACE432 isoforms. 
tBHP was used to generate ROS and initiate oxidative stress this caused significant 
increases in BACE476, BACE457 and BACE432 mRNA expression levels and a 
significant decrease in BACE501 mRNA expression. LPS was used to activate NF-
κB activation and stimulate the inflammatory immune response, this caused 
significant decreases in BACE501 and BACE476 mRNA expression levels.  
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Chapter 8: Summary and Final Discussion 
Prior to 2012 the knowledge relating to ZnT10 was limited to a single article. Here 
bioinformatic data found that the human SLC30A10 gene is localised to human 
chromosome 1 at the position q41. The gene spanned 15 kb with an arrangement of 4 
exons, and was predicted to code for a 52.7 kDa protein. When compared to other 
family members it was predicted that ZnT10 had the conserved 6 TMDs and a basic 
region between TMD IV and V. An in silico method was used to assess the tissue 
expression pattern. This was performed by using an expressed sequence tag (EST) data 
mining strategy whereby the programme BLASTN was used to run the predicted ZnT10 
transcript (ORF, 5' and 3' UTRs) against the human EST database, this gave a predicted 
ZnT10 expression profile. Interestingly, using this method ZnT10 was predicted to be 
restricted to foetal tissue and more specifically foetal liver and brain (Seve et al., 2004). 
The overall aim of my study was to confirm and extend the findings of Seve et al., 
(2004) in order to further characterise ZnT10 and investigate the role of this predicted 
transporter in neurodegeneration. 
In Chapter 3 I confirm the bioinformatic findings of Seve et al., (2004), predicting 6 
TMDs. The programmes used (TMPred, TMHMM) both predicted the conserved 
intracellular N- and C- termini. Further novel bioinformatic investigation demonstrated 
the presence of a CDF motif and identification of multiple sites for modification (3 N-
glycosylation sites, 1 O-glycosylation site and 15 possible phosphorylation sites). It was 
important to establish the expression profile of ZnT10 and this has led to the novel 
discovery that ZnT10 is expressed in both adult mouse and adult human tissue. The 
expression profile in humans was elucidated by RT-qPCR with relatively high levels of 
expression in the liver, brain, small intestines and testes with lower levels of expression 
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in the ovary, colon, cervix, placenta and prostate. Simultaneously, support for the 
presence of ZnT10 in adult human tissues has been provided by identification and 
characterisation of mutations in the SLC30A10 gene in dystonia with brain manganese 
accumulation (Stamelou et al., 2012, Tuschl et al., 2012) and its dysregulation in 
response to angiotensin II treatment (Patrushev et al., 2012). In addition to the 
expression profile, it was important to establish the function of ZnT10 and determine 
whether it has the ability to transport zinc. An in-direct functional assay was used, and 
this implied transport of zinc in the efflux direction, as would be expected from a 
member of the CDF family of transporters. 
The homeostasis of zinc is very tightly regulated and therefore it follows that the zinc 
transporters are under strict regulation. In Chapter 4 I assessed the regulation of ZnT10 
at both the mRNA and protein level in Caco-2 and SH-SY5Y cell line models, 
highlighting a down-regulation in response to increased extracellular zinc concentration. 
Furthermore, localisation was established which revealed ZnT10 to translocate in 
response to extracellular zinc treatment demonstrating a pattern of localisation to the 
Golgi apparatus under basal zinc conditions with movement towards the plasma 
membrane with the addition of 100 µM extracellular zinc, when assessed using SH-
SY5Y cells transiently expressing a ZnT10 construct tagged with the FLAG epitope at 
the N-terminus. Additionally, identification of a putative zinc responsive element 
(ZTRE) in the 5’UTR of the ZnT10 promoter led to investigation of the transcriptional 
regulation of ZnT10, which revealed that the ZTRE region is important for promoter 
repression in response to increased extracellular zinc. 
Given the regulation displayed for zinc and in the context of the evolution of CDF 
family members transporting various cations, ZnT10 regulation was assessed with 
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increased extracellular copper, cobalt and nickel. Interestingly, ZnT10 has very recently 
been shown to transport manganese therefore that the role for ZnT10 is broader than 
zinc transport (Tuschl et al., 2012). In Chapter 5 I demonstrate that ZnT10 is regulated 
by both extracellular nickel and cobalt at the mRNA and protein level. ZnT10 mRNA 
levels are decreased in response to extracellular cobalt. Conversely, extracellular nickel 
increases ZnT10 mRNA levels. At the protein level an increase in the p3xFLAG-ZnT10 
construct is evident with both extracellular cobalt and extracellular nickel treatments. 
Copper was not shown to elicit an effect on ZnT10 indicating that the Irving-Williams 
series may be implicated in its regulation (manganese < iron < cobalt < nickel < copper 
> zinc) (Irving and Williams, 1948). Furthermore, immunofluorescent analysis of 
p3xFLAG-ZnT10 transiently transfected SH-SY5Y demonstrated a translocation of 
ZnT10 by extracellular nickel treatment that is similar to that seen with extracellular 
zinc treatment. Treatment with extracellular cobalt displayed a more diffuse pattern of 
localisation compared with untreated basal cells, whereas extracellular copper treatment 
showed a pattern consistent with basal media. Transcriptional regulation by these 
cations was also investigated however no change in promoter activity was observed for 
the wild-type promoter in response to extracellular cobalt, nickel or copper indicating 
alternative mechanisms of regulation must be involved. Intriguingly, mutation of the 
promoter displayed an increase in promoter activity in response to extracellular cobalt 
perhaps mediated by a conformational change allowing other response elements (e.g. 
MRE) in this region to become accessible. These observations are intriguing especially 
given the recent publication identifying frame-shift mutations in the SLC30A10 gene in 
patients with the neurological conditions dystonia and Parkinsonism that lead to 
hypermanganesemia in brain regions (Quadri et al., 2012). Rescue experiments were 
performed in a yeast mutant demonstrating the ability of wild-type ZnT10 to restore 
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growth in a manganese sensitive yeast mutant Δpmr1 (Tuschl et al., 2012). Analysis of 
the zinc binding ability of ZnT5 has identified a region within this CDF that is known to 
be involved in selectivity of the transporter (Ohana et al., 2009). This region is 
conserved in ZnT10 (Figure 3.1). Mutational analysis of this region in ZnT10 would 
allow us to ascertain if these residues are involved in selectivity in this CDF member. 
Additionally, ZnT10 has a serine rich region opposed to the conventional histidine rich 
region found in most family members (Seve et al., 2004). It is possible that transporter 
ability may be attributed to this area. Interestingly ZnT6 also contains this serine rich 
region and it is known to act as a heterodimer with ZnT5 in order to transport zinc 
(Huang et al., 2002, Suzuki et al., 2005b). This knowledge could be used in order to 
support ZnT10 studies if ZnT6 also has manganese transporting capabilities. Further 
analysis of these findings and investigations into the role of manganese plus additional 
characterisation of the transport ability of ZnT10 would enable more conclusions to be 
drawn. 
Zinc dyshomeostasis has been implicated in the aetiology of AD but as yet its role has 
not been fully elucidated. ZnTs have been shown to be dysregulated in AD post-mortem 
brain tissue. For example up-regulation of the ZnT1 protein is evident in the 
hippocampus in AD brain tissue (Lovell et al., 2005). It is thought that this increase in 
ZnT1 expression in the disease state causes an increase in zinc ions available in the 
extracellular space for initiation of Aβ deposition and SP formation (Lyubartseva et al., 
2009). Therefore, I assessed ZnT10 levels in human AD and APP/PS1 Tg mouse brain 
frontal cortex, results of which are reported in Chapter 6.  A significant decrease in 
ZnT10 levels at the mRNA level was observed in both human AD brain tissue and brain 
tissue from APP/PS1 Tg mice compared with controls. Development and use of specific 
ZnT10 antibodies would allow further investigation at the protein level into the role of 
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ZnT10 in disease progression. Furthermore, RAS pathways involved in AD progression 
were investigated to further characterise the response of ZnT10. This identified an 
increase in ZnT10 mRNA in response to extracellular Ang II treatment. Conversely, 
LPS induced inflammatory immune response conferred a decrease in ZnT10 mRNA 
levels. Oxidative stress initiated by tBHP did not elicit a change in ZnT10 mRNA 
levels. These data highlights that ZnT10 may be implicated in AD pathology, however 
further research is required to elucidate its role further. 
Finally the role of zinc and other cations in the splicing of the BACE1 enzyme were 
investigated. In Chapter 7 I demonstrate that extracellular zinc treatment induces an 
increase in total BACE1, with significant increases contributed by BACE501 and 
BACE432 splice variants, however a significant decrease in BACE476 was also 
evident. The cations copper, cobalt and nickel also seem to be involved in these splicing 
events, with an overall increase in total BACE1 elicited by extracellular copper 
treatment; however a significant decrease in total BACE1 for both extracellular cobalt 
and nickel treatments was seen. Interestingly, a different profile of splice variant 
expression was revealed with each cation. This phenomenon highlights the importance 
of examining BACE1 at an individual variants level. Levels of BACE1 splice variants 
were investigated in order to establish a profile in human AD and APP/PS1 Tg mouse 
model post-mortem frontal cortex tissue. Intriguingly there was an inter-species 
variation with significant decreases in BACE457 and BACE432 in human AD 
compared with controls, whereas in the Tg mouse models BACE476 and BACE457 
displayed significant increases in expression. BACE1 splice variants were also 
investigated in response to the RAS. In summary, Ang II produced an increase in 
BACE501 levels, with decreased levels of BACE476 and BACE432. Initiation of 
oxidative stress using tBHP indicated an increase in BACE476, BACE457 and 
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BACE432 with a decrease in BACE501. Induction of the inflammatory immune 
response using LPS demonstrated decreases in BACE501 and BACE476.  
The dysregulation of ZnT10 that I have demonstrated in the AD brain may contribute to 
disease aetiology given that ZnT10 acts to efflux zinc. It is possible that these effects 
may be mediated through alteration in splicing events of BACE1 in response to 
alterations in zinc availability in the brain. Here I show that an increase in zinc gives an 
increase in the most active isoform; BACE501. Therefore, it follows that any 
dyshomeostasis of zinc within the brain may have the potential to increase Aβ 
production thereby exacerbating AD progression. Clearly the interactions of these 
proteins and cations are complex and, whilst this body of data is important, these 
processes require further experimentation. The novel observations presented here, of 
ZnT10 and BACE1 splice variant alterations in AD and SH-SY5Y cell models, may 
guide research that is hypothesis based. For example, future experiments could include 
investigation into the effect of over-expression and/ or siRNA knockdown of ZnT10 on 
BACE1 splice variants. This would establish whether the differing transporter levels 
have a direct effect on alteration of BACE1 splicing events. However, I feel that future 
research would benefit from a systems biology perspective, to try and confirm the 
interactions that are taking place between and within the whole body. This work has 
generated a lot of data that are difficult to piece together in the larger biological sense.  I 
believe the only way to accelerate this challenging research is to map these findings 
together and develop a model which uses a computational systems based approach, 
supported by laboratory based experiments. This would allow further insight into a 
complex, interacting network that is currently largely unknown by elucidating a general 
network of zinc metabolism and enable insight into networks and pathways that are 
regulated by zinc and its transporters in the brain.  
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To conclude, the work presented in this thesis has made novel contributions to the 
characterisation of ZnT10 and its role in cellular homeostasis in adult humans. This 
study has also implicated ZnT10 dysregulation in AD. Zinc is an important factor in the 
aetiology of AD and the role of ZnT family members needs to be investigated further. 
In addition, zinc alone seems to play a role in AD progression and work presented here 
shows that splicing events can be influenced by extracellular cations (zinc, copper, 
cobalt and nickel). These interactions may play an important role in unravelling the 
complex processes involved in AD. 
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Appendix B 
Vector map of pBlue TOPO 
 
  
   Appendices 
275 
 
Appendix C 
pEGFP-C1 vector map
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Appendix D 
p3xFLAG-10 vector map 
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Appendix E 
FLAG-BAP vector information 
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Appendix F 
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Appendix J 
BACE1 ClustalW 2.1 multiple alignment 
 
 
 
>BACE1variantB      GTGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAGCTGGGCACCGACCTGGTAA 900 
BACE1variantA       GTGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAGCTGGGCACCGACCTGGTAA 900 
BACE1variantD       GTGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAGCTGGGCACCGACCTG---- 896 
BACE1variantC       GTGTGTATGTGCCCTACACCCAGGGCAAGTGGGAAGGGGAGCTGGGCACCGACCTG---- 896 
                    ********************************************************     
 
>BACE1variantB      GCATCCCCCATGGCCCCAACGTCACTGTGCGTGCCAACATTGCTGCCATCACTGAATCAG 960 
BACE1variantA       GCATCCCCCATGGCCCCAACGTCACTGTGCGTGCCAACATTGCTGCCATCACTGAATCAG 960 
BACE1variantD       ------------------------------------------------------------ 
BACE1variantC       --------------CCTGACGACTCCCTGGAGCCTTTCTTTGACTCTCTGGTAAAGCAGA 942 
                                                                                 
 
>BACE1variantB      ACAAGTTCTTCATCAACGGCTCCAACTGGGAAGGCATCCTGGGGCTGGCCTATGCTGAGA 1020 
BACE1variantA       ACAAGTTCTTCATCAACGGCTCCAACTGGGAAGGCATCCTGGGGCTGGCCTATGCTGAGA 1020 
BACE1variantD       ------------------------------------------------------------ 
BACE1variantC       CCCACGTTCCCAACCTCTTCTCCCTGCAG------------------------------- 971 
                                                                                 
 
>BACE1variantB      TTGCCAG----------------------------------------------------- 1027 
BACE1variantA       TTGCCAGGCCTGACGACTCCCTGGAGCCTTTCTTTGACTCTCTGGTAAAGCAGACCCACG 1080 
BACE1variantD       ------------------------------------------------------------ 
BACE1variantC       ------------------------------------------------------------ 
                                                                                 
 
>BACE1variantB      ----------------------GCTTTGTGGTGCTGGCTTCCCCCTCAACCAGTCTGAAG 1065 
BACE1variantA       TTCCCAACCTCTTCTCCCTGCAGCTTTGTGGTGCTGGCTTCCCCCTCAACCAGTCTGAAG 1140 
BACE1variantD       -----------------------CTTTGTGGTGCTGGCTTCCCCCTCAACCAGTCTGAAG 933 
BACE1variantC       -----------------------CTTTGTGGTGCTGGCTTCCCCCTCAACCAGTCTGAAG 1008 
                                           ************************************* 
 
>BACE1variantB      TGCTGGCCTCTGTCGGAGGGAGCATGATCATTGGAGGTATCGACCACTCGCTGTACACAG 1125 
BACE1variantA       TGCTGGCCTCTGTCGGAGGGAGCATGATCATTGGAGGTATCGACCACTCGCTGTACACAG 1200 
BACE1variantD       TGCTGGCCTCTGTCGGAGGGAGCATGATCATTGGAGGTATCGACCACTCGCTGTACACAG 993 
BACE1variantC       TGCTGGCCTCTGTCGGAGGGAGCATGATCATTGGAGGTATCGACCACTCGCTGTACACAG 1068 
                    ************************************************************ 
 
BACE501 is variantA 
BACE476 is variantB 
BACE457 is variantC 
BACE432 is variantD 
Sequence variations are highlighted in yellow 
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